New approaches to optically active 2-tert-alkyl azaaryl compounds and 5,5-disubstituted hydantoins by Izquierdo Arruferia, Joseba
New Approaches to Optically Active 2-tert-Alkyl 
Azaaryl Compounds and 5,5-Disubstituted 
Hydantoins 
DOCTORAL THESIS 
Joseba Izquierdo Arruferia 
Donostia, 2018 
(c)2018 JOSEBA IZQUIERDO ARRUFERIA
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
INTRODUCTION 
The field of asymmetric catalysis is a lively, fascinating and highly competitive research 
field in organic chemistry. The continuous need for novel asymmetric reactions as well 
as the demands for cheaper and more environmentally friendly catalytic processes is a 
challenge for all chemists in this field.   
The search for new pronucleophiles to obtain tetrasubstituted asymmetric centers 
using chiral organocatalysts has been the subject of intense study in recent years.1 This 
task has gained a great concern due to the fact that optical purity is now a strict 
requirement for the commercialization of new pharmaceutical products.2 
On the one hand, 2-substituted pyridines, and more generally azaarenes, have 
attracted great part of attention since these structures are frequent in chiral 
compounds, as in pharmaceuticals or chiral ligands (Figure 1).  
 
Figure 1.  
One of the routes to obtain α-functionalized chiral 2-alkylpyridines by catalytic 
methods is by using 2-alkylpyridines as pronucleophiles (Scheme 1). 
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Scheme 1.  
 Despite the fact that the asymmetric addition of 2-alkylazaarenes to different 
electrophiles has been carried out with more or less success,3 the methods displayed 
present some limitations:  
1. If the alkyl azaarene is not activated, more than stoichiometric amounts of a 
strong base are needed. 
2. The use of preactivated substrates: EWG in either the azaarene ring or the Cα 
or both positions is needed.  
3. None of these methods address the generation of a quaternary Cα-
stereocenter, an issue of general importance in organic synthesis, and of 
particular significance to the present context given the interest of quaternary 
compounds as potential pharmacophores. 
On the other hand, hydantoins constitute a family of nitrogen heterocycles that are 
present in naturally occurring substances and medicinal compounds (Figure 2).4 
However, only few examples to access to optically active quaternary hydantoins 
involving new-carbon bond forming reaction have been reported.5  
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 Figure 2.  
Recently, our group introduced 1H-imidazol-4(5H)-ones 1 as novel nuchleophile in 
asymmetric synthesis.6 These compounds allowed a highly efficient construction of a 
tetrasubstituted stereogenic center and a direct access to 5,5-disubstituted hydantoins 
(3) and N-substituted (alkyl, allyl, aryl) α-amino acid derivatives (4) (Scheme 2). 
 
Scheme 2.  
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OBJECTIVES 
The first objective would be to synthesize highly activated 2-(cyanomethyl)azaarene 
N-oxides and test them for the first time as effective pronucleophiles for the addition to 
Michael acceptors utilizing a Brønsted base catalyst. This reaction would lead to 
otherwi e e u ive optica  y active α-quaternary alkylazaarenes, compounds that have 
not been described previously (Scheme 3). 
 
Scheme 3.  
The second objective of this work would be, following our previous work concerning 
the synthesis of 5,5-disubstituted hydantoins 3 from 1H-imidazol-4(5H)-ones 1 (Scheme 
2), the enantioselective synthesis of 5,5-disubstituted hydantoins 7 via Brønsted Base/H-
bond donors catalyzed Michael reactions utilizing new 1H-imidazol-4(5H)ones 5 and 1H-
imidazol-5(4H)ones 6 as pronucleophile templates (Scheme 4). If successful, a broad-
scope approach for the enantioselective synthesis of diversely 1,3,5-substituted 
hydantoins would be at hand. 
 
Scheme 4.  
RESULTS AND DISCUSION 
CHAPTER 2 
We envisioned that the 2-cyanoalkylpyridine could be good candidate to be 
deprotonated under Brønsted base catalysis, due to the incorporation of two EWG 
groups (nitrile and phenyl groups  in the Cα po ition of the azaarene  an  be a  e  to 
different electrophiles (Figure 3). 
 Figure 3. Proposed reaction for the investigation. 
Firstly, we evaluated several known bifunctional catalysts containing a Brønsted base 
and a H bond donor functionalities for the addition of 2-phenyl-2-(2-pyridyl)acetonitrile 
8 to α’-hydroxy enone 107 with poor conversion and selectivities. 
To increase the low reactivity of the nucleophile we decided to activate it by using the 
azaarene N-oxide 9 (Figure 4). On the one side, it is well known that the oxidation of the 
pyridine increases the acidity of the Cα8 and on the other  i e  the  →O group cou   
work as another strong coordinating site for catalyst binding.9 10 
 
Figure 4.  
We show that the N-oxide group in compound 9 plays a strategic role as a removable 
activating and stereodirecting element in conjunction with newly designed 
multifunctional squaramide-Brønsted base catalysts bearing a bulky silyl group (Figure 
5). 
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Figure 5.  
The reactions carried out with this new type of multifunctional organocatalyst yielded 
the desired products with very good performance and excellent enantioselectivity 
(Scheme 5). 
 
Scheme 5.  
The detailed mechanism of these catalytic transformation as well as the precise role 
played by each element involved remains unclear. However, the N-oxide group and its 
ortho- relationship to the cyanoalkyl substituent are key for the optimal reaction 
outcome. 
CHAPTER 3 
In the third part of this thesis we show a continuation of our previous work (see 
Scheme 6). The efficiency of 1H-imidazol-4(5H)ones 5 and 1H-imidazol-5(4H)ones 6 as 
new pronucleophiles in the enantio- and diastereoselective organocatalytic conjugate 
additions catalyzed by bifunctional Brønsted bases/H-bond donors (C3 or C4) with 
different electrophiles is shown. It should be mention that 5 and 6 show similar 
reactivity than 1H-imidazol-4(5H)-ones (1) and the corresponding final adducts were in 
general obtained in very good yields and excellent stereoselectivities (up to >98:2 dr; up 
to >99% ee) (Scheme 6). 
 Scheme 6.  
NMR studies were carried out to try to understand the interactions between the 
squaramide type catalyst and the reaction substrates and two plausible transition states 
(TS) were proposed (A or A') (Figure 6). 
 
Figure 6.  
 
 
 
CONCLUSIONS 
In summary, three new pronucleophiles and two new multifunctional organocatalysts 
have been described for the organocatalytic asymmetric formation of quaternary 
stereocentres. 
First, 2-cyanomethylazaarene N-oxides and catalyst C2 have demonstrated their utility 
a  efficient reagent  for the a ymmetric  ynthe i  of α-quaternary o-substituted 
alkylazaarenes via mild enolization conditions. 
Second, 1H-imidazol-4(5H)-ones 5 and 1H-imidazol-5(4H)-ones 6 have proved to be 
excellent substrates for the synthesis of enantiomerically enriched 5,5-disubstituted 
hydantoins. 
 
RESUMEN 
 
INTRODUCCIÓN 
 El hecho de que la pureza óptica sea ahora un requisito indispensable para la 
comercialización de nuevos productos farmacéuticos, hace que la búsqueda de nuevas 
condiciones de reacción para obtener centros asimétricos de manera eficaz esté 
siendo objeto de un intenso estudio.1 
El campo de la organocatálisis asimétrica, es decir el empleo de catalizadores 
quirales puramente orgánicos, ha experimentado un auge extraordinario en los 
últimos 15 años debido a las potenciales ventajas de dichos sistemas. Las razones 
esgrimidas para este inusitado interés son en primer lugar la facilidad de manejo, la no 
necesidad de secado de los disolventes y el no requerimiento de atmósfera inerte, y en 
segundo lugar la accesibilidad de los catalizadores en ambas formas enantioméricas.2  
Por un lado, las piridinas o-sustituidas con centro estereogénicos cuaternarios, y más 
generalmente los azaarenos, han atraído parte de la atención de los químicos 
sintéticos ya que estas estructuras son frecuentes en productos farmacéuticos o 
ligandos quirales (Figura 1).  
 
Figura 1. 
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El uso de 2-alquilpiridinas como pronucleófilos es una de las rutas principales para 
obtener 2-alquilpiridinas quirales α-funcionalizadas por métodos catalíticos (Esquema 
1). 
 
Esquema 1. 
 A pesar de que la adición de 2-alquilazaarenos a diferentes electrófilos se ha llevado 
a cabo con más o menos éxito,3 los métodos descritos hasta la fecha presentan serias 
limitaciones: 
1. En el caso de que el 2-alquil azaareno no esté activado, la utilización de una 
base fuerte es necesaria para llevar a cabo la reacción. 
2. Necesidad de utilizar sustratos preactivados: grupo electronatractor en el 
anillo del azaareno, en la posición Cα o en ambas posiciones al mismo 
tiempo. 
3. Ninguno de los métodos descritos aborda la generación de un estereocentro 
cuaternario en la posición Cα del azaareno, un hecho de gran importancia 
dado el interés de los compuestos cuaternarios como potenciales 
farmacóforos. 
Por otro lado, las hidantoínas constituyen una familia de heterociclos nitrogenados 
que están presentes en sustancias que poseen una gran importancia farmacológica 
(Figura 2).4 A pesar de su importancia, solo se han descrito algunos ejemplos aislados 
de acceso a hidantoínas cuaternarias ópticamente activas mediante la reacción de 
formación de nuevos enlaces C-C.5 
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 Figura 2.  
Recientemente, nuestro grupo ha introducido las 1H-Imidazol-4(5H)-onas (1) como 
nuevos nucleófilos en síntesis asimétrica.6 Estos compuestos han permitido de manera 
efica  la sín esis de un cen ro es ereogénico cua ernario en la posición Cα al grupo 
carbonilo y un acceso directo a hidantoínas 5,5-disustituidas (3) y derivados de α-
aminoácidos N-sustituidos (4) (Esquema 2). 
 
Esquema 2. 
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OBJETIVOS 
De acuerdo con las líneas expuestas anteriormente, nos propusimos como primer 
obje ivo general la sín esis de α-alquil azaarenos cuaternarios ópticamente activos. 
Para ello, nos propusimos adicionar bajo condiciones suaves de enolización 2-
(cianometil) azaarenos a distintos electrófilos (Esquema 3). 
 
Esquema 3. 
En el segundo apartado nos propusimos implementar el trabajo previo en la síntesis 
de hidantoinas 5,5-disustituidas (3) a partir de 1H-imidazolonas-4(5H)-onas (1), 
utilizando 1H-imidazol-4(5H)-onas (5) y 1H-imidazol-5(4H)-onas (6) como plantillas 
pronucleófilas equivalentes y sistemas catalíticos del tipo base de Brønsted/enlace de 
H (Esquema 4). Las etapas clave deberían ser la preparación de las imidazolonas  5 y 6 
y la etapa de adición asimétrica a los distintos electrófilos. 
 
Esquema 4. 
RESULTADOS Y DISCUSIÓN 
CAPÍTULO 2:  
En primer lugar, supusimos que la 2-cianoalquilpiridina comercialmente accesible 
podría ser un buen candidato para ser desprotonada bajo condiciones suaves de 
enolización, debido a la incorporación de dos grupos electroatractores (grupos nitrilo y 
fenilo  en la posición Cα de la piridina, y ser adicionada a diferentes electrófilos (Figura 
3). 
 Figura 3. 
Evaluamos varios catalizadores bifuncionales conocidos portadores de una base de 
Brønsted y una funcionalidad donante de enlace H para la adición de 2-fenil-2-(2-
piridil)acetonitrilo 8 a la α-hidroxi enona 9.7 Desafortunadamente los resultados no 
fueron los deseados y el producto de adición se obtuvo con conversiones y 
enantioselectividades muy pobres. 
 
Esquema 5. 
Para aumentar la baja reactividad del nucleófilo decidimos activarlo usando el 
correspondiente N-óxido 11 (Figura 4). Por un lado, es bien sabido que la oxidación de 
la piridina aumenta la acidez del carbono en la posición α8 y, por otro lado, el grupo 
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 →O podría funcionar como otro punto de anclaje para la unión al catalizador y dar 
mayor rigidez al estado de transición.9 
 
Figura 4. 
Con objeto de implementar la interacción entre 11 y el catalizador, se sintetizó una 
nueva familia de catalizadores multifuncionales del tipo base de 
Brønsted/escuaramida con un grupo sililo en su estructura. Afortunadamente las 
reacciones llevadas a cabo con este nuevo tipo de nucleófilo y catalizador condujeron a 
los productos deseados con muy buenos rendimientos y excelentes 
enantioselectividades (Esquema 6). 
 
Esquema 6. 
El mecanismo detallado de esta transformación catalítica así como el papel preciso 
desempeñado por cada elemento involucrado sigue sin estar claro. Se puede afirmar 
que el grupo N-óxido y su relación orto- con el sustituyente cianoalquilo y el 
catalizador multifuncional portador de un grupo sililo han resultado ser claves para el 
desarrollo eficiente de la reacción.  
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CAPÍTULO 3:  
En la tercera parte de esta tesis mostramos una continuación de nuestro trabajo 
previo basado en la adición de 1H-imidazol-4(5H)-onas (1) a nitroalquenos utilizando 
catalizadores bifuncionales quirales del tipo bases de Brønsted/enlaces de hidrógeno 
(ver Esquema 2). Aunque la metodología previamente descrita proporciona buenos 
rendimientos químicos y excelentes selectividades, está limitada al empleo de 
imidazolonas N-alquil derivadas.  
En este capítulo se muestra la eficacia de las imidazolonas 5 y 6  como nuevos 
pronucleófilos en adiciones conjugadas a nitroalquenos y α-hidroxi enonas (9) 
catalizadas por C3 y C4 (Esquema 7). Los aductos finales correspondientes se 
obtuvieron en general con muy buenos rendimientos y excelentes 
estereoselectividades (>98:2 dr; >99% ee). Nuestra propuesta ha dado como hecho 
más rotundo el acceso a la síntesis de hidantoinas sustituidas con funcionalidades 
adicionales en comparación al precedente expuesto. 
 
Esquema 7. 
Se llevaron a cabo estudios de RMN para tratar de comprender las interacciones 
entre el catalizador bifuncional C4 y los sustratos de partida y se propusieron dos 
estados de transición posibles. El primero de ellos, involucra al protón amídico en la 
activación intramolecular del propio catalizador (activación asistida) (Figura 5, Modelo 
A). En el segundo estado de transición propuesto, el protón amídico estaría 
involucrado en la activación de las correspondientes imidazolonas 5 o 6 (Figura 5, 
Modelo B).  
 
Figura 5. 
 
CONCLUSIONES 
En resumen, se han descrito tres nuevos pronucleófilos y dos nuevos 
organocatalizadores multifuncionales para la formación asimétrica organocatalítica de 
estereocentros cuaternarios. 
Por un lado, se ha descrito por primera vez un nuevo procedimiento altamente 
estereoselectivo para la obtención de 2-alquil azaarenos con un centro estereogénico 
cuaternario en la posición α. Como puntos novedosos se han utilizado por primera vez 
N-óxidos de 2-cianometil azaarenos como pronucleófilos carbonados y un nuevo 
catalizador multifuncional base de Brønsted/escuaramida portador de un grupo sililo.  
Por otro lado, las 1H-imidazol-4(5H)-onas 5 y 1H-imidazol-5(4H)-onas 6 han 
demostrado ser excelentes nucleófilos en la reacción asimétrica de Michael a 
ni roalquenos y α-hidroxi enonas. Los aductos obtenidos han demostrado su valor 
como intermedios sintéticos de hidantoinas 5,5-disustituidas enantiomericamente 
enriquecidas. Esta metodología ha sido empleada para obtener  inhibidores de la 
enzima ADAMTS-5 responsable de la degradación del tejido cartilaginoso.  
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ω Electrophilicity index 
Ac Acetyl (group) 
Al(Oi-Pr)3 Aluminum isopropoxide  
Ar Aryl (group) 
Å Årmstrong 
BB 
BINAM 
BINAP 
BINOL 
Brønsted base 
1,1’-Bi(2-naphthylamine) 
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
1,1’-Bi-2-naphthol 
Bn Benzyl (group) 
Boc 
BOX 
(Bpin)2 
tert-Butyloxycarbonyl (group) 
Bis(oxazoline) 
Bis(pinacolato)diboron 
iBu Isobutyl (group) 
tBu 
Bz 
tert-Butyl (group) 
Benzoyl (group) 
Cat. 
Conv. 
 Catalyst 
Conversion 
Cbz 
COD 
Benzyloxycarbonyl (group) 
1,5-Cyclooctadiene 
Cy 
DA 
DBU 
DCE 
DCM 
Cyclohexyl (group) 
Diels-Alder 
1,8-Diazabicyclo[5.4.0]undec-7-ene 
1,2-Dichloroethane 
Dichloromethane 
DIOP 
 
DIPAMP 
 
DIPEA 
O-Isopropyldiene-2,3-dihydroxy-1,4-
bis(diphenylphosphino)butane 
Ethane-1,2-
diylbis[(2methoxyphenyl)phenylphosphane] 
N,N-Diisopropylethylamine 
DMF 
DMPA 
Dimethyl formamide 
4-Dimethylaminopyridine 
DMSO 
DOPA        
DPEN  
Dimethyl sulfoxide 
3,4-Dihydroxyphenylalanine 
Diphenylethylenediamine 
dr Diastereomeric ratio 
E 
EDC 
Electrophile 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
ee Enantiomeric excess 
Et Ethyl (group) 
Et2O Diethyl ether 
EtOH Ethanol 
EWG Electron withdrawing group 
Hex 
HMPA 
Hexane 
Hexamethylphosphoramide 
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HOBt 
HOMO 
HPLC 
Hydroxybenzotriazole 
Highest occupied molecular orbital 
High performance liquid chromatography 
KHMDS  Potassium bis(trimethylsilyl)amide 
LDA 
LIHMDS 
LUMO 
Lithium diisopropylamide 
Lithium bis(trimethylsilyl)amide 
Lowest unoccupied molecular orbital 
m- 
mCPBA 
meta- 
meta-Chloroperoxybenzoic acid 
Me Methyl (group) 
MeOH Methanol 
MS Molecular sieves 
MTBE Methyl tert-butyl ether 
MVK Methyl vinyl ketone 
NHC 
NMO 
NMR 
N-heterocyclic carbene 
N-Methyl morpholine N-oxide 
Nuclear magnetic resonance 
Nu Nucleophile 
o- ortho- 
p- para- 
PG Protecting group 
Ph 
PHOX 
Piv 
pKa 
Phenyl (group) 
Phosphinooxazoline 
Pivaloil  
Acid dissociation constant (logarithmic scale) 
pKb 
PMP 
Base dissociation constant (logarithmic scale) 
para-Methoxyphenyl (4-MeO-C6H4-) 
nPr n-Propyl (group) 
iPr Isopropyl (group) 
PTC 
Py 
Phase-transfer catalysis 
Pyridine 
quant. Quantitative 
Ref. Reference 
r.t. 
SN 
Room temperature 
Nucleophilic substitution 
SOMO Singly occupied molecular orbital 
TADDOL 
TBDPS 
α,α,α,α-Tetraaryl-1,3-dioxolane-4,5-dimethanol 
tert-Butyldiphenylsilyl 
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1. Introduction 
1.1. Asymmetric catalysis 
1.1.1. General considerations 
The only life we know is three-dimensional in which molecular chirality plays a key 
role. A vast range of physical and biological functions are generated through precise 
molecular recognition that requires matching of chirality.1 Life itself depends on chiral 
recognition, because living systems interact with stereoisomers (spatial isomers)2 in 
decisively different manners. Then, it is not a surprise that two enantiomers of a drug 
could interact differently with the receptor, generating different effects.3  
An interesting example is L-DOPA, used in the treatment of Parkinson´s disease. The 
achiral compound dopamine is the active drug, generated after in vivo decarboxylation 
of L-DOPA. Dopamine cannot cross the blood-brain barrier to reach the required site of 
action, so the ‘’prodrug’’ L-DOPA is dispensed. L-DOPA is synthesized via asymmetric 
catalytic hydrogenation on an industrial scale by Monsanto (Scheme 1, Step 1).4 Enzyme-
catalized in vivo decarboxylation releases the drug in its active form. However, this 
enzyme (L-DOPA decarboxylase, Scheme 1, Step 2) only decarboxylates the L-
enantiomer, so it is necessary to administer DOPA in its pure L-form. The accumulation 
of D-DOPA may be dangerous, because enzymes cannot metabolize it. It is obvious then, 
that the synthesis of chiral compounds as a single enantiomer, also called asymmetric 
synthesis, has become an essential subject for research. 
                                                 
1
  Its basics were first discussed as “Key-lock principle” by Emil Fisher. a) Fisher, E. Chem. Ber. 1894, 27, 
2985–2993. For a short review about the key-lock theory and the induced fit theory, see: b) Koshland, D. 
E.  Angew. Chem. Int. Ed. 1994, 33, 2375–2378. 
2
 Stereoisomers are compounds that share identical molecular formulas, atom-to-atom linkages, and 
bonding distances, but differ in their three-dimensional arrangement. Diastereomers are stereoisomers 
which are nonsuperimposable, non-mirror images. Enantiomers are stereoisomers which are 
nonsuperimposable, mirror images.  
3
 a) McConathy, J.; Owens, M. J.  Prim. Care Companion J. Clin. Psychiatry 2003, 5, 70–73. b) Hutt, A. J.; 
Valentova, J. Universitas Comeniana. Acta Facultatis Pharmaceuticae 2003, 50, 7–23. c) Caner, H.; Groner, 
E.; Levy, L.; Agranat, I. Drug Discov. Today 2004, 9, 105–110. d) Smith, S. W. Toxicol. Sci. 2009, 110, 4–30. 
e) Kasprzyk-Hordern, B. Chem. Soc. Rev. 2010, 39, 4466–4503. f) Chiral Drugs: Chemistry and Biological 
Action (Lin, G.-Q. & You, Q.-D. & Chen, J.-F. ed., John Wiley & Sons, Inc.) 2011. g) Molecular, Clinical and 
Environmental Toxicology, Vol. 3 (Luch, A. ed., Springer Heidelberg Dondrecht London New York) 2012. 
Pages 413–436. 
4
 a) Knowles, W. S. Angew. Chem. Int. Ed. 2002, 41, 1998–2007. For a review on the history of L-Dopa in 
the treatment of Parkinson's disease, see: b) García, P. J.; Meseguer, E. Neurología 2002, 17, 214–217. c) 
Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions (Blaser, H.-U. & Federsel,   
H.-J. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2010. Pages 22–38. 
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Scheme 1.  Synthesis of dopamine. 
Nevertheless, optically pure pharmaceuticals may undergo racemization in vivo, 
canceling single enantiomer benefits or inducing unexpected effects, as it happened 
with thalidomide.5  
Three basic strategies can be considered for obtaining enantiomerically pure 
compounds: a) the resolution of racemates, b) the use of optically active molecules 
(chiral building blocks), c) asymmetric synthesis. The proposed methods would enable 
the synthesis of chiral compounds for testing of biological activity and for studies on 
structure-activity relationships (SAR).6 
 
Scheme 2. Methods to obtain enantiomerically pure compounds. 
 
The resolution of racemates is the most classic method and the most attractive at an 
industrial level due to its operational simplicity. The main methods are crystallization, 
                                                 
5
 For more information about thalidomide, see: a) Kim, J. H.; Scialli, A. R. Toxicol. Sci. 2011, 122, 1–6. b) 
González, B.; Hernández, L. Medicina Clínica 2007, 128, 133–137. c) Maruotti, N.; Cantatore, F. P.; Ribatti, 
D. Reumatismo 2006, 58, 187–190. 
6
 Pharmaceutical Process Development: Current Chemical and Engineering Challenges (Blacker, A. J. & M. 
T., ed., Royal Society of Chemistry: Cambridge) 2011. 
Enantiopure compounds 
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racemates 
direct crystallization, 
diastereomeric crystallization, 
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hydroxy acids, 
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synthesis 
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catalysis 
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chromatographic resolution, kinetic resolution and dynamic kinetic resolution.7 The 
maximum yield is 50% in the first three methods, however, with the dynamic kinetic 
resolution,8 which combines the kinetic resolution with an in situ racemization process, a 
single enantiomer can be obtained in quantitative yield. 
The "chiral pool" strategy is based on the use of optically pure chiral natural 
compounds (amino acids, sugars, terpenes…), as starting substrates for the synthesis of 
the desired compound while maintaining the configuration of the initial stereogenic 
units (Figure 1).9 This strategy is especially helpful if the desired molecule bears a great 
resemblance to cheap enantiopure natural products. On the contrary, this method may 
involve a long, tortuous synthesis with many steps and consequent losses in yield. At 
times, it may be difficult to find a suitable enantiopure starting material. 
 
Figure 1. Selected examples of chiral natural compounds used in “chiral pool” strategy. 
The third strategy for obtaining enantiomerically pure compounds is asymmetric 
synthesis.10 This method consists in the stereoselective synthesis of chiral compounds 
from non-chiral compounds. The configuration of the new sterogenic centers generated 
                                                 
7
 For a review on resolution methods, see: a) N. G. Anderson, Org. Proc. Res. Dev. 2005, 9, 800–813. b) 
Vedejs, E.; Jure, M. Angew. Chem. Int. Ed. 2005, 44, 3974–4001. c) Separation of Enantiomers: Synthetic 
Methods (Todd, M. H. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2014. 
8
 For a review of the subject, see: a) Huerta, F. F.; Minidis, A. B. E.; Bäckvall, J.-E. Chem. Soc. Rev., 2001, 30, 
321–331. b) Asymmetric Organic Synthesis with Enzymes (Gotor, V. & Alfonso, I. & García-Urdiales, E. ed., 
Wiley-VCH Verlag GmbH & Co. KGaA) 2009. Pages 87–113. c) Chirality from Dynamic Kinetic Resolution 
(Pellissier, H. ed., Royal Society of Chemistry) 2011. 
9
 a) Total Synthesis of Natural Products: The ‘Chiron’ Approach (Hanessian, S. ed., J. E. Pergamon, Oxford, 
UK) 1983. a) Blaser, H.-U. Chem. Rev. 1992, 92, 935–952.  b) S. Hanessian, Pure Appl. Chem. 1993, 65, 
1189–1204. c) Taylor, M. S.; Jacobsen, E. N. Proc. Natl. Acad. Sci. 2004, 101, 5368–5373. d) Nugent, W. A.; 
Rajanbabu, T. V.; Burk, M. J. Science 1993, 259, 479–483. For a review on chiral pool in total synthesis of 
terpenes, see: e) Brill, Z. G.; Condakes, M. L.; Ting, C. P.; Maimone, T. J. Chem. Rev. 2017, 117, 11753–
11795 and references therein. 
10
 a) Asymmetric Synthesis (Aitken, R. A. & Kilényi, S. N. ed., Chapman & Hall. Cambridge) 1992 b) 
Comprehensive Asymmetric Catalysis I-III (Jacobsen, E. N. & Pfaltz, A. & Yamamoto, H. ed., Springer-Verlag 
Berlin Heidelberg New York) 2000. c) Fundamentals of Asymmetric Catalysis (Walsh, P. J. & Kozlowski, M. 
C., ed., University Science Books) 2009. d) Asymmetric Synthesis Vol. I-II (Christmann, M. & Bräse, S. ed., 
Wiley-VCH Verlag GmbH & Co. KGaA) 2012. 
Introduction 
 
7 
 
can be controlled by chiral auxiliaries, biocatalytic methods, or by non-enzymatic chiral 
catalysts (asymmetric catalysis). 
Chiral auxiliaries are enantiomerically pure compounds that are linked to a substrate 
and influence the stereochemical course of a reaction (Figure 2).11 The auxiliary is 
introduced prior to the stereoselective reaction and removed afterwards. These 
additional synthetic steps and the cost of stoichiometric amounts of auxiliary seem to 
render this approach rather unattractive. 
 
Figure 2. Selected examples of chiral auxiliaries. 
Although powerful biocatalytic methods exist, their biomolecular homochirality often 
poses a problem when the “nonnatural” enantiomer of the product is desired.12 
In the latter case, asymmetric catalysis, the stereochemistry of the reaction is 
controlled by a catalyst that induces chirality in a manner similar to enzymes: the "chiral 
                                                 
11
  For a leading review, see: a) Gnas, Y.; Glorius, F. Synthesis 2006, 12, 1899–1930. For a recent book, see: 
b) Key Chiral Auxiliary Applications (Roos, G. ed., Academic Press) 2014. 
12
 For reviews on enzymatic desymmetrizations, see: a) García, E.; Alfonso, I.; Gotor, V. Chem. Rev. 2005, 
105, 313–354. b) Catalytic Asymmetric Synthesis (Ojima, I. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2010. 
Pages: 269–342. For reviews on biocatalysis, see: c) Bornscheuer, U. T.; Huisman, G. W.; Kazlauskas, R. J.; 
Lutz, S.; Moore, J. C.; Robins, K. Nature 2012, 485, 185–194. d) Diaz, A.; Lavandera, I., Gotor, V. Curr. Green 
Chem. 2015, 2, 192–211. e) Albarrán, J.; González, D.; Gotor, V. Biocatal. Biotransform. 2018, 36, 102–130. 
For enzymatic asymmetric synthesis of chiral amino acids, see: f) Xue, Y.-P.; Cao, C.-H.; Zheng, Y.-G. Chem. 
Soc. Rev. 2018, 47, 1516–1561.   
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pocket" formed in the transition state favors the formation of one enantiomer against 
another. 13 
The two fundamental areas within asymmetric catalysis are organometallic catalysis, 
in which chirality is induced by a chiral organic ligand metal complex, and 
organocatalysis, in which chiral organic molecules are used as catalysts. 
1.1.2. Milestones in catalytic asymmetric reactions 
The first catalytic asymmetric reaction was carried out on a racemic mixture (kinetic 
resolution) in an enzymatic reaction performed by Louis Pasteur in 1858. The organism 
Penicillium glauca consumed (D)-ammonium tartrate faster from a solution of a racemic 
(DL)-ammonium tartrate.14 In the coming years, many researches tried to prepare 
optically active compounds, but these attempts to generate enantiomercally enriched 
products were still performed by fermentation in presence of a microorganism. In 1908, 
Rosenthaler reported the synthesis of optically active mandelonitrile by addition of HCN 
to benzaldehyde and catalized by emulsin, an enzyme extracted from bitter almonds.15  
From 1960s to the end of the XX century, organometallic catalysts16 became the most 
actively studied homogeneous catalysts, culminating in the award of Nobel Prizes to 
Noyori, Sharpless and Knowles in 2001.17 By taking advantage of d orbitals of the 
transition metals used (Fe, Cu, Pd...), these catalysts can activate substrates and 
accelerate reactions through coordination, insertion, ligand exchange etc., and lead to 
the formation of C_H and C_C bonds. In this manner, the revelation that 
substoichiometric amounts of transition metals in combination with same amount of 
chiral ligand promoted stereoselective reactions entailed a revolution in organic 
synthesis.  
 In the 1960s, significant achievements were carried out in the field of asymmetric 
organometallic catalysis. In 1966 Nozaky and Noyori reported the cyclopropanation of 
alkenes using a salen-copper complex as a chiral catalyst. The enantiomeric excess of the 
                                                 
13
 a) Asymmetric Catalysis in Organic Synthesis (R. Noyori ed., John Wiley & Sons) 1993. For catalysis: 
concepts and green applications, see: b) Catalysis (Rothenberg, G. ed., Wiley-VCH Verlag GmbH & Co. 
KGaA) 2008. Asymmetric catalysis in complex target synthesis: c) Taylor, M. S.; Jacobsen, E. N. Proc. Natl. 
Acad. Sci. 2004, 101, 5368–5373. d) Catalytic Asymmetric Synthesis (Ojima, I. ed., Wiley-VCH Verlag GmbH 
& Co. KGaA) 2010. e) Principles of Asymmetric Synthesis (Gawley, R. E. & Aubé, J. ed., Elsevier Ltd.) 2012.   
14
 Pasteur, L. Compt. Rend. Acad. Sci. 1858, 46, 15.  
15
 Rosenthaler, L. Biochem Z. 1908, 14, 238–253. 
16
 Fundamentals of Organometallic Catalysis (Steinborn, D. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 
2011. 
17
 Ault, A. J. Chem. Educ. 2002, 79, 572–577.  
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resulting adducts did not surpass 6% ee. Despite these low values, further research 
started in this area (Scheme 3).18 
 
Scheme 3. Cyclopropanation of alkenes using a salen-copper chiral catalyst. 
Thanks to the milestone paper of Wilkinson´s group in 1966,19 which established the 
feasibility of homogeneous hydrogenation of alkenes with RhCl(PPh3)3 as the catalyst 
precursor, huge developments were achieved in the field of asymmetric 
hydrogenation.20  Researchers focused on introducing chiral ligands around rhodium and 
in 1968, Horner21 and Knowles22 independently reported the use of optically active (–) 
methylpropylphenylphosphine as the chiral ligand in the asymmetric reduction of α-
ethylstyrene and α-phenylacrylic acid respectively (Scheme 4). Although the outcome of 
these reactions were rather poor (<15% ee), these works established the possibility of 
transforming the Wilkinson catalyst into a chiral rhodium catalyst. 
 
Scheme 4. Asymmetric reduction α-ethylstyrene and α-phenylacrylic acid. 
                                                 
 
18
 a) Nozaki, H.; Moriuti, S.; Takaya, H.; Noyori, R. Tetrahedron Lett. 1966, 43, 5239–5244. Later, Aratani 
was able to rich high level of enantioselectivities tuning the structure of the copper catalyst: b) Aratani, T.; 
Yoneyoshi, Y.; Nagase, T. Tetrahedron Lett. 1975, 21, 1707–1710. For a leading review on stereoselective 
cyclopropanation reactions, see: c) Lebel, H.; Marcoux, J.-F.; Molinaro, C.; Charette, A. B. Chem. Rev., 
2003, 103, 977–1050. For a review on metal-salen complexes, see: d) Cozzi, P. G. Chem. Soc. Rev., 2004, 
33, 410–421. For more examples on asymmetric cyclopropanations, see: Asymmetric Synthesis of Three-
Membered Rings (Dalpozzo, R. & Lattanzi, A. & Pellissier, H. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 
2017. 
19
 a) Osborn, J. A.; Jardine, F. H.; Young, J. F.; Wilkinson, G. J. Chem. Soc. A: Inorg. Phys. Theor. 1966, 1711–
1732. b) Inorganic Syntheses, Vol. 28 (Angelici, R. J. ed., John Wiley & Sons) 1990. Pages 77–79. 
20
 a) Science of Synthesis: Stereoselective Synthesis, Vol. 2 (Molander, G. A. ed., Georg Thieme Verlag KG) 
2011. Pages 9–57. b) Comprehensive Chirality, Vol. 5 (Carreira, E. M. & Yamamoto, H. & Maruoka, K. ed., 
Elsevier) 2012. Pages 246–317. 
21
  Horner, L.; Siegel, H.; Büthe, H. Angew. Chem. Int. Ed. 1968, 7, 942.  
22
 a) Knowles, W. S.; Sabacky, M. J. Chem. Commun. 1968, 1445–1446. For a review, see: b) Knowles W. S.; 
Noyori, R. Acc. Chem. Res. 2007, 40, 1238–1239. 
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In the early 1970s, Kagan23 introduced for the first time C2-symmetric a chelating 
chiral diphosphine named DIOP generating an excellent rhodium dimer catalyst, which 
was able to give very good enantioselectivities (up to 88% ee) in an asymmetric catalytic 
hydrogenation. The chiral conformation of the chelate ring induced a preferential chiral 
array of the phenyl rings on phosphorus, enhancing the asymmetric induction (Scheme 
5).  
 
Scheme 5. Asymmetric catalytic hydrogenation. 
In 1979, Koga reported a pioneering work in the chiral Lewis-acid promoted Diels-
Alder (DA) reaction,24 in which the first catalytic asymmetric reaction proceeding in 
moderate enantio- and excellent exo selectivity was described. The chiral catalyst (–) 
menthoxyaluminium dichloride, prepared form EtAlCl2 and menthol, promoted the DA 
reaction of methacrolein and cyclopentadiene obtaining an enantiomeric excess of 72%. 
Though several chiral ligands containing the cyclohexyl moiety were studied, higher 
enantioselectivities were not achieved (Scheme 6). 
 
Scheme 6. Chiral Lewis-acid promoted DA reaction. 
The 1980s meant an impressive progress in the area of the asymmetric organometallic 
catalysis. In 1988, Sharpless achieved an asymmetric dihydroxylation of alkenes using 
                                                 
23
 a) Dang, T. P.; Kagan, H. B. Chem. Commun. 1971, 481. b) Kagan, H. B.; Dang, T. P. J. Am. Chem. Soc. 
1972, 94, 6429–6433. c) Modern Rhodium-Catalyzed Organic Reactions (Evans, P. A. ed., Wiley-VHC Verlag 
GmbH & Co. KGaA) 2005. Pages 1–31. d) Hydrogenation (Karamé, I. ed., InTech) 2012.  
24
 a) Hashimoto, S.-I.; Komeshima, N.; Koga, K. J. Chem. Soc., Chem. Commun. 1979, 437–438. For leading 
books about cycloaddition reactions in organic synthesis, see: b) Cycloaddition Reactions in Organic 
Synthesis (Kobayashi, S. & Jørgensen, K. A. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2001. c) Handbook of 
Cyclization Reactions Vol. 1 (Ma, S. ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim) 2010.  
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substoichiometric amounts of OsO4 and a catalytic amount of chiral cinchona alkaloid 
derived ligand, stoichimetric amounts of N-methyl morpholine N-oxide (NMO) being the 
secondary and less toxic oxidant to regenerate the OsO4 catalyst (Scheme 7).
25 
 
Scheme 7. Asymmetric dihydroxylation of alkenes. 
In the late 1980s through the early 1990s started the study of bisoxazoline ligands.26 
These privileged chiral ligands, containing two oxazoline rings, are the most useful ligand 
classes for asymmetric catalysis due to their capability to coordinate efficiently with a 
broad amount of transition metals (Cu, Fe, Mg, Zn…). The resulting chiral ligands possess 
                                                 
25
 a) Jacobsen, E. N.; Markó, I.; Mungall, W. S.; Schröder, G.; Sharpless, K. B. J. Am. Chem. Soc. 1988, 110, 
1968–1970. For a review on catalytic asymmetric dihydroxilation, see: b) Kolb, H. C.; Vannieuwenhze, M. 
S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483–2547. c) Transition Metals for Organic Synthesis (Beller, M. 
& Bolm, C. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2004. Pages 275–307. d) Stereoselective Synthesis 1, 
Stereoselective Reactions of Carbon-Carbon Double bonds (de Vries, J. G. ed., Thieme) 2011. Pages 5–67. 
26
 For the first synthesis of chiral bisoxazoline ligands, see: a) Lowenthal, R. E.; Abiko, A.; Masamune, S. 
Tetrahedron Lett. 1990, 31, 6005–6008. b) Lowenthal, R. E.; Masamune, S. Tetrahedron Lett. 1991, 32, 
7373–7376. For reviews on chiral bisoxazolines, see: c) Whitesell, J. K. Chem. Rev. 1989, 89, 1581–1590. d) 
Johnson, J. S.; Evans, D. A. Acc. Chem. Res. 2000, 33, 325–335. e) McManus, H. A.; Guiry, P. J. Chem. Rev. 
2004, 104, 4151–4202. f) Desimoni, G.; Faita, G.; Jørgensen, K. A. Chem. Rev. 2006, 106, 3561
_
3651. g) 
Rasappan, R.; Laventine, D.; Reiser, O. Coord. Chem. Rev. 2008, 252, 702–714.  h) Desimoni, G.; Faita, G.; 
Jørgensen, K. A. Chem. Rev. 2011, 111, PR284–PR437.  
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C2 symmetry, a characteristic that has proven most beneficial in designing asymmetric 
processes because of the reduction of possible reaction pathways caused by the 
equivalency of structures upon rotation by 180o (Figure 3).27 
 
Figure 3. C2-symmetrical metal-bis(oxazoline) complexes. BlueAllowed trajectories. 
The groups of Evans28 and Corey29 in back-to-back communications reported the 
synthesis and utility of bisoxazoline ligands bearing a fully substituted spacer unit 
(Scheme 8). Since then, these types of scaffolds have become heavily studied in the 
literature on the application of bisoxazoline ligands in asymmetric catalysis.   
 
Scheme 8.  
Traditionally, the most prominent chiral ligands in enantioselective transition-metal 
catalysis are shown in Figure 4. 
                                                 
27
 a) Pfaltz, A.; Drury, W. J. Proc. Natl. Acad. Sci. 2004, 101, 5723–5726. b) Privileged Chiral Ligands and 
Catalysts (Zhou, Q.-L. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2011. Pages 171–220. 
28
 Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726–727. 
29
 Corey E. J.; Zhang, H.-Y. J. Am. Chem. Soc. 1991, 113, 728–729.  
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Figure 4. Selected examples of chiral ligands. 
For many decades organocatalysis has been eclipsed by the successful transition-
metal catalysis.  The urge to reduce energy consumption, protect the environment and 
conserve natural resources boosted the research of chiral metal-free catalysts in the late 
1990s. Organocatalytic methods seem to be especially attractive for the preparation of 
compounds that do not tolerate metal contamination, e. g. pharmaceutical products.30 
This fact has changed the map of catalysis and many organic reactions are now carried 
out with organocatalysts. 
1.1.3. Organocatalysis 
Organocatalysis can be defined as the acceleration of chemical reactions with a 
substoichiometric amount of an organic compound, which does not contain any metallic 
atom. This activation path has become a very active field in organic synthesis showing 
several significant advantages over conventional organometallic catalysis. The reasons 
for this interest are firstly the ease of handing, dry conditions and inert atmosphere 
                                                 
30
 For reviews on toxicity of metal compounds, see: a) Egorova, K. S.; Ananikov, V. P. Angew. Chem. Int. Ed. 
2016, 55, 12150–12162. b) Egorova, K. S.; Ananikov, V. P. Organometallics 2017, 36, 4071–4090. For 
advances on steroelective organocatalytic reactions. Organocatalytic synthesis of natural products and 
drugs, see: c) Catalytic Methods in Asymmetric Synthesis: Advanced Materials, Techniques, and 
Applications (Gruttadauria, M. & Giacalone, F. ed., John Wiley & Sons, Inc.) 2011. d) For a review on 
toxicity of metal-free catalysts, see: e) Nachtergael, A.; Coulembier, O.; Dubois, P.; Helvenstein, M.; Duez, 
P.; Blankert, B.; Mespouille, L. Biomolecules 2015, 16, 507–514. 
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usually not being required, and secondly the availability of cheap catalysts normally in 
both enantiomeric forms.31 
In general, organocatalysts provide a chiral environment in the activation of the 
nucleophile or the electrophile or both at the same time through interactions that can 
be weak, as in the case of noncovalent activation (hydrogen bonding and ionic pair 
catalysis),32 or strong as in covalent bond mediated activation,33 e. g. in the case of 
iminium ion34 and enamine activation.35 
In 1912, Bredig reported the first nonenzymatic enantioselective catalytic reaction 
using pseudoenantiomeric bifunctional cinchona alkaloids, quinine and quinidine, in the 
preparation of mandelonitrile from benzaldehyde and hydrogen cyanide (Scheme 9). 
The enantioselectivities of the resulting adducts were less than 10%, however the 
importance of this reaction is conceptually revolutionary.36 
 
                                                 
31
  These reasons are not sufficient to claim the superiority of this approach since metal catalyzed and 
organocatalyzed reactions are often complementary providing in many cases different optically active 
compounds.  
32
 For a general review on the asymmetric catalysis mediated by hydrogen bonds, see: a) Yu, X.; Wang, W. 
Chem.-An Asian J. 2008, 3, 516–532. b) Knowles, R. R.; Jacobsen, E. N. Proc. Natl. Acad. Sci. 2010, 107, 
20678–20685.   
33
 For a review on asymmetric covalent catalysis, see:  Abbasov, M.; Romo, D. Nat. Prod. Rep. 2014, 31, 
1318–1327. 
34
 For general reviews on iminium ion catalysis, see: a) Lelais, G.; MacMillan, D. W. C. Aldrichimica Acta, 
2006, 39, 79–87. b) Pihko, P. M.; Majander, I.; Erkkila, A. Chem. Rev. 2007, 107, 5416–5470. c) Bartoli, G.; 
Melchiorre, P. Synlett, 2008, 12, 1759–1772. d) Brazier, J. B.; Tomkinson, N. C. O. Top. Curr. Chem. 2010, 
291, 281–347. e) Lewis base catalysis in Organic Chemistry (Vedejs, E. & Denmark, S. E. ed., Wiley-VCH 
Verlag GmbH & Co. KGaA) 2016. Pages 805–856. 
35
 For general reviews on enamine catalysis, see: a) Marigo, M.; Jørgensen, K. A. Chem. Commun. 2006, 
2001–2011. b) Pihko, P. M.; I. Majander, I.; Erkkila, A. Top. Curr. Chem. 2010, 291, 29–75. c) Lewis base 
catalysis in Organic Chemistry (Vedejs, E. & Denmark, S. E. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2016. 
Pages 857–902. 
36
 Bredig, G.; Fiske, P. S. Biochem. Z. 1912, 46, 7–23.  
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Scheme 9. First nonenzymatic enantioselective catalysis. 
Almost 50 years later, Pracejus developed the first organocatalytic reaction with an 
acceptable enantioselectivity (74% ee).37 He reported the methanolysis of phenyl methyl 
ketene to afford (_)-α-phenyl methylpropionate by using O-acetyl quinine as catalyst 
(Scheme 10). It should be noted that low temperature was needed to carry out the 
reaction more or less efficiently. 
 
Scheme 10. Methanolysis of phenyl methyl ketene using O-acetyl quinine as catalyst. 
An important milestone in this area of organocatalysis was the intramolecular aldol 
reaction catalized by L-proline reported in the early 1970s by the groups of Hajos and 
Parrish, and Ender, Sauer and Wiechert independently (Scheme 11).38 This reaction 
allowed a useful and enantioselective route to the Wieland-Miescher ketone.39 
Moreover, intermediates that are key in the synthesis of some natural products can be 
obtained.  
                                                 
37
 Pracejus, H. Justus Liebigs Ann. Chem. 1960, 634, 9–22. 
38
 a) Eder, U.; Sauer, G.; Wiechert, R. Angew. Chem. Int. Ed. 1971, 10, 496–497. b) Hajos, Z. G.; Parrish, D. 
R. J. Org. Chem. 1974, 39, 1615–1621. For the first moderate asymmetric Robinson-annulation based on 
the proline-derived enamines, see: c) Yamada, S.; Otani, G. Tetrahedron Lett. 1969, 10, 4237–4240. 
39
 a) Wieland, P.; Miescher, K. Helv. Chim. Acta  1950, 33, 2215–2228. For a review concerning the utility of 
this ketone, see: b) Bradshaw, B.; Bonjoch, J. Synlett  2012, 23, 337–356.  
Chapter 1 
16 
 
 
Scheme 11. Intramolecular aldol reaction catalized by L-proline. 
The beginning of the twenty first century brought great contributions in the area of 
organocatalysis with the works of List, Lerner and Barbas III concerning the direct aldol 
reaction via enamine activation40 and the work of MacMillan on Diels-Alder reactions via 
iminium activation41 opening the way (Scheme 12).  
 
Scheme 12. Iminium ion and enamine activation. 
Apart from the pioneering results depicted above, outstandig examples via iminium 
ion activation include: the Friedel-Crafts reaction to enals by MacMillan in 2001,42 the 
selective reduction of enals by List43 and MacMillan44 in 2005, and the conjugated 
amination of enals by MacMillan in 2006.45 Enamine activation also accomplished 
further examples: the α-oxidation of enolizable aldehydes using oxygen singlet by 
Córdova in 2004,46 the α-chlorination and sulfenilation of aldehydes by Jørgensen in 
                                                 
40
 List, B.; Lerner, R. A.; Barbas III, C. F. J. Am. Chem. Soc. 2000, 122, 2395–2396.  
41
 a) Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243–4244. For the first 
example on iminium ion-activation, see: b) Yamaguchi, M.; Shiraishi, T.; Hirama, M. Angew. Chem. Int. Ed. 
1993, 32, 1176–1178. c) Kawara, A.; Taguchi, T. Tetrahedron Lett. 1994, 35, 8805–8808.  
42
 Paras, N. a; MacMillan, D. W. C. J. Am. Chem. Soc. 2001, 123, 4370–4371.  
43
 Yang, J. W.; Hechavarria Fonseca, M. T.; Vignola, N.; List, B. Angew. Chem. Int. Ed. 2005, 44, 108–110.  
44
 Ouellet, S. G.; Tuttle, J. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 32–33.  
45
 Chen, Y. K.; Yoshida, M.; MacMillan, D. W. C. J. Am. Chem. Soc. 2006, 128, 9328–9329.  
46
 Córdova, A.; Sundén, H.; Engqvist, M.; Ibrahem, I.; Casas, J. J. Am. Chem. Soc. 2004, 126, 8914–8915.  
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2004 and 2005 respectively, 47 and the first Michael addition of aldehydes to nitroolefins 
by Hayashi in 2005.48  
Furthermore, both activation modes have also been combined for the consecutive 
formation of multiple stereocenters, as in the case of the first iminium ion/enamine 
tandem reactions by List,49 MacMillan50 and Jørgensen51 reported almost at the same 
time in 2005 (Scheme 13); and the multicomponent organocatalyzed 
Michael/Michael/aldol condensation by Enders in 2006.52 Through this methodology 
highly functionalized complex structures were synthesized in a one-pot reaction in 
excellent diastereo- and enantioselectivities. 
 
Scheme 13. Domino iminium ion-enamine catalyzed reaction. 
Other covalent activation modes have been developed and explored with success, 
including: asymmetric phospine catalysis,53 acylammonium catalysis,54 acylammonium 
                                                 
47
 For the α-chlorination of aldehydes with NCS, see: a) Halland, N.; Braunton, A.; Bachmann, S.; Marigo, 
M.; Jørgensen, K. A. J. Am. Chem. Soc. 2004, 126, 4790–4791. For the α-sulfenilation of aldehydes with 1-
(benzylsulfanyl)-1,2,4-triazole b) Marigo, M.; Wabnitz, T. C.; Fielenbach, D.; Jørgensen, K. A. Angew. Chem. 
Int. Ed. 2005, 44, 794–797. 
48
 Hayashi, Y.; Gotoh, H.; Hayashi, T.; Shoji, M. Angew. Chem. Int. Ed. 2005, 44, 4212–4215.  
49
 Yang, J. W.; Hechavarria Fonseca, M. T.; List, B. J. Am. Chem. Soc. 2005, 127, 15036–15037.  
50
 Huang, Y.; Walji, A. M.; Larsen, C. H.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 15051–15053.  
51
 Marigo, M.; Schulte, T.; Franzén, J.; Jørgensen, K. A. J. Am. Chem. Soc. 2005, 127, 15710–15711.  
52
 a) Enders, D.; Hüttl, M. R. M.; Grondal, C.; Raabe, G. Nature 2006, 441, 861–863. For a review 
concerning multicomponent and sequential organocatalytic reactions, see: b) Marson, C. M. Chem. Soc. 
Rev. 2012, 41, 7712–7722. For a review on enantioselective organocatalyzed domino synthesis of six-
membered carbocycles, see: c) Goudedranche, S.; Raimondi, W.; Bugaut, X.; Constantieux, T.; Bonne, D.; 
Rodriguez, J. Synthesis 2013, 45, 1909–1930.  
53
 a) Wei, Y.; Shi, M. Acc. Chem. Res. 2010, 43, 1005–1018. b) Xiao, Y.; Sun, Z.; Guo, H.; Kwon, O.  Beilstein 
J. Org. Chem. 2014, 10, 2089–2121. 
54
  Müller, C. E.; Schreiner, P. R. Angew. Chem. Int. Ed. 2011, 50, 6012–6042. 
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enolate (di-enolate) catalysis,55 N-heterocyclic carbene catalysis (NHC),56 ammonium 
aza-enolate catalysis,57 SOMO catalysis,58 sulphur ylide catalysis59 and ammonium ylide 
catalysis60 (Scheme 14). 
 
Scheme 14. Activation modes in covalent asymmetric catalysis. 
On the other hand, in noncovalent catalysis the interaction between the chiral catalyst 
and the substrate is established through weak interactions, such as: phase-transfer 
catalysis (PTC),61 chiral anion catalysis62 and hydrogen-bonding catalysis63 (Figure 5). 
                                                 
55
 a) Morril, L. C.; Smith, A. D. Chem. Soc. Rev. 2014, 43, 6214–6226. b) Vellalath, S.; Romo, D. Angew. 
Chem. Int. Ed. 2016, 55, 13934–13943. 
56
 a) Hopkinson, M. N.; Richter, C.; Schedler, M.; Glorius, F. Nature 2014, 510, 485–496. b) Janssen–Müller, 
D.; Schlepphorst, C.; Glorius, F. Chem. Soc. Rev. 2017, 46, 4845–4854. c) Zhang, C.; Hooper, J. F.; Lupton, D. 
W. ACS Catal. 2017, 7, 2583–2596. d) Murauski, K. J. R.; Jaworski, A. A.; Scheidt, K. A. Chem. Soc. Rev. 
2018, 47, 1773–1782.  
57
 a) The Chemistry of the Morita-Baylis-Hillman Reaction (Shi, M. & Wang, F. & Zhao, M.-X. & Wei, Y. ed., 
RSC Publishing) 2011. b) Wei, Y.; Shi, M. Chem. Rev. 2013, 113, 6659–6690. 
58
 a) Beeson, T. D.; Mastracchio, A.; Hong, J.-B.; Ashton, K.; MacMillan, D. W. C. Science 2007, 316, 582–
585. For a recent review, see: b) Mečiarová, M.; Tisovský, P.; Šebesta, R. New. J. Chem. 2016, 40, 4855–
4864. For a recent enantioselective catalytic β-alkylation of enals by UV excitation of iminium ions, see: c) 
Silvi, M.; Verrier, C.; Rey, Y. P.; Buzzeti, L.; Melchiorre, P. Nat. Chem. 2017, 9, 868–873. 
59
 a) Aggarwal, V. K.; Winn, C. L. Acc. Chem. Res. 2004, 37, 611–620. b) Comprehensive Enantioselective 
Organocatalysis: Catalysts, Reactions, and Applications (Dalko, P. I. ed., Wiley-VCH Verlag GmbH & Co. 
KGaA) 2013. Pages 548–565.  
60
 Jiang, K.; Chen, Y.-C. Tetrahedron Lett. 2014, 55, 2049–2055. 
61
 a) Uraguchi, D.; Sakaki, S.; Ooi, T. J. Am. Chem. Soc. 2007, 129, 12392–12393.  For information on 
asymmetric phase transfer catalysis, see: b) Asymmetric Phase Transfer Catalysis (Maruoka, K. ed., Wiley-
VCH Verlag GmbH & Co. KGaA) 2008.  c) Schörgenhumer, J.; Tiffner, M.; Waser, M. Beilstein J. Org. Chem. 
2017, 13, 1753–1769.  
62
 a) Mayer, S.; List, B. Angew. Chem. Int. Ed. 2006, 45, 4193–4195. b)  Mahlau, M.; List, B. Angew. Chem. 
Int. Ed. 2013, 52, 518–533. c) Phipps, R. J.; Hamilton, G. L.; Toste, F. D. Nat. Chem. 2012, 4, 603–614. 
63
 For a dual hydrogen bonding, see:  a) Zhang, Z.; Schreiner, P. R. Chem. Soc. Rev. 2009, 38, 1187–1198. b) 
Nishikawa, Y. Tetrahedron Lett. 2018, 59, 216–223. 
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Figure 5.  Activation modes in non-covalent asymmetric catalysis. 
In recent years, many efforts have been directed towards the development of more 
efficient organocatalytic asymmetric reactions through the use of several strategies. Two 
of them have been the development of more active organocatalysts and the 
development of new efficient pronucleophiles to be deprotonated under mild 
enolization conditions. 
1.1.3.1. Search of more active organocatalysts 
The desire of developing efficient synthetic methods encourage chemists to design 
novel catalysts with high activity and atom economy under environmentally benign 
conditions. Much effort has been done in the search of new multifunctional 
organocatalysts,64 molecules possessing two, or more, distinct functional groups ofLewis 
base,65 Lewis acid,66 Brønsted base,67 and Brønsted acid68 character to activate the 
substrates simultaneously in a controlled chiral environment. Multifunctional catalysis 
was first described by Shibasaki and coworkers,69 as an approximate strategy adopted 
from biomolecular catalysts in nature. This strategy has been applied mainly to polar 
addition reactions involving of nucleophile and an electrophile reagent (polar reactivity). 
                                                 
64
 a) Asymmetric Multifunctional Catalysis (Yu, J.-S. & Zhou, J. ed., John Wiley & Sons) 2014. b) Paull, D. H.; 
Abraham, C. J.; Scerba, M. T.; Alden-Danforth, E.; Lectka, T. Acc. Chem. Res. 2008, 41, 655–663. c) Serdyuk, 
O. V.; Heckel, C. M.; Tsogoeva, S. B. Org. Biomol. Chem. 2013, 11, 7051–7071. d) Multicatalyst System in 
Asymmetric Catalysis (Zhou, J. ed., John Wiley & Sons, Inc.) 2015. 
65
 Lewis Base Catalysis in Organic Synthesis (Vedejs, E. & Denmark, S. E. ed., Wiley-VCH Verlag GmbH & Co. 
KGaA, Weinheim, Germany) 2016. Pages 1215–1258. 
66
 Lewis Acids in Organic Synthesis, Vol. 1-2 (Yamamoto, H. ed., Wiley-VCH Verlag GmbH) 2000. 
67
 For a review about chiral Brønsted bases in asymmetric organocatalysis, see: a) Palomo, C.; Oiarbide, 
M.; López, R. Chem. Soc. Rev. 2009, 38, 632–653. b) Asymmetric Organocatalysis 2, Brønsted Base and 
Acid Catalysis and Additional Topics (Maruoka, K. ed., Thieme, Stuttgart), 2012. c) Asymmetric 
Organocatalysis: Vol. 291 (List, B. ed., Springer) 2012. 
68
 a) Akiyama, T.; Mori, K. Chem. Rev. 2015, 115, 9277–9306. b) Maji, R.; Mallojjala, S. C.; Wheeler, S. E. 
Chem. Soc. Rev. 2018, 47, 1142–1158. c) Carlone, A.; Bernardi, L. Org. Chem. Front. 2017, 4, 1651–1654. 
69
 Shibasaki, M.; Yoshikawa, N. Chem. Rev. 2002, 102, 2187–2210. 
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 Based on the way that multiple functional groups interplay, multifunctional catalysis 
can be split into four categories (Figure 6): (1) cooperative activation, namely the 
simultaneous activation of both nucleophile and electrophile by two functional groups 
of the catalyst; (2) double activation, that is, the concerted activation of a substrate by 
both functional groups; (3) assisted activation, namely one functional group was assisted 
by the other to enhance its capacity to activate the substrate; (4) synergistic activation,70 
where at least two different catalysts act on two different substrates simultaneously to 
allow reaction between the two activated molecules. In cases 1 and 4, the simultaneous 
LUMO lowering of the electrophile and the HOMO raising of the nucleophile maximize 
the energetic efficiency of these systems. 
 
Figure 6. A clasification of multifunctional catalysis with the underlying activation model. 
The cooperation model is the most common activation pattern for multifunctional 
catalysis.71 An early example, with control experiments to show the role of catalyst 
functionality, was reported in 1981 by Wynberg72 who described the cinchonidine 
                                                 
70
 a) Allen, A. E.; MacMillan D. W. C. Chem. Sci. 2012, 3, 633–658. b) Delaney, J. P.; Brozinski, H. L.; 
Henderson, L. C. Org. Biomol. Chem. 2013, 11, 2951–2960. c) Afewerki, S.; Córdova, A. Chem. Rev. 2016, 
116, 13512–13570. 
71
 a) L.-Q. Lu; X.-L. An; J.-R. Chen; W.-J. Xiao. Synlett 2012, 490–508. b) Cooperative Catalysis: Designing 
Efficient Catalysts for Synthesis (Peters, R. ed., Wiley-VCH Verlag GmbH & Co. KGaA) 2015. 
72
 Hiemstra, H.; Wynberg, H. J. Am. Chem. Soc. 1981, 103, 417–430. 
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catalyzed asymmetric Michael addition of benzenethiols to cyclic enones to afford the 
desired product in 62% ee. The hydroxyl group of the catalyst had great influence on the 
stereocontrol, as quinine afforded the Michael adduct in higher ee value than the 
corresponding O-acylated quinine (Scheme 15).  
 
Scheme 15.  
In 1998, Jacobsen utilized chiral thioureas as hydrogen bond donor organocatalysts 
for the first time in the hidrocyanation of aldimines (from both aromatic and aliphatic 
aldehydes) (Scheme 16).73 It should be noted that the two hydrogens of the urea and 
the phenol hydrogen are essential for optimal catalyst activity. 
                                                 
73
 a) Sigman, M. S.; Jacobsen, E. N. J. Am. Chem. Soc. 1998, 120, 4901–4902.  For a mechanistic analysis, 
see: b) Vachal, P.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 10012–10014.   
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Scheme 16. Strecker reaction catalyzed by a chiral Brønsted acid. 
More recently, Takemoto´s group74 described the first bifunctional Brønsted 
base/thiourea (H-bond) type organocatalyst and applied it in a highly enantioselective 
Michael addition of dimethyl malonates to nitroolefins (Scheme 17). The reaction 
mechanism proposed by the authors involves the cooperative formation of a 
trimolecular transition state complex where the nitroalkene interacts with the thiourea 
group by means of two hydrogen bonds and the dimethylamino group promotes the 
activation of the nucleophile by deprotonation. 
 
Scheme 17. Enantioselective Michael addition catalyzed by Brønsted base/thiourea type bifunctional 
organocatalyst. 
As a result of the demonstrated compatibility of tertiary amine-(thio)urea bifunctional 
catalyst shown by Takemoto, the combination of new Brønsted base/Hydrogen bond 
donor chiral catalysts such as thiourea/cinchona alkaloids has expanded rapidly and 
applied effectively in a vast number of asymmetric reactions.75   
                                                 
74
 a) Okino, T.; Hoashi, Y.; Takemoto, Y. J. Am. Chem. Soc. 2003, 125, 12672–12673. Chen's group 
determined the effectiveness of bifunctional catalysis using Takemoto’s thiourea in the enantioselective 
Michael reaction between aromatic thiols and carbonylic α,β-unsaturated compounds: b) Li, B.-J.; Jiang, L.; 
Liu, M.; Chen, Y.-C.; Ding, L.-S.; Wu, Y. Synlett 2005, 4, 603–606.  
75
 a) Connon, S. J. Chem. Commun. 2008, 2499–2510. For a recent review on Brønsted base/thiourea 
bifunctional catalysts, see: b) Fang, X.; Wang, C.-J. Chem. Commun. 2015, 51, 1185–1197. c) Singh, G.; 
Yeboah, E. Rep. Org. Chem. 2016, 6, 47–75. 
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A significant milestone in this kind of bifunctional asymmetric cooperative catalysis 
(Brønsted base/hydrogen bond) took place in 2008 when Rawal first introduced the 
squaramide derivatives as excellent hydrogen bond donors in the reaction between 
active methylenes and nitroalkenes (Scheme 18). The corresponding Michael adducts 
were obtained with excellent yields and enantiomeric excesses and diastereoselectivities 
ranging from poor to excellent.76 
 
Scheme 18. Enantioselective Michael addition catalyzed by squaramide bifunctional organocatalyst.  
Further advance in this area has been the development of highly active bifunctional 
thiosquaramides which appear to be more reactive than the parent squaramides.77 For 
instance, with these new catalysts, same reactivity, but better enantioselectivities than 
their corresponding oxosquaramide has been achieved in the conjugated addition 
reaction of lawsone to a β,γ-unsaturated α-keto ester (Scheme 19). 78  
                                                 
76
 a) Malerich, J. P.; Hagihara, K.; Rawal, V. R. J. Am. Chem. Soc. 2008, 130, 14416–14417. b) Zhu, Y.; 
Malerich, J. P.; Rawal, V. R. Angew. Chem. Int. Ed. 2010, 49, 153–156. For reviews on squaramide catalysis, 
see: c) Storer, R. I.; Aciro, C.; Jones, L. H. Chem. Soc. Rev. 2011, 40, 2330–2346. d) Alemán, J.; Parra, A.; 
Jiang, H.; Jørgensen, K. A. Chem. Eur. J. 2011, 17, 6890–6899. e) Chauhan, P.; Mahajan, S.; Kaya, U.; Hack, 
D.; Enders, D. Adv. Synth. Catal. 2015, 357, 253–281. 
77
 a) Rombola, M.; Sumaria, C. S.; Montgomery, D.; Rawal, V. H. J. Am. Chem. Soc. 2017, 139, 5297–5300. 
For the superior performance of (thio)squaramides over (thio)ureas in organocatalysis, see: b) Lu, T.; 
Wheeler, S. E. Chem. Eur. J. 2013, 19, 15141–15147.  
78
 Rombola, M.; Rawal, V. H. Org. Lett. 2018, 20, 514–517. 
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Scheme 19.  
In the same communication, the higher activity of these catalysts is demonstrated in 
the racemic aza-DA reaction between 2-silyloxydienes and N-benzylideneaniline. The 
reaction catalyzed by the thiosquaramide afforded DA-adduct in 77% yield with a 
diastereoselectivity of 2.7:1, while utilizing the oxosquaramide catalyst no reaction was 
observed (Scheme 20). 
 
Scheme 20.  
Three years after Takemoto´s work, Nagasawa and coworkers found that molecules 
comprised with conformationally flexible guanidinium salt/thiourea double functionality 
catalyze efficiently the diastereoselective Henry reaction with synthetically useful levels 
of selectivities.79 The reaction works under PTC with the assistance of KOH, and KI as an 
additive was required to overcome the retro-nitroaldol reaction. A bifunctional 
cooperative activation of the substrates predicting the formation of the syn adduct was 
proposed, in which, the Si-face of the nitronate would be set up to approach the Si-face 
of the aldehyde without significant sterical hindrance (Scheme 21). No reaction was 
observed when aromatic aldehydes were used. 
                                                 
79
 a) Shotome, Y.; Hashimoto, Y.; Nagasawa, K. Eur. J. Org. Chem. 2006, 2894–2897. For the first highly 
diastereo- and enantioselective catalytic Henry reactions of nitroalkanes and prochiral aldehydes using La-
Li-6,6´-disubstituted BINOL complexes, see: b) Sasai, H.; Tokunaga, T.; Watanabe, S.; Suzuki, T.; Itoh, N.; 
Shibasaki, M. J. Org. Chem. 1995, 60, 7388–7389. 
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Scheme 21. Diastereoselective and enantioselective Henry (nitroaldol) reaction utilizing a guanidine-
thiourea bifunctional organocatalyst. 
The organocatalyst assisted activation model is relatively less explored, but its 
potential is being gradually recognized by synthetic chemists (Figure 7).80  
 
Figure 7.  
In 2003, Rawal81 reported the first organocatalytic asymmetric hetero-DA reaction 
between aldehydes and Rawal’s diene catalyzed by a chiral diol (TADDOL), obtaining in 
general good yields and excellent enantioselectivities (Scheme 22). The internal H-bond 
might enhance the acidity of the second hydroxyl group and then get a more effective 
                                                 
80
 For a leading review, see: a) Auvil, T. J.; Schafer, A. G.; Mattson, A. E. Eur. J. Org. Chem. 2014, 2633–
2646. For the pioneering Lewis acid assisted Lewis acid metal catalysts by intramolecular activation, see: 
b) Ishitani, H.; Komiyama, S.; Kobayashi, S. Angew. Chem. Int. Ed. 1998, 37, 3186–3188. c) Ishitani, H.; 
Komiyama, S.; Hasegawa, Y.; Kobayashi, S.  J. Am. Chem. Soc. 2000, 122, 762–766. For an intermolecular 
activation version, see: d) Oishi, M.; Aratake, S.; Yamamoto, H. J. Am. Chem. Soc. 1998, 120, 8271–8272. 
For the pioneering intramolecular activation of Lewis acids by Brønsted acids using chiral boron catalyst, 
see: e) Ishihara, K.; Yamamoto, H. J. Am. Chem. Soc. 1994, 116, 1561–1562. For an intermolecular 
activation version, see: f) Ryu, D. H.; Corey, E. J. J. Am. Chem. Soc. 2003, 125, 6388–6390. 
81
 a) Huang, Y.; Unni, A. K.; Thadani, A. N.; Rawal, V. H. Nature 2003, 424, 146. For evidence of the assisted 
activation of axially chiral biaryl diol catalyst, see: b) Unni, A. K.; Takenaka, N. Yamamoto, H.; Rawal, V. H. 
J. Am. Chem. Soc. 2005, 127, 1336–1337.  
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activation of the electrophilic aldehyde through a single-point H-bond (upper right side 
of Scheme 22).   
 
Scheme 22. First organocatalytic asymmetric hetero-DA reaction by Brønsted acid catalysis. 
 
Assisted activation of (thio)ureas has proven to enhance (thio)urea acidity on more 
than one occasion. 
In 2008, Seidel and coworkers82 designed a more acidic thiourea catalyst through 
protonated 2-pyridyl substituent (Scheme 23). The authors proposed that the pyridinium 
subunit was engaged in an intramolecular N_H--S hydrogen bond interaction, resulting in 
a more active catalyst and similar selectivity compared to Ricci´s 3,5-
bis(trifluoromethyl)phenyl substituted thiourea organocatalyst83 in the enantioselective 
addition of indoles to nitroalkenes. Finally, the authors found that the removal of one of 
the thiourea nitrogen atoms greatly enhanced the LUMO lowering properties of the 
quinolinium thioamide catalyst, leading to full conversion after 1 h and increasing the 
enantioselectivity to 90%.84   
                                                 
82
 a) Ganesh, M.; Seidel, D. J. Am. Chem. Soc. 2008, 130, 16464–16465. For pyridyl thioureas as switchable 
anion receptors, see: b) Rashdan, S.; Light, M. E.; Kilburn, J. D. Chem. Commun. 2006, 4578–4580. 
83
 Herrera, R. P.; Sgarzani, V.; Bernardi, L.; Ricci, A. Angew. Chem. Int. Ed. 2005, 44, 6576–6579. 
84
 The increased catalyst acidity can result not only in rate acceleration but also in increased 
enantioselectivity, see also: Jensen, K. H.; Sigman, M. S. Angew. Chem. Int. Ed. 2007, 46, 4748–4750. 
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Scheme 23.  
1.1.3.2. Development of new activated pronucleophiles 
In 2009, Smith and coworkers85 described conformationally well-defined but flexible 
thiourea catalysts that benefit from cooperative ligand binding. The noncovalent 
interactions within β-turn catalyst structure lead to a significant improvement in the 
yield and slightly higher levels of catalytic efficiency in a Mukaiyama-Mannich reaction 
(Scheme 24). 
 
Scheme 24.  
                                                 
85
 a) Jones, C. R.; Pantoş, G. P.; Morrison, A. J.; Smith, M. D. Angew. Chem. Int. Ed. 2009, 48, 7391–7394. 
For a similar assisted catalytic activation in Mannich reaction, see: b) Probst, N.; Madarász, Á.; Valkonen, 
A.; Pápai, I.; Rissanen, K.; Neuvonen, A.; Pihko, P. M. Angew. Chem. Int. Ed. 2012, 51, 8495–8499. For a 
boronate/urea assited hydrogen bond donor catalysis, see:  c) Hong, B.; Dange, N. S.; Hsu, C.; Liao, J.; Lee, 
G. Org. Lett. 2011, 13, 2009–2012. 
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Five years later, List and coworkers86 reported the design of particularly active chiral 
disulfonimide (DSI) catalysts based on an assisted activation by hydroxyl groups. They 
envisioned that the bis-3,5-bis(trifluoromethyl)phenylmethanol group can increase the 
Lewis acidity (or the Brønsted acidity of DSI-3) of the disulfonimide group just by internal 
hydrogen-bond activation. With catalysts DSI-1 and DSI-2 no conversion was observed, 
while with the catalyst with free alcohols (DSI-3) conversion of 88% in just 30 minutes 
was obtained. A major disadvantage is the somewhat lengthy synthesis of the catalyst 
(Scheme 25). 
 
Scheme 25.  
The search of new pronucleophiles plays a central role mainly in pharmaceutical 
design and in molecular biology, and might play in a host of other fields in the chemical 
sciences as a supramolecular chemistry, materials, crystal engineering, etc. As a result of 
this broad importance, efforts are heading toward the search of new active methylenes 
that can be easily deprotonated. In these cases, a relatively weak amine is generally 
used to reversibly deprotonate a relatively acidic substrate. To date, the carbonyl 
components for these reactions are mostly restricted to 1,3 diones, β-ketoesters, α-
cyanoacetates, malonates, geminal bis(sulfones).87 
The reason for this is that pronucleophilic species bearing electron withdrawing 
groups (EWG) attached to the α C(sp3)-H functionality, present a lower pka at the 
                                                 
86
 a) Ratjen, L.; van Gemmeren, M.; Pesciaioli, F.; List, B. Angew. Chem. Int. Ed. 2014, 53, 8765–8769. For a 
review of disulfonimides in enantioselective organocatalisis, see: b) James, T.; van Gemmeren, M.; List, B. 
Chem. Rev. 2015, 115, 9388–9409. 
87
 a) de Figueiredo, R. M.; Mazziotta, A.; Pereira de Sant’ Ana, D.; Palumbo, C.; Gasperi, T. Curr. Org. Chem. 
2012, 16, 2231–2289. b) Mielgo, A.; Palomo, C. Beilstein J. Org. Chem. 2016, 12, 918–936. 
Introduction 
 
29 
 
desired deprotonation site increasing the reactivity. This is because the carbanion 
formed by the removal of a proton from the methylene group is stabilized by the 
adjacent EWG. Obviously, extra resonance stabilization of the enolate anion makes such 
C(sp3) more acidic than that adjacent to a single EWG. 
 
Scheme 26. pKa values of selected CH pronucleophiles. 
This strategy has often been used in organocatalysis, where the enantioselective 
transformation is accompanied by a thoughtful design of the nucleophile.88 The careful 
and efficient pronucleophile design can help us to elaborate more easily complex 
adducts that are present in biologically active compounds or in interesting synthetic 
structures (Scheme 27).89909192939495 
                                                 
88
 Sun, B.-F. Tetrahedron Letters 2015, 56, 2133–2140. 
89
 Bordwell, F. G.; Van der Puy, M.; Vanier, N. R. J. Org. Chem.  1976, 41, 1885–1886.  
90
 Bordwell, F. G.; Cheng, J.-P.; Bausch, M. J.; Bares, J. E. J. Phys. Org. Chem.  1988, 1, 209–223.  
91
 Bordwell, F. G.; Bares, J. E.; Bartmess, J. E.; McCollum, G. J.; Van der Puy, M.; Vanier, N. R.; Matthews, 
W. S. J. Org. Chem.  1977, 42, 321–325.  
92
 Bordwell, F. G.; Fried, H. E. J. Org. Chem.  1981, 46, 4327–4331. 
93
 Bordwell, F. G.; Van der Puy, M.; Vanier, N. R. J. Org. Chem.  1976, 41, 1883–1885.  
94
 Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456–463. 
95
 Olmstead, W. N.; Bordwell, F. G. J. Org. Chem.  1980, 45, 3299–3305.  
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Scheme 27. Selected examples of activated carbonyl compounds as nucleophiles.
 969798
 
To date, in the case of less acidic carbons, we are required to use superbases to 
abstract the proton to yield the desired carbanion species (Figure 8).99 
                                                 
96
 Buyck, T.; Wang, Q.; Zhu, J. Angew. Chem. Int. Ed. 2013, 52, 12714–12718. 
97
 Ishikawa, H.; Suzuki, T.; Hayashi, Y. Angew. Chem. Int. Ed. 2009, 48, 1304–1307. 
98
 Rueping, M.; Sugiono, E.; Merino, E. Angew. Chem. Int. Ed.  2008, 47, 3046–3049. 
99
 For selected examples, see: a) Bandar J. S.; Lambert, T. H.  J. Am. Chem. Soc. 2012, 134, 5552−5555. b) 
Avila, A.; Chinchilla, R.; Nájera, C. Tetrahedron: Asymmetry 2012, 23, 1625–1627. c) Núñez, M. G.; Farley, 
A. J. M.; Dixon, D. J. J. Am. Chem. Soc. 2013, 135, 16348–16351. d) Takeda, T.; Kondoh, A.; Terada, M. 
Angew. Chem. Int. Ed. 2016, 55, 4734–4737. For reviews, see: e) Superbases for Organic Synthesis: 
Guanidines, Amidines, Phosphazenes and Related Organocatalysts (Ishikawa, T. ed., Wiley-VCH Verlag 
GmbH & Co. KGaA) 2009. f) Selig, P; Synthesis 2013, 45, 703–718. g) Krawczyk, H.; Dzięgielewski, M.; 
Deredas, D.; Albrecht, A.; Albrecht, Ł. Chem. Eur. J. 2015, 21, 10268–10277. 
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Figure 8. pKbH+ (MeCN) of tertiary amine and some common superbases.
99c
 
However, despite the fact that chiral organosuperbases are promising catalysts in 
organic chemistry, they are difficult to modify or recycle, and their possible toxicity and 
instability means that their synthesis has not been developed properly. For this reasons, 
only a few groups have been able to obtain satisfactory results in terms of yields and 
selectivities.  
For example, Ooi et al.100 described in 2009 a highly efficient and enantioselective 
hydrophosphonylation of aldehydes catalyzed by a chiral tetraaminophosphonium salt. 
(Scheme 28). 
 
Scheme 28.   
More recently, Dixon and co-workers reported an efficient enantioselective ketimine 
phospha-Mannich reaction of diethyl phosphite to N-diphenylphosphine (DPP) ketimines 
catalized by a bifunctional iminophosphorane (BIMP) superbase organocatalyst.101 The 
reaction is applicable to ketimines bearing electron-rich and electron-poor aryl 
substituents and occurs with excellent yields and moderate enantioselectivities under 
mild reaction conditions (Scheme 29). 
                                                 
100
 Uraguchi, D.; Ito, T.; Ooi, T. J. Am. Chem. Soc. 2009, 131, 3836–3837. 
101
 Robertson, G. P.; Farley, A. J. M.; Dixon, D. J. Synlett 2016, 27, 21–24. Also, see ref 99c. 
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Scheme 29. Bifunctional iminophosphorane catalyzed enantioselective ketimine phospha-Mannich 
reaction. 
1.1.4. Formation of quaternary stereocenters  
For a long time, achiral aromatic and heteroaromatic molecules have been potential 
drug candidates due to their relative easy synthesis, principally since the rise of cross-
coupling reactions and parallel synthesis.102 Although many of these molecules have 
been developed into successful drugs, their absence of stereochemistry presents several 
disadvantages. Firstly, from a structural diversity perspective, a huge amount of 
possibilities have not been investigated. Secondly, interactions between target proteins, 
which have a three-dimensional structure, and two-dimensional aromatic molecules, will 
be restricted. As a result, high selectivity for binding to the desired molecule over 
undesired ones is hard to obtain. A promising solution to solve this issue has been the 
incorporation of sp3-hybridized carbon stereocenters into the molecule, especially 
quaternary stereocenters.103 Molecules with quaternary or tetrasubstituted carbon 
stereogenic centers are ubiquitous motifs in organic molecules with biological activity.104 
                                                 
102
 Metal-Catalyzed Cross-Coupling Reactions Vol. 1 and 2 (de Meijere, A. & Diederich, F. ed., Wiley-VCH 
Verlag GmbH & Co. KGaA) 2004. 
103
 a) Escape from flatland: Increasing saturation as an approach to improving clinical success: Lovering, F.; 
Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52, 6752–6756. b) Zhu, Y.; Han, J.; Wang, J.; Shibata, N.; 
Sodeoka, M.; Soloshonok, V. A.; Coelho, J. A. S.; Toste, F. D. Chem. Rev. 2018, 118, 3887–3964. 
104
 Carbon atoms to which four different carbon substituents are bonded, are defined as quaternary 
carbons, whereas structures bearing heteroatom substitutions (e.g. tertiary alcohols or thiols) are referred 
to tetrasubstituted carbons. 12% of the top 200 prescription drugs sold in the US in 2011 contained a 
quaternary stereocenter: Bartholow, M. Top 200 drugs of 2011. Pharm. Times 48–51. 
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Figure 9. Drug molecules containing quaternary stereocenters. 
Although the development of synthetic methodologies in the last decades has been 
really impressive, the stereoselective synthesis of quaternary carbon stereocentres 
remains an important challenge in the synthesis of biologically active compounds (Figure 
9).105 This task has gained a great concern due to the fact that optical purity is now a 
strict requirement for the commercialization of new pharmaceutical products. Thus, the 
more stereoselective procedures are feasible, the more efficiency could be obtained in 
the synthesis of such compounds.106 The formation of quaternary stereocenters in a 
                                                 
105
 Selected examples: Azadirachtin: a) Veitch, G. E.; Beckmann, E.; Burke, B. J.; Boyer, A.; Ayats, C.; Ley, S. 
V. Angew. Chem. Int. Ed.  2007, 46, 7633–7635. Diazonamide A: b) Knowles, R. R.; Carpenter, J.; Blakey, S. 
B.; Kayano, A.; Mangion, I. K.; Sinz, C. J.; MacMillan, D. W. C. Chem. Sci. 2011, 2, 308–311 and references 
therein. Taxol: c) Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.; 
Renaud, J.; Couladouros, E. A.; Paulvannan, K.; Sorensen, E. J.  Nature 1994, 367, 630–634.  
106
 For some selected reviews on the asymmetric formation of quaternary stereocenters, see: a) Corey, E. 
J.; Guzman-Perez, A. Angew. Chem. Int. Ed.  1998, 37, 388–401. b) Ramon, D.; Yus, M. Curr. Org. Chem.  
2004, 8, 149–183. c) Peterson, E. A.; Overman, L. E. 2004, 101, 11943–11948. d) Quaternary Stereocenters: 
Challenges and Solutions for Organic Synthesis (Christoffers, J. & Baro, A. ed., Wiley-VCH Verlag GmbH & 
Co. KGaA) 2005. e) Christoffers, J.; Baro, A. Adv. Synth. Catal. 2005, 1473–1482. f) Trost, B. M.; Jiang, C. 
Synthesis 2006, 369–396. g) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. Eur. J. Org. Chem.  2007, 5969–5994.  
h) Bella, M.; Gasperi, T. Synthesis 2009, 10, 1583–1614. i) Das, J. P.; Marek, I. Chem. Commun. 2011, 47, 
4593–4623. j) Quasdorf, K. W.; Overman, L. E. Nature  2014, 516, 181–191. k) Liu, Y.; Han, S.-J.; Liu, W.-B.; 
Stoltz, B. M. Acc. Chem. Res. 2015, 48, 740–751. For an all-carbon quaternary centers in natural products 
and medicinal chemistry, see: l) Ling, T.; Rivas, F. Tetrahedron 2016, 43, 6729–6777. For an asymmetric 
catalytic formation of quaternary carbons by iminium ion trapping radicals, see: m) Murphy, J. J.; Bastida, 
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complex molecule has its own limitations. Owing to steric hindrance,107 relatively harsh 
conditions (high concentration and temperatures and exceptionally long reaction times) 
are necessary and only limited combinations of nucleophile and electrophile can be 
suitable. This is why in most of the cases enantioselectivity can be strongly affected. 
Moreover, subtle changes either in the electrophile or in the nucleophile could lead to a 
complete loss of stereocontrol.108 For instance, in an SN2 reaction, it is unlikely for a 
nucleophile to attack a highly substituted carbon; on the other hand, a crowded tertiary 
anion could not react with electrophiles.  
To date, we can consider that two of the most common approaches to obtain 
quaternary or tetrasubstituted carbons are the polar addition of nucleophile species to 
trisubstituted unsaturated carbonyl substrates (Scheme 30, 1) and the addition of 
tertiary anions to electrophiles (Scheme 30, 2).109 
 
Scheme 30. Graphical depiction of attenuated reactivity of trisubstituted carbon nucleophile and 
electrophile. 
 
 
 
 
 
 
 
                                                                                                                                                  
D.; Paria, S.; Fagnoni, M.; Melchiorre, P. Nature 2016, 532, 218–222. For a review concerning to catalytic 
enantioselective desymmetrization reactions to get all-carbon quaternary stereocenters, see: n) Zeng, X.-
P.; Cao, Z.-Y.; Wang, Y.-H.; Zhou, F.; Zhou, J. Chem. Rev. 2016, 116, 7330–7396. 
107
 For the synthesis of adjacent quaternary stereocenters, see: Rauful, A.; Vollgraff, T.; Eriksson, L.; Szabó, 
K. J.  J. Am. Chem. Soc. 2015, 137, 11262−11265. 
108
 For an example, see: Wang, X.; Kitamura, M.; Maruoka, K. J. Am. Chem. Soc. 2007, 129, 1038–1039.   
109
 For different approaches in the construction of asymmetric quaternary carbon centers, see: Shimizu, 
M. Angew. Chem. Int. Ed. 2011, 50, 5998–6000 and references therein. 
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1.2. Working hypothesis and objectives 
The present work has been carried out in the line with the research field of the 
group and it is focused on the development of new asymmetric reactions employing 
organocatalysis as the main tool. 
Precedents mentioned in previous section make clear the importance of the 
development of new strategies for the stereoselective creation of carbon atoms 
bonded to four different substituents (quaternary stereocenters), since they are 
common structural motifs in complex molecules found in nature. Thus, the finding of 
new pronucleophiles for organocatalytic reactions that allow simpler synthetic 
pathways to compounds with quaternary α-C(sp3) moieties has been the aim of 
several research groups throughout decades.  
The objectives of this Ph. D. work will be design a new methodologies for the 
organocatalytic synthesis of optically active compounds, with possible biological 
activity, possessing quaternary stereocenters.  
O-Substituted pyridines, and more generally azaarenes, have attracted great part of 
attention since these structures are frequently found in pharmaceuticals or chiral 
ligands. Thus, the first objective of this work was to test activated 2-
(cyanomethyl)azaarenes for the first time as effective pronucleophiles. This reaction 
would lead to otherwise elusive optically active α-quaternary alkylazaarenes, 
compounds that have not been described previously (Scheme 31). 
 
Scheme 31.  
Based on previous observations from our laboratory, where we show that 
heterocycles of type I reacts smoothly with some Michael acceptors to yield 5,5-
disubstituted 2-alkylthio 1H-imidazol-4(5H)-ones, thus serving, after hydrolysis, as 5,5-
disubstituted hydantoins surrogates. Our next goal would be the evaluation of related 
heterocycles II and III to be engaged with selected Michael acceptors under catalytic 
mild enolization conditions. If the reaction proceeds in a satisfactory way the obtained 
Michael adducts could be transformed easily into the corresponding optically active 
5,5-disubstituted hydantoins through a water mediated nucleophilic displacement of 
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the thioether group. So, a broad-scope new method for the synthesis of diversely 5,5-
disubstituted hydantoins could be obtained. 
 
Scheme 32.  
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2. α-FUNCTIONALIZATION OF 2-(CYANOMETHYL)AZAARENE N-
OXIDES  
2.1. Introduction 
Nitrogen-containing heterocycles are among the most significant structural 
components of pharmaceuticals.110 In 2012, 1086 drugs were approved by U. S. Food 
and Drugs administration (FDA) and 59% of them include an N-heterocycle. Moreover, 
from the 10 most prescribed drugs in the U. S. in 2016, 7 of them also incorporated this 
structure (Figure 10).111 
 
Figure 10. Top pharmaceutical products by prescriptions in 2016. 
From all these N-heterocycles, pyridine containing basic heteroarene structure core 
were the second most commonly used (Figure 11a), being the C2-position the preferred 
position for substitution with a frequency of 66% (Figure 11b).112  
                                                 
110
 For a survey of the heterocyclic drugs approved by the U.S. from 2000 to 2012, see: a) Wu, Y.-J. Prog. 
Heterocycl. Chem. 2012, 24, 1–53. For a structure-activity relationship (SAR) study and design strategies of 
nitrogen-containing heterocyclic moieties for their anticancer activities, see: b) The Chemistry of 
Heterocycles (Eicher, T. & Hauptmann, S. ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim) 2003.  c) 
Asymmetric Synthesis of Nitrogen Heterocycles (Royer, J. ed.; Wiley-VCH Verlag GmbH & Co. KGaA, 
Weinheim) 2009. d) Heterocycles in Natural Product Synthesis (Majumdar, K. C. & Chattopadhyay, S. K. 
ed.; Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany) 2011. Pages 63–95. e) Akhtar, J.; Khan, A. 
A.; Ali, Z.; Haider, R.; Shahar Yar, M. Eur. J. Med. 2017, 125, 143–149. 
111
 http://njardarson.lab.arizona.edu/content/top-pharmaceuticals-poster 
112
 a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 57, 10257–10274. For a leading review 
on the synthesis of substituted pyridines, see: b) Yoshiaki, N. Synlett 2011, 20, 3209–3219. c) Bull, J. A.; 
Mousseau, J.; Pelletier, G.; Charette, A. B. Chem. Rev. 2012, 112, 2642–2713. d) Henry, G. D. Tetrahedron 
2004, 60, 6043–6061. For a review concerning to the pioneering work in pyridine chemistry, see: e) Lewis, 
D. E. Angew. Chem. Int. Ed. 2017, 56, 9660–9668. 
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Figure 11. Most frequent N-heterocycles and substituted pyridines in U. S. FDA approved drugs (2012). 
To emphasize the importance of C-2 substituted (o-substituted) aromatic N-
heterocycles or azaarenes, these are frequent structures in chiral compounds, as in 
pharmaceuticals,113 natural products,114 supramolecular chemistry,115 and as chiral 
ligands for asymmetric catalysis116 (Figure 12). Therefore, the synthesis of 2-substituted 
chiral azaarene-containing building blocks has gained much attention.117 
                                                 
113
 For information about doxylamine, see: a) Sperber, N.; Papa, D.; Schwenk, E.; Sherlock, M. J. Am. Chem. 
Soc. 1949, 71, 887–890. b) Nuangchamnong, N.; Niebyl, J. Int. J. Women's Health 2014, 6, 401–409. For 
information about disopyramide, see: c) Hinderling, P. H.; Garrett, E. R. J. Pharmacokinet. Biopharm. 1976, 
4, 199–230. d) Nelson, W. L.; Sneed, C. K. J. Med. Chem. 1981, 24, 614−617. e) Karim, A.; Nissen, C.; 
Azarnoff, D. L. J. Pharmacokinet. Biopharm. 1982, 10, 465–493. f) Kuroda, Y.; Matsumoto, S.; Shibukawa, 
A.; Nakagawa, T. Analyst 2003, 128, 1023−1027. For a review about norbormide, see: g) Bova, S.; Cima, L.; 
Golovina, V.; Luciani, S.; Cargnelli, G. Cardiovasc. Drug Rev. 2001, 19, 226–233.      
114
 Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Curr. Opin. Chem. Biol.  2010, 14, 347–361. 
115
 a) Supramolecular Chemistry – Concepts and Perspectives (Lehn, J. M. ed.; VCH, Weinheim) 1995. b) 
Supramolecular Chemistry: From molecules to Nanomaterials (Steed, J. W. & Gale, P. A. ed.; John Wiley & 
Sons) 2012. c) Liu, M.; Zhang, L.; Wang, T. Chem. Rev. 2015, 115, 7304–7397. 
116
 For reviews on azaarenes as a chiral ligands, see: a) Kwong, H.-L.; Yeung, H.-L.; Yeung, C.-T.; Lee, W.-S.; 
Lee, C.-S.; Wong, W.-L. Coord. Chem. Rev. 2007, 251, 2188–2222. b) Chelucci, G. Coord. Chem. Rev. 2013, 
257, 1887–1932. c) Li, W.; Zhang, J. Chem. Soc. Rev. 2016, 45, 1657–1677. 
117
 For reviews, see: a) Chelucci, G. Tetrahedron: Asymmetry 2005, 16, 2353–2383. b) Best, D.; Lam, H. W. 
J. Org. Chem.  2014, 79, 831–845.   
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Figure 12. C-2 substituted biologically active compounds and chiral ligands. 
There are three main routes to obtain α-functionalized chiral 2-alkylpyridines by 
catalytic methods; i) by nucleophilic addition to 2-acylpyridines or their imines (Scheme 
33a), ii) using 2-alkylpyridines as pronucleophiles (Scheme 33b) or iii) by asymmetric 
transfer hydrogenation of 2-acylpyridines or 2-pyridyl imines118 (Scheme 33c). 
 
Scheme 33.  
                                                 
118
 Using this protocol, only tertiary alcohols and tertiary amines can be obtained. 
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2.1.1. Nucleophilic addition to 2-acyl pyridines or imines derived thereof 
In recent years, a considerable advance in the development of asymmetric procedures 
for the addition of nucleophiles to 2-pyridine carboxaldehyde and to 2-pyridylimines 
leading to products with tertiary stereocenters has been achieved.119 In contrast, the 
asymmetric addition of nucleophiles to 2-acylpyridines and 2-pyridyl ketimines which 
will result in formation of a quaternary stereogenic center has experienced little 
progress, despite the significance of the resulting compounds (Scheme 34). 
 
Scheme 34.  
Among all processes described, the asymmetric addition of nucleophiles to 2-pyridyl 
ketones is the most widely used method for the synthesis of C-2 substituted pyridine 
derivatives with quaternary stereocenters. Next, the existing works to date will be 
explained. 
In 2002, Yamano and coworkers performed a highly enantioselective Reformatsky 
reaction of 2-pyridyl ketones forming a quaternary Cα-stereocenter with high yields and 
enantioselectivities.120 Nevertheless, 4 equivalents of pyridine as a basic coordinating 
additive and 1.5 equivalents of quinine are necessary to enhance the enantioselectivity 
and reactivity (Scheme 35). 
                                                 
119
 For selected examples, see: a) Zhuang, W.; Poulsen, T. B.; Jørgensen, K. A. Org. Biomol. Chem. 2005, 3, 
3284–3289. b) Landa, A.; Minkkilä, A; Blay, G.; Jørgensen, K. A. Chem. Eur. J. 2006, 12, 3472–3483. c) 
Clayden, J.; Hennecke, U. Org. Lett. 2008, 10, 3567–3570. d) Qu, Y.; Jing, L.; Wu, Z.; Wu, D.; Zhou, X. 
Tetrahedron: Asymmetry 2010, 21, 187–190. e) Pascual-Escudero, A.; González-Esguevillas, M.; Padilla, S.; 
Adrio, J.; Carretero, J. C. Org. Lett. 2014, 16, 2228–2231. f)  Beckendorf, S.; García-Mancheño, O. Synthesis 
2012, 44, 2162–2172. g) Lee, K. N.; Lei, Z.; Ngai, M.-Y. J. Am. Chem. Soc. 2017, 139, 5003–5006.  
120
 Ojida, A.; Yamano, T.; Taya, N.; Tasaka, A. Org. Lett. 2002, 4, 3051–3054. 
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Scheme 35. Asymmetric synthesis of tertiary alcohols via Reformatsky reaction. 
As already shown in the introductory part (chapter 1), the interplay of multiple 
catalyst can increase overall reactivity substantially. For instance, the group of Krische 
described an enantioselective reductive coupling of 1,3-enynes to 2-acetylpyridine and 
cyclopropyl 2-pyridyl ketone catalyzed by a chiral rhodium complex  and an achiral 
Brønsted acid (Scheme 36). The reaction was carried out in dichloroethane at 40 oC, 
rendering the reductive coupling products in excellent yields and enantioselectivities.121 
The proposed mechanism for the reductive coupling involves the activation of the 1,3-
enyne by the rhodium complex and the activation  of the 2-pyridinecarboxaldehyde 
(LUMO lowering) by the Brønsted acid cocatalyst (upper right Scheme 36).122  
 
Scheme 36. Asymmetric reductive coupling and plausible intermediate reaction. 
Shortly after the achievement of Kirsche, Hoveyda’s research group123 reported an 
aluminium-catalyzed asymmetric alkylation of pyridyl-substituted alkynyl ketones with 
dialkylzinc reagents (Et2Zn or Me2Zn). In the case of the addition of Et2Zn, the presence 
of a Brønsted acid (50 mol % of diethyl phosphoramidate) was necessary in order to get 
                                                 
121
 Komanduri, V.; Krische, M. J. J. Am. Chem. Soc. 2006, 128, 16448–16449. 
122
 The reaction using an achiral rhodium catalyst in the presence of 4 mol% of the Akiyama-Terada type 
chiral phosphoric acid catalyst derived from BINOL, gave moderate yield (56%) and ee (82%). 
123
 Friel, D. K.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2008, 130, 9942–9951. 
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good yields and enantioselectivities. Products that contain a quaternary carbon 
stereogenic center bearing three highly versatile substituents (an alcohol, a pyridine, 
and an alkyne) were generated in very good yields and excellent enantioselectivities 
(Scheme 37). 
 
Scheme 37. Al catalyzed asymmetric alkylations of pyridyl ynones. 
In 2011, Hong et al. reported a stereoselective organocatalytic domino Michael–Aldol 
reaction, affording highly functionalized cyclopentanecarbaldehyde with five new 
stereogenic centers in high yield and stereoselectivities from moderate to high.124 The 
best reaction conditions were obtained with 5 mol % of Jørgensen-Hayashi catalyst125 
(iminium-ion activation), needing in general long reaction times (Scheme 38). 
 
Scheme 38.  
                                                 
124
 Hong, B.-C.; Dange, N. S.; Hsu, C.-H.; Liao, J.-H.; Lee, G.-H. Org. Lett. 2011, 13, 1338–1341. 
125
 For reviews, see: a) Mielgo, A.; Palomo, C. Chem. Asian J. 2008, 3, 922–948. b) Jensen, K. I. M. L.; 
Dickmeiss, G.; Jiang, H. A. O.; Albrecht, Ł. U.; Jørgensen, K. A. Acc. Chem. Res. 2012, 45, 248–264. 
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Another application in the synthesis of α-functionalized chiral 2-alkylpyridines using 
enamine activation was reported by the group of Xu in 2011. They described the 
formation of trifluoromethylated tertiary alcohols through asymmetric primary amine 
catalyzed aldol reaction between aliphatic ketones and activated 2,2,2-trifluoro-1-
(pyridin-2-yl)ethan-1-one with excellent yields and moderate to very good 
enantioselectivities.126 Interestingly, both possible enantiomers of the final adduct were 
obtained using the proper cinchona catalyst. In the case of QN-NH2/Al(Oi-Pr)3 catalytic 
system, the role of Al(Oi-Pr)3 is attributed to the activation of the trifluoromethyl ketone 
and to the stabilization of the enamine transition state (TS)  (Scheme 39). 
 
Scheme 39.  
                                                 
126
 Yang, W.; Cui, Y.-M.; Zhou, W.; Li, L.; Yang, K.-F.; Zheng, Z.-J.; Lu, Y.; Xu, L.-W. Synlett 2014, 25, 1461–
1465. 
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Shortly after the achievements of Xu, and following the seminal works of Bolm and Fu 
using arylzinc reagents as nucleophiles,127 the group of Ito reported an efficient 
Zn(salen)-catalyzed enantioselective phenyl transfer to aldehydes and ketones with 
organozinc reagents. They performed just one example of the Zn(salen)-catalyzed 
enantioselective phenyl transfer to 2-acetylpyridine, unfortunately a racemic mixture of 
the tertiary carbinol was obtained (Scheme 40).128 
 
Scheme 40.  
Recently, in an original contribution, Buchwald’s group129 has reported one example 
of a copper-catalyzed asymmetric addition of 4-phenylstyrene to 2-acetyl pyridine with 
moderate yield and poor diastereoselectivity, but excellent enantioselectivity for both 
diastereomers (Scheme 41). It was proposed that the activation of C=C double bond of 
an olefin by chiral copper hydride catalyst (L*Cu-H) would provide the enantioenriched 
alkylcopper carbanion equivalent (upper right Scheme 41) that after interception of the 
ketone and ligand exchange with metyltert-butyl ether (MTBE) would furnish the 
asymmetric addition product. The absolute and relative configuration of the obtained 
adduct was not determined. 
                                                 
127
 a) Dosa, P. I.; Ruble, C.; Fu, G. C.  J. Org. Chem. 1997, 62, 444–445. b) Bolm, C.; Hermanns, N.; 
Hildebrand, J. P.; Muñiz, K. Angew. Chem. Int. Ed. 2000, 39, 3465–3467.  For a leading review concerning 
to the catalytic asymmetric synthesis of diarylmethanols and diarylmethylamines by aryl transfer reaction, 
see: c) Schmidt, F.; Stemmler, R. T.; Rudolph, J.; Bolm, C. Chem. Soc. Rev. 2006, 35, 454–470. 
128
  Shimizu, K.; Uetsu, H.; Gotanda, T.; Ito, K. Synlett 2015, 26, 1238–1242.  
129
 Yang, Y.; Perry, I. B.; Lu, G.; Liu, P.; Buchwald, S. L. Science 2016, 353, 144−149.  
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Scheme 41.  
The same year, Meggers and coworkers developed an asymmetric radical-radical 
cross-coupling reaction through visible-light activated iridium catalysis.130 With a chiral 
iridium complex as a dual Lewis acid/photoredox catalyst, optically active 1,2-amino 
alcohols were synthesized from trifluoromethyl ketones and tertiary amines. Just in one 
example a 2-pyridyl ketone was employed resulting in very good yield and excellent 
enantioselectivity (Scheme 42).   
 
Scheme 42.  
                                                 
130
 a) Wang, C.; Qin, J.; Shen, X.; Riedel, R.; Harms, K.; Meggers, E. Angew. Chem. Int. Ed.  2016, 55, 685–
688.  For a Brønsted acid catalyzed Michael addition of α-amino radicals to alkenylpyridines, see: b) 
Hepburn, H. B.; Melchiorre, P. Chem. Commun. 2016, 52, 3520–3523. For a recent article concerning to 
the direct addition of α-amino alkyl radicals to the 2-position of heteroarenes yielding tertiary 
stereocenters, see: c) Proctor, R. S. J.; Davis, H. J.; Phipps, R. J. Science 10.1126/science.aar6376. For a 
recent article concerning to the conjugate addition-enantioselective protonation of N-aryl glycines to α-
branched 2-vinylazaarenes via cooperative photoredox and asymmetric catalysis, see: d) Yin, Y.;  Dai, Y.; 
Jia, H.; Li, J.; Bu, L.; Qiao, B.; Zhao, X.; Jiang, Z. J. Am. Chem. Soc. 10.1021/jacs.8b01575. 
 
2-(Cyanomethyl)azaarene N-Oxides 
 
49 
 
Jørgensen and cowoworkers were the first to employ 2-acetylpyridine N-oxides in a 
oxo-HDA reaction catalyzed by a chiral copper(II)-BOX complex forming optically pure 
adducts with a quaternary Cα-stereocenter satisfactorily (Scheme 43).131 When using 
Danishefsky’s diene the unsaturated six membered ring was obtained, while with 
Brassard`s diene, non silylated vinylogous Mukaiyama-aldol adduct was formed. An 
explanation for the isolation of the Mukaiyama-aldol adduct could be the stability of the 
formed open-chain methyl ester, due to hydrogen-bond stabilization between the N-
oxide and the hydroxyl group. These observations indicated that the oxo-HDA reaction 
might proceed by a stepwise Mukaiyama-aldol mechanism. 
 
Scheme 43. Cu-Lewis acid catalyzed O-HDA by Jørgensen et al. 
Besides 2-pyridyl ketones, 2-pyridyl ketimines have also been used as electrophiles, 
although in less extent. Just a few examples can be found in the literature and in most of 
the cases a chiral auxiliary was employed. 
For instance, Spero132 and Palmieri133 have described the asymmetric synthesis of α,α-
disubstituted alkylamines via Grignard additions to ketimines bearing chiral auxiliaries 
derived from (S)-phenylglycinol and (R)-1-phenyl ethylamine (Figure 13a). Ellmans´ 
sulphinamide auxiliary134 has been used more frequently in the nucleophilic addition of 
                                                 
131
 a) Landa. A.; Richter, B.; Johansen, R. L.; Minkkilä A.; Jørgensen K. A. J. Org. Chem. 2007, 72, 240−245. 
For a recent example using 2-acylpyridine N-oxides generating a quaternary Cα-stereocenter in a Henry 
reaction, see: b) Holmquist, M.; Blay, G.; Muñoz, M. C.; Pedro, J. R. Org. Lett. 2014, 16, 1204–1207. For the 
L-phenylalanine potassium catalyzed asymmetric formal [3+3] annulations of 2-enoyl pyridine N-oxides 
with acetone, see: c) Xu, Y.; Zhang, S.; Li, L.; Wang, Y.; Zha, Z.; Wang, Z. Org. Chem. Front. 2018, 5, 376–
379. 
132
 Spero, D. M.; Kapadia, S. R. J. Org. Chem. 1997, 62, 5537–5541. 
133
 Cimarelli, C.; Palmieri, G.; Volpini, E. Tetrahedron: Asymmetry 2002, 13, 2011–2018. 
134
 Liu, G.; Cogan, D. A.; Ellman, J. A. J. Am. Chem. Soc. 1997, 119, 9913–9914. 
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diethyl thiophosphonate,135 acylsilanes,136 organolithium reagents,137 acetonitrile 
anion,138 and fluoro(phenylsulfonyl)methyl anion139 (Figure 13b). 
 
Figure 13. Ketimines bearing chiral auxiliaries. 
As far as we know, only two examples of asymmetric catalysis using 2-pyridyl 
ketimines as electrophiles have been described so far. 
In 2014, the group of Sasai and Takizawa reported an enantioselective formal [4+2] 
cycloaddition of N-sulfonyl ketimines with allenoates catalyzed by 20 mol % of a spiro-
type monoaryl phosphine catalyst.140 This transformation proceeds under mild reaction 
conditions to afford a tetrahydropyridine framework with a tetrasubstituted stereogenic 
carbon center in good yield and moderate enantioselectivity (Scheme 44).  
 
Scheme 44. Enantioenriched tetrahydropyridines via organocatalytic cycloaddition. 
                                                 
135
 Chen, Z.; Li, J.; Yuan, C. Synthesis, 2009, 23, 3930–3940. 
136
  Liu, B.; Lu, C.-D. J. Org. Chem. 2011, 76, 4205–4209.  
137
 Kamau, M. G.; Harikrishnan, L. S.; Finlay, H. J.; Qiao, J. X.; Jiang, J.; Poss, M. A.; Salvati, M. E.; Wexler, R. 
R.; Lawrence, R. M. Tetrahedron  2012, 68, 2696–2703.  
138
 Harikrishnan, L. S.; Finlay, H. J.; Qiao, J. X.; Kamau, M. G.; Jiang, J.; Wang, T. C.; Li, J.; Cooper, C. B.; Poss, 
M. A.; Adam, L. P.; Taylor, D. S.; Chen, A. Y. A.; Yin, X.; Sleph, P. G.; Yang, R. Z.; Sitko, D. F.; Galella, M. A.; 
Nirschl, D. S.; Van Kirk, K.; Miller, A. V.; Huang, C. S.; Chang, M.; Chen, X.-Q.; Salvati, M. E.; Wexler, R. R.; 
Lawrence, R. M. J. Med. Chem. 2012, 55, 6162–6175. 
139
 a) Liu, J.; Zhang, L.; Hu, J. Org. Lett. 2008, 10, 5377–5380. b) Liu, J.; Hu, J. Chem. Eur. J. 2010, 16, 11443–
11454. 
140
 Takizawa, S.; Arteaga, F.; Yoshida, Y.; Suzuki, M.; Sasai, H. Asian J. Org. Chem. 2014, 3, 412–415.  
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More recently, the same group reported the organocatalytic nucleophilic 
oxaziridination of N-sulfonyl ketimines with mCPBA promoted by 10 mol % of a basic C3-
symmetric chiral trisimidazoline (Scheme 45).141 Just in one example a 2-pyridyl 
substituent was employed resulting in very good yield and moderate enantioselectivity. 
 
Scheme 45.  
2.1.2. 2-Alkylazaarenes as pronucleophiles 
The α-deprotonation of 2-alkylazaarenes has a remarkable parallelism with the 
enolization of carbonyl compounds (Scheme 46). Though the second process has been 
used in many direct catalytic enantioselective C-C bond forming reactions (aldol, 
Mannich or Michael) (Scheme 46b), the use of 2-alkylazaarenes in analogous processes 
was vaguely explored (Scheme 46a). The principal obstacle in the development of such 
reactions is the lower acidity of 2-alkylazaarenes compared with the parent carbonyl 
compounds.  
 
Scheme 46. α-deprotonation of 2-alkylazaarenes and enolization of carbonyl compounds. 
                                                 
141
 Takizawa, S.; Kishi, K.; Abozeid, M. A.; Murai, K.; Fujioka, H.; Sasai, H. Org. Biomol. Chem. 2016, 14, 761–
767. 
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Despite these difficulties, several non asymmetric methods have been reported for 
the C(sp3)-H functionalization of 2-alkylazaarenes employing transition-metal 
catalysts.142 However, harsh reaction conditions were necessary, such as the use of more 
than stoichiometric amounts of strong bases (K2CO3, NaOtBu, and Cs2CO3), high reaction 
temperatures or microwave irradiation.  
The problems described above have compromised the development of the 
asymmetric version of these reactions and only a few precedents can be found in the 
literature concerning the catalytic enantioselective reactions of 2-alkylazaarenes as 
pronucleophiles. 
In 2008, Trost et al. have applied palladium chiral complexes for the asymmetric allylic 
alkylation of 2-methyl pyridines. Despite the excellents yields an enantioselectivities, 
over stoichiometric amounts of a strong base (LiHMDS, 3.5 equiv.) and a Lewis acid 
(BF3·OEt2, 1.3 equiv.) were required for the reaction to proceed to full conversion, thus 
compromising practicality (Scheme 47).143 
 
Scheme 47. Palladium-catalyzed asymmetric allylic alkylation. 
                                                 
142
 For the palladium-catalyzed direct arylation reaction, see: a) Campeau, L.-C.; Schipper, D. J.; Fagnou, K. 
J. Am. Chem. Soc. 2008, 130, 3266–3267. For the palladium-catalyzed addition to N-sulfonylaldimines, see: 
b) Qian, B.; Guo, S.; Shao, J.; Zhu, Q.; Yang, L.; Xia, C.; Huang, H. J. Am. Chem. Soc. 2010, 132, 3650–3651. 
For the palladium-catalyzed benzylic arylation reaction, see: c) Burton, P. M.; Morris, J. A. Org. Lett. 2010, 
12, 5359–5361. For the scandium-catalyzed addition to N-sulfonylaldimines, see:  d) Qian, B.; Guo, S.; Xia, 
C.; Huang, H. Adv. Synth. Catal. 2010, 352, 3195–3200. For the copper-catalyzed direct Mannich reaction, 
see: e) Rueping, M.; Tolstoluzhsky, N. Org. Lett. 2011, 13, 1095–1097. For the scandium-catalyzed addition 
to enones, see: f) Komai, H.; Yoshino, T.; Matsunaga, S.; Kanai, M. Org. Lett. 2011, 13, 1706–1709. For the 
palladium-catalyzed diarylation, see:  g) Song, G.; Su, Y.; Gong, X.; Han, K.; Li, X. Org. Lett. 2011, 13, 1968–
1971. For the catalyst-free benzylic C–H bond olefination, see: h) Yan, Y.; Xu, K.; Fang, Y.; Wang, Z. J. Org. 
Chem. 2011, 76, 6849–6855. For the ytterbium-catalyzed conjugate addition to methylenemalononitriles, 
see: i) Qian, B.; Shi, D.; Yang, L.; Huang, H. Adv. Synth. Catal. 2012, 354, 2146–2150.  
143
 a) Trost, B. M.; Thaisrivongs, D. A. J. Am. Chem. Soc. 2008, 130, 14092–14093. b) Trost, B. M.; 
Thaisrivongs, D. A. J. Am. Chem. Soc. 2009, 131, 12056–12057. c)  Trost, B. M.; Thaisrivongs, D. A.; Hartwig, 
J. J. Am. Chem. Soc.  2011, 133, 12439–12441. Also, see: d) Hamana, H.; Sugasawa, T. Chem. Lett. 1984, 13, 
1591–1594.   
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Milder conditions have been developed for the α-functionalization of preactivated 
substrates. In 2012, Lam and coworkers described the diastereo- and enantioselective 
Pd(II)-catalyzed additions of 2-alkylazaarenes to N-Boc imines and nitroalkenes (Scheme 
48).144 The incorporation of an EWG in the azaarene ring would further acidify the α-
carbon of the pendant alkyl substituent by stabilization of the conjugate base. The 
reactions are promoted by a chiral Pd(II)-BOX complex where an acetate ligand 
deprotonates the alkylazaarene. High temperature (50 oC) and long reaction times are 
required to perform the reactions in good yields, without compromising the 
estereoselectivity. 
 
Scheme 48.  
In the same year this group developed a similar strategy consisting of the Nickel (II) 
catalyzed Michael addition of activated alkyl azaarenes to nitroolefins.145 In this case, 
the activation of the pronucleophile was made incorporating and EWG in the Cα position 
of the azaarene ring (Scheme 49). It was proposed that the catalyst releases one diamine 
ligand that deprotonates the azaarene substrate to form the reactive enolate. When 
using azaarylacetates excellent enantioselectivities were achieved. However, after 
purification in column chromatography epimerization of the newly generated Cα 
stereocenter (R = CO2R) was observed. On the other hand, azaaryl acetamide products 
were configurationally stable and in these cases very good to excellent 
estereoselectivities were obtained after column chromatography. The presence of 3Å 
molecular sieves was necessary to get excellent ee values. 
                                                 
144
 Best, D.; Kujawa, S.; Lam, H. W. J. Am. Chem. Soc. 2012, 134, 18193–18196.  
145
 Fallan, C.; Lam, H. W. Chem. Eur. J. 2012, 18, 11214–11218.  
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Scheme 49. Asymmetric Michael additions of azaarylacetates and acetamides to nitroalkenes. 
Within the field of aminocatalysis, Melchiorre and coworkers146 reported in 2011 the 
asymmetric Michael addition of nitrobenzyl pyridines to enals via iminium ion activation. 
The reaction proceeded generally in poor diastereoselectivities and very good to 
excellent enantioselectivities for both diastereomers (Scheme 50). 
 
Scheme 50. Asymmetric Michael addition of nitrobenzyl pyridines to enals. 
                                                 
146
 a) Vera, S.; Liu, Y.; Marigo, M.; Escudero-Adán, E.; Melchiorre, P. Synlett  2011, 2011, 489–494. For more 
examples on aminocatalysis, see: b) Li, T.; Zhu, J.; Wu, D.; Li, X.; Wang, S.; Li, H.; Li, J.; Wang, W. Chem. Eur. 
J.  2013, 19, 9147–9150. c) Meazza, M.; Ceban, V.; Pitak, M. B.; Coles, S. J.; Ríos, R. Chem. Eur, J. 2014, 20, 
16853−16857. d) Meazza, M.; Potter, M.; Pitak, M. B.; Coles, S. J.; Mazzanti, A.; Ríos, R. Eur. J. Chem. 2017, 
719−725.  For related reactions involving 2-alkylarenes, see: e) Cid, M. B.; Duce, S.; Morales, S.; Rodrigo, E.; 
García-Ruano, J. L. Org. Lett. 2010, 12, 3586–3589. f) Duce, S.; Jorge, M.; Alonso, I.; García-Ruano, J. L.; Cid, 
M. B. Eur. J. Org. Chem. 2013, 7067−7075. g) Dell’Amico, L.; Companyó, X.; Naicher, T.; Bräuer, T. M.; 
Jørgensen, K. A. Eur. J. Org. Chem. 2013, 5262−5265. 
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Last year and after our work on this subject, Jørgensen´s research group147 described a 
synergistic estereoselective functionalization of unactivated alkyl quinolines with α,β-
unsaturated aldehydes combining a synergistic metal catalysis with organocatalytic 
activation. The reaction required neither pre-activated alkyl quinoline substrates with 
electron-withdrawing substituents nor highly activated electrophiles (Scheme 51).  
 
Scheme 51. Estereoselective functionalization of unactivated alkyl quinolines. 
As far as we know, at that time, there were no more examples on the use of 2-alkyl 
azaarenes as nucleophiles for the asymmetric formation of C-C bonds. 
Despite the fact that the addition of 2-alkylazaarenes to different electrophiles has 
been carried out with more or less success, the methods displayed above present some 
limitations:  
1. If the alkyl azaarene is not activated, more than stoichiometric amounts of a 
strong base are needed. 
                                                 
147
 a) Meazza, M.; Tur, F.; Hammer, N.; Jørgensen K. A. Angew. Chem. Int. Ed. 2017, 56, 1634–1638. For a 
highly enantioselective metallation-substitution α to a chiral nitrile, see: b) Sadhukan, A.; Hobbs, M. C.; 
Meijer, A. J. H. M.; Coldham, I. Chem. Sci. 2017, 8, 1436−1441. For a SN1-type alkylation of N-
heteroaromatics with alcohols, see: c) Xiao, M.; Ren, D.; Xu, L.; Li, S.-S.; Yu, L.; Xiao, J. Org. Lett. 2017, 19, 
5724–5727. For catalytic direct-type 1,4-addition reactions of alkylazaarenes, see: d) Suzuki, H.; Igarashi, 
R.; Yamashita, Y.; Kobayashi, S. Angew. Chem. Int. Ed. 2017, 56, 4520–4524. e) Lee, K. N.; Lei, Z.; Ngai, M.-
Y. J. Am. Chem. Soc. 2017, 139, 5003–5006. For the yttrium-catalyzed C(sp
3
)-H asymmetric addition of 2-
methyl azaarenes to cyclopropenes getting Cβ sereocenter, see: f) Luo, Y.; Teng, H.-L.; Nishiura, M.; Hou, 
Z. Angew. Chem. Int. Ed., 2017, 56, 9207–9210. For the racemic addition of alkylpyridines to styrenes using 
potassium bis(trimethylsilyl)amide as a strong base, see: g) Zhai, D.; Zhang, X.; Liu, Y.; Zheng, L.; Guan, B. 
Angew. Chem. Int. Ed., 2018, 57, 1650–1653. 
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2. The use of preactivated substrates: EWG in either the azaarene ring or the Cα 
or both positions is needed.  
3. None of these methods address the generation of a quaternary Cα-
stereocenter, an issue of general importance in organic synthesis, and of 
particular significance to the present context given the interest of quaternary 
compounds as potential pharmacophores. 
2.2.  Michael addition of 2-(cyanomethyl)azaarenes to α’-hydroxy enones 
2.2.1. Working hypothesis and synthetic plan 
As mentioned above, due to the lack of methods in the literature to generate a 
quaternary α-stereocenter using 2-alkylazaarenes as nucleophiles, this work was focused 
on the study of the enantioselective α-functionalization of o-substituted azaarenes via 
mild enolization conditions.  
We envisioned that the 2-cyanoalkylpyridine could be good candidate to be 
deprotonated under Brønsted base catalysis, due to the incorporation of two EWG 
groups (nitrile and phenyl) in the Cα position of the azaarene, and be added to different 
electrophiles (Scheme 52). 
 
Scheme 52. Proposed reaction for the investigation. 
In 2014, our group148 reported the first organocatalytic Brønsted based Michael 
addition of a range of enolizable heterocycles (α-subtituted 2-oxindoles, cyanoesters, 
oxazolones, thiazolones and azlactones) to α’-oxyenones as enabling Michael acceptors 
with ambivalent H-bond acceptor/donor character, creating a tetrasubstituted carbon 
stereocenter with excellent yields and selectivities (Scheme 53).  
                                                 
148
 a) Badiola, E.; Fiser, B.; Gomez-Bengoa, E.; Mielgo, A.; Olaizola, I.; Urruzuno, I.; García, J. M.; Odriozola, 
J. M.; Razkin, J.; Oiarbide, M.; Palomo. C. J. Am. Chem. Soc. 2014, 136, 17869–17881. For a review on the 
use of α‘-hydroxy enones in asymmetric synthesis, see: b) Palomo, C.; Oiarbide, M.; García, J. M. Chem. 
Soc. Rev. 2012, 41, 4150–4164. 
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Scheme 53.  
These electrophiles exhibit higher reactivity than most acrylate surrogates (e.g. methyl 
vinyl ketone (MVK)) favored by a lower HOMO-LUMO energy gap, due to the 
intramolecular interactions between the carbonyl and the hydroxyl (1a) or silyloxy group 
(1b) (Figure 14).  
 
Figure 14. Intramolecular interactions between the carbonyl and the hydroxyl or silyloxy group. 
 Moreover, the interest in this family of Michael acceptors comes from the synthetic 
potential of their adducts, since several functional groups , such as aldehydes, carboxylic 
acids and ketones can be accessed by simple elaboration processes (Scheme 54). 
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Scheme 54. Readily accessible functional groups via ketol scission. 
On these basis, the reaction of 2-phenyl-2-(2-pyridyl)acetonitrile 4, and α´-
hydroxyenones 1a-b was elected for evaluation under the presence of several BB 
catalysts (Scheme 55). 
 
Scheme 55.  
2.2.2. Results and discussion 
Compound 4 was prepared in good yield through a SNAr reaction between 2-phenyl-
ethanenitrile 2 and 2-bromo pyridine 3 in the presence of KOH in DMSO keeping the 
reaction temperature at 70 oC for 4 h (Scheme 56).149   
 
Scheme 56. Synthesis of 4. 
α´-Hydroxy enone 1a was prepared in high yield from commercially available 3-
hydroxy-3-methyl-2-butanone via aldol addition/elimination reaction sequence  
(Scheme 57).150 Enone 1a was silylated, via TMSOTf, mixing with 3-(trimethylsilyl)-2-
oxazolidinone (TMSO) and catalytic amounts of trifluoroacetic acid at room temperature 
                                                 
149
 Kawano, T.; Kurimoto, M.; Hatanaka, M.; Ueda, I. Chem. Pharm. Bull. 1992, 40, 3067–3071. 
150
 Adapted from: Bugarin, A.; Jones, K. D.; Connell, B. T. Chem. Commun. 2010, 46, 1715−1717. 
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under neat conditions.151 The desired α’-silyloxy enone 1b was obtained in excellent 
yield after column chromatography. 
 
Scheme 57. Synthesis of α´-hydroxy enone 1a and α’-silyloxy enone 1b. 
After having the starting materials in hand, our study began with the evaluation of 
several bifunctional catalysts (Brønsted base/H bond donor) for the addition of 2-
phenyl-2-(2-pyridyl)acetonitrile 4 to α’-hydroxy enone 1a (Table 1). First, quinine was 
tested for the reaction in dichloromethane at 0 oC with a 20 mol % catalyst loading, 
rendering poor conversion after 96 h. Similar conversion was obtained with bifunctional 
squaramide C1, improving it slightly at 40 oC but with poor enantioselectivity (10% ee). 
Thiourea-based catalyst C2 rendered better conversion, but still with poor 
enantioselectivity (33% ee).  
Table 1. Catalyst screening for the Michael addition of 4 to 1a.
[a]
 
 
[a] Reaction conditions: 4 (1 equiv., 0.2 mmol), 1a (3 equiv., 0.6 mmol), catalyst (20 mol %) were 
stirred at room temperature for 96 h in CH2Cl2. The reactions were performed on a 0.2 mmol scale. 
ee’s determined by HPLC:  chiralpak IC column, eluent Hex/iPr 90:10 f = 0.5 mL/min. 
At this point, to increase the low reactivity of the nucleophile we decided to activate it 
by using the pyridine oxide 6a (Scheme 57a). On the one side, it is well known that the 
                                                 
151
 Adapted from: Aizpurua, J. M.; Palomo, C., Palomo, A. L. Can. J. Chem. 1984, 62, 336−340. 
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oxidation of the pyridine increases the acidity of the Cα (Scheme 57b)152 and in the other 
side, the N→O group could work as another strong coordinating site for catalyst 
binding.153 As far as we know azaarene N-oxides have not been investigated within the 
context of asymmetric C(sp3)_H functionalizations.154 
 
Scheme 58. 
155
 
A reasonable approach to obtain the desired product was the direct oxidation of 2-
cyanomethylpyridine 4 in the presence of meta-chloroperoxybenzoic acid (mCPBA) 
oxidant. Unfortunately, the desired compound was not observed, obtaining only the 
benzoylpyridine N-oxide as a white solid in very good yield (Scheme 59).156 
 
Scheme 59. Direct oxidation of 2-cyanomethylpyridine 2 with mCPBA. 
Taking this result into account, the problem was solved performing the reaction of 2-
phenyl-ethanenitrile 2 and 2-bromo pyridine N-oxide 8 in the presence of potassium 
                                                 
152
 2-Alkylpyridine N-oxides are more acidic than the parent 2-alkylpyridines in about 3–4 pKa units in 
DMSO: a) Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456−463. b) 
http://www.chem.wisc.edu/areas/reich/pkatable/. c) Evans pKa table: 
http://evans.rc.fas.harvard.edu/pdf/evans_pKa_table.pdf/.  
153
 The oxygen atom in the N-oxide has stronger dipole than the oxygen atoms of other common oxo 
donor such as alcohols, ethers, and amides. a) Karayannis, N. M. Coord. Chem. Rev. 1973, 11, 93−159. b) 
Chelucci, G.; Murineddu, G.; Pinna, G. A. Tetrahedon: Asymmetry 2004, 15, 1373−1389. c) Malkov, A. V.; 
Kočoskçý, P. Eur. J. Org. Chem. 2007, 2007, 29−36. d) Liu, X.; Lin, L.; Feng, X. Acc. Chem. Res. 2011, 44, 
574−587. e) Desimoni, G.; Faita, G.; Quadrelli, P. Chem. Rev. 2014, 114, 6081−6129. 
154
 Use of pyridine N-oxides has been mainly applied to the activation of the pyridine core, see: a) Bull, J. 
A.; Mousseau, J. J.; Pelletier, G.; Charrette, A. B. Chem. Rev. 2012, 112, 2642–2713.  b) Yan, G.; Borah, A. J.; 
Yang, M. Adv. Synth. Catal. 2014, 356, 2375−2394. c) Wang, Y.; Zhang, L. Synthesis 2015, 47, 289–305. For 
an N-oxide-assisted α-C(sp
3
)-trifluoromethylation of (mainly) o-methyl pyridines, see: d) Kuninobu, Y.; 
Nagase, M.; Kanai, M. Angew. Chem. Int. Ed. 2015, 54, 10263−10266. For palladium-catalyzed Cα-arylation 
of 2-methyl azine N-oxides, see: e) Campeau, L.-C.; Schipper, D. J.; Fagnou, K. J. Am. Chem. Soc. 2008, 130, 
3266−3267. f) Schipper, D. J.; Campeau, L.-C.; Fagnou, K. Tetrahedron 2009, 65, 3155−3164. 
155
 Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456–463.  
156
 For a plausible mechanism for this transformation, see: a) Brünjes, M; Ford, M. J.; Dietrich H.; Wlison, 
K. Synlett 2015, 26, 1365–1370. For a recent synthesis of benzoylpyridine N-oxide, see: b) Sterckx, H.; 
Sambiagio, C.; Médran-Navarrete, V. Adv. Synth. Catal. 2017, 359, 3226–3236.  
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tert-butoxide at room temperature for 4 h. The desired product 6a was obtained in 90% 
yield (Scheme 60).149 
 
Scheme 60.  Synthesis of 6a. 
In order to check the reactivity of the new pronucleophile, the same catalysts 
employed before were evaluated (Table 2). As expected, N-oxide 6a showed greater 
reactivity than 4. Using quinine as catalyst a 72% conversion and 22% ee were reached 
after 2 days at ambient temperature. With catalyst C1 same conversion was obtained at 
room temperature, but the enantioselectivity increased significantly to 88% ee. Reaction 
conversion was improved to 92% increasing the temperature to 40 oC, however 
enantioselectivity dropped to 75%. Finally, changing the squaramide moiety for the 
thiourea moiety C2 did not perform well and lower conversion (60%) and 
enantioselectivity (17% ee) were obtained.157  
 
 
 
 
 
 
 
 
 
 
                                                 
157
 When using monofunctional Brønsted bases such as (DHQD)2PYR and (DHQD)2PHAL, no reaction was 
observed. 
Chapter 2 
62 
 
Table 2. Catalyst screening for the Michael addition of 2-(cyano(phenyl)methyl)pyridine 1-oxide 6a to α’-
hydroxyenone 1a.
[a]
 
 
 
[a] Reaction conditions: 6a (1 equiv., 0.2 mmol), 1a (3 equiv., 0.6 mmol), catalyst (20 mol %) were 
stirred at room temperature for 48 h in CH2Cl2. The reactions were performed on a 0.2 mmol scale. 
ee’s determined by HPLC: chiralpak AD-H column, eluent Hex/EtOH 50:50 f = 0.5 mL/min. 
In its turn, when α’-trimethylsilyloxy enone 1b was employed under best reaction 
condition for 1a (cat. C1 20 mol %, r.t., 48 h) low conversion (50%) of the substrate was 
achieved even after prolonged reaction time (196 h, r.t., 60% conversion). Enantiomeric 
excess was not calculated due to the low conversion of the reaction (Table 3).  
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Table 3. Catalyst screening for the Michael addition of 6a to 1b. 
 
After these rather disappointing results, we decided to focus in a way to improve both 
the conversion and the enantiocontrol of the reaction and the design of new catalyst 
with additional sites for substrate interactions was pursued.  
To this end, we were inspired by work by Hashimoto on the enantioselective allylation 
of aldehydes with allyltrichlorosilanes involving chiral azaarene N-oxide catalyst.158  They 
suggested that the allylations of aromatic and unsaturated aldehydes mediated by (S)-
3,3´-dimethyl-2,2´-biquinoline N,N´-dioxide proceed via cyclic chairlike transition 
structures, involving hypervalent silicates where one of a pair of N-oxide moieties 
occupies an axial position (Scheme 61).  
                                                 
158
 a) Nakajima, M.; Saito, M.; Shiro, M.; Hashimoto, S.-I. J. Am. Chem. Soc. 1998, 120, 6419–6420. For a 
similar activation pathways, see: b) Tao, B.; Lo, M.-C.; Fu, G. C. J. Am. Chem. Soc. 2001, 123, 353–354. c) 
Denmark, S. E.; Fan, Y. J. Am. Chem. Soc. 2002, 124, 4233–4235. d) Malkov, A. V.; Herrmann, P.; Meghani, 
P.; Kočovský, P. J. Org. Chem. 2003, 68, 9659–9668. e) Denmark, S. E.; Fan, Y.; Eastgate, M. D. J. Org. 
Chem. 2005, 70, 5235–5248. f) Chen, J.; Captain, B.; Takenaka, N. Org. Lett. 2011, 13, 1654–1657.  
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Scheme 61.  
Feng´s group developed an enantioselective cyanation of carbonyl compounds and 
imines utilizing trimethylsilylcyanide (TMSCN) as a nucleophile.159 The reactions were 
catalyzed by L-proline or L-piperidinamide based N,N´-dioxides activating cooperatively 
both TMSCN and the electrophile. The possible mechanism consists in generation of a 
hypervalent silicon intermediate from the bidentate N,N´-dioxide which enhances both 
the nucleophilicity of the cyano group and the rigidity of the reaction environment. 
Then, the electrophile, which is activated by the hydrogen bond of a nearby amide, is 
attacked by the cyano group (Scheme 62).  
                                                 
159
 a) Wen, Y.; Huang, X.; Huang, J.; Xiong, Y.; Qin, B.; Feng, X. Synlett 2005, 16, 2445–2448. b) Huang, J.; 
Liu, X.; Wen, Y.; Qin, B.; Feng, X.; V, S. U. J. Org. Chem. 2007, 72, 204–208. c) Qin, B.; Liu, X.; Shi, J.; Zheng, 
K.; Zhao, H.; Feng, X. J. Org. Chem. 2007, 72, 2374–2378. d) For a review on chiral N,N’-dioxides: new 
ligands and organocatalysts for catalytic asymmetric reactions, see: Liu, X.; Lin, L.; Feng, X. Acc. Chem. Res. 
2011, 44, 574–587. For the proline-based N-oxides as chiral catalysts in the enantioselective reactions with 
aldehydes, see: e) Traverse, J. F.; Zhao, Y.; Hoveyda, A. H.; Snapper, M. L. Org. Lett. 2005, 7, 3151–3154. 
 
 
2-(Cyanomethyl)azaarene N-Oxides 
 
65 
 
 
Scheme 62.  
Taking these works into account and given the high chemical affinity of silicon for 
oxygen, we envisioned a multifunctional catalyst based on N-oxide/silicon interactions 
as a suitable candidate to carry out satisfactorily the reaction (Figure 15). 
 
Figure 15. New design for the multifunctional squaramide-based Brønsted base catalyst. 
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The proposed general synthetic sequence for these catalysts is outlined in Scheme 63. 
The sequence involves the amination of the corresponding (chloromethyl)silyl derivative 
in a two steps sequence; first the synthesis of the azide by treatment of the alkyl 
chloride with 1.1 equivalents of NaN3 in HMPA at room temperature
160 and second, the 
addition of the azide to a suspension of LiAlH4 (1 equivalent) in dry Et2O at 0 
oC to obtain 
the amine.161 The coupling between the 3,4-dimethoxy-3-cyclobutene-1,2-diene and the 
amine was performed in MeOH at room temperature and, finally, the coupling of the 
second amino group containing the corresponding Brønsted base was performed also in 
MeOH at room temperature for 16 h. Using these reaction sequence, changing 
substituent at the silicon moiety and the Brønsted base, a series of new multifunctional 
catalysts were synthetized. Yield of different steps are summarized in Table 4. 
 
Scheme 63. Squaramide-based Brønsted base catalyst preparation. 
 
 
 
 
 
 
                                                 
160
 Otohiko, T.; Shuji, K.; Koyo, M. Chem. Lett. 1983, 7, 1131–1134.  
161
 Lettelier, M.; McPhee, D. J.; Griller, D. Synth. Commun. 1988, 18, 1975–1978. 
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Table 4. Yield by stages in the preparation of catalysts. 
 
Entry  Step 1 (%)[a] Step 2 (%) Step 3 (%) 
1 C3 --[b] 83 45 
2 C4 --[b] 83 68 
3 C5 90 70 70 
4 C6 80 70 75 
5 C7 81 90 60 
6 C8 84 85 67 
[a] Yield of the product after the SN2 and the reductive steps. [b] This 
intermediate is commercially available and was purchased. 
2.2.2.1. Catalysts screening 
Gratifyingly, we observed that catalyst C4 led to a full conversion in just 20 h at 40 oC 
and with high selectivity (90% ee). However, the conversion and selectivity dropped 
significantly after replacing the aminoquinine group in C4 with the 1,2-
diaminocyclohexane scaffold (C3, 83% conv., 58% ee). Then, we explored the effect of 
the bulkiness of the silyl group on the selectivity. For example, increasing the Lewis 
acidity and the bulkiness of the silyl group changing the methyl group of the silyl moiety 
for the phenyl group (C5), excellent enantioselectivity was achieved (92% ee) with full 
conversion after 64 h at room temperature.162 Nevertheless, a further increase of the 
size of the silyl site did not improve the enantioselectivity but it made it worse C6-C8. 
The use of more coordinating solvent as THF provided poorer results than the one 
obtained with DCM, just 14% ee was obtained after 48 h. In this case, solvent might 
interact with the catalyst, hindering coordination with the nucleophile. 
 
 
 
                                                 
162
 No reaction was observed using silylated enone 1b and C5 as catalyst at 40 
o
C for 24 h. 
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Table 5. Catalyst screening for the Michael addition of 6a to 1a.
[a]
 
[a] Reaction conditions: 6a (1 equiv., 0.2 mmol), 1a (3 equiv., 0.6 mmol), catalyst (20 mol %) were stirred 
in CH2Cl2. The reactions were performed on a 0.2 mmol scale. ee’s determined by HPLC: chiralpak AD-H 
column, eluent Hex/EtOH 50:50 f = 0.5 mL/min. [b] Using THF as a solvent had not positive effect on 
enantiomeric excess. 
 Thus, the optimal reaction conditions for the addition of 2-
(cyano(phenyl)methyl)pyridine 1-oxide 6a to the α’-hydroxyenone 1a (3 equiv.) included 
the presence of catalyst C5 at room temperature using dichloromethane as a solvent. 
2.2.2.2. Synthesis of α-substituted 2-(cyanomethyl)azaarene N-oxides  
With the best conditions found for the catalytic enantioselective Michael addition 
reaction, we continued with the preparation of the substrates for the study of the 
reaction scope.  
The same procedure used in the synthesis of the substrate 6a was followed for the 
preparation of adducts 6, 10, 11 and 12 in general obtaining very good yields. In the case 
of benzyl cyanides bearing strong EWGs, reaction was carried out at –40 oC to avoid 
decomposition of the substrate.  
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Table 6. Synthesis of adducts 6, 10, 11 and 12. 
 
Entry  R1 R2 X Y T(oC) Yield (%) 
1 6a H H CH 2-Br r.t. 90 
2 6b 6-Br H CH 2-Br r.t. 71 
3 6c 5-Me H CH 2-Br r.t. 70 
4 6d 5-Cl H CH 2-Br r.t. 68 
5 6e H 4-Me CH 2-Br r.t. 84 
6 6f H 4-Br CH 2-Br r.t. 88 
7 6g H 3-thiophene CH 2-Br _40 60 
8 6h H 4-OMe CH 2-Br r.t. 71 
9 6i H 4-CF3 CH 2-Br 
_40 56 
10 6j H 4-CO2Me CH 2-Br 
_40 80 
11 6k 5-Cl 4-Me CH 2-Br r.t. 83 
12 6l 6-Br 4-CF3 CH 2-Br 
_40 84 
13 10a H H N 2-Cl r.t. 87 
14 10b 6-Cl H N 2-Cl r.t. 50 
15 10c H 4-Br N 2-Cl r.t. 81 
16 11 H H CH 3-Br r.t. 70 
17 12 H H CH 4-Cl r.t. 65 
The 2-(α-cyanoalkyl)pyridine N-oxides 13a-d were prepared from 2-
(cyanomethyl)pyridine 1-oxide and the corresponding alkyl halide in the presence of 
potassium tert-butoxide using THF as a solvent. The desired products were isolated in 
good yields; adduct 13a (35% yield) being an exception (Table 7). 
Table 7. Synthesis of adducts 13a-d. 
 
 
 
                                          [a] Yield of isolated product. 
Entry  R X Yield (%)[a] 
1 13a Me I 35 
2 13b Ph Br 70 
3 13c 4-CF3C6H4 Br 74 
4 13d 4-ClC6H4 Br 71 
Chapter 2 
70 
 
Several attempts were made for the synthesis of 2-(cyano(phenyl)methyl)quinoline 1-
oxide 15 without any success. Under conditions employed for the synthesis of 6, 10, 11 
and 12, decomposition of the starting product 14 was observed. It was also observed 
that lower temperatures and different solvents, lead to the appearance of several by-
products in the reaction mixture of which only benzyl cyanide 2 could be identified. 
 
Scheme 64.  
2.2.2.3. Reaction scope 
Once the starting products were prepared, the scope and limitation of the system 
were investigated. As results in Table 8 show, it was found that the reaction tolerated 
well pyridine N-oxides with both electron-releasing and withdrawing groups attached at 
different positions of the pyridine ring (9b-d). Similarly, substrates bearing both 
electron-rich and -poor aryl substituents at Cα (9e-j) were equally effective in providing 
the corresponding addition adducts in generally very good yield and high 
enantioselectivity. Pyridine N-oxides with substituents in both pyridine ring and Cα also 
worked well, without compromising the yield or the stereocontrol of the reaction. It was 
found that 2-(cyanomethyl)pyridine N-oxides bearing electron-withdrawing groups (6b, 
6d, 6f, 6g, 6i, 6j and 6l) were more reactive than those with electron-releasing groups 
(6c, 6e, 6k) and in these cases full conversions were reached with lower temperatures. 
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Table 8. Scope of the reaction of α-substituted 2-(cyanomethyl)pyridine N-oxides 6a-l with 1a catalyzed by 
C5
[a]
 
 [a] Reactions conducted on a 0.2 mmol scale in 1 mL CH2Cl2 (molar ratio of 6/1a/catalyst 1:3:0.1). Yields 
of isolated product. Enantioselectivity determined by HPLC analysis using a chiral stationary phase. [b] 20 
mol % of C5 was used. 
The 2-cyanomethylpyrazines 10a-c showed to be compatively more reactive, so lower 
reaction temperatures could be applied (–10 oC or –30 oC) in order to improve the 
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results. The quaternary α,α-diaryl acetonitriles 16a-c were obtained in good yields, but 
somewhat lower enantioselectivities. 
Table 9. Scope of the reaction of α-substituted 2-(cyanomethyl)pyrazine N-oxides 10a-c with 1a catalyzed 
by C5.
[a]
 
 
[a] Reactions conducted on a 0.2 mmol scale in 1 mL CH2Cl2 (molar ratio of 10/1a/catalyst 
1:3:0.1). Yields of isolated product. Enantioselectivity determined by HPLC analysis using a 
chiral stationary phase. 
As we expected, the method was less efficient with the corresponding α-alkyl 
substituted 2-(cyanomethyl)azaarene N-oxides 13a-d (Table 10). For instance, 17a, with 
an ethyl substituent, led to only 33% conversion at 40 oC after 72 h. On the other side, 
better conversions were achieved when the substituent is benzyl. For instance, 
conversion of 70% and 80% ee was obtained for adduct 17b. Electron-withdrawing 
subtituent in the benzyl group did not improve conversions or enantioselectivities (17c 
and 17d). 
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Table 10. Scope of the reaction of α-substituted 2-(cyanomethyl)azaarene N-oxides with 1a catalyzed by 
C5.
[a]
 
 
[a] Reactions conducted on a 0.2 mmol scale in 1 mL CH2Cl2 (molar ratio of 13/1a/catalyst 
1:3:0.1). Yields of isolated product. Enantioselectivity determined by HPLC analysis using a 
chiral stationary phase.  
Apart from their suitability in C-C bond forming reaction, it was subsequently proven 
by Iñaki Bastida that these 2-cyanomethylpyridine N-oxides may also work as enabling 
substrates for stereoselective α-heterofunctionalization reactions under conditions 
similar to those mentioned above.163 For example, pyridine N-oxides 6 reacted with both 
di(tert-butyl) and dibenzyl azodicarboxylate in the presence of 10 mol % of the bulkiest 
catalyst C8 to afford the corresponding α-aminated adducts in yields and 
enantioselectivities from very good to excellent (Scheme 65).  
 
                                                 
163
 For more information, see: Izquierdo,  J.; Landa, A.; Bastida, I.; López, R.; Oiarbide, M.; Palomo, C. J. Am. 
Chem. Soc. 2016, 138, 3282–3285. 
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Scheme 65. Extension of the catalytic system to the α-amination reaction. 
2.2.2.4. Elaboration of adducts 
The next aspect that we explored was the modification of the reaction products. For 
instance, reduction of the N-oxide group on adduct 9a by treatment with (Bpin)2
164 
afforded pyridine 18 in 74% isolated yield and unaltered enantioselectivity (92% ee, 
Scheme 66).  
 
Scheme 66. Reduction of the N-oxide group on adduct 9a. 
As we mentioned in the introductory part, the high versatility of the oxyenone moiety 
allows the access to several functional groups. 
For instance, oxidative cleavage of the ketol moiety in adduct 18 employing NaIO4 in a 
mixture of MeOH/H2O at room temperature afforded carboxylic acid 19 in excellent 
yield (Scheme 67). 
                                                 
164
 Kokatla, H. P.; Thomson, P. F.; Bae, S.; Doddi, V. R.; Lakshman, M. K. J. Org. Chem. 2011, 76, 7842−7848. 
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Scheme 67.  
Aldehyde derivative 20 was obtained straightly from 18 through reduction of the 
carbonyl moiety with BH3·THF in THF at 0 
oC and subsequent oxidation of the resulting 
diol using sodium periodate in very good overall yield (Scheme 68). 
 
Scheme 68.  
Finally, access to ketone 21 required first nucleophilic methylation of 18 using 
MeMgBr in THF at 0 oC and then the oxidative cleavage employing sodium periodate. 
Under these conditions, the desired ketone was afforded in high yield (90%, after 2 
steps) without the loss of enantiopurity (Scheme 69). 
 
Scheme 69.  
The feasibility of the ketol moiety for several manifold elaboration pathways is of 
particular interest in that the direct conjugate addition of azaarene N-oxide 6a to simple 
enones, i.e. methyl vinyl ketone, or unsaturated esters, i.e. methyl acrylate, did not work 
under the present catalytic conditions. In addition, the reaction of 6a with acrolein 
afforded the corresponding 1,4-addition adduct, but with  only 14% ee (Scheme 70). 
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Scheme 70.  
Another illustration of the synthetic versatility of adducts is shown by transformation 
of the nitrile carboxylic acid 19 into the protected amine 22 in two steps (Scheme 71); 
firstly the isocyanate is formed throughout Curtius rearrangement and secondly the 
isocyanate undergoes attack of the alcohol. On the other side, amide 23 was obtained in 
excellent yield from 19 in the presence of concentrated H2SO4 at room temperature. 
These molecules have a structural resemblance with disopyramide, an antiarrhythic 
medication used in the treatment of ventricular tachycardia. 
 
Scheme 71.  
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Crystallization of adduct 9a allowed the determination of its absolute configuration by 
a single-crystal X-ray analysis (Figure 16). Configuration of the rest of adducts was 
established by assuming the uniformity of the reaction mechanism. 
 
Figure 16. ORTEP diagram of compound 9a. 
The detailed mechanism of these catalytic transformations as well as the precise role 
played by each element involved remains unsolved yet. However, data in Figure 17 
indicate that the N-oxide group and its ortho-relationship to the cyanoalkyl substituent 
are key for optimal reaction outcome. As a general trend, for the three positional 
isomers ortho, meta and para, the corresponding pyridine N-oxide was more reactive 
than the parent pyridine in both the catalyzed and uncatalyzed reactions. In fact, among 
the six experiments involving cyanoalkylpyridines, only that using p-cyanoalkylpyridine in 
the presence of C5 provided practical conversion after 24 h, leading to racemic product. 
Equally important is the position of the N-oxide group relative to the cyanoalkyl 
substituent on the ring. Among the three cyanoalkylpyridine N-oxides, the meta and 
para isomers proved to be inherently more reactive than the ortho isomer, also in the 
presence of catatalyst C5, although both led to essentially racemic product. In contrast, 
the ortho isomer led to 92% ee. 
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Figure 17. Conversion after 24 h for the reactions of 1a with o-, m-, and p- substituted cyanoalkylpyidine 
N-oxides. 
In order to establish the possible interactions between the catalyst and the substrates 
1H NMR spectra were recorded for compounds 4, 6a and 12 in the presence/absence of 
1 mmol equiv. of C5, respectively (Figure 18). As the insets in Figure 18 show (starred 
peaks), the singlet corresponding to the benzylic proton of pyridine N-oxide 6a at 6.12 
ppm (inset B) split into two peaks upon addition of C5 (inset C), while an upfield 
shielding of 0.14 ppm is observed. This large effect suggests that because of the strong 
interaction between catalyst C5 and N-oxide 6a, the two possible diastereomers created 
are distinguishable. On the contrary, the singlet at 5.30 ppm, corresponding to the 
benzylic proton of 4 (inset D), remained essentially unchanged after admixing with C5 
(inset E). Similarly, the spectrum of the p-substituted pyridine N-oxide 12 experienced 
no appreciable variation upon admixing with C5 (insets F and G). 
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Figure 18. Insets (3.8–6.4 ppm) of 
1
H NMR spectra taken in CDCl3 (0.1 M, 300 MHz) at r.t. 
 
On the other hand, to study the influence of the silicon group 1H NMR spectra were 
recorded for compound 6a in the presence/absence of 1 mmol equiv. of C5 and C9 
respectively (Figure 19). The singlet corresponding to the benzylic proton of pyridine N-
oxide 6a at 6.12 ppm remained almost unchanged in the presence of catalyst C9 (inset I), 
suggesting a weaker interaction between 6a and C9 compared to a catalyst containing a 
Si group (C5). Furthermore, lower enantioselectivity was obtained with catalyst C9 (84% 
ee), meaning that the incorporation of silicon to the catalyst is necessary in order to 
obtain enantioselectivities higher than 90%. 
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Figure 19. Insets (3.8
_
6.4 ppm) of 
1
H NMR spectra taken in CDCl3 (0.1 M, 300 MHz) at r.t. 
After this work, our group reported the ureidopeptide derived Brønsted base165 
catalyzed stereoselective α-functionalization of 2-azaaryl acetates N-oxide with N-Boc 
Imines (Scheme 73).166 The presence of N-oxide functionality was necessary to obtain 
reactivity and excellent selectivity and unlike Lam’s work,145 no epimerization at the Cα 
position was observed after column chromatography. 
                                                 
165
 Diosdado, S.; Etxabe, J.; Izquierdo, J.; Landa, A.; Mielgo, A.; Olaizola, I.; López, R.; Palomo, C. Angew. 
Chem. Int. Ed.  2013, 52, 11846–11851.  
166
 Bastida, I.; San Segundo, M.; López, R.; Palomo, C. Chem. Eur. J. 2017, 23, 13332–13336. 
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Scheme 73. Stereoselective α-functionalization of 2-azaaryl acetates with N-Boc imines. 
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3. Template based enantioselective synthesis of α-quaternary 
hydantoins 
3.1. Introduction 
Chiral heterocyclic structural skeletons are prevalent in natural products or bioactive 
substances.167 In many cases, a heteroatom is attached to the quaternary α C(sp3) 
position of a carbonyl moiety (Figure 20). Not unexpectedly, the type and extend of 
activity of these chiral compounds depend, among other things, on the configuration of 
this stereocenter. 
 
Figure 20. 
168
 
The development of new synthetic methodologies to access these targets in a 
stereochemically controlled manner is undoubtedly appealing in organic and medicinal 
chemistry. As mentioned in the general introduction, many efforts have been devoted to 
the search of new active methylenes with a defined structure that can be easily 
deprotonated and be used in the synthesis of biologically active compounds. One of the 
strategies for the generation of five member heterocycles with tetrasubstituted carbon 
stereocenters is the use of α-enolizable lactam or (thio)lactone-based heterocycles as 
pronucleophiles (Figure 21).  
                                                 
167
 Heterocycles in Natural Product Synthesis (Majumdar, K. C. & Chattopadhyay, S. K. ed., Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim, Germany) 2011. 
168
 For the first total synthesis of (-)-apaminal, see: a) Smith III, A. B.; Liu, Z. Org. Lett. 2008, 10, 4363–4365. 
For the aminocatalyzed synthesis of biyouyanagin A, see: b) For the total synthesis of (+)-gentiollactone, 
see: Kakuda, R.; Machida, K.; Yaoita, Y.; Kikuchi, M.; Kikuchi, M. Chem. Pharm. Bull. 2003, 51, 885–887. c) 
Nicolaou, K. C.; Sarlah, D.; Shaw, D. M. Angew. Chem. Int. Ed.  2007, 46, 4708–4711.   
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Figure 21. Selection of heterocyclic pronucleophiles employed in organocatalysis.
169170171
 
These heterocycles exhibit very interesting features; i) easy deprotonation under mild 
enolization conditions due to formation of an aromatic enolate (except for rhodanines); 
ii) the geometry of the resulting starting enolate or equivalent is fixed due to their cyclic 
nature, thus facilitating the control of the stereoselectivity; iii) they are substituted at 
the α-position of the carbonyl (R1 ≠ H) and therefore, after reaction with an electrophile, 
a tetrasubstituted stereocenter is created, iv) they have the potential to convert racemic 
starting materials to a single highly enantioenriched final products (enantioconvergent 
catalysis)172 and v) all of them can be opened under appropriate conditions to afford α-
mercapto, α-hydroxy and α-amino acid derivatives with a tetrasubstituted stereocenter.  
In the last years, these pronucleophiles have been employed with success in catalytic 
enantioselective addition to a large number of electrophiles and therefore only selected 
contributions will be presented here. 
3.1.1. Azlactones (Oxazol-5(4H)-ones) 
The azlactone scaffolds have been utilized in a diversity of transformations due to its 
dual behavior, meaning that can be used as both nucleophiles and electrophiles. This 
                                                 
169
 For reviews, see: a) Lesyk, R.; Zimenkovsky, B. Curr. Org. Chem.  2004, 8, 1547–1577. b) Tomasic, T.; 
Masic, L. Curr. Med. Chem.  2009, 16, 1596–1629. For the first organocatalyzed Michael addition of 
rhodanines to β-substituted enones, see: c) Yu, F.; Hu, H.; Gu, X.; Ye, J. Org. Lett.  2012, 14, 2038–2041.  
170
 For reviews on azlactones, see: a) Fisk, J. S.; Mosey, R. A.; Tepe, J. J. Chem. Soc. Rev. 2007, 36, 1432–
1440. b) Alba. A.-N. R.; Rios, R. Chem. Asian J. 2011, 6, 720–734. c) de Castro, P. P.; Carpanez, A. G.; 
Amarante, G. W. Chem. Eur. J. 2016, 22, 10294–10318. 
171
 For the first organocatalytic asymmetric reaction of thiazol-5(4H)-ones to N-Boc imines catalyzed by C1-
symmetic chiral ammonium betaine, see: Uraguchi, D.; Koshimoto, K.; Ooi, T. Chem. Commun. 2010, 46, 
300–302. 
172
 Mohr, J. T.; Moore, J. T.; Stoltz, B. M. Beilstein J. Org. Chem. 2016, 12, 2038–2045. 
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multiple reactivity can be directed depending on the counterpart that is added to the 
reaction (Scheme 74).  
 
Scheme 74.  
The acidity of the 4-substituted azlactones (pKa ≈ 9)173 allows its facile deprotonation 
with mild Brønsted bases to obtain an aromatic enolate, which in the presence of an 
electrophile would form a quaternary stereocenter contiguous to the carbonyl (Scheme 
75). These compounds are the most common heterocycles employed in the 
stereoselective synthesis of quaternary stereocenters, probably, due to its easy 
conversion into optically active structurally complex quaternary α-amino acids.174 
 
Scheme 75.  
In 1997, Trost and Ariza reported the first nucleophilic addition of azlactones in an 
asymmetric Tsuji-Trost α-allylation reaction catalyzed by chiral Salen-Pd complex 
(Scheme 76).175 The corresponding C-4 adducts were obtained in very good yields and 
enantioselectivities, presumably because a tightly embedded chiral pocket formed 
between the catalyst and the allyl moiety. The absolute configuration of the newly 
formed quaternary stereogenic center could be predicted by the enolate approach to 
                                                 
173
 Goodman, M.; Levine, L. J. Am. Chem. Soc.  1964, 86, 2918–2922.  
174
 a) Amino Acids, Peptides and Proteins in Organic Chemistry, Vols. 1&2 (Hughes, A. B. ed., Wiley-VCH, 
Weinheim) 2009. b) Bera, K.; Namboothiri, I. N. N. Asian J. Org. Chem. 2014, 3, 1234–1260 and references 
therein. c) Bera, K.; Namboothiri, I. N. N. Asian J. Org. Chem. 2014, 3, 1234–1260. d) Metz, A. E.; Kozlowski, 
M. C. J. Org. Chem. 2015, 80, 1–7. 
175
 a) Trost, B. M.; Ariza, X. Angew. Chem. Int. Ed. 1997, 36, 2635–2637. For later examples of Pd catalyzed 
alkylation of azlactones, see: b) Trost, B. M.; Czabaniuk, L. C. J. Am. Chem. Soc.  2012, 134, 5778–5781 and 
references therein. c) Zhou, H.; Yang, H.; Liu, M.; Xia, C.; Jiang, G. Org. Lett.  2014, 16, 5350–5353. For a 
rearrangement of O-acylated azlactones catalyzed by a planar-chiral derivative of 4-(pyrrolidino)pyridine, 
see: Ruble, J. C.; Fu, G. C. J. Am. Chem. Soc. 1998, 120, 11532–11533. 
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the π-allyl palladium chiral complex by its Si face (upper left side of Scheme 76). 
Interestingly, an alkylated azlactone (alkyl = CH3) was converted smoothly, upon acidic 
hydrolysis with TMSCl in MeOH, into the quaternary α-amino acid.  
 
Scheme 76.  
It was not until 2008 when Jørgensen et al.176 reported the first organocatalytic 
example; the nucleophilic addition of azlactones to α,β-saturated aldehydes catalyzed by 
10 mol % of Jørgensen-Hayashi catalyst proceeded at the C-4 position in moderate to 
high yields and diastereoselectivities and with high enantioselectivities. Wittig reaction 
followed by hydrolysis of one of the azlactones using HCl (conc.) in CH3CN provided an 
α,α-disubstituted amino acid derivative in moderate yield (Scheme 77).   
                                                 
176
 a) Cabrera, S.; Reyes, E.; Alemán, J.; Milelli, A.; Kobbelgaard, S.; Jørgensen, K. A. J. Am. Chem. Soc. 2008, 
130, 12031–12037. After this work several organocatalytic examples have been reported; for a highly 
enantioselective alkylation of azlactones with alkyl bromides, see: b) Uraguchi, D.; Asai, Y.; Seto, Y.; Ooi, T. 
Synlett 2009, 4, 658–660. c) Tarí, S.; Avila, A.; Chinchilla, R.; Najera, C. Tetrahedron: Asymmetry 2012, 23, 
176–180. For an asymmetric aldol reaction of azlactones and aliphatic aldehydes, see: d) Zheng, Y.; Deng, 
L. Chem. Sci. 2015, 6, 6510–6514. 
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Scheme 77.  
The same year, Ooi´s group developed a highly enantioselective direct Mannich-type 
reaction between azlactones and N-sulfonyl imines catalyzed by a chiral 
tetraaminophosphonium salt.177 It was thought that the basic carboxylate anion (–OPiv) 
present in the catalyst abstracts the acidic proton of the azlactone providing the chiral 
phosphonium enolate. One of the Mannich adduct was easily converted into the 
corresponding α,β-diamino acid dihydrochloride after two steps without loss of 
enantiopurity (Scheme 78). 
                                                 
177
 a) Uraguchi, D.; Ueki, Y.; Ooi, T. J. Am. Chem. Soc. 2008, 130, 14088–14089. For a selected examples of 
asymmetric Mannich type reaction between imines and azlactones, see: b) Zhang, H.; Yang, Z.; Zhao, B. N.; 
Li, G. J. Org. Chem. 2018, 83, 644–655 and references therein. 
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Scheme 78.  
As we comented above, since azlactone anions are ambifunctional nucleophiles, 
depending on the substituents and reaction conditions, they can react with activated 
electrophilic compounds through their C-2 or at C-4 positions (Figure 22). 
 
Figure 22. Regioselectivity of the addition of azlactones to electrophiles. 
Jørgensen et al. extended their previous work with enals describing the addition of 
azlactones to nitroalkenes (Scheme 79). The reaction was catalyzed by 5 mol % of a 
bifunctional cinchona alkaloid/thiourea derivative yielding the corresponding adducts 
with good yields, excellent diastereoselectivities, and enantioselectivities from moderate 
to good.178 The reaction was founded to be extremely catalyst and substituent 
                                                 
178
 a) Alemán, J.; Milelli, A.; Cabrera, S.; Reyes, E.; Jørgensen, K. A. Chem. Eur. J. 2008, 14, 10958–10966. 
After this work some examples reporting C-2 Michael addition reaction have been reported. For a 
diastereoselective addition to nitrostyrenes catalyzed by Et3N, see: b) Balaguer, A.-N.; Companyó, X.; 
Calvet, T.; Font-Bardía, M.; Moyano, A.; Rios, R. Eur. J. Org. Chem. 2009, 199–203. For an asymmetric 
organocatalytic addition to maleimides catalyzed by bifuctional thiourea-amine catalyst, see: c) Alba, A.-N. 
R.; Valero, G.; Calbet, T.; Font-Bardía, M.; Moyano, A.; Rios, R. Chem. Eur. J. 2010, 16, 9884–9889. For an 
asymmetric addition of a 2-unsubstituted azlactone to α,β-unsaturated acylbenzotriazoles, see: d) 
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dependent, addition to the electrophile took place selectively at C-4 position of the 
azlactone when R2 = tolyl, t-butyl and R1 = Ph. However, vinylogous C-2 addition was 
observed with some azlactones with R1 = alkyl and R2 = electron poor aromatic group. 
Again, the ring opening of 4-substituted azlactones, in the presence of TMSCl in MeOH, 
gave the α-amino acid esters in very high yields and without loss of enantioselectivity. 
 
Scheme 79.  
However, it should be noted that the nature of the electrophile and the catalyst also 
plays an important role in the regiochemisty of the addition.179  
                                                                                                                                                  
Uraguchi, D.; Ueki, Y.; Ooi, T. Science 2009, 326, 120–123. For C-4 1,6-addition of azlactones to δ-aryl 
dienyl carbonyl compounds, see: e) Uraguchi, D.; Yoshioka, K.; Ooi, T. Nat. Commun. 2017, 8, 14793. 
179
 α,β-unsaturated aldehydes appear to give C-4-substituted azlactones only independently of the nature 
of substitutent at the azlactone ring, see: Ref 176. 
5,5-disubstituted hydantoins 
 
93 
 
In 2010, Jørgensen and coworkers reported the asymmetric addition of azlactones to 
acyl phophonates (Scheme 80).180 They showed that employing the bifunctional 
cinchona alkaloid/thiourea catalyst C2, the nucleophilic addition of the azlactone took 
place exclusively at the C-2 position giving the N,O-aminals in moderate to good yields 
and excellent enantioselectivities. On the other hand, removing the basic site of the 
cinchona-derived catalyst and adding an additional hydroxy-directing group switched 
the regioselectivity completely from C-2 to C-4, although in this case moderate yield 
(53%) and bad enantioselectivity (13% ee) was achieved. As a limitation of the reaction, 
the Michael reaction was only shown to be efficient with aliphatic 2-enoylphosphonates 
(R2 = alkyl). 
 
Scheme 80.  
Recently, Lu`s group reported a phosphine-catalyzed C-2 and C-4 selective γ-addition 
of azlactones to 2,3-butadienoates in a highly enantioselective manner (Scheme 81).181 
Unlike other cases, when 2-aryl-4-alkyloxazol-5-(4H)-ones were employed C-4 selective 
γ-addition of oxazolones occurred, while C-2 selective γ-addition took place with 2-alkyl-
4-aryloxazol-5-(4H)-ones. 
                                                 
180
 Jiang, H.; Paixão, M. W.; Monge, D.; Jørgensen, K. A. J. Am. Chem. Soc. 2010, 132, 2775–2783. 
181
 Wang, T.; Yu, Z.; Hoon, D. L.; Phee, C. Y.; Lan, Y.; Lu, Y. J. Am. Chem. Soc. 2016, 138, 265–271. 
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Scheme 81.  
3.1.2. Oxazolones (Oxazol-4(5H)-ones) 
Oxazol-4(5H)-ones differ from azlactones in the relative position of oxygen and 
nitrogen atoms and have been employed as highly reactive equivalents of α-alkyl α-
hydroxy acids (Figure 23). The facility to deprotonate oxazol-4(5H)-ones compared to 
other acyclic equivalents of α-alkyl α-hydroxy acids,182 as it happens with azlactones, is 
attributed to the aromatization resulting from enolization of 5H-oxazol-4-ones. 
 
Figure 23.  
In 2004, Trost et al.183 introduced oxazolones in an asymmetric allylic alkylation 
reaction catalyzed by a chiral molybdenum C2-symmetric complexes. The presence of 
the strong and hindered base lithium hexamethyldisilamide (LiHMDS) was found to be 
necessary for optimal asymmetric induction. Subsequent NaOH mediated saponification 
of obtained adducts provided the corresponding quaternary α-hydroxy amides in good 
yields (Scheme 82).  
                                                 
182
 For oxazolidindiones as α-hydroxy acid surrogates, see: Ooi, T.; Fukumoto, K.; Maruoka, K. Angew. 
Chem. Int. Ed.  2006, 45, 3839–3842.  
183
 Trost, B. M.; Dogra, K.; Franzini, M. J. Am. Chem. Soc. 2004, 126, 1944–1945. 
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Scheme 82.  
Sugimura and coworkers have also applied oxazolones as pronucleophiles in an 
organocatalytic syn-aldol reaction, wherein 5 mol % of chiral guanidines bearing a free 
hydroxyl group afforded the corresponding adducts without observing retro-aldol 
reaction. In this reaction, syn-aldol adducts with contiguous quaternary-tertiary 
stereocenters were obtained in variable yields and diastereoselectivities and with 
excellent enantiomeric excesses.184 One of the aldol adduct was easily converted into a 
α,β-dihydroxycarboxylic ester after saponification, acid hydrolysis and sterification (71% 
overall yield after 3 steps)  without loss of enantiopurity. 
 
Scheme 83.  
                                                 
184
 a) Misaki, T.; Takimoto, G.; Sugimura, T. J. Am. Chem. Soc. 2010, 132, 6286–6287. For asymmetric 1,4-
addition of 5H-oxazol-4-ones to alkynyl carbonyl compounds, see: b) Misaki, T.; Kawano, K.; Sugimura, T. J. 
Am. Chem. Soc.  2011, 133, 5695–5697. c) Misaki, T.; Jin, N.; Kawano, K.; Sugimura, T. Chem. Lett.  2012, 
41, 1675–1677.  
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Reactive intermediates derived from oxazolones have recently been employed as 
nucleophiles in a number of transformations including Mannich,185 Michael,186 phase-
transfer,187α-sulfenylation188 and [4+2] cycloaddition189 reactions. 
3.1.3. 5H-thiazol-4-ones 
Sulfur-functionalized quaternary carbon stereocenters are present in natural or non-
natural products with interesting biological activities and as mentioned before, a 
catalytic asymmetric strategy to access these entities would involve the nucleophilic 
addition of S-containing prochiral carbon centers (Figure 24). 
 
Figure 24. 
190
 
In 2013, our group191 employed for the first time 5H-thiazol-4-ones, as α-mercapto 
carboxylate surrogates, in the catalytic Michael reaction to nitroolefins providing α,α-
                                                 
185
 a) Han. Z.; Yang, W.; Tan, C.-H.; Jiang, Z. Adv. Synth. Catal. 2013, 355, 1505–1511. For the highly 
diastereo- and enantioselective zinc-catalyzed Mannich reaction, see: b) Zhao, D.; Wang, L.; Yang, D.; 
Zhang, Y.; Wang, R. Angew. Chem. Int. Ed. 2012, 51, 7523–7527.  
186
 a) Huang, H.; Zhu, K.; Wu, W.; Jin, Z.; Ye, J. Chem. Commun. 2012, 48, 461–463. For the first 
organocatalytic addition of 5H-oxazol-4-ones to nitroolefins catalyzed by a thiourea-based bifunctional 
Brønsted base, see: b) Qiao, B.; An, Y.; Liu, Q.; Yang, W.; Liu, H.; Shen, J.; Yan, L.; Jiang, Z. Org. Lett. 2013, 
15, 2358–2361. For the first addition to nitroolefins catalyzed by Zn, see: c) Trost, B. M.; Hirano, K. Angew. 
Chem. Int. Ed.  2012, 51, 6480–6483. For our group contribution to this field, see: d) Ref 157. For a chiral 
guanidine catalyzed 1,4- and 1,6-addition to enones and dienones, see: e) Morita, A.; Misaki, T.; Sugimura, 
T. Tetrahedron Lett. 2015, 56, 264–267. For a tertiary amine-catalized asymmetric addition to maleimides, 
see: f) Li, J.; Qiu, S.; Ye, X.; Zhu, B.; Liu, H.; Jiang, Z. J. Org. Chem. 2016, 81, 11916–11923. 
187
 Duan, S.; Li, S.; Ye, X.; Du, N.-N.; Tan, C.-H.; Jiang, Z. J. Org. Chem. 2015, 80, 7770–7778. 
188
 Xu, M.; Qiao, B.; Duan, S.; Liu, H.; Jiang, Z. Tetrahedron 2014, 70, 8696–8702. 
189
 Zhu, B.; Lee, R.; Li, J.; Ye, X.; Hong, S.-N.; Qiu, S.; Coote, M. L.; Jiang, Z. Angew. Chem. Int. Ed. 2016, 55, 
1299–1303. 
190
 a) Liu, L.; Zhang, S.-L.; Xue, F.; Lou, G.-S.; Zhang, H.-Y.; Ma, S.-C.; Duan, W.; Wang, W. Chem. Eur. J. 
2011, 17, 7791–7795. b) Salyden, R. A.; Lee, R. E.; Armour, J. W.; Cooper, A. M.; Orme, I. M.; Brennan, P. J.; 
Besra, G. S. Antimicrob. Agents. Chemother. 1996, 2813–2819. c) Song, Y.; Dou, H.; Gong, W.; Liu, X.; Yu, Z.; 
Li, E.; Tan, R.; Hou, Y. Eur. J. Pharmacol. 2013, 705, 49–60. 
191
 a) Diosdado, S    t abe,     Izquierdo,      anda,     Mielgo,     Olaizola, I     pez, R.; Palomo, C. Angew. 
Chem. Int. Ed. 2013, 52, 11846−11851. For an asymmetric iridium-catalyzed allylation, see: b) Chen, W.; 
Hartwig, J. F. J. Am. Chem. Soc. 2014, 136, 377–382. For an asymmetric phosphine-catalyzed  γ-addition to 
allenoates, see: c) Wang, T.; Yu, Z.; Hoon, D. L.; Huang, K.-W.; Lan, Y.; Lu, Y. Chem. Sci. 2015, 6, 4912–4922. 
For a dipeptide-based chiral tertiary amine-catalyzed asymmetric conjugated addition to maleimides, see: 
d) Li, J.; Qiu, S.; Ye, X.; Zhu, B.; Liu, H.; Jiang, Z. J. Org. Chem. 2016, 81, 11916–11923.  
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disubstituted α-mercapto carboxylic acid derivatives with good yields and high 
diastereo- and enantioselectivities (Scheme 84). The reaction was conducted using 20 
mol % of a novel bifunctional ureopeptide-based Brønsted base catalyst and it should be 
noted that quinoline N atom of the thiazolone template plays a significant role in 
reaction stereocontrol. It was proposed that the coordination between the quinolinyl 
group of the nucleophile with the aminal moiety in the catalyst would enhance the 
fixation of the transition state, thus providing better stereocontrol during the reaction 
(upper right side of Scheme 84).  Adducts were transformed into the α,α-disubstituted 
α-mercapto carboxylic acid derivatives, by simple ring opening under acidic conditions 
and subsequent saponification of the resulting thioester intermediate. Finally, the 
corresponding S-alkylated adduct were obtained in the presence of a series of alkyl 
iodides and sodium hydride as a base. 
 
Scheme 84.  
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3.1.4. 1H-Imidazol-4(5H)-ones 
 The stereoselective preparation of α,α-disubstituted quaternary α-amino acids have 
gained much attention in the last years.192 They have proved to be useful as 
pharmaceuticals (e.g. methyldopa) or as building blocks for the construction of 
peptidomimetics.193 As previously mentioned, a principal enantioselective approach to 
quaternary NH α-amino acids consists in the α-functionalization of nucleophilic 
templates. However, the majority of these methods are unable to afford the N-
substituted analogues directly, and an additional N-alkylation process is required.194 
Some of these procedures are illustrated in Scheme 85. 
 
Scheme 85. Pronucleophiles for synthesis of quaternary amino acids. 
                                                 
192
 See Ref 174. 
193
 Although peptides and proteins have several conformations in solution due to their flexible nature, 
only a few conformers are responsible for their diverse biological properties  Cα-tetrasubstituted amino 
acids are useful tools to reduce the conformational space available in the peptide-protein or protein-
protein interactions and these peptidomimetics are often more resistant to chemical and enzymatic 
degradation. a) Toniolo, C.; Crisma, M.; Formaggio, F.; Peggion, C. Peptide Science 2001, 60, 396–419. b) 
Toniolo, C.; Formaggio, F.; Kaptein, B.; Broxterman, Q. B. Synlett 2006, 2006, 1295–1310. 
194
 Synthetic preparation of N-methyl α-amino acids: Aurelio, L.; Brownlee, R. T. C.; Hughes, A. B. Chem. 
Rev. 2004, 104, 5823–5846. 
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On the other side, hydantoins or 2,4-imidazolidinediones, constitute a family of 
nitrogen heterocycles that are present in naturally occurring substances, such as marine 
organisms and bacteria.195 The finding of biological activities of hydantoins has made big 
progress during the last decades, and in particular, it has been demonstrated that 
optically 5-substituted and 5,5-disubstituted hydantoins are important medicinal 
compounds (Figure 25). 
 
Figure 25. Biologically active 5,5-disubstituted hydantoins.
196197198 
Hydantoins are also interesting from a purely chemical point of view. 5-Substituted 
hydantoins have been employed in the context of molecular recognition,199 chiral 
auxiliaries in organic synthesis,200 or constituents of optically active polymers201 and 
metal complexes.202 Structurally, they can be viewed as masked α-amino acids and, as 
such, 5-substituted hydantoins also serve as precursors to unnatural α-amino acid 
derivatives.203 
                                                 
195
 For reviews of hydantoin chemistry, see: a) López, C. A.; Trigo, G. G. Adv. Heterocycl. Chem. 1985, 38, 
177–228. b) Meusel, M.; Gütschow, M. Org. Prep. Proced. Int. 2004, 36, 391–443. c) Konnert, L.; Lamaty, 
F.; Martinez, J.; Colacino, E. Chem. Rev. 2017, 117, 13757–13809. 
196
 Zhang, H.; Watterson, S. H.; Xiao, Z.; Dhar, T. G. M.; Balasubramanian, B.; Barrish, J. C.; Chen, B. Org. 
Process Res. Dev. 2010, 14, 936–938.  
197
 Shiozaki, M. Carbohydr. Res. 2001, 335, 147–150. 
198
 Wiley, M. R.; Durham, T. B.; Adams, L. A.; Chambers, M. G.; Lin, C.; Liu, C.; Marimuthu, J.; Mitchell, P. 
G.; Mudra, D. R.; Swearingen, C. A.; Toth, J. L.; Weller, J. M.; Thirunavukkarasu, K. J. Med. Chem. 2016, 59, 
5810–5822. 
199
 Famulok, M.; Jeong, K.-S.; Deslongchamps, G.; Rebek Jr., J. Angew. Chem. Int. Ed. 1991, 30, 858−860. 
200
 Feng, C.; Cuifen, L.; Junqi, N.; Zuxing, C.; Guichun, Y. Chem. Res. Chin. Univ. 2016, 32, 219–225. 
201
 a) Faghihi, K.; Zamani, K.; Mirsamie, A.; Reza Sangi, M. Eur. Polym. J. 2003, 39, 247–254. b) Faghihi, K.; 
Naghavi, H., J. Appl. Polym. Sci. 2005, 96, 1776–1782. 
202
 Ambroladze, L. N.; Turkadze, T. D.; Moseshvili, I. Z. Russ. J. Inorg. Chem. 2008, 53, 714–717. 
203
 Férnandez-Nieto, F.; Mas Roselló, J.; Lenoir, S.; Hardy, S.; Clayden, J. Org. Lett. 2015, 17, 3838–3841. 
Chapter 3 
 
100 
 
 
Scheme 86.  
The first efforts to prepare hydantoins were devoted to the synthesis of 5- and 5,5-
disubstituted hydantoins. Principally, three different methods are known:  
1. The Biltz reaction and the historical process for the synthesis of phenytoin. 
2. The Bucherer-Bergs reaction: involving a carbonyl compound, potassium cyanide 
or sodium cyanide and ammonium carbonate. 
3. The Read synthesis: consists on the reaction between amino acid derivatives and 
isocyanates or equivalents. 
Carried out by Heinrich Biltz in 1908,204 the reaction consists on the double 
condensation of urea with benzyl in strong basic conditions to yield the cyclic 
antiepileptic drug phenytoin (dilantin) (Scheme 87).  
 
Scheme 87. Biltz synthesis. 
In the last decade, new conditions have been described for this reaction, for instance 
using heterogeneous catalysts,205 microwave irradiation206 and ultrasonication.207 These 
alternative methods that afford phenytoin derivatives in excellent yield make the 
reaction faster than the original methodology. 
                                                 
204
 Biltz, H. Ber. Dtsch. Chem. Ges. 1908, 41, 1379–1393. 
205
 a) Sachdev, D.; Dubey, A. Catal. Commun. 2010, 11, 1063–1067. b) Tang, Y.; Cheng, Q.; Wang, S.; Zhang, 
J. Monatsh. Chem. 2014, 145, 1501–1506. 
206
 a) Safari, J.; Naeimi, H.; Ghanbari, M. M.; Sabzi Fini, O. Russ. J. Org. Chem. 2009, 45, 477–479. b) 
Gbaguidi, F. A.; Kpoviessi, S. S. D.; Kapanda, C. N.; Muccioli, G. G.; Lambert, D. M.; Accrombessi, G. C.; 
Moudachirou, M.; Poupaert, J. H. Afr. J. Pure Appl. Chem. 2011, 5, 168–175.  
207
 a) Arani, N. M.; Safari, J. Ultrason. Sonochem. 2011, 18, 640−643. b) Safari, J.; Moshtael Arani, N.; 
Ramezan Isfahani, A.  Chin. J. Chem. 2010, 28, 255−258. c) Du, T.; Li, J.; Min, L. Adv. Mater. Res. 2012, 
518−523, 3917−3920. 
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The classic Bucherer-Bergs reaction208 is carried out between carbonyl compounds 
(aldehyde or ketone), ammonia and a cyanide anion forming an α-amino nitrile. 
Subsequent carbamoylation with carbon dioxide, issued from (NH4)2CO3, and cyclization 
followed by rearrangement of the five-membered ring affords the desire hydantoin 
(Scheme 88). An important limitation of the Bucherer-Bergs reactions is that it only has 
one point of diversity. Only changes in the structure of the starting ketone or aldehyde 
will lead to variations in the final hydantoin. Moreover, heating an aqueous solution of 
highly toxic KCN poses several hazards, formation of hydrogen cyanide due to hydrolysis, 
especially on large scale. 
 
Scheme 88. Bucherer-Bergs reaction. 
The Read reaction209 is the main synthetic route to obtain 5-substituted hydantoins, 
starting from the corresponding α-amino acid derivative. The reaction involves the 
condensation with an isocyanate or equivalent promoted by some highly reactive 
coupling reagents (Scheme 89).210 While this route is in principle simple and 
straightforward, lacks generality as depends on the availability of the corresponding α-
amino acid precursor in enantiomerically pure form. This is a serious problem, especially 
when 5,5-disubstituted (quaternary) hydantoins are targeted.211 
                                                 
208
 a) Bucherer, H. T.; Libe, V. A. J. Prakt. Chem. 1934, 141, 5–43. b) Bucherer, H. T.; Steiner, W. J. Prakt. 
Chem. 1934, 140, 291–316. For recent examples using this methodology to access 5,5-disubstituted 
hydantoins, see: c)  Faghihi, K.; Zamani, K.; Mirsamie, A.; Reza Sangi, M. Eur. Polym. J. 2003, 39, 247–254. 
d) Safari, J.; Gandomi-Ravandi, S.; Javadian, L. Synth. Commun. 2013, 43, 3115−3120. c) Kumar, V.; Rana, 
H.; Sankolli, R.; Kaushik, M. P. Tetrahedron Lett. 2011, 52, 6148–6151. e) Safari, J.; Javadian, L. C. R. Chim. 
2013, 16, 1165–1171. 
209
 a) Read, W. T. J. Am. Chem. Soc. 1922, 44, 1746–1755. b) DeWitt, S. H.; Kiely, J. S.; Stankovic, C. J.; 
Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6909–6913. 
210
  For recent examples, see: a) Johnson, A.; Saunders, M. J.; Back, T. G. Org. Biomol. Chem., 2015, 13, 
1463–1469. b) Konnert, L.; Gonnet, L.; Halasz, I.; Suppo, J.-S.; de Figueiredo, R. M.; Campagne, J.-M.; 
Lamaty, F.; Martinez, J.; Colacino, E. J. Org. Chem. 2016, 81, 9802–9809. For a semi-continuous flow 
synthesis of hydantoins using a photoo idative cyanation step, see: c) Vukelić, S   Koksch, B   Seeberger, P. 
H.; Gilmore, K. Chem. Eur. J. 2016, 22, 13451–13454. For a synthesis of hydantoins from carbamates, see: 
d) Tanwar, D. K.; Ratan, A.; Gill, M. S. Synlett 2017, 28, 2285–2290. 
211
 For the synthesis of racemic quaternary hydantoins through rearrangement of aminobarbituric acid, 
see: a) Meusel, M    mbrożak,     Hecker, T  K   Gütschow, M  J. Org. Chem. 2003, 68, 4684–4692; through 
a domino process: b) Gao, M.; Yang, Y.; Wu, Y.-D.; Deng, C.; Shu, W.-M.; Zhang, D.-X.; Cao, L.-P.; She, N.-F.; 
Wu, A.-X. Org. Lett. 2010, 12, 4026−4029; through Cα-functionalylation of hydantoins (C-prenylation) c) 
Schmitt, D. C.; Lee, J.; Dechert-Schmitt, A.-M. R.; Yamaguchi, E.; Krische, M. J. Chem. Commun. 2013, 49, 
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Scheme 89. Conventional synthesis of optically active 5,5-disubstituted hydantoins from the chiral pool. 
To the best of our knowledge, at the time of the work presented herein started, no 
examples to access optically active quaternary hydantoins involving new-carbon bond 
forming reaction had been reported.  
Only very recently practical syntheses of enantiomerically enriched quaternary 
hydantoins have appeared.212  
In 2015, Clayden and co-workers213 developed a protocol to access quaternary 
hydantoins and compounds derived thereof in good enantioselectivity. This method is 
based on an asymmetric arylation at the α position of available α-amino acids, ligated to 
pseudoephedrine as a chiral auxiliary, followed by a cyclization. The arylation avoids the 
use of heavy-metal additives, and is successful with a range of amino acids and with aryl 
rings of varying electronic character. This represents truly remarkable results, but 
unfortunately only migration of N-aryl groups to the α position of the amino acid can be 
done (Scheme 90). 
 
Scheme 90.  
A year later, Terada214 reported a chiral phosphoric acid-catalyzed Friedel-Crafts-type 
addition of 2-methoxyfuran to in situ generated aliphatic ketimines. The enantiopure 
                                                                                                                                                  
    –        ryla on) d)  ern ndez-Nieto,     Mas  osell , J.; Lenoir, S.; Hardy, S.; Clayden, J. Org. Lett. 
2015, 17, 3838–3841. 
212
 For the asymmetric synthesis of 5-substituted hydantoins throughout α-amination of esters with 
diaziridinone, see: Song, J.; Zhang, Z.-J.; Chen, S.-S.; Fan, T.; Gong, L.-Z. J. Am. Chem. Soc. 2018, 140, 3177–
3180. 
213
 a)  tkinson,    C    ern ndez-Nieto,     Mas  osell , J.; Clayden, J. Angew. Chem. Int. Ed. 2015, 54, 
8961–8965. b) Maury, J.; Clayden, J. J. Org. Chem. 2015, 80, 10757−10768. Also, see: c) Tomohara, K.; 
Yoshimura, T.; Hyakutake, R.; Yang, P.; Kawabata, T. J. Am. Chem. Soc. 2013, 135, 13294–13297. 
214
 Kondoh, A.; Ota, Y.; Komuro, T.; Egawa, F.; Kanomata, K.; Terada, M. Chem. Sci. 2016, 7, 1057−1062. 
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chiral Brønsted acid catalyst serves both to form the ketimine and induce asymmetry. 
Adducts possessing a quaternary stereogenic center were obtained in moderated to 
excellent yields with good to excellent enantioselectivities. The excellent results are 
limited to just 2-methoxyfuran as a nucleophile (Scheme 91). 
 
Scheme 91. Chiral Brønsted acid-catalyzed Friedel-Crafts reaction of in situ-generated ketimines. 
Despite these significant advances, the scope of optically active quaternary 
hydantoins available continues to be rather narrow (essentially restricted to some 5-aryl 
hydantoins). 
Recently, we introduced 1H-imidazol-4(5H)-ones 24 as novel nucleophile in 
asymmetric synthesis.215 These compounds allowed a highly efficient construction of a 
tetrasubstituted stereogenic center and a direct access to N-substituted (alkyl, allyl, aryl) 
α-amino acid derivatives and 5, 5-disubstituted hydantoins (Scheme 92). Unlike 
azlactones, these heterocycles do not present the C-2/C-4 selectivity problem. One 
drawback of the reaction is the limited thermal stability of template 24, which partially 
decomposes upon storage at room temperature for several hours, or during standard 
silica gel chromatographic purification, making storage in the freezer at –40 °C 
necessary. 
                                                 
215
 Etxabe, J.; Izquierdo, J.; Landa, A.; Oiarbide, M.; Palomo, C. Angew. Chem. Int. Ed. 2015, 54, 6883−6887.  
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Scheme 92. Our preliminary finding. 
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3.2. Working hypothesis and synthetic plan 
Due to the lack of procedures in the literature to generate optically active quaternary 
hydantoins, our preliminary plan was to develop a catalyst-controlled, enantioselective 
method for the synthesis of diversely functionalized 5,5-disubstituted hydantoins. Taking 
into account our previous work and given the simplicity and the high selectivity of the 
method, we sought to investigate the behavior of the related heterocyclic systems II and 
III (Scheme 93). If successful, a broad-scope approach for the enantioselective synthesis 
of diversely 1,3,5-substituted hydantoins would be at hand. 
 
Scheme 93. Template-based catalytic enantioselective synthesis of diversely substituted quaternary 
hydantoins. 
The effectiveness of template I to react under the above mild enolization conditions 
may be ascribed to the aromatic character of the transiently formed enolate I’   rom a 
similar reasoning, it was envisaged that the related heterocyclic systems II and III, with 
an N1-acyl and an N3-aryl substituents, respectively, would lead, in the presence of a 
base promoter, the corresponding aromatic enolates II’ and III’. Moreover, in view of the 
structural similarities of the three enolates, their interaction with the protonated 
amine/squaramide catalyst might be equally productive in order to afford the addition 
adducts (Figure 26). 
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Figure 26. Imidazolone templates with various substitution patterns and their enolization. 
3.3. Results and discussion 
3.3.1. Preparation and evaluation as pronucleophiles of N1-acyl templates (II) 
First, the preparation of N-acyl thiohydantoin 28 was carried out accordingly to the 
procedure of Burgess.216 Thus, racemic phenylalanine and NH4SCN were mixed in Ac2O 
for 30 min at 100 oC affording the racemic thiohydantoin 28 in 78% yield (Scheme 94).  
 
Scheme 94.  
Alternative methods were employed for the preparation of the remaining 
thiohydantoins. Thus, condensation reaction between thiourea and the corresponding 
aliphatic amino acid217 followed by an acylation with benzoyl chloride afforded N-
benzoyl thiohydantoins 29 in yields from moderate to good after two steps (Table 11). 
 
 
 
 
 
 
                                                 
216
 Reyes, S.; Burgess, K. J. Org. Chem. 2006, 71, 2507−2509. 
217
 Han, J.; Wang, J.; Dong, H.; Lei, J.; Wang, M.; Fang, J. Molecules 2011, 16, 2833−2845. 
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Table 11. Synthesis of thiohydantoins 29. 
 
Entry  R 
Yield (%)[a] 
 2 steps 
1 29A Me 58 
2 29B Et 53 
3 29C Bn 69 
4 29D iBu 56 
5 29E nHex 50 
6 29F CH3S(CH2)2 48 
                                                           
[a] Overall yield after column chromatography. 
Finally, the synthesis of N-Boc and N-Cbz thiohydantoins 30 and 31 was achieved by 
condensation of the corresponding N-Boc or N-Cbz protected α-amino acid and 
ethoxycarbonyl isothiocyanate in the presence of 4 equivalents of pyridine, which 
generally proceeded in very good yields (Table 12).218  
Table 12. Synthesis of thiohydantoins 30 and 31. 
 
 
Entry  R1 R2 Yield (%)[a] 
1 30A Me Boc 88 
2 30B Et Boc 86 
3 30C Bn Boc 90 
4 30D iBu Boc 83 
5 30E nHex Boc 75 
6 30G BnOCH2 Boc 90 
7 30H Ph Boc 72 
8 31C Bn Cbz 81 
9 31G BnOCH2 Cbz 82 
[a] Overall yield after column chromatography. 
                                                 
218
 Boyd, V. L.; Bozzini, M.; Guga, P. J.; Zon, G., U.S. Patent 5185266, Feb 9, 1993. 
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After O-silylation of 28-31 with trimethylchlorosilane and triethylamine,219 the crude 
reaction was treated again with Et3N and with benzyl bromide giving, after the 
hydrolysis of the O-sylilated enolate, the desired N1-acyl imidazolones 32-35 in good 
overall yields (Table 13).  
Table 13. Synthesis of 1H-imidazol-4(5H)-ones 32, 33, 34 and 35. 
 
Entry  R1 R2 Yield (%)[a] 
1 32C Bn Ac 75 
2 33A Me Bz 76 
3 33B Et Bz 72 
4 33C Bn Bz 81 
5 33D iBu Bz 70 
6 33E nHex Bz 70 
7 33F CH3S(CH2)2 Bz 64 
8 34A Me Boc 84 
9 34B Et Boc 76 
10 34C Bn Boc 80 
11 34D iBu Boc 80 
12 34E nHex Boc 72 
13 34G BnOCH2 Boc 82 
14 34H Ph Boc 82 
15 35A Me Cbz 76 
16 35C Bn Cbz 70 
17 35G BnOCH2 Cbz 78 
[a] Overall yield after column chromatography. 
Thus, this synthetic strategy allowed us a rapid access to a variety of 1H-imidazol-
4(5H)-ones and an important point is that these N-acyl dihydroimidazolones (32-35) 
were observed to be stable solids for months at room temperature under air 
atmosphere. 
                                                 
219
 This step was necessary to avoid a mixture of O-benzyl and O,S-dibenzyl products due to the greater 
reactivity of enolate respect to the thiocarbonyl moiety.  
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3.3.2. Catalyst screening. Reaction between N-acyl-templates and nitroolefins 
To assess the viability of these substrates, we started evaluating the behavior of 32C 
and 33C against nitroolefin 36a. Gratifyingly, as the brief screening in Table 14 shows, 
the reaction of N-acetyl 32C with nitrostyrene 36a to afford adduct 37Ca proceeded at 
room temperature in the presence of various bifunctional Brønsted base catalysts with 
remarkable selectivity, whilst reactivity was more catalyst-dependent. For instance, both 
catalysts C10 and C11220 were able to afford adduct 37Ca as a 97:3 mixture of 
diastereomers in very high (but opposite) enantioselectivity, although no full conversion 
could be reached in either case after 24 h (entries 1, 5). As expected, catalyst ent-C10 
(entry 2) afforded the same enantiomer as C11 with reproducible reactivity and 
selectivity compared to C10. The newly developed catalyst C12221 was more active, 
leading to essentially full conversion after 24 h (90% conversion after 16 h) with nearly 
the same degree of diastereo- and enantiocontrol (entry 8). Regardless the catalyst 
employed, the N-benzoyl analog 33C proved to be more reactive than the N-acetyl 
derivative 32C and upon reaction with nitrostyrene afforded the corresponding adduct 
38Ca, again, in essentially perfect diastereo- and enantioselectivity (entries 3, 6 and 9). 
This same order of catalyst activity, namely ent-C10 < C11 < C12, was observed at 
subzero temperatures. Thus, whilst ent-C10 was completely unactive at –20 °C, C11 
(entry 7) and specially the catalyst C12 (entry 10), did promote the reaction between 
33C and nitrostyrene at that temperature, affording compound 38Ca in very high yield 
and selectivity. With the N-Me derivative C13 longer reaction times are needed and 
gives same diastereoselectivity but worst enantioselectivity (90% ee). It should be noted 
that catalyst ent-C10 and C13 were completely soluble at the conditions employed, but 
C11 and C12 were only partially soluble. It was also observed that cinchona-based 
squaramide catalyst C1 was equally active, albeit less selective (dr 90:10, entry 12), 
whilst the corresponding thiourea analog C2 was both less active and selective (entry 
13). In their turn, quinine and (DHQD)2PYR were completely ineffective catalyst for this 
reaction. 
 
 
 
 
 
 
                                                 
220
 Hu, K.; Lu, A.; Wang, Y.; Zhou, Z.; Tang, C. Tetrahedron: Asymmetry 2013, 24, 953−957. 
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Table 14.  Catalyst screening for the reaction of 32C/33C with nitrostyrene 36a.
[a]
 
 
Entry Cat. R1 T(oC) T(h) Conv. (%)[b] dr[c] ee (%)[d] 
1 C10 COMe r.t. 24 80 97:3 _98 
2 ent-C10 COMe r.t. 24 80 97:3 98 
3  COPh r.t. 16 >98 >98:2 98 
4   _20 96 NR -- -- 
5 C11 COMe r.t. 24 50 97:3 98 
6  COPh r.t. 16 >98 >98:2 97 
7   _20 96 65 >98:2 98 
8 C12 COMe r.t. 16 90 98:2 99 
9  COPh r.t. 2 >98 98:2 99 
10   _20 48 >98 >98:2 98 
11 C13 COPh r.t. 2 77 >98:2 90 
12 C1 COMe r.t. 16 95 90:10 99 
13 C2 COMe r.t. 16 60 80:20 90 
[a] The reactions were performed using 0.3 mmol of 32C/33C, 0.6 mmol of nitrostyrene 36a 
and 10 mol % of the catalyst in 0.6 mL CH2Cl2. [b] The conversion was estimated from the crude 
by  
1
H-NMR. [c] Diastereomeric ratio determined by 
1
H-NMR and by chiral HPLC. [d] Ee of major 
diastereomer was determined by HPLC. 
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Thus, the optimal conditions for the addition of 32C or 33C with the nitroolefin 36a (2 
equiv.) included the presence of 10 mol % catalyst C12 at room temperature and in 
dichloromethane as a solvent.  
3.3.3. Scope and limitations 
With the optimized conditions for the catalytic diastereo- and enantioselective 
Michael addition reaction at hand, the scope and the limitation of the system were 
investigated. 
The reactions of N-acyl imidazolone 32C with nitroolefins 36a-c proceeded with very 
good yields and excellent stereocontrol, regardless of the electron neutral, rich or poor 
character of the β-aryl substituent in the nitroalkene (Table 15). 
Table 15. Conjugate addition of imidazolone 32C to nitroolefins 36a-c promoted by catalyst C12.
[a]
  
 
[a] Reaction conditions: dihydroimidazolone 32C (1 equiv., 0.2 mmol), nitroolefins 36a-c (2 equiv., 0.4 
mmol), and C12 (10 mol %) were stirred at r.t. in 1.0 mL of CH2Cl2 for 16 h. Diastereomeric ratios and ee 
were determined by 
1
H-NMR and by chiral HPLC. 
 
The reaction between N-benzoyl imidazolones 33 bearing different C5-substituents 
(e.g. methyl, ethyl, benzyl, isobutyl, n-hexyl and methyl tioethyl) and nitroolefins 36a-g 
also rendered in high yields and enantioselectivities (92-98% ee), and 
diastereoselectivities generally higher than 96:4, adducts 38Cg (dr = 85:15) and 38Ce (dr 
= 74:26) being exceptions (Table 16).  
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Table 16. Conjugate addition of imidazolones 33A-F to nitroolefins 36a-g promoted by catalyst C12.
[a]
  
 [a] Reaction conditions: dihydroimidazolone 33 (1 equiv., 0.2 mmol), nitroolefins 36a-g (2 equiv., 0.4 
mmol), and C12 (10 mol %) were stirred at 20 °C in 1.0 mL of CH2Cl2 for 16 h. Diastereomeric ratios and ee 
were determined by 
1
H-NMR and by chiral HPLC. [b] Reaction run for 48 h. 
 
The reactions involving the more problematic aliphatic nitroolefins did also proceed 
with very good diastereo- and enantioselectivity (adducts 38Ch and 38Ci). However, 
these latter substrates resulted comparatively less reactive than the aromatic congeners 
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and required 5 equiv. of nitroalkene and 20 mol % catalyst in DCE at 50 oC for practical 
reaction conversions (Table 17). 
Table 17. Conjugate addition of imidazolone 33C to nitroolefins 36h-i promoted by catalyst C12.
[a]
  
[a] Reaction conditions: dihydroimidazolone 33C (1 equiv., 0.2 mmol), nitroolefins 36h-i (5 equiv., 1.0 
mmol), and C12 (20 mol %) were stirred at 50 °C in 1.0 mL of DCE for 48 h. Diastereomeric ratios and ee 
were determined by 
1
H-NMR and by chiral HPLC. 
N-Boc dihydroimidazolone templates 34 were also competent substrates for this 
reaction, affording adducts 39 with essentially perfect stereoselectivity and good yields. 
As formation of product 39Ha in 69% yield and high selectivity proves, the method is 
also suitable for templates with an aryl group at the C5 position (Table 18). 
Table 18. Conjugate addition of dihydroimidazolones 34A,C,G,H to nitroolefins 36a,d promoted by 
catalyst C12.
[a]
  
 
[a] Reaction conditions: dihydroimidazolones 34 (1 equiv., 0.2 mmol), nitroolefins 36a,d (2 equiv., 0.4 
mmol), and C12 (10 mol %) were stirred at 20 °C in 1.0 mL of CH2Cl2 for 16 h. Diastereomeric ratios and ee 
were determined by 
1
H-NMR and by chiral HPLC. [b] Reaction run for 72 h. 
 
Finally, N-Cbz imidazolones 35 were also tested. Thus, moderate yield (60 %) and 
excellent selectivity (>98:2 dr, 99% ee) was obtained in the reaction between 35C and 
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nitroestirene 36a, while excellent yield (91%) and selectivity (95:5 dr, 98% ee) was 
observed for the reaction between 35G and 36d (Table 19).  
Table 19. Conjugate addition of dihydroimidazolones 35C-G to nitroolefins 35a,d promoted by catalyst 
C12.
[a]
  
 
[a] Reaction conditions: dihydroimidazolones 35C-G (1 equiv., 0.2 mmol), nitroolefins 36a,d (2 equiv., 0.4 
mmol), and C12 (10 mol %) were stirred at 20 °C in 1.0 mL of CH2Cl2 for 16 h. Diastereomeric ratios and ee 
were determined by 
1
H-NMR and by chiral HPLC. [b] Reaction run for 48 h. 
3.3.4. Addition of N-acyl-templates (II) to other Michael acceptors 
Given the excellent results regarding both the reactivity and stereocontrol afforded in 
the Michael addition of 1H-imidazol-4(5H)-ones to nitroolefins using a bifunctional 
squaramide/Brønsted base catalyst, and seeing the synthetic possibilities that these 
heterocycles bear, we decided to test our proucleophiles with a different electrophile, in 
this case, Michael acceptors, especially simple vinyl ketones (Scheme 95). 
 
Scheme 95. Proposed reaction. 
Our study began with the evaluation of several Brønsted bases for the addition of the 
imidazolone 33C to methyl vinyl ketone 41a at room temperature in dichloromethane. 
Catalysts showed a trend in activity and selectivity similar to that observed with 
nitroalkenes. Thus, ent-C10 could promote the addition of 33C to 41a, although the 
reaction progressed slowly, 50% conversion after 48 h, and with suboptimal 
enantioselectivity (72% ee). In contrast, catalyst C12 and, especially, C11 resulted 
comparatively more active (reaction conversion after 48 h at room temperature, 70% 
and 85%, respectively) and led to ee’s of  5% and   %  With C1 the reactivity improved 
to almost full conversion, however only 80% of enantioselectivity was obtained. Thus, 
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the optimal reaction conditions included the presence of catalyst C11 at room 
temperature in dichloromethane. 
Table 20. Catalyst screening for the Michael addition of dihydroimidazolone 33C to methyl vinyl ketone.
[a]
 
 [a] Reaction conditions: dihydroimidazolone 33C (1 equiv., 0.3 mmol), methyl vinyl ketone 41a (2 equiv., 
0.6 mmol), and catalyst (10 mol %) were stirred at r.t. in 0.6 mL of CH2Cl2 for 48 h. Ee was determined by 
chiral HPLC.  
 
Once with the optimal conditions in hand, we then started to check the generality of 
the method, testing different vinyl ketones and dihydroimidazolones. 
Firstly, the reactions of dihydroimidazolones 33, 34 and 35 with methyl vinyl ketone 
41a were explored. As data in Table 21 shows, independently of the substitution 
pattern, each imidazolone was equally competent reaction partner giving rise to the 
respective Michael adducts 42, 43 and 44 in generally moderate yields and excellent 
enantioselectivities.  
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Table 21. Conjugate addition of dihydroimidazolones 33-35 to methyl vinyl ketone  promoted by catalyst 
C11.
 [a]
 
 
[a] Reaction conditions: 33-35 (1 equiv., 0.3 mmol), methyl vinyl ketone 41a (2 equiv., 0.6 mmol), 
and C11 (10 mol %) were stirred at r.t. in 0.6 mL of CH2Cl2 for 48 h. Ee was determined by chiral 
HPLC. 
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Michael addition of the N-benzoyl and N-Boc substrates 33 and 34 to aryl vinyl 
ketones 41b-d was also tested, resulting again in excellent enantioselectivities in all 
cases. As expected, aryl vinyl ketones 41b-d showed more reactivity than methyl vinyl 
ketone 41a and led to better conversions and yields (Table 22). 
Table 22. Conjugate addition of dihydroimidazolones 33 and 34 to aryl vinyl ketones 41b-d promoted by 
catalyst C11.
[a]
 
[a] Reaction conditions: 33-34 (1 equiv., 0.3 mmol), 41b-d (2 equiv., 0.6 mmol), and C11 (10 mol %) were 
stirred at r.t. in 0.6 mL of CH2Cl2 for 48 h. Ee was determined by HPLC. 
Unlike nitroolefins and vinyl ketones which had led to successful reaction, α,β-
unsaturated esters appeared to be unsuitable reaction partners likely due to their 
attenuated reactivity/electrophilicity as compared to the later. Thus, when Michael 
addition of imidazolone 33C to methyl acrylate was tested, no conversion was obtained 
neither with achiral nor with chiral catalysts (Scheme 96). 
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Scheme 96. Addition of imidazolone 33C to methyl acrylate. 
On the other hand, the reaction of dihydroimidazolones 33 and 34 to highly 
electrophilic α´-hydroxy enone 1a (see chapter 2, page 56) provided adducts 45 and 46 
in excellent yields and enantioselectivities (Table 23). 
Table 23. Conjugate addition of imidazolones 33-34 to α´-hydroxy enone 1a promoted by catalyst C11. [a] 
 
[a] Reaction conditions: 33-34 (1 equiv., 0.3 mmol), 1a (2 equiv., 0.6 mmol), and C11 (10 mol %) were 
stirred at r.t. in 0.6 mL of CH2Cl2 for 48 h. Ee was determined by chiral HPLC. 
 
3.3.5. Elaboration of adducts 
Next, the chemical elaboration of adducts was investigated. On the one side, as shown 
in Scheme 97, treatment of N1 benzoyl adduct 38Ca with HCl 6M in dioxane at 65 
oC for 
6 hours gave rise, after water mediated nucleophilic displacement of the thioether 
group, to N-acyl hydantoin 47 in 80% yield. Under these conditions no hydrolysis of the 
benzoyl imide function occurred. Crystallization of adduct 47 allowed the determination 
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of its absolute and relative configuration by a single-crystal X-ray analysis, which was 
extrapolated to the remaining adducts by assuming a uniform reaction mechanism. 
 
Scheme 97.  
On the other hand, hydantoin 48 was obtained from compounds 47 and 39Ca 
following a basic hydrolysis or alternatively from 39Ca through acid hydrolisis. Thus, 
saponification of 47 with NaOH 6M at 100 oC for 2 hours gave the free hydantoin 48 in 
77% yield (Scheme 98). On the other hand, the concomitant acidic hydrolysis of the Boc 
group and the displacement of the thioether group afforded also the free hydantoin 48 
in 73% overall yield. 
 
Scheme 98.  
Finally, alkylation of imide nitrogen in adduct 47 under standard Williamson 
conditions at reflux of toluene for 36 hours, allowed access to the corresponding N-
benzylated adduct 49 in moderate yield (Scheme 99). 
 
Scheme 99.  
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3.3.6. Synthesis of ADAMTS-5 inhibitors 52 and 53 
Starting from adduct 46H, we designed a three-step sequence for the synthesis of 
cartilage degrading enzyme ADAMTS-5 inhibitors 52 and 53 used for the treatment of 
osteoarthritis degenerative joint diseases.222  
First, an acid hydrolysis of the S-benzylisothiourea moiety in 46H afforded in good 
yield 50 after washing the solid crude once with warm Et2O optically pure hydantoin 
(Scheme 100). 
 
Scheme 100.  
Afterwards, cleavage of the ketol moiety in adduct 50 employing periodic acid, 
afforded carboxylic acid 51 in very good yield (Scheme 101), with acetone being the only 
mayor organic side product formed.  
 
Scheme 101.  
Finally, coupling of acid 51 with piperidine and N-phenyl piperazine using EDC/HOBt 
coupling reagents led to amides 52 and 53 in 65% and 70% yield respectively. 
Preservation of the configurational integrity of adduct 52 was assesed (Scheme 102). 
                                                 
222
 Brebion, F. L; Alvey, L. J.; Amantini, D.; Deprez, P. M. M. J.; Gosmini, R. L. M.; Jary, H. M.; Peixoto, C.; 
Varin, M. L. C.; De Ceuninck, F. A.; Pop-Botez, I. E. PCT Int. Appl. (2016), WO 2016102347 A1. 
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Scheme 102.  
3.3.7. Preparation and evaluation as pronucleophiles of N1-acyl templates (III) 
Our next goal was to check the behavior of related heterocyclic systems III (Scheme 
103).  While it was expected that these compounds would also provide an extended 
aromatic enolate species III’ upon enolization in the presence of a bifunctional Brønsted 
base catalyst, whether or not these latter would react as efficiently as I’/II’ was 
unanswered yet.  
 
Scheme 103.  
3.3.8. Preparation of N3-aryl templates 
The preparation of the N3-aryl templates 61–66 (Scheme 104) started according to a 
established procedure,223 from the condensation of the respective amino acid with 
phenyl(aryl) isothiocyanate 54 and triethylamine to yield the corresponding 
thiohydantoins 55–60. Each one was S-benzylated by treatment with benzyl bromide 
and diisopropyl ethyl amine to yield the corresponding adducts 61–66. It is important to 
note at this point that these compounds also turned out to be comparatively more 
stable than the corresponding N–alkylated compounds I (see Figure 26).  
                                                 
223
 Zhu, L.; Lu, C.; Chen, Z.; Yang, G.; Li, Y.; Nie, J. Tetrahedron: Asymmetry 2015, 26, 6−15. 
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Scheme 104.  
3.3.9. Screening of conditions for the addition reaction to nitroolefins 
To begin the study, the reaction of 61A with β-nitrostyrene 36a was carried out in the 
presence of different base catalysts. As the results in Table 24 show, catalyst ent-C10 
was able to promote the formation of the contiguous quaternary and tertiary carbon 
stereoceters of 67Aa with good isolated yield, moderate diastereoselectivity (62:38) and 
very high enantioselectivity for the major isomer. Under such smooth reaction 
conditions, with both catalyst C11 and C12 better results were achieved, affording 
product 67Aa in nearly quantitative yield, diastereoselectivities higher than 95:5 and 
excellent enantioselectivity (96% and 95% ee, respectively). On the other side, 
squaramide C1 did not perform so well (88% ee and diastereoselectivity of 83:17) and 
with thiourea C2 enantioselectivity dropped to 75% and diasteroselectivity to 60:40. 
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Table 24. Catalyst screening for the reaction of 61A with nitrostyrene 36a.
 [a]
 
 
[a] The reactions were performed using 0.3 mmol of 61A, 0.6 mmol of nitrostyrene 36a and 10 mol % 
catalyst in 0.6 mL CH2Cl2. Ee of major diastereomer was determined by 
1
H-NMR and by chiral HPLC. 
 
Thus, the optimal reaction conditions for the addition of 61A with the nitroolefin 36a 
(2 equiv.) involved the use of catalyst C11 (10 mol %) at –20 oC in dichloromethane as a 
solvent. 
3.3.10. Reaction scope 
Once with the optimal conditions in hand, we then checked the generality of the 
method for dihydroimidazolones 61-66. 
During his PhD Thesis, Julen Etxabe from our research group performed the Michael 
addition of imidazolone 61A to aryl-substituted nitroolefins 36a-n (Table 25). Aryl-
substituted nitroolefins with either electron-rich, neutral or poor character were equally 
competent reaction partners affording the corresponding adduct 67 in very good yields 
and with nearly perfect diastereo- and enantioselectivity in most cases. During these 
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substrate screening, catalyst C12 revealed to be less efficient than C13, as the inferior 
diastereoselectivity attained for products 67Ac and 67Al indicates (compare entries 2/3 
and 8/9). 
Table 25. Scope of the catalytic reaction of 1H-imidazol-5(4H)-one 61A with nitroolefins 36a-n.
[a]
 
 
Entry Ar product Cat. yield (%) dr ee (%) 
1 4-Br-C6H4 67Ab C11 95 >98:2 99 
2 4-Me-C6H4 67Ac C11 87 >98:2 90 
3   C12 83 84:16 90 
4 2-Cl-C6H4 67Ad C11 90 >98:2 99 
5 3-Cl-C6H4 67Ae C11 86 >98:2 99 
6 4-Cl-C6H4 67Aj C11 94 >98:2 99 
7 4-CN-C6H4 67Ak C11 88 >98:2 96 
8 4-MeO-C6H4 67Al C11 85 95:5 98 
9   C12 86 70:30 99 
10 3-MeO-C6H4 67Am C11 94 >98:2 98 
11 4-Me2N-C6H4 67An C11 92 >98:2 99 
[a] Reaction conditions: 61A (1 equiv., 0.3 mmol), 36a-n (2 equiv., 0.6 mmol), catalyst (10 mol 
%) were stirred at ‒2  °C for 15–20 h in 0.6 mL of CH2Cl2. Diastereomeric ratio and ee for the 
major diastereomer were determined by 
1
H-NMR and by chiral HPLC. 
To complete Dr. Etxabe´s work, I studied the variation of the R substituent of the 
imidazolidinone substrate, without observing appreciable impact on the reaction 
outcome (Table 26). Thus, not only methyl, but also benzyl, i-butyl and functionalized 
aliphatic chains were tolerated at the substrate C4 position without affecting the 
reaction efficiency and selectivity. 
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Table 26. Scope of the catalytic reaction of 1H-imidazol-5(4H)-ones 61C-I with β-nitroestirene 36a. 
[a]
 
 
[a] Reaction conditions: 61C-I (1 equiv., 0.3 mmol), 36a-n (2 equiv., 0.6 mmol), C11 (10 mol %) were 
stirred at ‒2  °C for 15–20 h in 0.6 mL of CH2Cl2. Diastereomeric ratio and ee for the major diastereomer 
were determined by 
1
H-NMR and by chiral HPLC. 
 
Finally, Eider Duñabeitia from our research group, during her Master work, carried out 
the Michael reaction with N-aryl substrates 62-66 (Table 27). Aromatic groups 
substituted with electron withdrawing and electron donating substituents at the para 
position show comparable results to the unsubstituted imidazolone 61A (see Table 24). 
Whereas the imidazolone possessing an electron withdrawing substituent at the meta 
position (Ar = 3-ClC6H4) shows same diastereoselectivity and lower enantioselectivity 
(87% ee).    
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Table 27. Scope of the catalytic reaction of 1H-imidazol-5(4H)-ones 62-66 with nitroalkenes 36a-l.
[a]
 
 
Entry Ar R product yield (%) dr ee (%) 
1 4-MeC6H4 Ph 68Aa 89 93:7 97 
2 4-ClC6H4 Ph 69Aa 90 >98:2 94 
3 4-BrC6H4 Ph 70Aa 86 >98:2 99 
4 4-MeOC6H4 2-ClC6H4 71Ad 91 >98:2 94 
5 3-ClC6H4 4-MeOC6H4 72Al 90 >98:2 87 
[a] Reaction conditions: 62-66 (1 equiv., 0.3 mmol), 36a-l (2 equiv., 0.6 mmol), C11 (10 mol %) 
were stirred at ‒2  °C for 15–20 h in 0.6 mL of CH2Cl2. Diastereomeric ratio and ee for the major 
diastereomer were determined by 
1
H-NMR and by chiral HPLC. 
3.3.11. Elaboration of adducts 
Duñabeitia also worked in the elaboration of adducts (Scheme 105). Hydrolysis of N-
phenylthio-4,5-dihydroimidazol-4-one 67Aa to the respective hydantoin 73 could be 
carried out by treatment with HCl 1M at room temperature. Temperature control for 
this reaction is important for clean hydrolysis. The same reaction carried out at more 
forcing conditions (65 °C) led to a 1:1 mixture of compounds 73 and the thio-analog 74. 
In any event, the resulting adduct 73 could be fully converted into its thiohydantoin 
analog 74 applying  awesson’s reagent, which served to establish the compound identity 
and configuration by X-ray analysis. On the other hand, Nef type oxidation of the nitro 
group in 73 under Mioskowski conditions224 proceeded smoothly to furnish the 
carboxylic acid 74 in 79% isolated yield. Configurational integrity of adducts was not 
affected during all these transformations and the final products were obtained as 
essentially single enantiomer (99% ee). 
                                                 
224
 Hatt, C.; Wagner, C.; Mioskowski, C. J. Org. Chem. 1997, 62, 234−235   
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Scheme 105.  
3.3.12. Michael addition of 1H-imidazol-5(4H)-ones to vinyl ketones 
Given the excellent results obtained in the Michael addition of 1H-imidazol-4(5H)-
ones 32-35 to vinyl ketones 1a and 41a, we decided to test 1H-imidazol-5(4H)-one 61A 
for the analog reaction. 
Gratifingly, vinyl ketones 1a and 41a were competent electrophilic partners in the 
reactions of dihydroimidazolone 61A. However, in contrast to what was observed with 
the nitroalkenes, the reactions involving vinyl ketones followed two divergent pathways, 
one producing the 4-addition products 76 and that producing the 2-addition aminal 76’ 
(Scheme 106). Attempts to favour either reaction pathway were unsuccessful, regardless 
the catalyst and reaction temperature, an essentially equimolar ratio of either product 
was formed for the studied cases. As mentioned above, similar observations were 
previously reported in Brønsted base catalyzed addition reactions involving azlactones 
as the nucleophile.225 
 
Scheme 106. Splitting reaction pathway between imidazolone 61A and vinyl ketones. 
                                                 
225
  See Ref 178a and 178b. 
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3.3.13. Control experiments using the related thiohydantoins 
To put in context the reactivity and, particularly, selectivity profiles of templates I–III 
under the present mild enolization conditions, the behavior of 29C, 55A, 78 and 80, four 
parent thiohydantoins with comparable substitution patterns at N1 and N3, was explored 
(Scheme 107). Initial control experiments showed that, in contrast to templates I–III, 
none of these four thiohydantoins reacted at all with nitrostyrene 36a in the presence of 
catalyst C12 at low temperature (experiments carried out at –20 °C). This lack of 
reactivity was most evident in the case of thiohydantoin 29C which remained unchanged 
even after stirring the mixture for 24 h at 0 °C. Again, we ascribe the comparatively 
higher reactivity of templates I–III to their tendency towards enolization owing to the 
aromatic character of the resulting enol/enolate intermediate species. At higher 
temperatures (0 °C) N3-phenyl thiohydantoin 55A reacted with nitrostyrene 36a in the 
presence of catalyst C12, but product 77 was obtained as a 66:34 mixture of 
diastereomers. Similarly, N1-methyl thiohydantoin 78 also reacted with nitrostyrene 36a 
at 0 °C, but, led to a roughly equimolecular mixture of diastereomers with marginal 
enantioselection. In its turn, it has been reported by Rios226 that 55H upon treatment 
with nitrostyrene at room temperature gave a complex mixture. Finally, the N,N-
dibenzoyl derivative 80 showed to be completely unreactive under these conditions. 
                                                 
226
 Ceban, V.; Hands, K.; Meazza, M.; Light, M. E.; Rios, R. Tetrahedron Lett. 2013, 54, 71 3−71 7  
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Scheme 107. Reactivity profile of the related thiohydantoins 29C, 55A, 55H, 78, 80. 
3.3.14. Mechanistic proposal 
The description of a reaction model which would accurately explain the outcome of 
the reaction was our next concern. For that purpose several experiments were carried 
out in order to get insights on the reaction mechanism.  
In a first set of experiments (Figure 27), the conversion for the reaction between 34C 
and 36a was measured as a function of time, maintaining the concentration of 36a 
pseudoconstant (15 equiv.) and in the presence of 10 mol % of catalyst C12. The plotting 
in of –ln([34C]/[34C]ₒ) versus time gave a straight line   2 = 0.996) which indicates first-
order dependence in the nucleophile. The reaction order in the electrophilic component 
was determined similarly by measuring the reaction conversion as a function of time 
under pseudoconstant concentration of nucleophile 34C (15 mol equiv.) and in the 
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presence of 10 mol % of catalyst C12. In this instance, plotting ln([36a]/[36a]ₒ) versus 
time afforded again a straight line (R2 = 0.9815) indicating first-order reaction with 
respect to the acceptor component too. Unfortunately, the reaction order in the catalyst 
could not be determined by this means due to the limited solubility of the catalyst. 
 
Figure 27. Ploting of reaction conversion vs. time for the C12-catalyzed reaction between 34C and 36a 
under pseudoconstant concentration of 36a () and 34C (■). 
On the other hand, the collective experimental data shown above reveal the unique 
reactivity profile of templates I–III, as opposite to the variable results attained with the 
parent thiohydantoins (see Scheme 107). An interesting aspect of this high reactivity is 
that it appears quite general regardless the catalyst employed, and therefore it should 
be ascribed to an inherent feature of the template design. As shown in Figure 26, the 
pseudoaromatic character of the enolic forms I’–III’ would facilitate the enolization 
process, but this effect alone would not necessarily justify the subsequent reactivity 
against the electrophilic acceptor. In order to get additional insights in this respect, and 
more specifically with regard to the affinity of the templates for these type of 
bifunctional catalysts, we performed competitive 1H NMR experiments involving 
template 33C, nitrostyrene 36a and catalyst ent-C10 (Scheme 108). Catalyst ent-C10 was 
chosen because its complete solubility in halogenated solvents as noted above. As the 
comparison of spectra 1, 2 and 4 shows, admixing 36a and ent-C10 caused a slight 
downfield shift of the olefinic protons Hc/Hd of 36a along with an upfield shift of Ha and 
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Hb of ent-C10, quite significant ( 0.1 ppm) in the former case, clearly indicating some 
degree of molecular recognition between nitrostyrene 36a and the catalyst. In its turn, 
variation of the chemical shifts when admixing the template 33C and the catalyst 
(compare spectra 2, 3 and 5) seemed to be less pronounced, with only a slight downfield 
shift of Hb. However, spectrum 6, in which both substrates 36a and 33C must compete 
for best catalyst binding, reveals that the molecular affinity between 33C and ent-C10 is 
relatively high. Indeed, the chemical shift pattern of ent-C10 in 6, in particular the 
chemical shifts of both Ha and Hb, remained essentially that of spectrum 5 and distinct 
from spectrum 4. 
 
Scheme 108. Insets of 
1
H NMR spectra corresponding to individual samples of 33C, 36a, ent-C10, and 
three 1:1 combinations of them taken in CDCl3 at r.t. (concentration ~0.1 M). 
These observations reinforce the idea that the new hydantoin template upon 
enolization would remain tightly bound to the catalyst during the key C–C bond-forming 
event, allowing an efficient transfer of chiral information.  
In order to get more insights on the structural/functional requirements of these 
catalysts for optimal activity and selectivity, the performances of catalyst C12, featuring 
a free NH amide, and its N-Me derivative were compared. As the conversion profiles in 
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Figure 28 show for the reaction between 33C and 36a, catalyst C12 resulted significantly 
more active than its N-methylated form. For instance, with C12 the reaction conversion 
was over 70% after 30 min at r.t. (over 90% after 1 h), whilst with C13 barely reached 
27% after 30 min (45% after 1 h). While erosion of the stereoselectivity was less 
important (C12, dr = 98:2, 99% ee, Table 14, entry 9; C13, dr>98:2, 90% ee), the 
difference in catalyst activity is significant, especially considering that, unlike C12, C13 is 
completely soluble, and may be attributable to the ability of the free amide in C12 for 
additional H-bonding.  
 
Figure 28. Conversions for the reaction between 33C and 36a catalyzed by C12 (▲) and its N-Me 
derivative C13 (), respectively, under standard conditions. 
Although the number of individual H-bond interactions within the substrate-catalyst 
complex in the transition state, and their precise orientation, are unknown yet, and 
based on previous studies in the literature for related catalytic systems,227 a 
simultaneous activation of both reactants as in stereomodel A/A’ (Figure 29) may be 
proposed tentatively for the reactions catalyzed by C12. The free amide NH would be H-
bonded internally as in A (assited activation), to assist catalyst preorganization or 
intermolecularly as in A’ to better fix one of the approaching reactants. Similar models 
are conceivable for the remaining templates and catalysts in which the approaching 
trajectory of both reactants correctly explains the observed configuration, both relative 
and absolute, of adducts. 
 
                                                 
227
 Kótai, B.; Kardos, G.; Hamza A.; Farkas V.; Pápai, I.; Soós, T. Chem. Eur. J. 2014¸ 20, 5631–5639. 
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Figure 29. Plausible TS stereomodels for the C12-catalyzed reaction between templates II and nitroolefins. 
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4. CONCLUSIONS 
In summary, three new pronucleophiles have been described for the organocatalytic 
asymmetric formation of quaternary stereocentres. 
2-Cyanomethylazaarene N-oxides have demonstrated their utility as efficient reagents 
for the asymmetric synthesis of α-quaternary o-substituted alkylazaarenes via soft 
enolization conditions. The N-oxide group plays a strategic role as a removable activating 
and stereodirecting element in conjunction with newly designed multifunctional 
squaramide-Brønsted base catalysts bearing a bulky silyl group. Taking advantage of the 
high modulability of the adducts, several useful transformations have been carried out. 
 
Scheme 109.  
1H-Imidazol-4(5H)-ones II and 1H-Imidazol-5(4H)-ones III have proved to be excellent 
substrates for the organocatalytic Michael reaction of enantiomerically enriched 5,5-
disubstituted hydantoins. Among the catalysts examined, C11 and the newly prepared 
squaramide-tertiary amine catalyst C12 provided the highest selectivity in the reactions 
with either nitroolefins or vinyl ketones as acceptors. Various modifications of the 
adducts have been carried out, including the synthesis of ADAMTS-5 inhibitors.  
 
Scheme 110.  
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5. EXPERIMENTAL SECTION 
5.1. Materials and general techniques 
5.1.1. General experimental 
All non–aqueous reactions were performed using oven–dried glassware and were 
magnetically stirred unless otherwise stated. Yields refer to chromatographically 
purified and spectroscopically pure compounds, unless otherwise stated. 
5.1.2. Solvents and reagents 
All reagents bought from commercial sources were used as sold. Organic solvents 
were evaporated under reduced pressure using a Büchi rotary evaporator. Anhydrous 
dichloromethane was dried over CaH2, and diethyl ether and tetrahydrofuran were 
dried by filtration through activated alumina (powder ≈ 150 mesh, pore size 58 Å, 
basic, Sigma Aldrich) columns. (DHQD)2PYR was purchased from Sigma Aldrich, quinine 
was purchased from Alfa Aesar. 
5.1.3. Chromatography 
Reactions were monitored by thin layer chromatography (TLC) using Merck silica gel 
60 F254 plates and visualized by fluorescence quenching under UV light. In addition, 
TLC plates were stained with a dipping solution of potassium permanganate (1 g) in 
EtOH (limited lifetime), followed by heating. Chromatographic purification was 
performed on ROCC 60 silica gel 40–63 μm. 
5.1.4. Melting points 
Melting points were obtained on a Stuart SHP3 melting point apparatus and 
microscope and are uncorrected. 
5.1.5. Mass spectra 
MS spectra were recorded on an ESI–ion trap Mass spectrometer (Agilent 1100 
series LC/MSD, SL model) 
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5.1.6. Infrared spectra 
Infrared spectra were recorded on a Bruker Alpha FT-IR spectrometer as a thin film. 
Only selected maximum absorbances are reported. 
5.1.7. NMR spectra 
NMR spectra were recorded using a Bruker Avance 300 MHz or 500 MHz 
spectrometer, chemical shifts (δ) are quoted in parts per million referenced to the 
residual solvent peak. In case of diastereomeric mixture, data of the major 
diastereomer were provided. The multiplicity of each signal is designated using the 
following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; brs, 
broad singlet. Coupling constants (J) are reported in Hertz (Hz). 
5.1.8. Determination of enantiomeric excesses 
Enantiomeric excesses were determined using analytical high performance liquid 
chromatography (HPLC) performed on a Waters 600 (Photodiode Array Detector 
Waters 2996) (column and solvent conditions are given with the compound). 
5.1.9. Optical rotations 
Optical rotations were recorded using a Jasco P-2000 polarimeter; specific rotation 
(SR) ([α]D) are reported in 10
–1 deg∙cm2∙g–1; concentrations (c) are quoted in g/100 mL; 
D refers to the D-line of sodium (589 nm); temperatures (T) are given in degree Celsius 
(°C). 
5.1.10.  Chemical names of the heterocyclic compounds involved (Chapter 3) 
The numbering of atoms within the three main heterocyclic systems involved in this 
work according to the IUPAC rules is represented in the top structures below. We have 
applied such a numbering to both structure families, I/II and (thio)hydantoins across 
the main Manuscript and the Supporting Information. However, for the sake of clarity 
and in order to keep a consistent numbering for the three heterocyclic systems 
(templates I/II, templates III and the final (thio)hydantoins), we have adopted a 
modified numbering for heterocycles III and their derivatives (bottom structure) across 
the Manuscript. As per the Supporting Information, both chemical nomenclatures, 
namely the one following IUPAC rules and the alternate, are given for compounds III 
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and their derivatives. An example is provided in the scheme. There exist precedents in 
the literature applying either nomenclature to heterocycles related to III.228 
 
 
  
                                                 
228
 Example of using IUPAC nomenclature for heterocyckes III: a) A. S. Salman, A. Abdel-Aziem, M. J. 
Alkubbat, Am. J. Org. Chem 2015, 5, 57–72. Example of using the same modified nomenclature 
employed by us: b) S. Gosling, C. El Amri, A. Tatibouët, Synthesis 2014, 46, 1079–1084. 
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5.2. General procedure for the synthesis of catalysts 
(DHQ)2PYR is commercially available and was purchased from commercial suppliers.  
5.2.1. Preparation of 9-amino-(9-deoxy)epiquinine229 
 
1st step:230 A mixture of quinine (1 equiv., 16.2 g, 50 mmol) and triethylamine (3.6 
equiv., 25.1 mL, 180 mmol) in dry THF (250 mL) was cooled to 0 oC and then 
methanesulfonyl chloride (1.8 equiv., 7.0 mL, 90 mmol) was added dropwise. The 
mixture was stirred overnight at room temperature. The reaction was quenched with 
water (40 mL) and then THF was removed under vacuum. The residue was dissolved in 
dichloromethane (40 mL) and washed with water (30 mL) and saturated sodium 
bicarbonate (30 mL). The organic layer was dried over MgSO4, filtered and concentred 
under vacuum to afford crude mesylated product with 96% yield, which was used in 
the next step without further purification. 
2nd step:231 The crude mesylated product (1 equiv., 19.3 g, 48 mmol) was dissolved in 
DMF (150 mL). The solution was cooled to 0 oC and NaN3 (2 equiv., 6.2 g, 96 mmol) was 
added portionwise. The mixture was stirred at 70 oC for 16 h and after this time the 
reaction was quenched with water (80 mL) and then ethyl acetate (150 mL) was added. 
The organic layer was separated and washed with saturated NaCl thoroughly (5 x 60 
mL), dried over MgSO4, filtered and evaporated under reduced pressure to obtain the 
                                                 
229
 Adapted from: Brunner, H.; Büegler, J.; Nuber, B. Tetrahedron: Asymmetry, 1995, 6, 1699–1702. 
230
 Adapted from: Zielinska-Blajet, M.; Kucharska, M.; Skarzewski, J. Synthesis, 2006, 7, 4383–4387. 
231
 Adapted from: Sudermeier, U.; Döbler, C.; Mehltretter, G. M.; Baumann, W.; Beller, M. Chirality, 
2003, 15, 127–134. 
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crude azide derived product in quantitative yield which was used in the next step 
without further purification. 
3rd step:231 The azide derived crude product was dissolved in THF (250 mL) and PPh3 (1 
equiv., 12.6 g, 48 mmol) was added. The reaction mixture was heated to 40 oC and 
stirred until the gas evolution ceased (5 h). Then H2O (8 mL) was added and the 
mixture was stirred overnight at 40 oC. The solvent was removed under vacuum and 
the residue was dissolved in dichloromethane (150 mL). HCl 6M (250 mL) was added 
and the aqueous phase was separated and washed with dichloromethane (2 x 100 mL). 
Then the aqueous layer was cooled to 0 oC and basified until pH > 10 with NaOH 40%. 
The aqueous phase was then extracted with dichloromethane (3 x 150 mL), dried over 
MgSO4 and concentrated under reduced pressure to afford 9-amino-(9-
deoxy)epiquinine as a yellow viscous oil. Yield: 8.7 g, 26.9 mmol, 56%. All data were 
consistent with those previously reported. 1H NMR (300 MHz, CDCl3), δ: 8.75 (d, J = 4.6 
Hz, 1H), 7.36 – 8.05 (m, 4H), 5.79 (m, 1H), 4.97 (m, 2H), 4.57 (d, J = 10.4 Hz, 1H), 3.97 
(s, 3H), 3.02 – 3.34 (m, 3H), 2.77 (m, 2H), 2.27 (m, 1H), 2.08 (s, 2H), 1.26 – 1.63 (m, 4H), 
0.80 (m, 1H). 
5.2.2. Preparation of squaramide-based catalysts C1 
5.2.2.1. Preparation of squaric ester monoamine234 
 
To a solution of 3,4-dimethoxy-3-cyclobutane-1,2-dione (1 equiv., 1.42 g, 10 mmol) 
in MeOH (20 mL) was added 3,5-bis(trifluoromethyl)aniline (1 equiv., 1.56 mL, 10 
mmol). The reaction mixture was stirred at room temperature for 48 h. The formed 
precipitate was filtered and dried under vacuum to give title compound as a white 
solid. Yield: 2.25 g, 6.6 mmol, 66%. m.p. = 179–181 oC. All data were consistent with 
those previously reported. 1H NMR (300 MHz, DMSO-d6) δ: 11.18 (s, 1H), 8.04 (s, 2H), 
7.78 (s, 1H), 4.41 (s, 3H). 
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5.2.2.1.1. Preparation of catalyst C1 
3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-(((S)-(6-methoxyquinolin-4-
yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino )cyclobut-3-ene-1,2-dione 
(C1)¡Error! Marcador no definido. 
 
To a solution of squaric ester monoamide prepared as above (1 equiv., 2.25 g, 6.6 
mmol) in dichloromethane (33 mL), 9-amino-(9-deoxy)epiquinine (1 equiv., 2.13 g, 6.6 
mmol) was added. The reaction mixture was stirred for 48 h at room temperature, the 
solvent evaporated, and the residue was purified by flash column chromatography on 
non acid silica gel (eluting with hexane/ethyl acetate  80/20 → ethyl acetate)  to afford 
C1 as white solid. Yield: 2.91 g, 4.6 mmol, 70%. m. p. = 224–225 oC. All data were 
consistent with those previously reported. 1H NMR (300 MHz, DMSO-d6) δ: 9.88 (brs, 
1H), 8.80 (d, J = 4.5 Hz, 1H), 8.36 (brs, 1H), 8.04 – 7.86 (m, 3H), 7.76 (d, J = 10.0 Hz, 1H), 
7.67 (d, J = 4.5 Hz, 1H), 7.58 (s, 1H), 7.47 (d, J = 6.8 Hz, 1H), 6.19 – 5.73 (m, 2H), 5.13 – 
4.92 (m, 2H), 3.95 (s, 3H), 3.52 – 3.42 (m, 1H), 3.30 – 3.25 (m, 1H), 2.77 – 2.58 (m, 2H), 
2.35 – 2.20 (m, 1H), 1.60 – 1.47 (m, 4H), 0.66 (m, 1H). 
5.2.3. Preparation of thiourea containing Brønsted base catalyst C2232 
 
To a solution of 9-amino-(9-deoxy)epiquinine (1 equiv., 1.6 g, 5 mmol) in dry THF 
(7.5 mL) at 0 oC, a solution of bis(trifluomethyl)phenyl isothiocyanate (1.1 equiv., 1.5 g, 
5.5 mmol) in dry THF (2.5 mL) was added dropwise. The reaction mixture was stirred 
                                                 
232
 Adapted from: Vakulya, B.; Varga, S.; Csámpai, A. Soós, T. Org. Lett. 2005, 7, 1967–1969. 
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overnight at room temperature and then concentrated under reduced pressure. The 
residue was purified by flash column chromatography on non acid silica gel (eluting 
with hexane/ ethyl acetate  80/20 → ethyl acetate)  to afford the title compound. 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)thiourea (C2)  
White solid, yield: 2.6 g, 4.4 mmol, 88%. m.p. = 123–125 
oC. All data were consistent with those previously 
reported. 1H NMR (300 MHz, CD3OD) δ: 8.68 (d, J = 4.7 
Hz, 1H), 8.11 (brs, 2H), 8.07 (d, J = 2.6 Hz, 1H), 7.95 (d, J = 
9.3 Hz, 1H), 7.59 (br s, 1H), 7.55 (d, J = 4.7 Hz, 1H), 7.44 
(dd, J = 9.3, 2.6 Hz, 1H), 6.32 (d, J = 11.0 Hz, 1H), 5.84 
(ddd, J = 17.2, 10.5, 6.2 Hz, 1H), 5.02 (dt, J = 10.5, 1.5 Hz, 1H,), 4.98 (dt, J = 17.2, 1.5 Hz, 
1H), 4.03 (s, 3H), 3.56 – 3.53 (m, 1H), 3.39 – 3.37 (m, 1H), 3.29 (dd, J = 13.6, 9.9 Hz, 1H), 
2.82 (ddd, J = 15.6, 13.8, 4.9 Hz, 1H), 2.79 (ddd, J = 13.6, 4.7, 2.3 Hz, 1H), 2.38 – 2.35 
(m, 1H), 1.71 – 1.68 (m, 2H), 1.64 – 1.61 (m, 1H), 1.45 (ddd, J = 13.3, 10.4, 2.7 Hz, 1H), 
0.89 (dd, J = 13.3, 10.4 Hz, 1H). 
5.2.4. Synthesis of catalysts C3-C8 
5.2.4.1. Preparation of (chloromethyl)silyl derivatives 
(Chloromethyl)dimethyl(phenyl)silane 
 
The title compound was purchased from Sigma Aldrich. 
(Chloromethyl)(methyl)diphenylsilane4a 
 
To a solution of dichloro(chloromethyl)methylsilane (1 equiv., 60 mmol, 7.62 mL) in 
anhydrous diethyl ether (30 mL) Grignard reagent (3.0 M in ether) (2 equiv., 120 mmol, 
40 mL) was added dropwise at room temperature and the reaction mixture was 
refluxed for 16 h. Then, the mixture was cooled to 0 oC, saturated solution of NH4Cl (20 
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mL) was added and it was extracted with ethyl acetate (3 x 30 mL). The combined 
extracts were dried over MgSO4 and concentred under reduced pressure. The crude 
material was purified by flash column chromatography on silica gel (eluting with 
hexane) to afford the title compound as a colourless liquid; yield: 33.0 mmol, 8.22 g, 
55%. 1H NMR (300 MHz, CDCl3) δ: 7.64 – 7.52 (m, 4H), 7.49 – 7.32 (m, 6H), 3.26 (s, 2H), 
0.72 (s, 3H). 
(Chloromethyl)triphenylsilane4b 
 
The title compound was prepared according to the procedure shown above from 
trichloro(chloromethyl)silane (1 equiv., 10 mmol, 1.25 mL) and phenylmagnesium 
bromide (3.0 M in ether) (3 equiv., 30 mmol, 10 mL). The crude material was purified 
by crystallization on methanol. The crystals were washed with petroleum ether to 
afford the title compound as a white solid; yield: 4.5 mmol, 1.40 g, 45%. m. p. 110-113 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.68 – 7.52 (m, 6H), 7.53 – 7.29 (m, 9H), 3.53 (s, 2H). 
(chloromethyl)dimethyl(naphthalen-2-yl)silane4c 
 
To a solution of chloro(chloromethyl)dimethylsilane (1 equiv., 20 mmol, 2.63 mL) in 
anhydrous diethyl ether (15 mL,) Grignard reagent (0.5 M in THF) (1.4 equiv., 28 mmol, 
56 mL) was added dropwise at room temperature and the reaction mixture was 
refluxed for 16 h. Then, the mixture was cooled to 0 oC, saturated solution of NH4Cl (20 
mL) was added and it was extracted with ethyl acetate (3 x 30 mL). The combined 
extracts were dried over MgSO4 and concentred under reduced pressure. The crude 
material was purified by flash column chromatography on silica gel (eluting with 
hexane) to afford the title compound as a colourless liquid; yield: 10.0 mmol, 2.34 g, 
50%. 1H NMR (300 MHz, CDCl3) δ: 8.04 (s, 1H), 7.86 – 7.45 (m, 6H), 3.02 (s, 2H), 0.50 (s, 
6H). 
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5.2.4.2.  General procedure for the preparation of aminomethyl silanes233 
 
Step 1: To a solution of the corresponding chloromethyl sylane (20.0 mmol) in HMPA 
(10 mL) was added sodium azide (1.43 g, 22 mmol) and the reaction mixture was 
stirred for 5 h at room temperature. Then, the mixture was poured into H2O (30 mL) 
and extracted with hexane (3 x 30 mL). The combined extracts were washed with 
saturated solution of NH4Cl, dried over MgSO4 and concentred under reduced 
pressure. The residue was used in the next step without further purification. 
Step 2: To a suspension of LiAlH4 (1 equiv., 10.0 mmol) in dry Et2O (10 mL) was slowly 
added at 0 oC a solution of the corresponding azide (10.0 mmol) in dry diethyl ether (5 
ml). The mixture was stirred in an ice bath for 10 min and then stirred at room 
temperature until liberation of nitrogen ceased (30 min). The, the reaction was 
quenched with 1 mL of NH4OH 1% aqueous solution. The mixture was filtered through 
celite, the filtered was dried over MgSO4 and solvent was evaporated under reduced 
pressure. The residue was used in the next step without further purification. 
(Trimethylsilyl)methylamine 
The title compound was purchased from Fluka. 
(dimethyl(phenyl)silyl)methanamine 
The title compound was prepared according to the general 
procedure. Colourless liquid; yield: 18.0 mmol, 2.97 g, 90%. 1H NMR 
(300 MHz, CDCl3) δ: 7.57 – 7.53 (m, 2H), 7.38 – 7.36 (m, 3H), 2.40 (s, 2H), 0.33 (s, 6H). 
(methyldiphenylsilyl)methanamine 
The title compound was prepared according to the general 
procedure. Colourless liquid; yield: 16.2 mmol, 3.68 g, 81 %. 1H NMR (300 MHz, CDCl3) 
δ: 7.60 – 7.55 (m, 4H), 7.41 – 7.34 (m, 6H), 2.72 (s, 2H), 0.63 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ: 135.4, 134.5, 133.9, 129.4, 129.2, 127.8, 127.6, 29.1, –5.7.  UPLC-DAD-QTOF: 
C14H18NSi [M+H]
+ calcd.: 228.1209, found: 228.1197. 
 
                                                 
233
 Lettelier, M.; McPhee, D. J.; Griller, D. Synthetic Commun. 1988, 18, 1975–1978. 
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(Dimethyl(2-naphthyl)silyl)mathanamine  
The title compound was prepared according to the general 
procedure. Colourless liquid; yield: 3.68 g, 16.2 mmol, 80%. 
1H NMR (300 MHz, CDCl3), δ: 8.04 (s, 1H), 7.87 – 7.81 (m, 3H), 7.63 – 7.60 (m, 1H), 7.51 
– 7.48 (m, 2H), 2.49 (s, 2H), 0.42 (s, 6H).  
(Methyldiphenylsilyl)methanamine 
The title compound was prepared according to the general procedure. 
Colourless liquid; yield: 16.8 mmol, 4.85 g, 84%. 1H NMR (300 MHz, 
CDCl3) δ: 7.66 – 7.54 (m, 6H), 7.54 – 7.31 (m, 9H), 3.04 (s, 2H). 
5.2.4.3. Preparation of squaric ester monoamine234 
 
To a solution of 3, 4-dimethoxycyclobut-3-ene-1,2-dione (0.71 g, 5.0 mmol) in 10 mL 
MeOH was added the corresponding (amino methyl)silane. The reaction mixture was 
stirred for 48 h at room temperature and white precipitate was generated. The 
reaction product was filtered and the filtration residue was washed with Et2O to give 
the monosubstituted secondary amine, as a white solid. 
3-methoxy-4-((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. White solid; yield: 4.15 mmol, 884.0 mg, 83%. m. p. 
119–122 oC. IR (/cm-1): 3205, 3014, 2969, 2948, 2357, 1790, 
1692, 1576, 1493, 1366, 1228, 862, 584. 1H NMR (300 MHz, CDCl3) δ: 5.68 (s, 1H, NH), 
4.40 (s, 3H), 2.99 (m, 2H), 0.12 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 189.4, 182.1, 176.9, 
172.1, 60.1, 35.8, –3.42. UPLC-DAD-QTOF: C9H16NO3Si [M+H]
+ calcd.: 214.0899, found: 
214.0892. 
3-((dimethyl(phenyl)silyl)methylamino)-4-methoxycyclobut-3-ene-1,2-dione 
                                                 
234
 Adapted from Yang, W.; Du, D. Org. Lett. 2010, 12, 5450–5453. 
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 The title compound was prepared according to the general 
procedure. White solid; yield: 3.50 mmol, 962.8 mg, 70%. m. 
p. 117–120 oC. IR (/cm-1): 3247, 3135, 3046, 2968, 2359, 
1799, 1691, 1586, 1357, 1229, 1112, 1051, 980, 934, 807, 
697, 587, 467. 1H NMR (300 MHz, CDCl3) δ: 7.53 – 7.48 (m, 2H), 7.42 – 7.35 (m, 3H), 
6.20 (s, 1H, NH), 4.32 (s, 3H), 3.18 (m, 2H), 0.40 (s, 6H). 13C NMR (75 MHz, CDCl3) δ: 
189.5, 182.6, 177.4, 172.5, 134.9, 133.9, 130.2, 128.4, 60.5, 35.6, –4.6. UPLC-DAD-
QTOF: C14H18NO3Si [M+H]
+ calcd.: 276.1056, found: 276.1058. 
3-methoxy-4-((methyldiphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. White solid; yield: 4.50 mmol, 1633.5 mg, 90%. 
m. p. 148–152 oC. IR (/cm-1): 3247, 3051, 2968, 2898, 2359, 
1810, 1691, 1643, 1536, 1463, 1354, 1062, 933, 854, 816, 745, 648, 483. 1H NMR (300 
MHz, CDCl3) δ: 7.54 – 7.37 (m, 10H), 5.86 (s, 1H, NH), 4.30 (s, 3H), 3.49 – 3.46 (m, 2H), 
0.67 (s, 3H). UPLC-DAD-QTOF: C19H20NO3Si [M+H]
+ calcd.: 338.1212, found: 338.1218. 
3-(((dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-methoxycyclobut-3-ene-1,2-
dione  
The title compound was prepared according to the 
general procedure. White solid; yield: 3.50 mmol, 
1137.9 mg, 70%. m. p. 140–144 oC. IR (/cm-1): 3277, 
3065, 3001, 2939, 2904, 1803, 1696, 1622, 1495, 1396, 1275, 1109, 918, 848, 779, 725, 
580, 459. 1H NMR (300 MHz, CDCl3) δ: 8.00 (s, 1H), 7.86 – 7.81 (m, 3H), 7.55 – 7.49 (m, 
3H), 6.63 (s, 1H, NH), 4.23 (s, 3H), 3.21 (d, J = 6Hz, 1H), 0.48 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ: 189.7, 182.3, 177.3, 172.2, 135.0, 134.1, 132.9, 129.5, 128.2, 127.9, 127.6, 
127.0, 126.4, 60.4, 35.6, –4.5. UPLC-DAD-QTOF: C18H20NO3Si [M+H]
+ calcd.: 326.1212, 
found: 326.1212. 
3-methoxy-4-(triphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. White solid; yield: 1702.0 mg, 4.25 mmol, 85%. m. p. 
167–171 oC. IR (ν/cm-1): 3254, 3046, 1801, 1702, 1601, 1426, 
1360, 1111, 698, 505. 1H NMR (300 MHz, CDCl3) δ: 7.63 – 7.35 (m, 15H), 5.32 (s, 1H), 
4.28 (s, 3H), 3.76 (s, 2H). 13C NMR (75 MHz, CDCl3) δ: 188.9, 182.9, 177.6, 172.9, 136.0, 
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135.7, 130.8, 128.7, 60.5, 27.8. UPLC-DAD-QTOF: C24H21NO3Si [M+H]
+ calcd.: 400.1363, 
found: 400.1360. 
5.2.4.4. Formation of catalysts C3-C8 
 
To a solution of monosubstituted squarate (1.5 mmol) in 6 mL MeOH was added the 
corresponding cinchona-base chiral amine (3.0 mmol) and the reaction mixture was 
stirred for 48 h at room temperature. The reaction product was obtained after flash 
column chromatography on basic silica gel (eluting with ethyl acetate) to afford the 
desired catalysts C3-C8. 
3-(((1S,2S)-2-(piperidin-1-yl)cyclohexyl)amino)-4-
(((trimethylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C3) 
The title compound C3 was prepared according to the 
general procedure. White solid; yield: 0.68 mmol, 247.0 
mg, 45%. m. p. 239–242 oC. [α]D
25= +42.1 (c = 0.25, DMSO-
d6). IR (/cm
-1): 3160, 3014, 2929, 2851, 1791, 1633, 1551, 
1462, 1365, 1216, 846, 762. 1H NMR (300 MHz, DMSO) δ: 
7.10 (s, 1H), 3.82 (s, 1H), 3.21 – 3.08 (m, 2H), 2.63 – 2.47 (m, 2H), 2.30 – 2.20 (m, 2H), 
2.04 – 1.99 (m, 1H), 1.83 – 1.63 (m, 2H), 1.41 – 1.14 (m, 8H), 0.06 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ: 182.3, 181.6, 168.1, 167.6, 68.4, 53.8, 49.3, 34.4, 26.4, 24.9, 24.6, 24.6, 
23.8, –3.1. UPLC-DAD-QTOF: C19H34N3O2Si [M+H]
+ calcd.: 364.2420, found: 276.2409.  
3-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C4) 
The title compound C4 was prepared according to the 
general procedure. White solid; yield: 1.02 mmol, 514.3 
mg, 68%. m. p. 209–213 oC. [α]D
25= –102.6 (c = 0.25, 
CH2Cl2). IR (/cm
-1): 3203, 3014, 2936, 2871, 1788, 
1636, 1545, 1455, 1366, 1232, 1037, 842. 1H NMR (300 
MHz, CDCl3) δ: 8.66 (d, J = 4.5 Hz, 1H), 8.06 – 8.02 (d, J = 
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9.2 Hz, 1H), 7.84 (s, 1H), 7.56 (d, J = 3 Hz, 1H), 7.40 (dd, J = 3,3 Hz, 1H), 5.85 – 5.73 (m, 
1H), 5.01 – 4.91 (m, 2H), 3.92 (s, 3H), 3.51 – 3.06 (m, 6H), 2.78-2.68 (m, 2H), 2.24 (s, 
broad signal, 1H), 1.62 – 1.42 (m, 4H), 0.78 – 0.72 (m, 1H), 0.02 (s, 3H),  –0.06 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ: 183.5, 181.8, 181.7, 168.0, 167.7, 158.7, 147.9, 144.9, 
141.5, 132.0, 128.0, 122.3, 114.8, 101.9, 56.1, 41.0, 39.7, 36.0, 35.9, 29.8, 28.0, 27.7, 
26.2, –2.9. UPLC-DAD-QTOF: C28H37N4O3Si [M+H]
+ calcd.: 505.2635, found: 505.2597. 
3-((dimethyl(phenyl)silyl)methylamino)-4-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-
vinylquinuclidin-2-yl)methylamino)cyclobut-3-ene-1,2-dione (C5) 
The title compound C5 was prepared according to 
the general procedure. White solid; yield: 1.05 
mmol, 594.6 mg, 70%. m. p. 221–224 oC. [α]D
25= –
106.0 (c = 0.25, CH2Cl2). IR (/cm
-1): 3183, 3047, 
2919, 2862, 1788, 1631, 1542, 1455, 1399, 1232, 
1032, 838, 711, 469. 1H NMR (300 MHz, CDCl3) δ: 
8.62 (d, J = 3.4 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.77 
(s, 1H), 7.42 – 7.38 (m, 2H), 7.35 – 7.32 (m, 2H), 7.22 – 7.19 (m, 3H), 5.80 – 5.68 (m, 
1H), 5.02 – 4.94 (m, 2H), 3.93 (s, 3H), 3.45-7.39 (m, 2H), 3.29-3.12 (m, 3H), 2.77 – 2.67 
(m, 2H), 2.29 (s, 1H), 1.68 – 1.61 (m, 3H), 1.50 – 1.42 (m, 1H), 0.83 – 0.77 (m, 1H), 0.19 
(s, 6H). 13C NMR (75 MHz, CDCl3), δ: 183.4, 181.0, 168.3, 167.2, 158.8, 147.7, 145.0, 
140.9, 135.5, 133.8, 132.0, 129.9, 128.1, 122.6, 115.2, 101.8, 56.2, 41.0, 39.4, 35.1, 
27.5, 26.1, –4.5. UPLC-DAD-QTOF: C33H39N4O3Si [M+H]
+ calcd.: 567.2791, found: 
567.2800. 
3-(((dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-(((S)-(6-methoxyquinolin-4-
yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)cyclobut-3-ene-1,2-dione (C6) 
The title compound was C6 prepared 
according to the general procedure. White 
solid; yield: 1.12 mmol, 693 mg, 75%. m. p. 
229–232 oC. [α]D
25= –109.5 (c = 0.5, CH2Cl2). 
IR (/cm-1): 3227, 2937, 2862, 1790, 1637, 
1567, 1544, 1264, 1086, 1038, 817. 1H NMR 
(300 MHz, CDCl3) δ: 8.54 (s, 1H), 8.00 (d, J = 
9.2 Hz, 1H), 7.84 (s, 1H), 7.75 – 7.70 (m, 4H), 7.43 – 7.35 (m, 5H), 5.78 – 5.65 (m, 1H), 
4.98 – 4.89 (m, 2H), 3.89 (s, 3H), 3.31 – 3.06 (m, 5H), 2.71 – 2.61 (m, 2H), 2.22 (m, 1H), 
1.62 – 1.52 (m, 3H), 1.41 – 1.32 (m, 1H), 0.77-0.70 (m, 1H), 0.20 – 0.18 (m, 6H). 13C 
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NMR (75 MHz, CDCl3) δ: 184.0, 182.8, 167.7, 159.2, 148.1, 145.5, 141.9, 135.3, 134.5, 
133.3, 132.5, 130.0, 128.5, 128.3, 128.0, 127.4, 126.8, 122.9, 115.2, 102.2, 56.5, 41.3, 
40.1, 35.2, 28.4, 28.0, 26.7, –4.0. UPLC-DAD-QTOF: C37H41N4O3Si [M+H]
+ calcd.: 
617.2948, found: 617.2961. 
3-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((methyldiphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C7) 
The title compound C7 was prepared according to 
the general procedure. White solid; yield: 0.9 mmol, 
565.5 mg, 60%. m. p. 152–156 oC. [α]D
23= –105.3 (c = 
1.0, CH2Cl2). IR (/cm
-1): 3193, 2929, 2859, 1788, 
1628, 1547, 1456, 1230, 1114, 803, 760, 730, 700, 
489.  1H NMR (300 MHz, CDCl3) δ: 8.49 (d, J = 5.1 Hz, 
1H), 8.00 (d, J = 9.2 Hz, 1H), 7.79 (s, 1H), 7.48 – 6.97 
(m, 12H), 5.75 (ddd, J = 17.6, 10.9, 7.6 Hz, 1H), 5.08 – 4.80 (m, 2H), 3.89 (s, 3H), 3.43 
(ddd, J = 32.6, 16.8, 9.5 Hz, 4H), 3.15 (dd, J = 13.8, 10.0 Hz, 1H), 2.68 (dq, J = 14.9, 7.5, 
6.1 Hz, 2H), 2.15 (s, 2H), 1.73 – 1.18 (m, 4H), 0.86 – 0.65 (m, 1H), 0.44 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ: 183.6, 181.9, 167.8, 158.7, 147.6, 144.9, 141.6, 134.6, 133.6, 133.5, 
131.9, 130.1, 128.2, 128.2, 122.5, 114.7, 101.9, 56.1, 40.9, 39.7, 33.7, 28.0, 27.7, 26.3, -
5.7.  UPLC-DAD-QTOF: C38H41N4O3Si [M+H]
+ calcd.: 629.2948, found:  629.2956. 
3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methylamino)-
4-((triphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C8) 
The title compound C8 was prepared according to the 
general procedure. White solid; yield: 687.5 mg, 1.0 
mmol, 67%. m. p. 252–256 oC. [α]D
23= –58.9 (c = 1.0, 
CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 8.40 (s, 1H), 7.96 
(d, J = 9.2 Hz, 1H), 7.77 (s, 1H), 7.61 – 7.08 (m, 19H), 
5.71 (dt, J = 17.4, 9.3 Hz, 1H), 5.03 – 4.83 (m, 2H), 3.90 
(s, 3H), 3.72 (td, J = 20.5, 20.0, 10.0 Hz, 3H), 3.36 – 3.01 
(m, 3H), 2.63 (dt, J = 14.6, 7.5 Hz, 2H), 2.23 (dt, J = 10.8, 6.3 Hz, 1H), 1.72 – 1.28 (m, 
4H), 0.72 (q, J = 7.6, 6.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 183.6, 182.0, 167.9, 167.8, 
158.7, 147.4, 144.9, 141.5, 135.9, 135.7, 135.4, 131.8, 130.3, 128.4, 128.3, 128.2, 
128.0, 122.7, 114.7, 101.9, 56.2, 40.8, 39.6, 32.6, 28.0, 27.8, 27.7, 26.4. UPLC-DAD-
QTOF: C43H43N4O3Si [M+H]
+ calcd.: 691,3104, found:  691.3129. 
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5.2.5. Preparation of catalyst C10235 
 
Aqueous glutaraldehyde (50%, 1.0 mL) was added dropwise into a mixture of 
NaBH(OAc)3 (4.24g, 20.0 mmol) and (1S,2S)-1,2-diaminocyclohexane (570 mg, 5.0 
mmol) in dichloroetane (30 mL) at room temperature. The resulting mixture was 
stirred at room temperature for 3h, and then quenched with aqueous NaOH (10%, 20 
mL). The organic layer was separated and the aqueous layer was extracted with CH2Cl2 
(3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over 
anhydrous Na2SO4, and concentrated to give the crude product as a yellow liquid (820 
mg, 90% yield). 
To a solution of the crude amine (273 mg, 1.5 mmol) in 5 mL CH2Cl2 was added 
squaric ester monoamine (271 mg, 1.0 mmol). The reaction was stirred at room 
temperature for 24 h. Then the mixture was concentrated and purified by basic silica 
gel column chromatography (using CH2Cl2 as eluant) to afford the desired product VII 
as a pale yellow solid (347 mg, 71% yield). m.p. 134−136 °C, [α]D
25 = +150.3 (c = 0.62, 
CH2Cl2). All spectroscopic data were identical to those reported in the literature. 
1H 
NMR (500 MHz, CDCl3) δ: 7.97 (s, 2H), 7.42 (s, 1H), 4.00 (s, 1H), 2.62 (br s, 2H), 2.35 − 
2.27 (m, 3H), 2.18 − 2.16 (m, 1H), 1.89 − 1.87 (m, 1H), 1.78 (d, J = 10.5 Hz, 1H), 1.70 (d, 
J = 11.0 Hz, 1H), 1.40 − 1.12 (m, 10H). 
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5.2.6. Preparation of catalyst C11 
Step 1) Protection of the amine and amide formation236 
 
Na2CO3 (2.12 g, 20 mmol, 2 equiv.) and Boc2O (3.3g, 15 mmol, 1.5 equiv.) were 
added to a solution of t-leucine (1.31 g, 10 mmol, 1 equiv.) in water (20 mL) and THF (5 
mL) at 0 °C. After stirring for 12 h at room temperature HCl (10 %) was added until pH 
2 and the mixture was extracted with EtOAc (3 x 30 mL). The aqueous phases were 
united and washed with brine (50 mL) and dried over MgSO4, after which the solvent 
was removed under reduced pressure. The residue was then redissolved in dry DMF 
dissolution (20 mL) and DIPEA (2.58 g, 20 mmol, 2 equiv.) and HBTU (5.7 gm 15 mmol, 
1.5 equiv.) were added. After stirring for 1 h piperidine (0.94 g, 11 mmol, 1.1 equiv.) 
was added and the mixture was stirred for further 16 h. The reaction was quenched 
adding HCl 1 M (20 mL) and the mixture was extracted with EtOAc (2 x 20 mL). The 
organic phases were united and washed with a HCl 1 M and brine (20 mL) and dried 
over MgSO4, after which the solvent was removed under reduced pressure. The 
residue was purified by flash column chromatography on silica gel (eluting with 
hexane/ EtOAc 85/15) to afford tert-butyl (S)-(3,3-dimethyl-1-oxo-1-(piperidin-1-
yl)butan-2-yl)carbamate as a white solid. Yield: 2.5 g, 8.3 mmol, 83%. All spectroscopic 
data were identical to those reported in the literature. 1H NMR (300 MHz, CDCl3) δ: 
0.98 (s, 9H), 1.43 (s, 9H), 1.52 – 1.62 (m, 6H), 3.46 – 3.69 (m, 4 H), 4.54 (d, J = 9.7 Hz, 
1H), 5.38 (d, J = 9.6 Hz, 1H). 
Step 2) Deprotection and reduction 
 
Previously obtained amide (2.5 g, 8 mmol, 1 equiv.) was dissolved in a mixture of 
CH2Cl2 (8 mL) and trifluoroacetic acid (2 mL) and stirred at 40 °C until no more starting 
material was observed by TLC (eluting with hexane/EtOAc 70/30). The solvent was 
then removed under reduced pressure and the residue was redissolved in CH2Cl2 (10 
mL). The solution was washed with NaOH (40%), dried over MgSO4 and the solvent was 
                                                 
236
 Adapted from: Gao, Y.; Ren, Q.; Wang, L.; Wang, J. Chem. Eur. J. 2010, 16, 13068–13071. 
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removed under reduced pressure obtaining the aminoamide as a yellow oil. The 
aminoamide was then dissolved in dry diethyl ether (10 mL) and was added dropwaise 
over a suspension of lithium aluminiumhydride (879 mg, 24 mmol, 3 equiv.) in diethyl 
ether (40 mL) at 0 oC under nitrogen atmosphere. The mixture was stirred at the same 
temperature for some minutes and afterwards it was stirred at room temperature for 
16 h. The reaction was quenched adding water (1.2 mL), NaOH 15% (1.2 mL) and water 
(3.6 mL) at 0 oC. The result was filtered and the liquid was extracted with diethyl ether 
(2 x 10 mL). The combined organic layers were dried over MgSO4 and the solvent was 
eliminated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (eluting with hexane/EtOAc 1/1) to afford (S)-3,3-
dimethyl-1-(piperidin-1-yl)butan-2-amine as yellow oil. Yield: 1.16 g, 6.8 mmol, 92%. 
All spectroscopic data were identical to those reported in the literature. 1H NMR (500 
MHz, CDCl3) δ: 2.66 (dd, J = 11.0, 2.5 Hz, 1H), 2.52 (d, J = 12.3 Hz, 4H), 2.28 (dd, J = 
12.3, 2.8 Hz, 3H), 2.13 (dd, J = 12.1, 11.2 Hz, 1H), 1.61 – 1.53 (m, 4H), 1.44 – 1.42 (m, 
2H), 0.90 (s, 9H). 
Step 3) Amine coupling237 
 
To a solution of the diamine (780 mg, 4,6 mmol, 1 equiv.) in methanol (30 mL) the 
squaric ester monoamide obtained above (1.56 g, 4,6 mmol, 1 equiv.) was added and 
the mixture was stirred until complete disappearance of the starting amide as 
monitored by TLC (16 h). The white precipitate was filtered and washed with CH2Cl2 to 
afford essentially pure C11 as a white solid. m.p. 246‒248 °C. Yield: 1.29 g, 2.6 mmol, 
59%. All spectroscopic data were identical to those reported in the literature. 
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5.2.7. Preparation of catalyst C12238 
Catalyst C12 was prepared according to the literature 
procedure. All data were consistent with those 
previously reported. 
 
 
 
 
5.2.8. Preparation of catalyst C13 
Step 1) Peptide coupling239 
 
1-Methylimidazole (2.5 equiv., 15.5 mmol, 1.2 mL) was added to a slurry of 3-nitro-
5-(trifluoromethyl)benzoic acid  (1 equiv., 6.2 mmol, 1.5 g) in DCM (2.5 mL/mmol) at 0 
oC, and the mixture was stirred for 10 min. MsCl (1.5 equiv., 9.3 mmol, 0.7 mL) in DCM 
(0.1 mL/mmol) was added to the mixture under –5 oC. After the mixture was stirred 
under that temperature for 20 minutes, N-methyl-3,5-bis(trifluoromethyl)aniline (1 
equiv., 6.2 mmol, 1.0 mL) was added. The mixture was stirred at room temperature for 
2 hours. H2O (10 mL/mmol) was added to the mixture and a solid precipitated, which 
was dissolved in EtOAc (10 mL/mmol). The organic layer was washed with brine (3 x 10 
mL/mmol), dried over MgSO4 and evaporated under reduced pressure. The crude was 
crushed with diethyl ether to afford the pure compound as a white solid. Yield: 4.8 
mmol, 2.2 g, 78%. 1H NMR (300 MHz, CDCl3) δ: 8.44 (s, 1H), 8.36 (s, 1H), 7.85 (s, 1H), 
7.76 (s, 1H), 7.59 (s, 2H), 3.60 (s, 3H).  
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Step 2) Hydrogenation 
 
 
 
To a solution of N-(3,5-Bis(trifluoromethyl)phenyl)-N-methyl-3-nitro-5-(trifluoro-
methyl)benzamide (4.8 mmol, 2.2 g)  in EtOAc (10 mL) under inert atmosphere, Pd/C 
was added (Pd 10% in activated carbon, 10% in weight). The reaction mixture was 
stirred under H2 atmosphere (1 atm) at room temperature for 20 hours. After that the 
mixture was filtered over celite and the filtrate was concentrated under reduced 
pressure to afford the pure hydrogenated product. White solid. Yield: 1.9 g, 4.7 mmol, 
99%. 1H NMR (300 MHz, CDCl3) δ: 7.69 (s, 1H), 7.53 (s, 2H), 6.87 (s, 1H), 6.83 (s, 1H), 
6.69 (s, 1H), 3.92 (s, 2H), 3.53 (s, 3H).  
 
Step 3) Benzamide coupling with methyl squarate240 
 
 
 
To a solution of 3,4-dimethoxy-3-cyclobutane-1,2-dione (1 equiv., 4.3 mmol, 613 
mg) in MeOH (2 mL/mmol) N-(3,5-Bis(trifluoromethyl)phenyl)-3-amino-5-(trifluoro-
methyl)-N-methyl benzamide (1.1 equiv., 4.7 mmol, 2.0 g) was added at room 
temperature. The mixture was stirred at room temperature for 15 h. The white 
precipitate was filtrated and washed with MeOH. White solid. Yield: 4.08 mmol, 2.2 g, 
>95%. 1H NMR (300 MHz, CDCl3) δ: 7.70 (d, J = 5.0 Hz, 2H), 7.57 (s, 2H), 7.51 (s, 1H), 
7.18 (s, 1H), 4.52 (s, 3H), 3.58 (s, 3H). 
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Step 4) Amine coupling 
 
To a suspension of 3-(2-Methoxy-3,4-dioxocyclobut-1-enylamino)-N-(3,5-
bis(trifluoromethyl)phenyl)-N-ethylbenzamide (1 equiv., 2.0 mmol, 653 mg) in MeOH 
(10 mL) (S)-3,3-dimethyl-1-(piperidin-1-yl)butan-2-amine was added (1 equiv., 2.0 
mmol, 368 mg) at room temperature. The reaction mixture was stirred vigorously at 
room temperature for 2 days. The reaction mixture was evaporated and purified by 
column chromatography (eluting with 50:50 Hex:EtOAc; 0:100 Hex:EtOAc to 90:10 
CH2Cl2:MeOH). Yellow solid. Yield: 969 mg, 1.4 mmol, 70%. 
1H NMR (300 MHz, DMSO-
d6) δ: 8.04 (s, 2H), 7.92 (s, 1H), 7.80 (s, 1H), 7.78 – 7.74 (m, 1H), 7.20 (s, 1H), 4.14 – 3.91 
(m, 1H), 3.47 (s, 3H), 2.39 – 2.13 (m, 2H), 1.39 (m, 6H), 0.94 (s, 1H). 13C NMR (75 MHz, 
Acetone-d6) δ: 185.6, 181.5, 172.0, 169.3, 163.3, 147.0, 141.7, 139.1, 132.8 (q, J = 32.7 
Hz, 2CF3), 132.0 (q, J = 30.0 Hz, 1CF3), 128.7, 121.8, 120.7, 118.9, 116.2, 61.5, 59.9, 
55.4, 38.4, 35.00, 26.7, 26.4, 24.6. UPLC-DAD-QTOF: C32H34F9N4O3 [M+H]
+ calcd.: 
692.2409, found: 692.2413. 
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5.2.9. Representative NMR spectra 
3-methoxy-4-((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
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3-((dimethyl(phenyl)silyl)methylamino)-4-methoxycyclobut-3-ene-1,2-dione 
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3-methoxy-4-((methyldiphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
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3-(((dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-methoxycyclobut-3-ene-1,2-
dione  
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3-(((1S,2S)-2-(piperidin-1-yl)cyclohexyl)amino)-4-
(((trimethylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C3) 
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3-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C4) 
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3-((dimethyl(phenyl)silyl)methylamino)-4-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-
vinylquinuclidin-2-yl)methylamino)cyclobut-3-ene-1,2-dione (C5) 
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3-(((dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-(((S)-(6-methoxyquinolin-4-
yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)cyclobut-3-ene-1,2-dione (C6) 
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3-(((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)-
4-(((methyldiphenylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C7) 
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3-(((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)-
4-(((triphenylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C8) 
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(S)-N-(3,5-bis(trifluoromethyl)phenyl)-3-((2-((3,3-dimethyl-1-(piperidin-1-yl)butan-2-
yl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-5-(trifluoromethyl)benzamide (C12) 
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(S)-N-(3,5-Bis(trifluoromethyl)phenyl)-3-((2-((3,3-dimethyl-1-(piperidin-1-yl)butan-2-
yl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-N-methyl-5-
(trifluoromethyl)benzamide (C13) 
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5.3. Experimental section of chapter 2 
5.3.1. General procedure for the synthesis of α’-hydroxy enone 1a241 
 
Commercially available 3-hydroxy-3-methyl-2-butanone (1 equiv., 5.3 mL, 50 mmol) 
and paraformaldehyde (2 equiv., 3 g, 100 mmol) were added to a solution of iPr2NH (2 
equiv., 14.0 mL, 100 mmol) and TFA (2.5 equiv., 9.6 mL, 125 mmol) in THF (250 mL). 
The mixture was refluxed and paraformaldehyde (2 equiv., 3 g, 100 mmol) was added 
every 2 h three times. The mixture was stirred at reflux overnight and then was cooled 
to room temperature. CH2Cl2 (100 mL) was added and the mixture was washed with 1N 
HCl (75 mL), 1N NaOH (75 mL) and brine (75 mL), and the organic layer was dried over 
MgSO4. The solvent was removed under reduced pressure (230 mbar/ bath 40 
oC). The 
residue was purified by flash column chromatography on silica gel (eluent: diethyl 
ether) to afford 4-hydroxy-4-methylpent-1-en-3-one (1a) as colorless oil. Yield: 5.0 g, 
44.5 mmol, 89%. 1H NMR (CDCl3) δ: 6.73 (dd, J = 9.5 Hz, 16.8 Hz, 1H), 6.50 (dd, J = 2.2 
Hz, 16.8 Hz, 1H), 5.82 (dd, J = 2.2 Hz, 10.3 Hz, 1H), 1.38 (s, 6H). 13C NMR (CDCl3) δ: 
202.3, 131.1, 128.8, 75.4, 26.1.  
5.3.2. General procedure for the synthesis of α’-silyloxienone 1b242 
 
3-(Trimethylsilyl)-2-oxazolidinone (TMSO) (3.4 mL, 22.5 mmol, 1.5 equiv) and 3 
drops of trifluoromethanesulfonic acid were added to 4-hydroxy-4-methylpent-1-en-3-
one (1.68 g, 15 mmol, 1 equiv). The reaction mixture was stirred at room temperature 
for 2 h. The resulting brown suspension was diluted with pentane (20 mL) and 
subsequently washed with water (20 mL) and NaHCO3 sat. (20 mL), dried with MgSO4 
and concentrated under reduced pressure. The crude product was purified by silica gel 
flash column chromatography (eluent pentane/Et2O, 98:2) to afford the title 
compound (1b) as a colorless oil. Yield: 2.6 g, 14.0 mmol, 93%. 1H NMR (300 MHz, 
                                                 
241
 Palomo, C.; Oiarbide, M.; García, J.; González, A.; Arceo E. J. Am. Chem. Soc. 2003, 125, 13942–13943. 
242
 Adapted from: Aizpurua, J. M.; Palomo, C.; Palomo A. L. Can. J. Chem. 1984, 62, 336–340. 
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CDCl3) δ: 7.03 (dd, J = 17.3, 10.4 Hz, 1H), 6.38 (dd, J = 17.3, 2.1 Hz, 1H), 5.72 (dd, J = 
10.4, 2.1 Hz, 1H), 1.37 (s, 6H), 0.14 (s, 9H). 
5.3.3. Synthesis of 2-cyanoalkyl pyridine 4243 
Compound 4 was prepared according the literature provedure. All 
data were consistent with those previously reported.  White solid, 
yield: 68%. 
 
5.3.4. Synthesis of cyanoalkyl azaarene N-oxides 
5.3.4.1.  Oxidation of 2-bromo and 3-bromo-pyridines 
 
General procedure A:244 To a solution of corresponding bromo-pyridine (30 mmol) in 
CH2Cl2 (2 mL/mmol) was added mCPBA (1.4 equiv.) and the resulting mixture was 
stirred at room temperature for 3-4 days. The organic layer was removed and the 
crude was purified purified by flash column chromatography on silica gel.  
General procedure B:245 To a solution of corresponding bromo-pyridine (10 mmol) in 
CHCl3 (2 mL/mmol) was added m-CPBA (1.4 equiv.) and the resulting mixture was 
stirred overnight at 50 oC. The organic layer was removed and the crude was purified 
by flash column chromatography on silica gel. 
General procedure C:246 To an ice–cold solution of corresponding bromo-pyridine (10 
mmol) in trifluoroacetic acid (12 mL) was added dropwise an aqueous solution of H2O2 
(30%) (3.3 mL). The reaction mixture was heated to 100 oC overnight and then cooled 
to rt, poured into 50 mL of water and the precipitate filtered. The solid obtained was 
the starting material. The filtrate was extracted with CH2Cl2 (3 x 20 mL) and the 
combined organic layers were washed with 0.5 M K2CO3 solution (3 x 20 mL). The 
                                                 
243
 Kawano, T.; Kurimoto, M.; Hatanaka, M.; Ueda, I. Chem. Pharm. Bull. 1992, 40, 3067–3071. 
244
 PCT Int. Appl., 2011150156, 01 Dec 2011. 
245
 Brasse, M.; Cámpora, J.; Palma, P.; Álvarez, E. Organometallics 2008, 27, 4711–4723. 
246
 PCT Int. Appl., 2012045124, 12 Apr 2012. 
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organic layer was dried over MgSO4, filtered and concentrated under reduced 
pressure.  
2-bromopyridine 1-oxide 
The title compound was prepared from 2-bromopyridine (30 mmol, 4.74 g) 
according to procedure A. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc, 50:50 to 0:100) to 
afford the title compound as a grey oil; yield: 24.0 mmol, 4.15 g, 80%. IR 
(/cm–1): 3096, 3035, 1697, 1589, 1541, 1411, 1251, 1121, 1065, 1037, 838, 762, 674, 
565, 519, 446. 1H NMR (300 MHz, CDCl3) δ: 8.40 – 8.38 (m, 1H), 7.68 – 7.64 (m, 1H), 
7.28 – 7.22 (m, 1H), 7.14 – 7.08 (m, 1H). 
2,6-dibromopyridine 1-oxide 
The title compound was prepared from 2,6-dibromopyridine (10 mmol, 
2.37 g) according to procedure C. White solid; yield: 8.4 mmol, 2.10 g, 
84%. m.p. 180–183 oC. IR (/cm–1): 3090, 3034, 1696, 1554, 1403, 
1268, 1125, 1066, 1032, 808, 743, 660, 567, 528, 444. 1H NMR (300 MHz, CDCl3) δ: 7.64 
(d, J = 9 Hz, 2H), 6.93 (t, J = 6, 9 Hz, 1H). 
2-bromo-5-methylpyridine 1-oxide 
The title compound was prepared from 2-bromo-5-methylpyridine (10 
mmol, 1.71 g) according to procedure B. The crude material was purified 
by flash column chromatography on silica gel (eluting with ethyl 
acetate/methanol, 100:0 to 90:10) to afford the title compound as a white solid; yield: 
1.70 g, 9.1 mmol, 91%. m.p. 65–69 oC. IR (/cm–1): 3088, 3054, 3021, 1697, 1467, 1367, 
1307, 1276, 1208, 1172, 1130, 1066, 1018, 951, 806, 743, 617, 573, 523, 454.  1H NMR 
(300 MHz, CDCl3) δ: 8.26 (s, 1H), 7.53 (d, J = 6 Hz, 1H), 6.95 (d, J = 9 Hz, 1H), 2.28 (s, 
3H). 
2-bromo-5-chloropyridine 1-oxide 
The title compound was prepared from 2–bromo–5–chloropyridine (10 
mmol, 1.91 g) according to procedure B. The crude material was 
purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc, 80:20 to 50:50) to afford the title compound; yield: 1.45 g, 
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7.0 mmol, 70%. m. p. 103–106 oC. IR (/cm–1): 3094, 3067, 3023, 170, 1573, 1475, 
1353, 1297, 1251, 1229, 1110, 1067, 919, 847, 823, 746, 708, 651, 590, 568, 447. 1H 
NMR (300 MHz, CDCl3) δ: 8.42 – 8.41 (m, 1H), 7.59 (d, J = 6 Hz, 1H), 7.14 – 7.11 (m, 1H). 
 
3-bromopyridine 1-oxide 
The title compound was prepared from 3-bromopyridine (10 mmol, 1.57 
g) according to procedure A. Brown oil; yield: 8.6 mmol, 1.49 g, 86%. IR 
(/cm–1): 3087, 3030, 1699, 1589, 1532, 1462, 1417, 1290, 1247, 1155, 
1083, 1008, 886, 780, 664, 546, 489. 1H NMR (300 MHz, CDCl3) δ: 8.37 – 
8.36 (m, 1H), 8.17–8.14 (m, 1H), 7.42 – 7.39 (m, 1H), 7.18 – 7.13 (m, 1H). 
5.3.4.2.  Oxidation of 2-chloro-pyrazines247 
 
To a stirred solution of corresponding 2-choro-pyrazine (10 mmol) in 7.5 mL of 
H2SO4 at 0 
oC is gradually added K2S2O8 (1.1 equiv.). The reaction mixture is stirred for 
24 h at room temperature and carefully poured into ice water. The aqueous solution is 
extracted with CH2Cl2 and the extract is washed with saturated NaHCO3 solution and 
brine and dried over magnesium sulfate. Evaporation of the solvent affords the desired 
compound which was used without further purification. 
2-chloropyrazine 1-oxide 
The title compound was prepared from 2-chloropyrazine (10 mmol, 1.30 
g) according to the general procedure. White solid; yield: 0.62 g, 4.8 
mmol, 48 %. m. p. 131–134 oC. IR (/cm–1): 3085, 3040, 1689, 1556, 1501, 
1454, 1289, 1247, 1105, 1097, 1004, 887, 780, 651, 552. 1H NMR (300 
MHz, CDCl3) δ: 8.64 (m, 1H), 8.36 – 8.35 (m, 1H), 8.23 – 8.21 (m, 1H). 
2,6-dichloropyrazine 1-oxide 
                                                 
247
 Mixan, C. E.; Pews, R. G. J. Org. Chem. 1977, 42, 1869–1871. 
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The title compound was prepared from 2,6-dichloropyrazine (10 
mmol, 1.48 g) according to the general procedure. White solid; yield: 
4.6 mmol, 0.68 g, 46%. m. p. 120–123 oC. IR (/cm–1): 3067, 3001, 
1709, 1576, 1465, 1424, 1304, 1247, 1155, 1083, 1008, 923, 648, 567.  
1H NMR (300 MHz, CDCl3) δ: 8.55 (s, 2H). 
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5.3.4.3.  Synthesis of adducts 6, 10, 11 and 12 
 
General procedure A: To a solution of potassium tert-butoxide (2 equiv., 6 mmol, 673 
mg) in dry THF (10 mL) at room temperature was added 2-phenylacetonitrile (1.5 
equiv., 4.5 mmol) and the resulting mixture was stirred for 45 min at the same 
temperature. Afterwards the corresponding pyridine N-oxide (1 equiv., 3 mmol) was 
added as a solution in dry THF (5 mL) and the mixture was stirred for an additional 3 h 
at the same temperature. The reaction mixture was quenched with H2O and diluted 
with CH2Cl2. The aqueous layer was extracted with CH2Cl2 and the combined organic 
extracts were dried (MgSO4) and concentrated to afford the crude product which was 
purified by flash column chromatography on silica gel.  
General procedure B: To a solution of potassium tert-butoxide (2 equiv., 6 mmol, 673 
mg) in dry THF (10 mL) at –40 oC was added 2–phenylacetonitrile (1.5 equiv.) and the 
resulting mixture was stirred for 45 min at the same temperature. A solution of the 
corresponding pyridine N-oxide (1 equiv., 3 mmol) in dry THF (5 mL) was added as a 
solution in dry THF and the mixture was stirred for an additional 3 h at –40 oC and then 
warmed to room temperature over 30 min. The reaction mixture was quenched with 
H2O and diluted with CH2Cl2. The aqueous layer was extracted with CH2Cl2 and the 
combined organic extracts were dried (MgSO4) and concentrated to afford the crude 
product which was purified by flash column chromatography on silica gel.  
(Note: Pyridine N-Oxides 6, 10, 11 and 12 decompose over time and should be stored 
in a refrigerator (at –30 oC they are stable for several months)). 
2-(cyano(phenyl)methyl)pyridine 1-oxide (6a) 
The title compound was prepared from 2-bromopyridine 1-oxide (3 
mmol, 0.52 g) and 2-phenylacetonitrile (4.5 mmol, 0.52 mL) 
according to procedure A. The crude material was purified by flash 
column chromatography on silica gel (eluting with hexane/ethyl 
acetate, 50:50) to afford the title compound as a yellow solid; yield: 2.70 mmol, 567.0 
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mg, 90%. m. p. 112–115 oC. IR (/cm–1): 3110, 3052, 2894, 2246, 1489, 1438, 1246, 
884, 794, 696. 1H NMR (300 MHz, CDCl3) δ: 8.29 – 8.27 (m, 1H), 7.52 – 7.28 (m, 8H), 
6.11 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 146.2, 139.6, 132.0, 129.3, 12.9, 128.1, 125.8, 
125.7, 125.4, 117.5, 36.8. UPLC–DAD–QTOF: C13H11N2O3 [M+H]
+ calcd.: 211.0871, 
found: 211.0863. 
2–bromo-6-(cyano(phenyl)methyl)pyridine 1-oxide (6b) 
The title compound was prepared from 2,6–dibromopyridine 1–
oxide (3 mmol, 0.75 g) and 2–phenylacetonitrile (4.5 mmol, 0.52 
mL) according to procedure A. The crude material was purified 
by flash column chromatography on silica gel (eluting with 
hexane/ethyl acetate, 50:50) to afford the title compound as a yellow solid; yield: 2.13 
mmol, 613.4 mg, 71%. m. p. 100–104 oC. IR (/cm–1): 3067, 3029, 2969, 2881, 2241, 
1450, 1403, 1366, 1254, 1204, 783, 695, 666. 1H NMR (300 MHz, CDCl3) δ: 7.69 – 7.66 
(m, 1H), 7.51 – 7.36 (m, 6H), 7.12 (t, J = 8 Hz, 1H), 6.07 (s, 1H). 13C NMR (75 MHz, CDCl3) 
δ: 148.3, 134.2, 132.2, 131.0, 129.9, 129.6, 128.8, 125.7, 124.6, 117.9, 38.6.  UPLC–
DAD–QTOF: C13H10BrN2O [M+H]
+ calcd.: 288.9976, found: 288.9983. 
2-(cyano(phenyl)methyl)-5-methylpyridine 1-oxide (6c) 
The title compound was prepared from 2–bromo–5–
methylpyridine 1–oxide (3 mmol, 0.56 g) and 2–
phenylacetonitrile (4.5 mmol, 0.52 mL) according to procedure A. 
The crude material was purified by flash column chromatography 
on silica gel (eluting with ethyl acetate) to afford the title compound as a white solid; 
yield: 470.4 mg, 2.10 mmol, 70%. m. p. 98–102 oC. IR (/cm–1): 3126, 3050, 2902, 2245, 
1611, 1491, 1451, 1401, 1278, 1199, 1177, 965, 829, 756, 730, 692, 642, 573, 525, 446. 
1H NMR (300 MHz, CDCl3) δ: 8.09 (s, 1H), 7.46 – 7.29 (m, 6H), 7.08 – 7.05 (m, 1H), 6.05 
(s, 1H), 2.26 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 143.3, 139.3, 136.6, 132.3, 129.2, 
128.8, 128.0, 127.2, 124.7, 117.7, 36.5, 18.1. UPLC–DAD–QTOF: C14H13N2O [M+H]
+ 
calcd.: 276.1028, found: 225.1027. 
5–chloro–2–(cyano(phenyl)methyl)pyridine 1–oxide (6d) 
The title compound was prepared from 2–bromo–5–
chloropyridine 1–oxide (3 mmol, 0.62 g) and 2–
phenylacetonitrile (4.5 mmol, 0.52 mL) according to procedure 
A. The crude material was purified by flash column 
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chromatography on silica gel (eluting with Hex/EtOAc, 50:50) to afford the title 
compound as a red oil; yield: 2.04 mmol, 497.8 mg, 68%. IR (/cm–1): 3103, 3052, 2246, 
1690, 1599, 1481, 1453, 1374, 1242, 1090, 925, 825, 730, 695, 633, 562, 524, 437. 1H 
NMR (300 MHz, CDCl3) δ: 8.31 (s, 1H), 7.50 – 7.27 (m, 7H), 6.01 (s, 1H). 
13C NMR (75 
MHz, CDCl3) δ: 145.0, 138.8, 133.1, 131.6, 129.4, 129.1, 128.1, 126.0, 125.2, 117.2, 
36.5. UPLC–DAD–QTOF: C13H10ClN2O [M+H]
+ calcd.: 245.0482, found: 245.0478. 
2–(cyano(p–tolyl)methyl)pyridine 1–oxide (6e) 
The title compound was prepared from 2-bromopyridine 1-oxide 
(3 mmol, 0.52 g) and 2-(p-tolyl)acetonitrile (4.5 mmol, 0.60 mL) 
according to procedure A. The crude material was purified by flash 
column chromatography on silica gel (eluting with hexane/ethyl 
acetate, 50:50 to 0:100) to afford the title compound as a yellow solid; yield: 2.52 
mmol, 564.5 mg, 84%. m. p. 96–99 oC. IR (/cm–1): 3082, 3042, 3013, 2909, 2247, 1687, 
1513, 1488, 1429, 1279, 1242, 837, 798, 765, 705. 1H NMR (300 MHz, CDCl3) δ: 8.26 – 
8.23 (m, 1H), 7.43 – 7.33 (m, 3H), 7.27 – 7.24 (m, 2H), 7.20 – 7.17 (m, 2H), 6.03 (s, 1H), 
2.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 146.5, 139.6, 138.9, 130.0, 129.0, 128.1, 
125.8, 125.6, 125.4, 117.7, 36.5, 21.1. UPLC–DAD–QTOF: C14H13N2O [M+H]
+ calcd.: 
225.1028, found: 225.1046. 
2-((4-bromophenyl)(cyano)methyl)pyridine 1-oxide (6f) 
The title compound was prepared from 2-bromopyridine 1-oxide 
(3 mmol, 0.52 g) and 2-(4-bromophenyl)acetonitrile (4.5 mmol, 
0.87 g) according to procedure A. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc, 50:50 to 0:100) to afford the title compound as a red oil; yield: 2.64 
mmol, 760.3 mg, 88%. IR (/cm–1): 3112, 3078, 3050, 3023, 2896, 2247, 1692, 1587, 
1484, 1428, 1404, 1237, 1047, 1010, 824, 782, 729, 625. 1H NMR (300 MHz, CDCl3) δ: 
8.27 – 8.24 (m, 1H), 7.53 – 7.50 (m, 3H), 7.39 – 7.39 (m, 2H), 7.32 – 7.29 (m, 2H), 6.05 
(s, 1H). 13C NMR (75 MHz, CDCl3) δ: 145.9, 139.8, 132.6, 131.2, 129.9, 125.3, 123.3, 
117.3, 36.6. UPLC-DAD-QTOF: C13H10N2OBr [M+H]
+ calcd.: 288.9977, found: 288.9973. 
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2-(cyano(thiophen-3-yl)methyl)pyridine 1-oxide (6g) 
The title compound was prepared from 2-bromopyridine 1-oxide (3 
mmol, 0.52 g) and 2-(thiophen-3-yl)acetonitrile (4.5 mmol, 0.56 g) 
according to procedure B. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc, 50:50 
to 0:100) to afford the title compound as a red oil; yield: 1.80 mmol, 383 mg, 60%. IR 
(/ cm–1): 3114, 3083, 2890, 2240, 1711, 1604, 1483, 1427, 1272, 1237, 1142, 943, 837, 
762, 621. 1H NMR (300 MHz, CDCl3) δ: 8.30 – 8.28 (m, 1H), 7.51 – 7.50 (m, 1H), 7.45 – 
7.42 (m, 1H), 7.38 – 7.35 (m, 1H), 7.32 – 7.26 (m, 2H), 7.15 – 7.13 (m, 1H), 6.18 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ: 145.8, 139.6, 131.5, 127.6, 126.7, 126.0, 125.8, 125.2, 
124.6, 117.3, 32.5. UPLC-DAD-QTOF: C11H9N2OS [M+H]
+ calcd.: 217.0436, found: 
217.0428. 
2-(cyano(4-methoxyphenyl)methyl)pyridine 1-oxide (6h) 
The title compound was prepared from 2-bromopyridine 1-
oxide (3 mmol, 0.52 g) and 2-(4-methoxyphenyl)acetonitrile 
(4.5 mmol, 0.66 g) according to procedure A. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc, 50:50 to 0:100) to afford the title compound as a red oil; 
yield: 2.13 mmol, 511 mg, 71%. IR (/cm–1): 3110, 3071, 3013, 2934, 2837, 2245, 1607, 
1583, 1509, 1429, 1365, 1178, 1027, 830, 762. 1H NMR (300 MHz, CDCl3) δ: 8.21 – 8.19 
(m, 1H), 7.38 – 7.33 (m, 3H), 7.23 – 7.20 (m, 2H), 6.87 – 6.84 (m, 2H), 5.95 (s, 1H), 3.73 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ: 159.8, 146.3, 139.5, 129.3, 125.8, 125.5, 125.1, 
123.7, 117.7, 114.6, 55.3, 36.1. UPLC-DAD-QTOF: C14H13N2O2 [M+H]
+ calcd.: 241.0977, 
found: 241.0974. 
2-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine 1-oxide (6i) 
The title compound was prepared from 2-bromopyridine 1-
oxide (3 mmol, 0.52 g) and 2-(4-
(trifluoromethyl)phenyl)acetonitrile (4.5 mmol, 0.83 g) 
according to procedure B. The crude material was purified by 
flash column chromatography on silica gel (eluting with Hex/EtOAc, 50:50 to 0:100) to 
afford the title compound as a red oil; yield: 1.68 mmol, 459 mg, 56%. IR (/cm–1): 
3115, 3075, 3019, 2924, 2248, 1727, 1617, 1487, 1431, 1322, 1240, 1164, 1110, 1066, 
1018, 847, 832, 763. 1H NMR (300 MHz, CDCl3) δ: 8.26 – 8.23 (m, 1H), 7.62 (s, 4H), 7.55 
– 7.52 (m, 1H), 7.32 – 7.29 (m, 2H), 6.14 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 145.3, 
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139.7, 136.0, 128.7, 126.3, 126.2, 126.2, 126.0, 125.4, 117.0, 36.8. UPLC-DAD-QTOF: 
C14H10N2OF3 [M+H]
+ calcd.: 279.0745, found: 279.0736. 
2-(cyano(4-(methoxycarbonyl)phenyl)methyl)pyridine 1-oxide (6j) 
The title compound was prepared from 2-bromopyridine 1-
oxide (3 mmol, 0.52 g) and methyl 4-(cyanomethyl)benzoate 
(4.5 mmol, 0.79 g) according to procedure B. The crude 
material was purified by flash column chromatography on 
silica gel (eluting with Hex/EtOAc, 50:50 to 0:100) to afford the title compound as a red 
oil; yield: 2.40 mmol, 643 mg, 80%. IR (/cm–1): 3111, 3080, 3013, 2926, 2245, 1710, 
1620, 1590, 1469, 1240, 1113, 1054, 840, 631. 1H NMR (300 MHz, CDCl3) δ: 8.28 – 8.25 
(m, 1H), 8.06 – 8.02 (m, 2H), 7.58 – 7.49 (m, 3H), 7.32 – 7.29 (m, 2H), 6.16 (s, 1H), 3.90 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ: 166.3, 145.7, 139.8, 136.9, 130.9, 130.6, 128.3, 
126.1, 126.0, 125.5, 117.2, 52.4, 36.9. UPLC-DAD-QTOF: C15H13N2O3 [M+H]
+ calcd.: 
269.0926, found: 269.0923. 
5-chloro-2-(cyano(p-tolyl)methyl)pyridine 1-oxide (6k) 
The title compound was prepared from 2-bromo-5-
chloropyridine 1-oxide (3 mmol, 0.62 g) and 2-(p-
tolyl)acetonitrile (4.5 mmol 0.59 g) according to procedure A. 
The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc, 80:20 to 50:50) to afford the 
title compound as a red oil; yield: 2.49 mmol, 642.4 mg, 83%. IR (/cm–1): 3103, 3039, 
2919, 2246, 1687, 1599, 1511, 1459, 1374, 1243, 1112, 1090, 925, 836, 810, 728. 1H 
NMR (300 MHz, CDCl3) δ: 8.30 – 8.29 (m, 1H), 7.38 – 7.19 (m, 6H), 5.94 (s, 1H), 2.35 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ: 145.0, 139.0, 138.7, 132.9, 129.9, 128.4, 127.9, 125.9, 
125.1, 117.2, 36.2, 21.1. UPLC-DAD-QTOF: C14H12N2OCl [M+H]
+ calcd.: 259.0638, found: 
259.0635. 
2-bromo-6-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine 1-oxide (6l) 
The title compound was prepared from 2,6–
dibromopyridine 1-oxide (3 mmol, 0.75 g) and 2-(4-
(trifluoromethyl)phenyl)acetonitrile (4.5 mmol, 0.83 g) 
according to procedure B. The crude material was purified 
by flash column chromatography on silica gel (eluting with Hex/EtOAc, 70:30 to 0:100) 
to afford the title compound as a red solid; yield: 2.52 mmol, 897 mg, 84%. m. p. 92–96 
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oC. IR (/cm–1): 3086, 3043, 2984, 2893, 2248, 1691, 1618, 1576, 1556, 1462, 1378, 
1322, 1240, 1163, 1113, 1066, 857, 844, 783. 1H NMR (300 MHz, CDCl3) δ: 7.73 – 7.55 
(m, 6H), 7.18 (t, J = 8.1 Hz, 1H), 6.12 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 146.9, 135.7, 
133.9, 133.0, 128.9, 126.4, 126.4, 125.5, 124.1, 117.0, 38.0. UPLC-DAD-QTOF: 
C14H9N2OF3Br [M+H]
+ calcd.: 356.9850, found: 356.9843. 
2-(cyano(phenyl)methyl)pyrazine 1-oxide (10a) 
 The title compound was prepared from 2-chloropyrazine 1-oxide (3 
mmol, 0.52 g) and 2-phenylacetonitrile (4.5 mmol, 0.52 ml) 
according to procedure A. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc, 80:20 
to 0:100) to afford the title compound as a white solid; yield: 2.61 mmol, 551 mg, 87%. 
m. p. 123–127 oC. IR (/cm–1): 3082, 3064, 2893, 2249, 1586, 1451, 1421, 1308, 1214, 
899, 847, 742, 696, 508. 1H NMR (300 MHz, CDCl3) δ: 8.57 (s, 1H), 8.44 (d, J = 4.1 Hz, 
1H), 8.13 (d, J = 4.0 Hz, 1H), 7.49 – 7.38 (m, 6H), 5.84 (s, 1H). 13C NMR (75 MHz, CDCl3) 
δ: 147.3, 147.0, 141.8, 133.6, 130.7, 129.6, 129.4, 128.2, 116.4, 35.0. UPLC-DAD-QTOF: 
C12H10N3O [M+H]
+ calcd.: 212.0824, found: 212.0836. 
2-chloro-6-(cyano(phenyl)methyl)pyrazine 1-oxide (10b) 
The title compound was prepared from 2,6-dichloropyrazine 1-
oxide (3 mmol, 0.49 g) and 2-phenylacetonitrile (4.5 mmol, 0.52 
ml) according to procedure A. The crude material was purified by 
flash column chromatography on silica gel (eluting with 
Hex/EtOAc, 90:10 to 70:30) to afford the title compound as a red oil; yield: 367 mg, 
1.50 mmol, 50%. IR (/cm–1): 3060, 3029, 2969, 2250, 1718, 1581, 1495, 1405, 1321, 
1217, 1144, 866, 731, 697, 546. 1H NMR (300 MHz, CDCl3), δ: 8.63 (s, 1H), 8.49 (s, 1H), 
7.51 – 7.45 (m, 2H), 7.44 – 7.38 (m, 3H), 5.83 (s, 1H). UPLC-DAD-QTOF: C12H9N3OCl 
[M+H]+ calcd.: 246.0434, found: 246.0447. 
2-((4-bromophenyl)(cyano)methyl)pyrazine 1-oxide (10c) 
The title compound was prepared from 2-chloropyrazine 1-oxide 
(3 mmol, 0.52 g) and 2-(4-bromophenyl)acetonitrile (4.5 mmol, 
0.88 g) according to procedure A. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc, 70:30 to 0:100) to afford the title compound as a white solid; yield: 
2.43 mmol, 702 mg, 81%. m. p. 106–109 oC. IR (/cm–1): 3084, 3065, 2887, 2250, 1582, 
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1487, 1455, 1426, 1309, 1210, 1073, 1011, 981, 899, 776, 508. 1H NMR (300 MHz, 
CDCl3), δ: 8.65 (s, 1H), 8.48 (d, J = 4.1 Hz, 1H), 8.12 (d, J = 4.1 Hz, 1H), 7.54 (d, J = 8.5 Hz, 
2H), 7.36 (d, J = 8.5 Hz, 2H), 5.79 (s, 1H). 13C NMR (75 MHz, CDCl3), δ: 147.6, 146.8, 
141.3, 133.7, 132.8, 129.9, 129.8, 123.8, 116.0, 34.7. UPLC-DAD-QTOF: C12H9N3OBr 
[M+H]+ calcd.: 289.9929, found: 289.9937. 
3-(cyano(phenyl)methyl)pyridine 1-oxide (11) 
The title compound was prepared from 3-bromopyridine 1-oxide (3 
mmol, 0.52 g) and 2-phenylacetonitrile (4.5 mmol, 0.52 mL) according to 
procedure A. The crude material was purified by flash column 
chromatography on silica gel (eluting with EtOAc to MeOH: CH2Cl2 
10:90) to afford the title compound as a brown oil; yield: 2.10 mmol, 
441 mg, 70%. IR (/ cm–1): 3071, 3029, 3004, 2910, 2243, 1665, 1596, 1481, 1448, 
1265, 1155, 1004, 783, 697, 679, 551, 495. 1H NMR (300 MHz, CDCl3) δ: 8.12 – 8.07 (m, 
2H), 7.40 – 7.20 (m, 7H), 5.08 (s, 1H). UPLC-DAD-QTOF: C13H11N2O3 [M+H]
+ calcd.: 
211.0871, found: 211.0870. 
4-(cyano(phenyl)methyl)pyridine 1-oxide (12) 
The title compound was prepared from 4-chloropyridine 1-oxide (3 
mmol, 0.39 g) and 2-phenylacetonitrile (4.5 mmol, 0.52 mL) according to 
procedure A. The crude material was purified by flash column 
chromatography on silica gel (eluting with EtOAc to MeOH: CH2Cl2 10:90) 
to afford the title compound as a brown oil; yield: 1.95 mmol, 409 mg, 
65%. IR (/ cm–1): 3105, 3061, 3033, 2241, 1656, 1606, 1475, 1446, 1246, 1170, 1002, 
912, 829, 728, 695, 599. 1H NMR (300 MHz, CDCl3) δ: 8.18 (d, J = 7.2 Hz, 2H), 7.45 – 
7.41 (m, 2H), 7.34 – 7.31 (m, 2H), 7.25 – 7.23 (m, 2H), 5.10 (s, 1H). UPLC–DAD–QTOF: 
C13H11N2O3 [M+H]
+ calcd.: 211.0871, found: 211.0877. 
5.3.4.4.  Preparation of 2-(α-cyanoalkyl)pyridine N-oxides 13 
 
To a solution of potassium tert-butoxide (1.03 equiv., 3.1 mmol, 336 mg) in dry THF 
(10 mL) at –10 oC was added 2-(cyanomethyl)pyridine 1-oxide (1.0 equiv., 3 mmol, 402 
mg) as a solution in dry THF (5 mL) and the resulting mixture was stirred for 2 h at the 
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same temperature. Afterwards the corresponding alkyl halide (1.03 equiv., 3.1 mmol) 
was added dropwise and the mixture was stirred for an additional 16 h at room 
temperature. The reaction mixture was quenched with H2O and extracted with EtOAc 
and the combined organic extracts were dried (MgSO4) and concentrated to afford the 
crude product which was purified by flash column chromatography on silica gel. 
2-(1-cyanopropyl)pyridine 1-oxide (13a) 
The title compound was prepared from 2-(cyanomethyl)pyridine 1-
oxide (3 mmol, 0.39 g) and iodoethane (3.1 mmol, 249 µL) according to 
the general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc, 50:50 to 
MeOH/CH2Cl2, 10:90) to afford the title compound as a pink oil; yield: 1.05 mmol, 170 
mg, 35%. IR (/cm–1): 3117, 3080, 2972, 2935, 2878, 2242, 1646, 1489, 1431, 1228, 
840, 768. 1H NMR (300 MHz, CDCl3) δ: 8.28 – 8.26 (m, 1H), 7.62 – 7.59 (m, 1H), 7.36 – 
7.28 (m, 2H), 4.77 (dd, J = 8.4, 4.7 Hz, 1H), 2.22 – 2.09 (m, 1H), 2.01 – 1.87 (m, 1H), 
1.16 (t, J = 7.4 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 145.9, 139.7, 125.9, 125.6, 125.4, 
125.0, 118.6, 33.6, 23.8, 11.3. UPLC-DAD-QTOF: C9H11N2O [M+H]
+ calcd.: 163.0871, 
found: 163.0875. 
2-(1-cyano-2-phenylethyl)pyridine 1-oxide (13b) 
The title compound was prepared from from 2-
(cyanomethyl)pyridine 1-oxide (3 mmol, 0.39 g) and benzyl 
bromide (3.1 mmol, 369 µL) according to the general procedure. 
The crude material was purified by flash column chromatography 
on silica gel (eluting with Hex/EtOAc, 50:50 to 0:100) to afford the title compound as a 
white solid; yield: 2.10 mmol, 470 mg, 70%. m. p. 100–103 oC.  IR (/cm–1):  3107, 
3085, 2997, 2931, 2912, 2245, 1485, 1428, 1270, 1231, 1151, 842, 771, 751, 706, 580, 
557, 540, 486, 410. 1H NMR (300 MHz, CDCl3) δ: 8.33 – 8.30 (m, 1H), 7.39 – 7.21 (m, 
8H), 5.02 (dd, J = 8.2, 4.1 Hz, 1H), 3.46 – 3.40 (m, 2H), 3.21 – 3.14 (m, 2H). 13C NMR (75 
MHz, CDCl3) δ: 145.2, 139.6, 135.7, 129.3, 128.6, 127.6, 125.6, 125.5, 118.4, 35.6, 34.9. 
UPLC-DAD-QTOF: C14H13N2O [M+H]
+ calcd.: 225.1028, found: 225.1031. 
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2-(1-cyano-2-(4-(trifluoromethyl)phenyl)ethyl)pyridine 1-oxide (13c) 
The title compound was prepared from 2-
(cyanomethyl)pyridine 1-oxide (3 mmol, 0.39 g) and 4-
(trifluoromethyl)benzyl bromide (3.1 mmol, 369 µL) 
according to the general  procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting with Hex/EtOAc, 50:50 
to 0:100) to afford the title compound as a yellow solid; yield: 2.22 mmol, 648 mg, 
74%. m. p. 139–141 oC. IR (/ cm–1): 3110, 3071, 3057, 3027, 2927, 2243, 1617, 1488, 
1442, 1328, 1254, 1159, 1107, 1067, 840, 767, 597. 1H NMR (300 MHz, CDCl3) δ: 8.37 – 
8.35 (m, 1H), 7.63 – 7.60 (m, 2H), 7.47 – 7.28 (m, 5H), 5.04 (dd, J = 8.4, 4.0 Hz, 1H), 3.56 
– 3.50 (m, 2H), 3.30–3.23 (m, 2H).  13C NMR (75 MHz, CDCl3) δ: 144.7, 139.9, 139.7, 
129.7, 125.8, 125.8, 125.6, 125.6, 125.3, 122.2, 118.0, 35.3, 34.7. UPLC-DAD-QTOF: 
C15H12N2OF3 [M+H]
+ calcd.: 293.0902, found: 293.0907. 
5.3.5. General procedure for the BB-catalized addition of 6 and 10 to enone 1a 
 
To a solution of the 2-cyanoalkyl pyridine N-oxide 6 or 2-cyanoalkyl pirazine N-oxide 
10 (1 equiv., 0.2 mmol) in dichlorometane (1 mL) the enone 1a (3.0 equiv., 0.6 mmol) 
and the catalyst were added at the corresponding temperature (see below).  The 
resulting mixture was stirred until consumption of the pyridine N-oxide (monitored by 
1H-NMR). Afterwards, the reaction mixture was washed with 0.1 M aqueous solution 
of HCl and extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were dried 
over MgSO4 and concentrated under reduced pressure. The residues were purified by 
flash column chromatography on silica gel to afford the expected adducts. 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide (9a) 
The title compound 9a was prepared from 2-
(cyano(phenyl)methyl)pyridine 1-oxide 6a (0.2 mmol, 42.0 mg) 
and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 68.4 
mg) according to the general procedure at r.t. The crude 
material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 50:50 to 0:100) to give the title compound as a white solid; yield: 0.16 
mmol, 53.1 mg, 82%. m. p. 188–191 oC. [α]D
25= +102.9 (c = 1.00, 92% ee, CH2Cl2). IR 
(/cm-1): 3333, 3119, 3059, 2973, 2926, 2236, 1711, 1599, 1428, 1261, 1191, 760, 733, 
698, 569. 1H NMR (300 MHz, CDCl3) δ: 8.15 (dd, J = 1.6 Hz, 1H), 7.56 (dd, J = 2.3 Hz, 1H), 
7.39 – 7.27 (m, 6H), 3.60 (s, 1H), 3.03 – 2.82 (m, 2H), 2.65 – 2.47 (m, 2H), 1.29 (s, 3H), 
1.21 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.1, 147.6, 140.7, 135.1, 129.0, 128.5, 
126.6, 126.0, 125.3, 124.3, 118.1, 48.4, 31.7, 31.6, 26.6, 26.5. UPLC-DAD-QTOF: 
C19H21N2O3 [M+H]
+ calcd.: 325.1552, found: 325.1538.  
(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
(9b) 
The title compound 9b was prepared from 2-bromo-6-
(cyano(phenyl)methyl)pyridine 1-oxide 6b (0.2 mmol, 57.6 
mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 
68.4 mg) according to the general procedure at 0 oC. The 
crude material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 50:50 to 0:100) to give the title compound as a white foam; yield: 0.17 
mmol, 66.7 mg, 83%. [α]D
25= +61.1 (c = 1.00, 94% ee, CH2Cl2). IR (/cm
-1): 3444, 3026, 
2969, 2935, 2238, 1716, 1463, 1376, 1216, 1033, 911, 759, 728, 697. 1H NMR (300 
MHz, CDCl3) δ: 7.73 (dd,  J = 1.8 Hz, 1H), 7.53 (dd,  J = 1.9 Hz, 1H), 7.55 – 7.29 (m, 5H), 
7.19 (t, J = 8.1 Hz, 1H), 3.38 (s, 1H), 3.04 – 2.81 (m, 2H), 2.66 – 2.44 (m, 2H), 1.32 (s, 
3H), 1.22 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.0, 149.1, 134.7, 130.9, 129.1, 128.6, 
126.7, 124.5, 123.1, 117.9, 49.3, 32.0, 31.6, 26.7, 26.5. UPLC-DAD-QTOF: C19H20N2O3Br 
[M+H]+ calcd.: 403.0657, found: 403.0651.  
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)-5-methylpyridine 1-oxide 
(9c) 
The title compound 9c was prepared from 2-
(cyano(phenyl)methyl)-5-methylpyridine 1-oxide 6c (0.2 
mmol, 45 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a 
(0.6 mmol, 68.4 mg) according to the general procedure at 
40 oC. The crude material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 50:50 to 0:100) to give the title compound as a white foam.  
Yield: 45.6 mg, 0.13 mmol, 66%. [α]D
25= +65.2 (c = 1.00, 90% ee, CH2Cl2). IR (/cm
-1): 
3327, 3061, 3027, 2969, 2929, 2236, 1714, 1448, 1374, 1274, 1197, 1019, 962, 730, 
697, 575. 1H NMR (300 MHz, CDCl3) δ: 8.01 (s, 1H), 7.45 – 7.15 (m, 7H), 3.57 (s, 1H), 
3.02 – 3.82 (m, 2H), 2.64 – 2.46 (m, 2H), 2.30 (s, 3H), 1.30 (s, 3H), 1.22 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ: 213.2, 144.7, 140.5, 136.9, 135.5, 129.0, 128.4, 126.7, 126.5, 123.6, 
118.3, 48.2, 31.8, 31.6, 26.7, 26.5, 18.1.  UPLC-DAD-QTOF: C20H23N2O3 [M+H]
+ calcd.: 
339.1709, found: 339.1712.  
(R)-5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
(9d) 
The title compound 9d was prepared from 5-chloro-2-
(cyano(phenyl)methyl)pyridine 1-oxide 6d (0.2 mmol, 49 
mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 
68.4 mg) at 0 oC  according to the general procedure. The 
crude material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 70:30 to 0:100) to give the title compound as a white foam.  Yield: 0.14 
mmol, 51.5 mg, 72%. [α]D
25= +66.8 (c = 1.00, 89% ee, CH2Cl2). IR (/cm
-1): 3398, 3110, 
3056, 2970, 2238, 1710, 1484, 1449, 1375, 1260, 1187, 1095, 1018, 947, 805, 756, 697, 
579, 523. 1H NMR (300 MHz, CDCl3) δ: 8.19 (m, 1H), 7.52 – 7.49 (m, 1H), 7.37 – 7.28 (m, 
6H), 3.45 (s, 1H), 3.02 – 2.79 (m, 2H), 2.63 – 2.45 (m, 2H), 1.31 (s, 3H), 1.22 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ: 213.0, 146.5, 139.9, 134.7, 133.6, 129.1, 128.7, 126.5, 125.5, 
124.2, 117.7, 48.1, 31.7, 31.5, 26.7, 26.5. UPLC-DAD-QTOF: C19H20N2O3Cl [M+H]
+ calcd.: 
359.1162, found: 359.1165.  
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide (9e) 
The title compound 9e was prepared from 2-(cyano(p-
tolyl)methyl)pyridine 1-oxide 6e (0.2 mmol, 45 mg) and 4-
hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 68.4 mg) at 
40 oC  according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 
50:50 to 0:100) to give the title compound as a white foam. . Yield: 0.16 mmol, 53.4 
mg, 79%. [α]D
25= +52.6 (c = 1.00, 90% ee, CH2Cl2). IR (/cm
-1): 3333, 3119, 2974, 2929, 
2870, 2237, 1709, 1427, 1359, 1248, 1190, 956, 765, 730, 520. 1H NMR (300 MHz, 
CDCl3) δ: 8.18-8.16 (m, 1H), 7.54 – 7.51 (m, 1H), 7.37 – 7.24 (m, 4H), 7.16 – 7.13 (m, 
2H), 3.51 (s, 1H), 3.04 – 2.85 (m, 2H), 2.66 – 2.47 (m, 2H), 2.31 (s, 3H), 1.33 (s, 3H), 1.24 
(s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.1, 147.9, 140.8, 138.4, 132.0, 129.8, 126.6, 
125.9, 125.2, 124.3, 118.3, 48.2, 31.7, 31.5 26.7, 26.5, 21.1. UPLC-DAD-QTOF: 
C20H23N2O3 [M+H]
+ calcd.: 339.1709, found: 339.1712.  
(R)-2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9f) 
The title compound 9f was prepared from 2-((4-
bromophenyl)(cyano)methyl)pyridine 1-oxide 6f (0.2 mmol, 
57.6 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 
mmol, 68.4 mg) at 0 oC  according to the general procedure. The 
crude material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 50:50 to 0:100) to give the title compound as a yellow oil. Yield: 0.18 mmol, 
72.4 mg, 90%. [α]D
25= +58.4 (c = 1.00, 90% ee, CH2Cl2). IR (/ cm
-1): 3343, 3118, 3058, 
2974, 2930, 2237, 1712, 1586, 1487, 1428, 1262, 1192, 1076, 1009, 836, 766, 735, 518. 
1H NMR (300 MHz, CDCl3) δ: 8.21 – 8.18 (m, 1H), 7.53 – 7.47 (m, 2H), 7.45 – 7.34 (m, 
2H), 7.30 – 7.25 (m, 2H), 3.43 (s, 1H), 3.06 – 2.84 (m, 2H), 2.67 – 2.50 (m, 2H), 1.36 (s, 
3H), 1.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.9, 147.2, 140.8, 134.4, 132.2, 128.3, 
126.3, 125.4, 124.1, 122.7, 117.8, 31.8, 31.5, 26.7, 26.6. UPLC-DAD-QTOF: 
C19H20BrN2O3 [M+H]
+ calcd.: 403.0657, found: 403.0659.  
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(thiophen-3-yl)hexyl)pyridine 1-oxide 
(9g) 
The title compound 9g was prepared from 2-
(cyano(thiophen-3-yl)methyl)pyridine 1-oxide 6g (0.2 mmol, 
43.2 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 
mmol, 68.4 mg) at 0 oC  according to the general procedure. 
The crude material was purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 50:50 to 0:100) to give the title compound as a white foam.  Yield: 
0.14 mmol, 46.2 mg, 70%. [α]D
25= +13.4 (c = 1.00, 94% ee, CH2Cl2). IR (/cm
-1): 3382, 
3102, 3040, 2235, 1710, 1570, 1421, 1348, 1271, 1187, 1023, 854, 775, 532. 1H NMR 
(300 MHz, CDCl3) δ: 8.24 – 8.22 (m, 1H), 7.48 – 7.46 (m, 1H), 7.41 – 7.38 (m, 1H), 7.33 – 
7.19 (m, 3H), 7.06 (dd, J = 1.5, 1.5 Hz, 1H), 3.48 (s, 1H), 3.21 – 2.97 (m, 2H), 2.65 – 2.53 
(m, 2H), 1.36 (s, 3H), 1.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.0, 147.4, 140.8, 
135.5, 127.6, 126.3, 125.9, 125.5, 124.7, 124.6, 118.4, 45.7, 32.0, 29.9, 26.8, 26.6. 
UPLC-DAD-QTOF: C17H19N2O3S [M+H]
+ calcd.: 331.1116, found: 331.1119.  
(R)-2-(1-cyano-5-hydroxy-1-(4-methoxyphenyl)-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9h) 
The title compound 9h was prepared from 2-(cyano(4-
methoxyphenyl)methyl)pyridine 1-oxide 6h (0.2 mmol, 48 mg) 
and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 68.4 
mg) at room temperature  according to the general procedure. 
The crude material was purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 50:50 to 0:100) to give the title compound as a white foam. Yield: 0.14 
mmol, 49.6 mg, 71%. [α]D
25= +69.1 (c = 1.00, 89% ee, CH2Cl2). IR (/cm
-1): 3331, 3118, 
3058, 2961, 2928, 2236, 1711, 1607, 1509, 1427, 1250, 1182, 1029, 829, 764, 732, 535. 
1H NMR (300 MHz, CDCl3) δ: 8.19 – 8.17 (m, 1H), 7.52 – 7.48 (m, 1H), 7.36 – 7.27 (m, 
4H), 6.89 – 6.86 (m, 2H), 3.78 (s, 3H), 3.46 (s, 1H), 3.04 – 2.88 (m, 2H), 2.67 – 2.48 (m, 
2H), 1.34 (s, 3H), 1.26 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.1, 159.6, 148.0, 140.8, 
128.1, 126.7, 125.9, 125.3, 124.2, 118.4, 114.5, 55.4, 47.9, 31.7, 31.3, 26.7, 26.6. UPLC-
DAD-QTOF: C20H23N2O4 [M+H]
+ calcd.: 355.1658, found: 355.1666.  
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4-
(trifluoromethyl)phenyl)hexyl)pyridine 1-oxide (9i) 
The title compound 9i was prepared from 2-(cyano(4-
(trifluoromethyl)phenyl)methyl)pyridine 1-oxide 6i (0.2 mmol, 
55.6 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 
mmol, 68.4 mg) at 0 oC  according to the general procedure. 
The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title 
compound as a white foam. Yield: 0.15 mmol, 58.8 mg, 75%. [α]D
25= +107.6 (c = 1.00, 
92% ee, CH2Cl2). IR (/cm
-1): 3292, 2976, 2930, 2233, 1701, 1618, 1430, 1324, 1167, 
1117, 1068, 1016, 917, 838, 773, 721, 570. 1H NMR (300 MHz, CDCl3) δ: 8.19 – 8.16 (m, 
1H), 7.73 – 7.34 (m, 7H), 3.34 (s, 1H), 3.04 – 2.84 (m, 2H), 2.68 – 2.47 (m, 2H), 1.32 (s, 
3H), 1.26 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.7, 146.9, 140.8, 139.5, 127.0, 126.5, 
126.1 126.0, 125.5, 124.2, 117.6, 48.4, 32.0, 31.5 26.7 26.6. UPLC-DAD-QTOF: 
C20H20N2O3F3 [M+H]
+ calcd.: 393.1426, found: 393.1425.  
(R)-2-(1-cyano-5-hydroxy-1-(4-(methoxycarbonyl)phenyl)-5-methyl-4-
oxohexyl)pyridine 1-oxide (9j) 
The title compound 9j was prepared from 2-(cyano(4-
(methoxycarbonyl)phenyl)methyl)pyridine 1-oxide 6j (0.2 
mmol, 53.6 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a 
(0.6 mmol, 68.4 mg) at 0 oC  according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title 
compound as a yellow foam. Yield: 0.16 mmol, 62.7 mg, 82%. [α]D
25= +111.2 (c = 1.00, 
94% ee, CH2Cl2). IR (/cm
-1): 3469, 3124, 3073, 2923, 2250, 1715, 1684, 1569, 1425, 
1334, 1179, 1112, 1054, 990, 771, 569. 1H NMR (300 MHz, CDCl3) δ: 8.15 (dd, J = 1.6, 
1.5 Hz, 1H), 8.02 – 7.97 (m, 2H), 7.67 (dd, J = 2.2, 2.1 Hz, 1H),  7.45 – 7.33 (m, 4H), 3.88 
(s, 3H), 3.43 (s, 1H), 3.04 – 2.82 (m, 2H), 2.66 – 2.44 (m, 2H), 1.30 (s, 3H), 1.23 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ: 212.8, 166.3, 147.1, 140.7, 140.4, 130.2, 126.6, 126.3, 
125.5, 124.2, 117.6, 32.0, 31.5, 26.7, 26.6. UPLC-DAD-QTOF: C21H23N2O5 [M+H]
+ calcd.: 
383.1607, found: 383.1616.  
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(R)-5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide 
(9k) 
The title compound 9k was prepared from 5-chloro-2-
(cyano(p-tolyl)methyl)pyridine 1-oxide 6k (0.2 mmol, 51.6 
mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 
68.4 mg) at room temperature  according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 80:20 to 0:100) to give the title 
compound as a yellow foam. Yield: 64.7 mg, 0.17 mmol, 87%. [α]D
25= +78.2 (c = 1.00, 
87% ee, CH2Cl2). IR (/cm
-1): 3378, 3108, 3050, 2971, 2924, 2235, 1710, 1595, 1483, 
1374, 1259, 1188, 1095, 937, 810, 575, 524. 1H NMR (300 MHz, CDCl3) δ: 8.19 (d, J = 
1.9 Hz, 1H), 7.47 – 7.44 (m, 1H),  7.34 – 7.31 (m, 1H),  7.26 – 7.23 (m, 2H), 7.19 – 7.15 
(m, 2H), 3.39 (s, 1H), 3.03 – 2.82 (m, 2H), 2.63 – 2.46 (m, 2H), 2.32 (s,3H), 1.33 (s, 3H), 
1.25 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.0, 146.7, 140.0, 138.7, 133.6, 131.5, 
129.9, 126.6, 125.4, 124.2, 117.9, 48.0, 31.6, 31.4, 26.7, 26.6, 21.6. UPLC-DAD-QTOF: 
C20H22N2O3Cl [M+H]
+ calcd.: 373.1319, found: 373.1323.  
(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4-
(trifluoromethyl)phenyl)hexyl)pyridine 1-oxide (9l) 
The title compound 9l was prepared from 2-bromo-6-
(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine 1-oxide 
6l (0.2 mmol, 71.2 mg) and 4-hydroxy-4-methylpent-1-en-3-
one 1a (0.6 mmol, 68.4 mg) at 0 oC according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 70:30 to 0:100) to give the title 
compound as a brown foam. Yield: 79.9 mg, 0.17 mmol, 85%. [α]D
25= +69.6 (c = 0.5, 
94% ee, CH2Cl2). IR (/cm
-1): 3444, 3105, 2978, 2235, 1714, 1618, 1596, 1466, 1380, 
1326, 1167, 1120, 1070, 1016, 960, 843, 773, 699. 1H NMR (300 MHz, CDCl3) δ: 7.79 – 
7.48 (m, 6H), 7.29 – 7.24 (m, 1H), 3.27 (s, 1H), 3.04 – 2.79 (m, 2H), 2.67 – 2.44 (m, 2H), 
1.31 (s, 3H), 1.25 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.7, 148.3, 139.1, 134.8, 131.3, 
126.9, 126.1, 124.8, 123.0, 117.4, 49.2, 32.4, 31.5, 26.7, 26.6. UPLC-DAD-QTOF: 
C20H19N2O3BrF3 [M+H]
+ calcd.: 471.0531, found: 471.0526.  
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide (16a) 
The title compound 16a was prepared from 2-
(cyano(phenyl)methyl)pyrazine 1-oxide 10a (0.2 mmol, 53.6 
mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 
68.4 mg) at –10 oC  according to the general procedure. The 
crude material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 70:30 to 0:100) to give the title compound as a white solid. m. p. 154-157 
oC. Yield: 53.3 mg, 0.16 mmol, 82%. [α]D
25= +65.2 (c = 0.5, 85% ee, CH2Cl2). IR (/cm
-1): 
3409, 3102, 3059, 2977, 2239, 1713, 1587, 1449, 1407, 1325, 1186, 945, 836, 734, 698, 
538. 1H NMR (300 MHz, CDCl3) δ: 8.73 (s, 1H), 8.48 (d, J = 4.1 Hz, 1H), 8.06 (d, J = 4.0 
Hz, 1H), 7.40 – 7.33 (m, 5H),  3.40 (s, 1H), 3.04 – 2.88 (m, 2H), 2.74 – 2.48 (m, 2H), 1.32 
(s, 3H), 1.24 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.6, 147.5, 145.7, 143.5, 134.6, 
133.7, 129.3, 129.0, 126.6, 117.2, 47.1, 31.5, 30.8, 26.7, 26.6. UPLC-DAD-QTOF: 
C18H20N3O3 [M+H]
+ calcd.: 326.1505, found: 326.1500.  
(R)-2-chloro-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide 
(16b) 
The title compound 16b was prepared from 2-chloro-6-
(cyano(phenyl)methyl)pyrazine 1-oxide 10b (0.2 mmol, 
49.0 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 
mmol, 68.4 mg) at –10 oC  according to the general 
procedure. The crude material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 70:30 to 0:100) to give the title compound as a yellow 
solid. m. p. 188–191 oC. Yield: 0.16 mmol, 56.0 mg, 78%. [α]D
25= +72.1 (c = 0.5, 84% ee, 
CH2Cl2). IR (/cm
-1): 3357, 3055, 2980, 2951, 2241, 1717, 1585, 1403, 1189, 1164, 974, 
909, 867, 738, 695, 576, 503. 1H NMR (300 MHz, CDCl3) δ: 8.69 (s, 1H), 8.63 (s, 1H), 
7.43 – 7.34 (m, 5H), 3.27 (s, 1H), 3.05 – 2.88 (m, 2H), 2.76 – 2.67 (m, 1H), 2.58 – 2.47 
(m, 1H), 1.34 (s, 3H), 1.24 (s, 3H). 13C NMR (75 MHz, CDCl3) δ:  212.5, 147.2, 144.6, 
142.8, 140.5, 133.3, 129.5, 129.2, 126.7, 116.9, 47.6, 31.5, 31.1, 26.8, 26.6. UPLC-DAD-
QTOF: C18H19N3O3Cl [M+H]
+ calcd.: 360.1115, found: 360.1109.  
(R)-2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyrazine 1-oxide 
(16c) 
The title compound 16c was prepared from 2-((4-
bromophenyl)(cyano)methyl)pyrazine 1-oxide 10c (0.2 mmol, 
58.0 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 
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mmol, 68.4 mg) at –30 oC  according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 70/30 
to 0/100) to give the title compound as a white solid. Yield: 0.11 mmol, 43.6 mg, 54%. 
m. p. 152–155 oC. [α]D
25= +90.6 (c = 0.3, 86% ee, CH2Cl2). IR (/cm
-1): 3361, 3097, 2974, 
2952, 2907, 2242, 1715, 1583, 1463, 1405, 1325, 1186, 1074, 1005, 840, 540, 523. 1H 
NMR (300 MHz, CDCl3) δ: 8.81 (s, 1H), 8.52 (d, J = 4.0 Hz, 1H), 8.07 (d, J = 4.0 Hz, 1H), 
7.53 – 7.50 (m, 2H), 7.30-7.27 (m, 2H),  3.34 (s, 1H), 3.05 – 2.87 (m, 2H), 2.74 – 2.49 (m, 
2H), 1.34 (s, 3H), 1.28 (s, 3H). 13C NMR (75 MHz, CDCl3) δ:  212.4, 147.7, 145.6, 143.0, 
134.6, 133.0, 132.4, 128.3, 123.2, 116.8, 46.7, 31.5, 30.9, 26.7, 26.7. UPLC-DAD-QTOF: 
C18H19N3O3Br [M+H]
+ calcd.: 404.0610, found: 404.0609. 
(S)-2-(3-cyano-7-hydroxy-7-methyl-6-oxooctan-3-yl)pyridine 1-oxide (17a) 
The title compound 17a was prepared from 2-(1-
cyanopropyl)pyridine 1-oxide 13a (0.2 mmol, 32.4 mg) and 4-
hydroxy-4-methylpent-1-en-3-one 1a (0.8 mmol, 91.2 mg) at 
40 oC  according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 
70/30 to MeOH/CH2Cl2 10/90) to give the title compound as a pink oil. An inseparable 
mixture of 5m and 4m was obtained after column chromatography. The NMR spectra, 
1H and 13C, were recorded from the racemic reaction. IR (/cm-1): 3406, 3077, 2972, 
2934, 2878, 2241, 1719, 1608, 1489, 1431, 1171, 1092, 1049, 941, 906, 841, 768, 724, 
643, 570, 549. 1H NMR (300 MHz, CDCl3) δ: 8.22 – 8.20 (m, 1H), 7.68 – 7.64 (m, 1H), 
7.35 – 7.30 (m, 2H), 3.52 (s, 1H), 3.15 – 3.05 (m, 2H),  2.87 – 2.69 (m, 2H), 2.57 – 2.33 
(m, 2H), 2.19 – 2.07 (m, 1H),  1.33 (s, 3H), 1.29 (s, 3H), 0.93 (t, J = 7.4 Hz, 1H). 13C NMR 
(75 MHz, CDCl3) δ: 212.7, 145.4, 141.6, 126.8, 125.8, 125.7, 120.8, 49.1, 32.2, 28.6, 
27.9, 26.8, 26.7, 10.2. UPLC-DAD-QTOF: C15H21N2O3 [M+H]
+ calcd.: 277.1552, found: 
277.1557.  
(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-phenylheptan-2-yl)pyridine 1-oxide (17b) 
The title compound 17b was prepared from 2-(1-cyano-2-
phenylethyl)pyridine 1-oxide 13b (0.2 mmol, 44.8 mg) and 4-
hydroxy-4-methylpent-1-en-3-one 1a (0.8 mmol, 91.2 mg) at 
35 oC  according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 70/30 to 0/100) to give the title compound as a white foam. 
An inseparable mixture of 17b and 13b was obtained after column chromatography. 
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The NMR spectra, 1H and 13C, were recorded from the racemic reaction. IR (/cm-1): 
3318, 2971, 2925, 2853, 2236, 1711, 1487, 1425, 1362, 1243, 1170, 962, 763, 733, 703, 
569, 545, 494. 1H NMR (300 MHz, CDCl3) δ: 8.29 – 8.23 (m, 1H),7.31 – 7.23 (m, 2H), 
7.18 – 7.08 (m, 6H), 4.19 (d, J = 13.3 Hz, 1H),  3.61 (s, 1H), 3.35 – 3.31 (m, 2H),  2.86 – 
2.74 (m, 1H), 2.57 – 2.42 (m, 2H), 1.34 (s, 3H), 1.31 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 
212.6, 144.8, 141.4, 135.0, 129.7, 128.4, 127.6, 127.2, 125.8, 125.6, 120.6, 50.3, 39.6, 
32.2, 29.8, 28.8, 26.8, 26.7. UPLC-DAD-QTOF: C20H23N2O3 [M+H]
+ calcd.: 339.1709, 
found: 339.1713.  
(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)heptan-2-
yl)pyridine 1-oxide (17c) 
The title compound 17c was prepared from 2-(1-cyano-2-(4-
(trifluoromethyl)phenyl)ethyl)pyridine 1-oxide 13c (0.2 mmol, 
58.4 mg) and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.8 
mmol, 91.2 mg) at rt according to the general procedure. The 
crude material was purified by flash column chromatography 
on silica gel (eluting with Hex/EtOAc 70/30 to 0/100) to give 
the title compound as a white solid. An inseparable mixture of 17c and 13c was 
obtained after column chromatography. The NMR spectra, 1H and 13C, were recorded 
from the racemic reaction. m. p. 162–164 oC. IR (/cm-1): 3246, 2979, 2933, 2233, 
1707, 1617, 1492, 1430, 1321, 1240, 1170, 1107, 1065, 1019, 965, 848, 772, 687, 661, 
570, 487. 1H NMR (300 MHz, CDCl3) δ:  8.27 (d, J = 6.3 Hz, 1H), 7.44 – 7.41 (m, 2H), 7.35 
– 7.24 (m, 2H), 7.18 – 7.12 (m, 1H), 4.36 (d, J = 13.2 Hz, 1H), 3.58 (s, 1H), 3.36 – 3.32 
(m, 2H),  2.86 – 2.74 (m, 1H), 2.56 – 2.43 (m, 2H), 1.33 (s, 3H), 1.30 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ: 212.5, 144.2, 141.5, 139.2, 130.0, 129.7, 127.3, 126.1, 125.8, 125.4, 
125.3, 122.2, 120.3, 50.2, 39.3, 32.2, 28.6, 26.7. UPLC-DAD-QTOF: C21H22F3N2O3 [M+H]
+ 
calcd.: 407.1583, found: 407.1571.  
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5.3.6. Elaboration of adduct 9a 
5.3.6.1. Reduction of 9a to the parent pyridine 18248 
 
A solution of adduct 9a (1 equiv., 1 mmol, 324 mg) in acetonitrile (10 mL) was stirred 
in an oven-dried reaction vial, bis(pinacolato)diboron ((pinB)2) (3 equiv., 3 mmol, 
761.82 mg) was added and the mixture was stirred at 70 oC for 24 h. Afterwards 3 
equiv. more of (pinB)2 were added and the reaction stirred at 70 
oC for additional 24 h. 
Then, ethylendiamine (120 equiv, 120 mmol, 8 mL) was added to the mixture, and the 
stirring was continued for 1 h at room temperature. The reaction mixture was then 
diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The organic phase 
was dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 80/20 to 50/50) to give the desired compound as a colourless oil. Yield: 228 
mg, 0.74 mmol, 74%. [α]D
25= +21.0 (c = 1.00, 92% ee, CH2Cl2). IR (/cm
-1): 3408, 3001, 
2969, 2945, 2236, 1709, 1588, 1430, 1365, 1216, 1139, 1012, 971, 789, 749, 694, 622, 
542. 1H NMR (300 MHz, CDCl3) δ: 8.62 – 8.59 (m, 1H), 7.69 – 7.63 (m, 1H), 7.49 – 7.42 
(m, 3H), 7.37 – 7.21 (m, 4H), 3.61 (s, 1H), 3.01 – 2.96 (m, 1H), 2.84 – 2.58 (m, 3H), 1.31 
(S, 3H), 1.28 (S, 3H). 13C NMR (75 MHz, CDCl3) δ: 213.1, 157.5, 149.1, 138.6, 137.5, 
129.1, 128.3, 126.5, 123.1, 122.4, 121.6, 53.5, 33.2, 32.3, 26.5, 26.5. UPLC-DAD-QTOF: 
C19H21N2O2 [M+H]
+ calcd.: 309.1606, found: 309.1606.  
5.3.6.2. Synthesis of carboxylic acid 19 
 
                                                 
248
 Adapted from Kokatla, H. P.; Thomson, P. F.; Bae, S.; Doddi, V. R.; Lakshman, M. K.; J. Org. Chem. 
2011, 76, 7842–7848. 
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To a solution of 18 (1 equiv., 0.75 mmol, 231 mg) in MeOH (3 mL) a water (1.5 mL) 
solution of NaIO4 (5 equiv., 3.75 mmol, 800 mg) was added at 0 
oC. After stirring the 
reaction mixture at room temperature for 8 h, MeOH was evaporated under reduce 
pressure. Water (10 mL) was added to the crude product and the resulting mixture was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were dried over 
MgSO4, filtered and evaporated under reduced pressure, affording essentially pure 
product 19. White solid; Yield: 0.72 mmol, 191 mg, 95%. m. p. 100–104 oC. IR (/cm-1): 
3445, 3034, 2969, 2237, 1713, 1588, 1535, 1446, 1345, 1216, 1143, 1054, 966, 860, 
789, 749, 701, 634. 1H NMR (300 MHz, CDCl3) δ: 11.20 (s, 1h, broad signal), 8.67 – 8.65 
(m, 1H), 7.52 – 7.49 (m, 3H), 7.40 – 7.24 (m, 4H), 3.13 – 3.03 (m, 1H), 2.87 – 2.77 (m, 
1H), 2.65 – 2.44 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 178.0, 157.3, 149.4, 138.4, 137.6, 
129.1, 128.4, 126.5, 123.2, 122.6, 121.3, 55.3, 33.8, 30.7. UPLC-DAD-QTOF: C16H15N2O2 
[M+H]+ calcd.: 267.1134, found: 267.1131. 
5.3.6.3. Synthesis of aldehyde 20 
 
To a solution of 18 (1 equiv., 0.3 mmol, 92.4 mg) in dry THF (2 mL) at 0 oC BH3·THF 
complex (1 M in THF, 2 equiv., 0.6 mmol, 0.6 mL) was added. The resulting solution 
was stirred at the same temperature for 2 h (the reaction was monitored by TLC 
(Hex/EtOAc, 50:50)) and after completion, MeOH (1 mL) was added and the resulting 
mixture stirred at room temperature for 30 min. The solvents were evaporated under 
reduced pressure and the residue thus obtained was disolved in MeOH (2 mL) and a 
suspension of NaIO4 (320 mg, 1.5 mmol, 5 equiv) in water (1 mL) was added at room 
temperature. The reaction mixture was stirred at the same temperature for 2 h and 
solvents were evaporated under reduced pressure. Water (6 mL) was added to the 
crude product and the resulting mixture was extracted with CH2Cl2 (3 x 6 mL). The 
combined organic phases were dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude product was purified by silica gel flash column 
chromatography (Hex/EtOAc, 80:20) affording title product 20 as a colorless oil. Yield: 
0.24 mmol, 60 mg, 80%. [α]D
25= +62.8 (c = 1.00, 92% ee, CH2Cl2). IR (/cm
-1): 3059, 
2969, 2831, 2726, 2238, 1718, 1586, 1493, 1448, 1430, 1363, 1216, 1031, 993, 963, 
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912, 746, 697, 538. 1H NMR (300 MHz, CDCl3) δ: 9.74 (s, 1H), 7.70 – 7.64 (m, 1H), 7.51 – 
7.21 (m, 7H), 3.10 – 2.97 (m, 1H), 2.85 – 2.52 (m, 1H). 13C NMR (75 MHz, CDCl3) δ: 
200.1, 157.4, 149.5, 138.6, 137.5, 129.1, 128.4, 126.5, 123.1, 122.6, 121.5, 53.4, 40.6, 
31.5. UPLC-DAD-QTOF: C16H15N2O [M+H]
+ calcd.: 251.1184, found: 251.1182. 
5.3.6.4. Synthesis of ketone 21 
 
MeMgBr (3 M in Et2O, 5 equiv., 0.5 mmol) was added to a solution of α-hydroxy 
ketone 18 (1 equiv., 0.3 mmol, 92.4 mg) in dry THF (1.5 mL) at 0 oC and the resulting 
solution was stirred at the same temperature until the reaction was finished 
(monitored by TLC). Then a saturated aqueous solution of NH4Cl (9 mL) was added at 0 
oC and the resulting mixture was extracted with CH2Cl2 (3 x 15 mL). The solvents were 
evaporated under reduced pressure and the residue thus obtained was disolved in 
MeOH (1.8 mL). A suspension of NaIO4 (5 equiv., 1.5 mmol, 321 mg) in water (0.9 mL) 
was added to the solution at room temperature and the resulting mixture was stirred 
at the same temperature for 1 h. Then solvents were evaporated under reduced 
pressure, water (9 mL) was added to the residue and the resulting mixture was 
extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over 
MgSO4, filtered and evaporated under reduced pressure, affording essentially pure 
product 21 as a colorless oil. Yield: 0.27 mmol, 71.3 mg, 90%. [α]D
25= +30.7 (c = 0.5, 
92% ee, CH2Cl2). IR (/cm
-1): 3080, 3004, 2918, 2849, 2236, 1715, 1573, 1466, 1433, 
1369, 1165, 993, 765, 749, 697, 541. 1H NMR (300 MHz, CDCl3) δ: 8.63 – 8.60 (m, 1H), 
7.69 – 7.63 (m, 1H), 7.50 – 7.42 (m, 3H), 7.38 – 7.19 (m, 4H), 3.01 – 2.89 (m, 1H), 2.78 – 
2.69 (m, 1H), 2.66 – 2.49 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 206.8, 157.2, 149.5, 
138.8, 137.4, 129.1, 128.3, 126.6, 123.0, 122.3, 121.7, 53.5, 40.0, 32.9, 30.1. UPLC-
DAD-QTOF: C17H17N2O [M+H]
+ calcd.: 265.1341, found: 265.1342.  
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5.3.6.5. Synthesis of Boc-amine 22 
 
To a solution of acid 19 (0.4 mmol, 106.5 mg) in toluene (1 mL) were added Et3N 
(0.40 mmol, 55 µL) and diphenylphosphoryl azide (DPPA) (0.4 mmol, 86 µL), and the 
reaction mixture was heated at 80 oC for 2 h. After cooling to 50 oC, tert-butanol (4 
mmol, 0.38 mL) was added and the resulting mixture was stirred at 50 oC for 16 h. The 
reaction mixture was allowed to cool to room temperature and the solvents were 
removed by rotary evaporation. The resulting oil was diluted with 10 mL of Et2O, 5 mL 
of water, and 2.5 mL of saturated solution of Na2CO3. The aqueous layer was separated 
and extracted with DCM (3 x 15 mL), and the combined organic layers were washed 
with 15 mL of brine, dried over MgSO4, filtered and evaporated. The crude material 
was purified by flash column chromatography on silica gel (eluting wit Hex/EtOAc 
90:10 to 70:30) to give the desired compound as a colorless oil. Yield: 0.30 mmol, 
102.5 mg, 76%. [α]D
25= +36.5 (c = 0.26, 89% ee, CH2Cl2). IR (/cm
-1): 3412, 3066, 297, 
2929, 2240, 1687, 1585, 1494, 1470, 1432, 1366, 1272, 1248, 1161, 1053, 977, 921, 
859, 782, 732, 694, 651, 542. 1H NMR (300 MHz, CDCl3) δ: 8.63 – 8.60 (m, 1H), 7.69 – 
7.63 (m, 1H), 7.51 – 7.44 (m, 3H), 7.38 – 7.19 (m, 4H), 4.66 (s, 1H, NH), 3.30 – 3.23 (m, 
2H), 2.94 – 2.84 (m, 1H), 2.73 – 2.63 (m, 1H), 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 
157.9, 155.8, 149.5, 138.8, 137.5, 129.2, 128.3, 126.6, 123.0, 122.4, 121.6, 79.4, 38.9, 
37.8, 28.5. UPLC-DAD-QTOF: C20H24N3O2 [M+H]
+ calcd.: 338.1869, found: 338.1872.  
5.3.6.6. Synthesis of amide 23 
 
To a round-bottom flask with (R)-4-cyano-4-phenyl-4-(pyridin-2-yl)butanoic acid 19 
(0.6 mmol, 159.7 mg) at 0 oC was added slowly concentrated H2SO4 (1.2 mL). The 
reaction mixture was stirred at room temperature overnight. Afterwards, an aqueous 
solution of NaOH 6 M was added to the reaction until white precipitate appeared (pH = 
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4–5). The solution was then extracted with EtOAc (3 x 10 mL), dried over MgSO4 and 
concentrated under vacuum to give the title compound as a white solid. Yield: 0.58 
mmol, 163.8 mg, 96%. m.p. 185–188 oC. [α]D
25= +43.1 (c = 1.00, 90% ee, CH2Cl2). IR 
(/cm-1): 3180, 3087, 2855, 1726, 1687, 1587, 1428, 1332, 1273, 1210, 1183, 955, 861, 
776, 743, 688, 617, 543, 499, 409. 1H NMR (300 MHz, CDCl3) δ: 8.80 (s, 1H), 8.63 (s, 
1H), 7.60 (m, 1H), 7.42 – 7.34 (m, 3H), 7.28 – 7.20 (m, 3H), 7.04 (d, J = 8.0 Hz, 1H), 3.35 
– 3.24 (m, 1H), 2.71 – 2.61 (m, 2H), 2.54 – 2.42 (m, 1H). 13C NMR (75 MHz, CDCl3) δ: 
174.1, 172.9, 160.2, 148.7, 139.7, 136.6, 128.9, 127.9, 124.8, 122.6, 59.0, 30.2, 29.6. 
UPLC-DAD-QTOF: C16H17N2O3 [M+H]
+ calcd.: 285.1239, found: 285.1225. 
5.3.7. Conversion for the reaction of o-, m- and p-substituted cyanoalkylpyridines 
and pyridine N-oxides with enone 1a 
 
To a solution of the corresponding cyanoalkylpyridine or pyridine N-oxides (1 equiv., 
0.2 mmol) in dichlorometane (1 mL) the α’-hydroxy enone 1a (3.0 equiv., 0.6 mmol) 
and the catalyst (0.2 equiv., 0.04 mmol) were added at the corresponding temperature 
(see below).  The resulting mixture was stirred for 24 h (reaction conversion was 
calculated by 1H-NMR). Afterwards, the reaction mixture was washed with 0.1 M 
aqueous solution of HCl and purified by flash column chromatography on silica gel to 
afford the expected adducts. 
6-hydroxy-6-methyl-5-oxo-2-phenyl-2-(pyridin-4-yl)heptanenitrile 
The title compound was prepared from 2-phenyl-2-(pyridin-4-
yl)acetonitrile (0.2 mmol, 38.8 mg) and 4-hydroxy-4-methylpent-
1-en-3-one (0.6 mmol, 68.4 mg) at rt according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 80/20 to 
50/50) to give the title compound as a white foam. Yield: 0.16 
mmol, 49.3 mg, 80%. IR (/cm-1): 3391, 3237, 3060, 2974, 2929, 2238, 1713, 1593, 
1493, 1448, 1410, 1363, 1193, 1085, 966, 816, 759, 699, 650, 554. 1H NMR (300 MHz, 
CDCl3) δ: 8.64 – 8.62 (s, 2H), 7.42 – 7.32 (m, 6H), 3.36 (s, 1H), 2.80 – 2.67 (m, 4H), 1.31 
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(s, 3H), 1.30 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.7, 150.8, 148.6, 137.5, 129.6, 
129.0, 126.8, 121.6, 120.6, 77.6, 50.9, 32.8, 32.2, 26.7, 26.7. UPLC-DAD-QTOF: 
C19H21N2O2 [M+H]
+ calcd.: 309.1606, found: 309.1603.  
(R)-3-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
The title compound was prepared from 3-
(cyano(phenyl)methyl)pyridine 1-oxide 11 (0.2 mmol, 58.0 mg) 
and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 68.4 mg) 
at r.t.  according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 70/30 to 0/100) to give the title 
compound as a yellow oil. Yield: 0.16 mmol, 51.8 mg, 79%. IR (/cm-1): 3398, 3098, 
2956, 2913, 2235, 1711, 1610, 1407, 1267, 1145, 771, 730, 678, 559. 1H NMR (300 
MHz, CDCl3) δ: 8.23 – 8.21 (s, 1H), 8.13 – 8.10 (s, 1H), 7.44 – 7.25 (m, 7H), 4.00 (s, 1H), 
2.85 – 2.63 (m, 4H), 1.32 (s, 3H), 1.29 (s, 3H). UPLC-DAD-QTOF: C19H21N2O3 [M+H]
+ 
calcd.: 325.1552, found: 325.1555.  
4-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
The title compound was prepared from 4-
(cyano(phenyl)methyl)pyridine 1-oxide 12 (0.2 mmol, 58.0 mg) 
and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.6 mmol, 68.4 mg) 
at r.t.  according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 70/30 to 0/100) to give the title 
compound as a white foam. Yield: 0.16 mmol, 50.5 mg, 78%. IR (/cm-1): 3420, 3115, 
3068, 2965, 2236, 1710, 1587, 1413, 1261, 1167, 764, 732, 701, 556.  1H NMR (300 
MHz, CDCl3) δ: 8.17 (d, J = 7.4 Hz, 1H), 7.43 – 7.39 (m, 5H), 7.28 (d, J = 7.4 Hz, 1H), 3.29 
(s, 1H), 2.79 – 2.64 (m, 4H), 1.33 (s, 3H), 1.30 (s, 3H). UPLC-DAD-QTOF: C19H21N2O3 
[M+H]+ calcd.: 325.1552, found: 325.1548.  
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5.3.8. X-Ray Analysis: ORTEP diagram of compound 9a 
CCDC 1437384 contains the supplementary crystallographic data for the structural 
analysis of 9a. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/deposit/. 
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5.3.9. 1H and 13C NMR Spectra 
2-(cyano(phenyl)methyl)pyridine 1-oxide (6a) 
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2-bromo-6-(cyano(phenyl)methyl)pyridine 1-oxide (6b) 
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2-(cyano(phenyl)methyl)-5-methylpyridine 1-oxide (6c) 
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5-chloro-2-(cyano(phenyl)methyl)pyridine 1-oxide (6d) 
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2-(cyano(phenyl)methyl)-3-methoxypyridine 1-oxide (6e) 
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2-((4-bromophenyl)(cyano)methyl)pyridine 1-oxide (6f) 
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2-(cyano(thiophen-3-yl)methyl)pyridine 1-oxide (6g) 
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2-(cyano(4-methoxyphenyl)methyl)pyridine 1-oxide (6h) 
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2-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine 1-oxide (6i) 
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2-(cyano(4-(methoxycarbonyl)phenyl)methyl)pyridine 1-oxide (6j) 
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5-chloro-2-(cyano(p-tolyl)methyl)pyridine 1-oxide (6k) 
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2-bromo-6-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine 1-oxide (6l) 
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2-(cyano(phenyl)methyl)pyrazine 1-oxide (10a) 
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2-chloro-6-(cyano(phenyl)methyl)pyrazine 1-oxide (10b) 
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2-((4-bromophenyl)(cyano)methyl)pyrazine 1-oxide (10c) 
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2-(1-cyanopropyl)pyridine 1-oxide (13a) 
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2-(1-cyano-2-phenylethyl)pyridine 1-oxide (13b)  
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2-(1-cyano-2-(4-(trifluoromethyl)phenyl)ethyl)pyridine 1-oxide (13c) 
 
 
 
Experimental section 
223 
 
3-(cyano(phenyl)methyl)pyridine 1-oxide (11) 
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4-(cyano(phenyl)methyl)pyridine 1-oxide (12) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide (9a) 
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(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
(9b) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)-5-methylpyridine 1-oxide 
(9c) 
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5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide (9d) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide (9e) 
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(R)-2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9f) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(thiophen-3-yl)hexyl)pyridine 1-oxide 
(9g)
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(R)-2-(1-cyano-5-hydroxy-1-(4-methoxyphenyl)-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9h) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4(trifluoromethyl)phenyl)hexyl)pyridine 
1-oxide (9i) 
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(R)-2-(1-cyano-5-hydroxy-1-(4-(methoxycarbonyl)phenyl)-5-methyl-4 
oxohexyl)pyridine 1-oxide (9j) 
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(R)-5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide 
(9k) 
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(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4 
(trifluoromethyl)phenyl)hexyl)pyridine 1-oxide (9l) 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide (16a) 
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(R)-2-chloro-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide 
(16b) 
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(R)- 2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyrazine 1-oxide 
(16c) 
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(S)-2-(3-cyano-7-hydroxy-7-methyl-6-oxooctan-3-yl)pyridine 1-oxide (17a) 
 
 
 
Experimental section 
241 
 
(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-phenylheptan-2-yl)pyridine 1-oxide (17b) 
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(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)heptan-2-
yl)pyridine 1-oxide (17c) 
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(R)-6-hydroxy-6-methyl-5-oxo-2-phenyl-2-(pyridin-2-yl)heptanenitrile (18) 
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(R)-4-cyano-4-phenyl-4-(pyridin-2-yl)butanoic acid (19) 
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(R)-5-oxo-2-phenyl-2-(pyridin-2-yl)pentanenitrile (20) 
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(R)-5-oxo-2-phenyl-2-(pyridin-2-yl)hexanenitrile (21) 
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tert-butyl (R)-(3-cyano-3-phenyl-3-(pyridin-2-yl)propyl)carbamate (22) 
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(R)-5-amino-5-oxo-4-phenyl-4-(pyridin-2-yl)pentanoic acid (23) 
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6-hydroxy-6-methyl-5-oxo-2-phenyl-2-(pyridin-4-yl)heptanenitrile 
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5.3.10. HPLC chromatograms 
(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide (9a) 
 The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 12.9 min (min.) and 15.2 min (major.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 13.293 50.08 
2 16.424 49.92 
 
 
 Retention Time % Area 
1 12.887 4.29 
2 15.200 95.71 
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(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
(9b) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 60/40, flow rate = 0.5 
mL/min, retention times: 12.8 min (min.) and 14.0 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 12.825 49.42 
2 14.122 50.58 
 
 
 Retention Time % Area 
1 12.816 3.29 
2 13.976 96.71 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)-5-methylpyridine 1-oxide 
(9c)  
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 70/30, flow rate = 0.5 
mL/min, retention times: 25.9 min (min.) and 28.6 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 26.267 49.20 
2 29.166 50.80 
 
 
 Retention Time % Area 
1 25.903 5.08 
2 28.582 94.92 
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(R)-5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
(9d) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 
0.5 mL/min, retention times: 16.5 min (min.) and 18.9 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 15.940 49.91 
2 18.171 50.09 
 
 
 Retention Time % Area 
1 16.486 4.71 
2 18.857 95.29 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide (9e) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 15.7 min (min.) and 23.0 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 15.692 49.97 
2 23.352 50.03 
 
 
 Retention Time % Area 
1 15.662 5.14 
2 23.029 94.86 
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(R)-2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9f) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 16.5 min (min.) and 18.9 min (major.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 15.940 49.91 
2 18.171 50.09 
 
 
 Retention Time % Area 
1 16.486 4.71 
2 18.857 95.29 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(thiophen-3-yl)hexyl)pyridine 1-oxide 
(9g) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 13.3 min (major.) and 14.8 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 13.594 47.82 
2 14.439 52.18 
 
 
 Retention Time % Area 
1 13.555 96.66 
2 14.957 3.34 
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(R)-2-(1-cyano-5-hydroxy-1-(4-methoxyphenyl)-5-methyl-4-oxohexyl)pyridine 1-oxide 
(9h) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 18.6 min (min.) and 31.0 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 19.197 50.51 
2 32.201 49.49 
 
 
 Retention Time % Area 
1 18.633 5.56 
2 31.042 94.44 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4(trifluoromethyl)phenyl)hexyl)pyridine 
1-oxide (9i) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 70/30, flow rate = 0.5 
mL/min, retention times: 19.2 min (min.) and 21.8 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 19.272 49.72 
2 21.873 50.28 
 
 
 Retention Time % Area 
1 19.223 4.10 
2 21.779 95.90 
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(R)-2-(1-cyano-5-hydroxy-1-(4-(methoxycarbonyl)phenyl)-5-methyl-4-
oxohexyl)pyridine 1-oxide (9j) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 25.8 min (min.) and 28.4 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 22.575 50.51 
2 24.818 49.49 
 
 
 Retention Time % Area 
1 25.797 2.87 
2 28.358 97.13 
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(R)-5-chloro-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(p-tolyl)hexyl)pyridine 1-oxide 
(9k)  
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 
0.5 mL/min, retention times: 24.4 min (min.) and 45.4 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 26.007 49.39 
2 48.443 50.61 
 
 
 Retention Time % Area 
1 26.139 6.63 
2 48.857 93.37 
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(R)-2-bromo-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-(4 
(trifluoromethyl)phenyl)hexyl)pyridine 1-oxide (9l) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 35/65, flow rate = 
0.5 mL/min, retention times: 9.7 min (min.) and 13.8 min 
(major.). Processed Channel Descr.: PDA 264.0 nm). 
 
 Retention Time % Area 
1 9.353 50.74 
2 13.423 49.26 
 
 
 Retention Time % Area 
1 9.700 3.02 
2 13.847 96.98 
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(R)-2-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide (16a) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/ethanol 60/40, flow rate = 0.5 
mL/min, retention times: 24.6 min (min.) and 32.5 min (major.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 25.594 49.55 
2 34.054 50.45 
 
 
 Retention Time % Area 
1 24.594 7.46 
2 32.480 92.54 
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(R)-2-chloro-6-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyrazine 1-oxide 
(16b) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 70/30, flow rate = 0.5 
mL/min, retention times: 29.2 min (min.) and 33.8 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 29.480 51.61 
2 34.178 48.39 
 
 
 Retention Time % Area 
1 29.431 8.14 
2 34.133 91.86 
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(R)-2-(1-(4-bromophenyl)-1-cyano-5-hydroxy-5-methyl-4-oxohexyl)pyrazine 1-oxide 
(16c) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 28.8 min (major.) and 37.7 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 30.366 50.17 
2 39.383 49.83 
 
 
 Retention Time % Area 
1 28.809 92.91 
2 37.733 7.09 
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(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-phenylheptan-2-yl)pyridine 1-oxide (17b) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 13.1 min (min.) and 14.9 min (major.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 13.584 49.98 
2 15.460 50.02 
 
 
 Retention Time % Area 
1 13.126 8.26 
2 14.995 91.74 
 
 
 
 
 
 
 
 
A
U
0,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
Minutes
10,00 11,00 12,00 13,00 14,00 15,00 16,00 17,00 18,00 19,00 20,00
1
3
,5
8
4
1
5
,4
6
0
A
U
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
Minutes
10,00 10,50 11,00 11,50 12,00 12,50 13,00 13,50 14,00 14,50 15,00 15,50 16,00 16,50 17,00 17,50 18,00
1
3
,1
2
6 1
4
,9
9
5
Chapter 5 
266 
 
(R)-2-(2-cyano-6-hydroxy-6-methyl-5-oxo-1-(4-(trifluoromethyl)phenyl)heptan-2-
yl)pyridine 1-oxide (17c) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 10.7 min (major.) and 12.6 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 
 Retention Time % Area 
1 10.793 50.05 
2 12.471 49.95 
 
 
 Retention Time % Area 
1 10.658 91.61 
2 12.577 8.39 
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(R)-6-hydroxy-6-methyl-5-oxo-2-phenyl-2-(pyridin-2-yl)heptanenitrile (18) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 90/10, flow rate = 0.5 
mL/min, retention times: 51.3 min (min.) and 56.3 min (major.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 50.100 49.93 
2 55.279 50.07 
 
 
 Retention Time % Area 
1 51.269 4.23 
2 56.336 95.77 
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(R)-5-oxo-2-phenyl-2-(pyridin-2-yl)hexanenitrile (21) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IB, hexane/isopropanol 90/10, flow rate = 0.5 mL/min, 
retention times: 20.5 min (major.) and 25.2 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 19.664 50.32 
2 23.020 49.68 
 
 
 Retention Time % Area 
1 20.518 95.50 
2 25.167 4.50 
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tert-butyl (R)-(3-cyano-3-phenyl-3-(pyridin-2-yl)propyl)carbamate (22) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol/ethanol 90/5/5, 
flow rate = 0.5 mL/min, retention times: 27.0 min (min.) and 
30.7 min (major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 30.408 49.44 
2 33.845 50.56 
 
 
 Retention Time % Area 
1 26.982 5.56 
2 30.679 94.44 
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6-hydroxy-6-methyl-5-oxo-2-phenyl-2-(pyridin-4-yl)heptanenitrile 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/isopropanol 90/10, flow rate = 0.5 mL/min, 
retention times: 31.0 min and 36.0 min. Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 31.043 49.08 
2 35.968 50.92 
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(R)-3-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
The enantiomeric ratio was determined by HPLC analysis (Daicel 
Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 mL/min, 
retention times: 16.5 min (major.) and 20.6 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 18.414 49.93 
2 22.914 50.07 
 
 
 Retention Time % Area 
1 16.528 54.01 
2 20.551 45.99 
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4-(1-cyano-5-hydroxy-5-methyl-4-oxo-1-phenylhexyl)pyridine 1-oxide 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/ethanol 50/50, flow rate = 0.5 
mL/min, retention times: 17.1 min and 22.7 min. Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 17.069 50.89 
2 22.700 49.11 
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5.4. Experimental section of chapter 3 
5.4.1. General procedure for the synthesis of nitroalkenes 36a–c, 36e and 36l 
36a–c, 36e and 36l are commercially available and were purchased from commercial 
suppliers. Nitroalkenes 36d, 36f–g, 36j–k, 36m–n were prepared according to the 
general procedure A. Aliphatic nitroalkenes 36h–i were prepared according to the 
general procedure B. 
5.4.1.1. General procedure A249 
The corresponding aldehyde (2 mmol), ammonium acetate (0.1 g, 2.6 mmol) and 
nitromethane (3 mL) were placed in a 10 mL round bottomed flask equipped with a 
condenser. The mixture was refluxed and stirred for 2 hours and then evaporated to 
give a residue that was dissolved in CH2Cl2 (5 mL), washed successively with saturated 
brine and water, and the organic layer was evaporated to give the target compounds 
that were used without further purification (yields: 70–95%). 
5.4.1.2. General procedure B250 
Nitromethane (1 equiv., 1.1 mL, 20 mmol) was added to a stirred solution of the 
corresponding aldehyde (1 equiv., 20 mmol) in ethanol (35 mL) at 0 oC, followed by 
dropwise addition of 10N NaOH solution (1.05 equiv., 201 mL, 21 mmol). The resulting 
mixture was stirred at 0 oC for 1 hour and then a mixture of 1:1 HCl 37%: H2O (12 
mL:12 mL) was added. The reaction mixture was stirred at 0 oC for 1 hour, then 
extracted with dichloromethane (3 x 50 mL), dried over MgSO4, filtered, and the 
solvent evaporated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (yields: 70–95%).  
  
                                                 
249
 Cheng, P.; Chen, J.-J.; Huang, N.; Wang, R.-R.; Zheng, Y.-T.; Liang, Y.-Z. Molecules 2009, 14, 3176–
3186. 
250
 Bourguignon, J.; Le Nard, G.; Queguiner, G. Can. J. Chem. 1985, 63, 2354–2361. 
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5.4.2. Preparation of N1-Acyl templates 32-35 
5.4.2.1. Synthesis of 1-acetyl-5-benzyl-2-thioxoimidazolidin-4-one 28251 
 
Phenylalanine (1 equiv., 4 mmol, 661 mg) and NH4SCN (1 equiv., 4 mmol, 334 mg) 
were mixed in Ac2O (6 equiv., 24 mmol, 2.26 mL). The resulting mixture was heated at 
100 oC for 30 min in an oil bath, by which time all solids dissolved. The reaction was 
then quenched with ice and H2O (30 mL) and the aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were dried (MgSO4), concentrated in 
vacuo, and the crude product purified by column chromatography on silica gel. Yield: 
3.1 mmol, 774 mg, 78%. m. p. 163–166 oC. 1H NMR (300 MHz, CDCl3) δ: 9.09 (s, 1H), 
7.30 – 7.25 (m, 3H), 7.08 – 7.02 (m, 2H), 5.03 (dd, J = 5.9, 2.6 Hz, 1H), 3.59 (dd, J = 14.0, 
5.9 Hz, 1H), 3.30 (dd, J = 14.0, 2.6 Hz, 1H), 2.80 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 
179.9, 171.4, 170.7, 133.3, 129.5, 128.9, 127.9, 64.3, 35.2, 27.6.UPLC-DAD-QTOF: 
C12H13N2O2S [M+H]
+ calcd.: 249.0698, found: 249.0699. UPLC-DAD-QTOF: C12H13N2O2S 
[M+H]+ calcd.: 249.0698, found: 249.0704. 
5.4.2.2. Synthesis of N-benzoyl 2-thiohydantoins 29. 
 
5.4.2.2.1. Synthesis of 2-thiohydantoins252 
 
A mixture of the corresponding racemic amino acid (1 equiv., 40 mmol) and thiourea 
(3 equiv., 120 mmol) was placed in a flask and heated under stirring. When the 
                                                 
251
 Gosling, S.; Rollin, P.; Tatiboët, A. Synthesis 2011, 22, 3649–3660.  
252
 Wang, Z. D.; Sheikh, S. O.; Zhang, Y. Molecules  2006, 11, 739–750.  
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reaction temperature reached 180 oC, the mixture started to melt (m. p. of thiourea 
175–178 oC) and about 5 minutes later (when the temperature reached 190 oC) the 
homogenous liquid started to fume and reflux and the solution turned an amber color. 
After 10 minutes, the fuming ceased and the reaction mixture was kept at this 
temperature for an additional 30 min. The flask was allowed to cool down and water 
(20 mL) was added while the flask was still warm. The solution was reheated to 
dissolve all the solids and allowed to cool to room temperature, then extracted with 
ethyl acetate (3 x 30 mL). The organic solvent was evaporated under reduced pressure 
and afterwards to this residue 100 mL of H2O was added. This mixture was warm up to 
50 oC and stirred for 30 min (to remove the excess of thiourea). The water phase was 
discarded. This process was repeated 3 times. To the organic residue was added 100 
mL of Et2O. The orange solid was filtered off to yield the title compound. 
5-Benzyl-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-phenylalanine (6.60 g, 40 
mmol) according to the general procedure. Orange solid. Yield: 7.25 g, 
35.2 mmol, 88%. 1H NMR (300 MHz, MeOD) δ: 7.45 – 6.92 (m, 5H), 
4.51 (dd, J = 5.6, 4.7 Hz, 1H), 3.25 – 2.99 (m, 3H). 
5-Methyl-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-alanine (3.56 g, 40 mmol) 
according to the general procedure. Orange solid. Yield: 4.68 g, 36.0 
mmol, 90%. 1H NMR (300 MHz, MeOD) δ: 4.29 – 4.19 (m, 1H), 1.42 (d, J 
= 7.1 Hz, 5H). 
5-Ethyl-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-2-aminobutyric acid (4.12 g, 
40 mmol) according to the general procedure. Orange solid. Yield: 5.24 
g, 36.4 mmol, 91%. 1H NMR (300 MHz, MeOD) δ: 4.19 (dd, J = 6.1, 5.0 Hz, 
1H), 2.00 – 1.67 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 
5-Isobutyl-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-leucine (5.24 g, 40 mmol) 
according to the general procedure. Orange solid. Yield: 6.26 g, 36.4 
mmol, 91%. 1H NMR (300 MHz, MeOD) δ: 1.95 – 1.80 (m, 1H), 4.25 (dd, 
J = 8.4, 5.0 Hz, 1H), 1.75 – 1.54 (m, 2H), 1.00 (d, J = 6.6 Hz, 9H). 
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5-Hexyl-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-2-aminooctanoic acid 
(6.37 g, 40 mmol) according to the general procedure. Orange solid. 
Yield: 6.80 g, 34.0 mmol, 85%.  
5-(2-(Methylthio)ethyl)-2-thioxoimidazolidin-4-one 
The title compound was prepared from DL-methionine (5.97 g, 40 
mmol) according to the general procedure. Orange solid. Yield: 
5.32 g, 28.0 mmol, 70%. 1H NMR (300 MHz, MeOD) δ: 4.37 (dd, J = 
7.1, 5.1 Hz, 1H), 2.75 – 2.58 (m, 3H), 2.23 – 1.92 (m, 5H). 
5.4.2.2.2. Synthesis of N-benzoyl 2-thiohydantoins 29 
 
To a solution of the corresponding 2-thiohydantoin (1 equiv., 4 mmol) in dry CH2Cl2, 
DMAP (1.05 equiv., 4.2 mmol, 513 mg) and benzoyl chloride (1.05 equiv., 4.2 mmol, 
487.9 µL) was added at 0 oC. Afterwards, the reaction was stirred at room temperature 
for 5 h. After concentration under vacuum, the crude product was purified by column 
chromatography on silica gel to give the desires compound. 
1-Benzoyl-5-methyl-2-thioxoimidazolidin-4-one (29A) 
 The title compound was prepared from 5-methyl-2-
thioxoimidazolidin-4-one (4 mmol, 521 mg) and benzoyl chloride 
(4.2 mmol, 486 µL) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 95:5 to 80:20) to give the title compound 
as a yellow solid. Yield: 3.0 mmol, 707 mg, 76%. m. p. 159–161 oC. 1H NMR (300 MHz, 
CDCl3) δ: 8.61 (s, 1H), 7.73 – 7.70 (m, 2H), 7.62 – 7.56 (m, 1H), 7.48 – 7.42 (m, 2H), 5.04 
(q, J = 6.9 Hz, 1H), 1.66 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ:
 180.1, 173.0, 
169.9, 133.8, 133.3, 129.5, 128.4, 59.5, 15.5. UPLC-DAD-QTOF: C11H11N2O2S [M+H]
+ 
calcd.: 235.0541, found: 235.0542.  
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1-Benzoyl-5-ethyl-2-thioxoimidazolidin-4-one (29B) 
The title compound was prepared from 5-ethyl-2-
thioxoimidazolidin-4-one (4 mmol, 577 mg) and and benzoyl 
chloride (4.2 mmol, 486 µL) according to the general procedure. The 
crude material was purified by flash column chromatography on 
silica gel (eluting with Hex/EtOAc 90:10 to 50:50) to give the title 
compound as a white solid. Yield: 2.9 mmol, 719 mg, 73%. m. p. 144–147 oC. 1H NMR 
(300 MHz, CDCl3) δ: 8.37 (s, 1H), 7.76 – 7.73 (m, 2H), 7.63 – 7.57 (m, 1H), 7.48 – 7.42 
(m, 2H), 5.08 (dd, J = 5.3, 4.0 Hz, 1H), 2.20 – 2.10 (m, 2H), 1.06 (t, J = 7.5 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ: 180.7, 172.3, 169.9, 133.7, 133.3, 129.8, 128.4, 64.3, 22.5, 8.2. 
UPLC-DAD-QTOF: C12H13N2O2S [M+H]
+ calcd.: 249.0698, found: 249.0695. 
1-Benzoyl-5-benzyl-2-thioxoimidazolidin-4-one (29C) 
The title compound was prepared from 5-benzyl-2-
thioxoimidazolidin-4-one (4 mmol, 824 mg) and benzoyl chloride 
(4.2 mmol, 486 µL) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound 
as a yellow foam. Yield: 3.4 mmol, 1.06 g, 85%. 1H NMR (300 MHz, CDCl3) δ: 9.16 (s, 
1H), 7.60 – 7.50 (m, 1H), 7.43 – 7.25 (m, 7H), 7.18 – 7.11 (m, 2H), 5.30 (dd, J = 5.7, 3.1 
Hz, 1H), 3.61 – 3.43 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 180.3, 171.7, 169.8, 133.8, 
133.4, 133.0, 130.8, 130.6, 129.9, 129.9, 129.1, 128.0, 128.0, 64.2, 34.0. UPLC-DAD-
QTOF: C17H15N2O2S [M+H]
+ calcd.: 311.0854, found: 311.0858. 
1-Benzoyl-5-isobutyl-2-thioxoimidazolidin-4-one (29D) 
The title compound was prepared from 5-isobutyl-2-
thioxoimidazolidin-4-one (4 mmol, 689 mg) and benzoyl chloride 
(4.2 mmol, 486 µL) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 95:5 to 80:20) to give the title compound 
as a white solid. Yield: 2.4 mmol, 662 mg, 80%. m. p. 160–162 oC. 1H NMR (300 MHz, 
CDCl3) δ: 9.18 (s, 1H), 7.79 – 7.68 (m, 2H), 7.64 – 7.54 (m, 1H), 7.52 – 7.36 (m, 2H), 5.06 
(dd, J = 7.2, 4.5 Hz, 1H), 2.24 – 1.70 (m, 3H), 0.98 (t, J = 6.4 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ: 180.4, 172.7, 170.0, 133.5, 129.8, 128.5, 61.9, 38.9, 24.6, 23.1, 22.1. UPLC-
DAD-QTOF: C14H17N2O2S [M+H]
+ calcd.: 277.1011, found: 277.1013. 
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1-Benzoyl-5-hexyl-2-thioxoimidazolidin-4-one (29E) 
The title compound was prepared from 5-hexyl-2-
thioxoimidazolidin-4-one (4 mmol, 800 mg) and benzoyl chloride 
(4.2 mmol, 486 µL) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 95:5 to 80:20) to give the title compound 
as a yellow solid. Yield: 2.9 mmol, 875 mg, 72%. m. p. 79–83 oC. 1H NMR (300 MHz, 
CDCl3) δ: 9.93 (s, 1H), 7.80 – 7.72 (m, 2H), 7.64 – 7.56 (m, 1H), 7.51 – 7.42 (m, 2H), 5.10 
(dd, J = 5.6, 4.0 Hz, 1H), 2.17 – 2.03 (m, 2H), 1.55 – 1.25 (m, 9H), 0.90 – 0.85 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ: 181.7, 173.9, 170.8, 134.6, 134.2, 131.2, 130.6, 129.3, 
64.4, 32.4, 30.1, 29.8, 24.7, 23.4, 15.0. UPLC-DAD-QTOF: C16H21N2O2S [M+H]
+ calcd.: 
305.1324, found: 305.1324. 
5.4.2.3. Synthesis of N1-Boc and N1-Cbz 2-thiohydantoins 30 and 31253 
 
To a solution of the corresponding N-Boc or N-Cbz amino acid (1.0 equiv, 4 mmol) in 
CH3CN, pyridine (4 equiv., 16 mmol, 1.23 mL) and ethoxycarbonyl isothiocyanate (1.1 
equiv., 4.4 mmol, 519 µL) were added at room temperature. The reaction mixture was 
stirred for 2 h at the same temperature. Afterwards, the solvent was evaporated under 
reduced pressure and the resulting crude product was purified by silica gel flash 
column chromatography to obtain the desired product. 
tert-Butyl 5-methyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30A) 
The title compound was prepared from (tert-butoxycarbonyl)alanine (4 
mmol, 757 mg) and ethoxycarbonyl isothiocyanate (4.4 mmol, 519 µL)  
according to the general procedure. The crude material was purified by 
flash column chromatography on silica gel (eluting with Hex/EtOAc 
50:50 to 0:100) to give the title compound as a white solid. Yield: 3.5 mmol, 810 mg, 
88%. m. p. 138–140 oC. 1H NMR (300 MHz, CDCl3) δ: 9.72 (s, 1H), 4.54 (q, J = 6.9 Hz, 
1H), 1.59 (d, J = 6.9 Hz, 3H), 1.53 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 178.7, 173.0, 
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148.4, 85.4, 59.8, 28.0, 16.9. UPLC-DAD-QTOF: C9H14N2O3SNa* [M+Na]
+ calcd.: 
253.0623, found: 253.0632. 
tert-Butyl 5-ethyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30B) 
The title compound was prepared from 2-((tert-
butoxycarbonyl)amino)butanoic acid (4 mmol, 812 mg) and 
ethoxycarbonyl isothiocyanate (4.4 mmol, 519 µL)  according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title 
compound as a white solid. Yield: 3.4 mmol, 839 mg, 86%. m. p. 70–72 oC. 1H NMR 
(300 MHz, CDCl3) δ: 4.49 (dd, J = 6.0, 3.0 Hz, 1H), 2.10 – 1.86 (m, 2H), 1.42 (s, 9H), 0.76 
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 179.2, 172.4, 148.2, 84.8, 64.0, 27.6, 
23.4, 6.9. UPLC-DAD-QTOF: C10H16N2O3SNa* [M+Na]
+ calcd.: 267.0779, found: 
267.0788. 
tert-Butyl 5-benzyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30C) 
 The title compound was prepared from (tert-
butoxycarbonyl)phenylalanine (4 mmol, 1.06 g) and ethoxycarbonyl 
isothiocyanate (4.4 mmol, 519 µL)  according to the general procedure. 
The crude material was purified by flash column chromatography on 
silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title compound as a white 
solid. Yield: 3.6 mmol, 1.10 g, 90%. m. p. 120–122 oC. 1H NMR (300 MHz, CDCl3) δ: 9.05 
(s, 1H), 7.11 – 7.06 (m, 3H), 7.11 – 7.06 (m, 2H), 4.82 (dd, J = 5.6, 2.8 Hz, 1H), 3.49 (dd, J 
= 14.1, 5.6 Hz, 1H), 3.29 (dd, J = 14.1, 2.9 Hz, 1H), 1.65 (s, 9H). 13C NMR (75 MHz, CDCl3) 
δ: 178.3, 171.5, 148.6, 133.0, 129.6, 128.8, 127.8, 85.5, 64.4, 35.9, 28.1. UPLC-DAD-
QTOF: C15H18N2O3SNa* [M+Na]
+ calcd.: 329.0936, found: 329.0940. 
tert-Butyl 5-isobutyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30D) 
The title compound was prepared from (tert-butoxycarbonyl)leucine 
(4 mmol, 925 mg) and ethoxycarbonyl isothiocyanate (4.4 mmol, 519 
µL)  according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 50:50 to 0:100) to give the title compound as a yellow oil. Yield: 3.3 mmol, 
903 mg, 83%. 1H NMR (300 MHz, CDCl3) δ: 9.92 (s, 1H), 4.55 – 4.49 (m, 2H), 1.93 – 1.79 
(m, 3H), 1.51 (s, 9H), 0.89 – 0.86 (m, 6H). 13C NMR (75 MHz, CDCl3) δ: 178.9, 172.8, 
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148.2, 85.1, 62.2, 39.2, 27.8, 23.7, 23.3, 22.0. UPLC-DAD-QTOF: C12H20N2O3SNa* 
[M+Na]+ calcd.: 295.1092, found: 295.1096. 
tert-Butyl 5-hexyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30E) 
 The title compound was prepared from 2-((tert-
butoxycarbonyl)amino)octanoic acid (4 mmol, 1.04 g) and 
ethoxycarbonyl isothiocyanate (4.4 mmol, 519 µL)  according to the 
general procedure at 50 oC. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give 
the title compound as a yellow oil. Yield: 3.0 mmol, 900 mg, 75%. 1H NMR (300 MHz, 
CDCl3) δ: 8.84 (s, 1H), 4.58 (dd, J = 6.3, 3.2 Hz, 1H), 2.13 – 1.98 (m, 2H), 1.57 (s, 9H), 
1.36 – 1.23 (m, 8H), 0.89 – 0.84 (m, 3H). 13C NMR (75 MHz, CDCl3) δ: 178.9, 171.9, 
148.5, 85.4, 63.8, 31.5, 30.6, 28.9, 28.1, 23.0, 22.6, 14.1. UPLC-DAD-QTOF: 
C14H24N2O3SNa* [M+Na]
+ calcd.: 323.1405, found: 323.1409. 
tert-Butyl 5-((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (30G) 
The title compound was prepared from O-benzyl-N-(tert-
butoxycarbonyl)serine (4 mmol, 1.18 g) and ethoxycarbonyl 
isothiocyanate (4.4 mmol, 519 µL)  according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title 
compound as an orange oil. Yield: 3.6 mmol, 1.21 g, 90%. 1H NMR (300 MHz, CDCl3) δ: 
8.67 (tt, J = 4.0, 2.0 Hz, 1H), 7.69 (tt, J = 7.7, 1.8 Hz, 1H), 7.33 – 7.20 (m, 4H), 4.58 – 4.39 
(m, 2H), 4.04 – 3.89 (m, 1H), 1.46 (d, J = 1.3 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ: 180.8, 
171.4, 148.9, 148.7, 148.4, 137.1, 136.8, 136.6, 128.4, 127.8, 127.4, 123.9, 123.89, 
84.8, 84.8, 73.3, 66.6, 64.2, 27.9. UPLC-DAD-QTOF: C16H20N2O4SNa* [M+Na]
+ calcd.: 
359.1041, found: 359.1046. 
tert-Butyl 4-oxo-5-phenyl-2-thioxoimidazolidine-1-carboxylate (30H) 
The title compound was prepared from 2-((tert-
butoxycarbonyl)amino)-2-phenylacetic acid (4 mmol, 1.00 g) and 
ethoxycarbonyl isothiocyanate (4.4 mmol, 519 µL)  according to the 
general procedure. The crude material was purified by flash column chromatography 
on silica gel (eluting with Hex/EtOAc 50:50 to 0:100) to give the title compound as a 
white solid. Yield: 2.9 mmol, 841 mg, 72%.  m. p. decomposition at 238 oC. 1H NMR 
(300 MHz, DMSO-d6) δ: 12.64 (s, 1H), 7.46 – 7.39 (m, 3H), 7.25 – 7.23 (m, 2H), 5.63 (s, 
1H), 1.18 (s, 9H). 13C NMR (75 MHz, DMSO) δ: 180.9, 171.3, 147.5, 134.9, 129.0, 128.7, 
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126.4, 83.3, 66.7, 27.2. UPLC-DAD-QTOF: C14H16N2O3SNa* [M+Na]
+ calcd.: 315.0779, 
found: 315.0787. 
Benzyl 5-benzyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (31C) 
 The title compound was prepared from 
((benzyloxy)carbonyl)phenylalanine (4 mmol, 1.20 g) and 
ethoxycarbonyl isothiocyanate (4.4 mmol, 519 µL)  according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 80:20 to 50:50) to give the title 
compound as a white solid. Yield: 3.2 mmol, 1.10 g, 81%. 1H NMR (300 MHz, CDCl3) δ: 
8.96 (s, 1H), 7.54 – 7.35 (m, 4H), 7.24 – 7.13 (m, 3H), 6.94 – 6.87 (m, 2H), 5.46 – 5.33 
(m, 2H), 4.84 (dd, J = 5.6, 2.8 Hz, 1H), 3.42 (dd, J = 14.1, 5.6 Hz, 1H), 3.23 (dd, J = 14.1, 
2.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 177.9, 171.2, 150.2, 134.4, 132.8, 129.5, 129.1, 
129.0, 128.9, 128.8, 127.8, 69.5, 64.6, 35.8. UPLC-DAD-QTOF: C18H17N2O3S [M+H]
+ 
calcd.: 341.0960, found: 341.0963. 
Benzyl 5-((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (31G) 
The title compound was prepared from O-benzyl-N-
((benzyloxy)carbonyl)serine (4 mmol, 1.32 g) and ethoxycarbonyl 
isothiocyanate (4.4 mmol, 519 µL)  according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 80:20 to 50:50) to give the title 
compound as a white solid. Yield: 3.3 mmol, 1.21 g, 82%. m. p. 154–158 oC. 1H NMR 
(300 MHz, CDCl3) δ: 8.56 (s, 1H), 7.39 – 7.18 (m, 10H), 5.23 (s, 2H), 4.53 – 4.35 (m, 2H). 
3.95 (qd, J = 10.2, 2.3 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ: 178.7, 169.9, 150.0, 137.2, 
134.4, 129.0, 128.9, 128.7, 128.7, 128.1, 127.7, 73.4, 69.4, 66.3, 64.5. UPLC-DAD-QTOF: 
C19H18N2O4SNa* [M+Na]
+ calcd.: 393.0885, found: 393.0885. 
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5.4.2.4. S-Benzylation of N1-acyl thiohydantoins 28-31. Products 32-3527 
 
A solution of the corresponding thiohydantoin  (1 equiv., 3 mmol) in freshly distilled 
anhydrous CH3CN (2 mL/mmol) at 0 °C was treated with freshly distilled triethylamine 
(0.50 mL, 3.6 mmol, 1.2 equiv.) and, after 5 min at 0 °C, freshly distilled TMSCl (0.45 
mL, 3.6 mmol, 1.2 equiv) was added. A white precipitate formed instantaneously. The 
reaction mixture was warmed up to room temperature and stirred for 2 hours. 
Afterwards, freshly distilled triethylamine (1.7 mL, 12 mmol, 4 equiv.) and benzyl 
bromide (0.714 mL, 6 mmol, 2 equiv.) were added at the same temperature. The 
mixture was monitored by TLC (Hex/EtOAc, 1:2). After reaction completion (2-3 h), the 
reaction mixture was diluted with CH2Cl2 and washed with water. The clear yellow 
solution was dried over MgSO4, filtered and concentrated under reduced pressure. The 
crude product was purified by silica gel flash column chromatography. 
1-Acetyl-5-benzyl-2-(benzylthio)-1H-imidazol-4(5H)-one (32C) 
The title compound was prepared 1-acetyl-5-benzyl-2-
thioxoimidazolidin-4-one (3 mmol, 744 mg) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 50:50) 
to give the title compound as a white solid. Yield: 3.0 mmol, 1.01 g, 
75%. m. p. 132–135 oC. 1H NMR (300 MHz, CDCl3) δ: 7.34 – 7.02 (m, 10H), 4.63 (t, J = 
4.4 Hz, 1H), 4.32 – 4.22 (m, 2H), 3.39 (d, J = 4.4 Hz, 2H), 2.34 (s, 3H).  13C NMR (75 MHz, 
CDCl3) δ: 185.2, 184.3, 167.3, 135.1, 133.1, 129.4, 129.4, 128.8, 128.7, 127.8, 64.5, 
37.9, 37.5, 24.0. UPLC-DAD-QTOF: C19H19N2O2S [M+H]
+ calcd.: 339.1167, found: 
339.1170. 
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1-Benzoyl-2-(benzylthio)-5-methyl-1H-imidazol-4(5H)-one (33A) 
 The title compound was prepared from 1-benzoyl-5-methyl-2-
thioxoimidazolidin-4-one (3 mmol, 702 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
95:5 to 50:50) to give the title compound as a colourless oil. Yield: 
2.3 mmol, 739 mg, 76%. 1H NMR (300 MHz, CDCl3) δ: 7.58-7.23 (m, 10H), 4.60 (q, J = 
7.0 Hz, 1H), 4.47 (s, 2H), 1.14 (d, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 185.6, 
185.1, 167.0, 134.96, 133.2, 132.4, 129.4, 128.9, 128.65, 127.7, 127.2, 60.5, 38.1, 16.8. 
UPLC-DAD-QTOF: C18H17N2O2S [M+H]
+ calcd.: 325.1011, found: 325.1011. 
1-Benzoyl-2-(benzylthio)-5-ethyl-1H-imidazol-4(5H)-one (33B) 
 The title compound was prepared from 1-benzoyl-5-ethyl-2-
thioxoimidazolidin-4-one (3 mmol, 744 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 95:5 
to 80:20) to give the title compound as a white solid. m. p. 116 –
119 oC. Yield: 2.2 mmol, 730 mg, 72%. 1H NMR (300 MHz, CDCl3) δ: 7.66 – 7.19 (m, 
10H), 4.64 (dd, J = 6.1, 2.7 Hz, 1H), 4.54 – 4.34 (m, 2H), 1.86 – 1.73 (m, 1H), 1.37 – 1.27 
(m, 1H), 0.68 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 185.7, 185.1, 167.1, 135.0, 
133.3, 132.6, 129.4, 129.0, 128.7, 127.8, 127.2, 65.2, 38.2, 23.4, 6.8. UPLC-DAD-QTOF: 
C19H19N2O2S [M+H]
+ calcd.: 339.1167, found: 339.1162. 
1-Benzoyl-5-benzyl-2-(benzylthio)-1H-imidazol-4(5H)-one (33C) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
thioxoimidazolidin-4-one (3 mmol, 930 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 70:30) to give the title compound as a yellow solid. m. p. 
131 – 135 oC. Yield: 2.4 mmol, 973 mg, 81%. 1H NMR (300 MHz, CDCl3) δ: 7.65 – 7.48 
(m, 5H), 7.29 – 7.26 (m, 8H), 7.05 – 7.02 (m, 2H), 5.01 (dd, J = 6.1, 2.8 Hz, 1H), 4.32 (s, 
2H), 3.26 (dd, J = 14.3, 2.8 Hz, 1H), 2.88 (dd, J = 14.2, 6.1 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ: 185.4, 184.6, 166.9, 135.0, 133.3, 133.1, 132.8, 129.3, 129.2, 128.9, 128.6, 
128.0, 127.7, 127.5, 65.2, 38.0, 35.7. UPLC-DAD-QTOF: C24H21N2O2S [M+H]
+ calcd.: 
401.1324, found: 401.1319. .UPLC-DAD-QTOF: C24H21N2O2S [M+H]
+ calcd.: 401.1323, 
found: 401.1324. 
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1-Benzoyl-2-(benzylthio)-5-isobutyl-1H-imidazol-4(5H)-one (33D) 
The title compound was prepared from 1-benzoyl-5-isobutyl-2-
thioxoimidazolidin-4-one (3 mmol, 828 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 50:50) to give the title compound as a white solid. Yield: 
2.1 mmol, 769 mg, 70%. m. p. 133-135 oC. 1H NMR (300 MHz, CDCl3) δ: 7.64 – 7.30 (m, 
10H), 4.66 – 4.62 (s, 1H), 4.57 – 4.46 (m, 2H), 1.86 – 1.73 (m, 1H), 1.51 – 1.40 (m, 2H), 
0.74 (d, J = 6.7 Hz, 1H), 0.67 (d, J = 6.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 185.5, 
185.2, 167.3, 135.2, 133.5, 132.7, 129.6, 129.1, 128.9, 128.0, 127.6, 63.4, 39.6, 38.3, 
23.5, 23.3, 21.8. UPLC-DAD-QTOF: C21H23N2O2S [M+H]
+ calcd.: 367.1480, found: 
367.1483. 
1-Benzoyl-2-(benzylthio)-5-hexyl-1H-imidazol-4(5H)-one (33E) 
The title compound was prepared from 1-benzoyl-5-hexyl-2-
thioxoimidazolidin-4-one (3 mmol, 912 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 95:5 
to 50:50) to give the title compound as a white solid. Yield: 2.1 mmol, 827 mg, 70%. m. 
p. 96–99 oC. 1H NMR (300 MHz, CDCl3) δ: 7.62-7.21 (m, 10H), 4.63 (dd, J = 6.4, 2.9 Hz, 
1H), 4.57 – 4.39 (m, 2H), 1.88 – 1.55 (m, 1H), 1.41 – 0.94 (m, 9H), 0.81 (t, J = 7.0 Hz, 
3H).  13C NMR (75 MHz, CDCl3) δ: 185.7, 185.3, 167.3, 135.2, 133.5, 132.7, 129.6, 129.2, 
128.9, 128.0, 127.4, 64.7, 38.3, 31.3, 30.2, 28.6, 22.5, 22.5, 14.0. .UPLC-DAD-QTOF: 
C23H27N2O2S [M+H]
+ calcd.: 395.1798, found: 395.1793. 
1-Benzoyl-2-(benzylthio)-5-(2-(methylthio)ethyl)-1H-imidazol-4(5H)-one (33F) 
The title compound was prepared from 1-benzoyl-5-(2-
(methylthio)ethyl)-2-thioxoimidazolidin-4-one (3 mmol, 882 
mg) according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 80:20 to 60: 40) to give the title compound as a red oil. Yield: 
1.9 mmol, 737 mg, 64%. 1H NMR (300 MHz, CDCl3) δ: 7.60 – 7.23 (m, 10H), 4.78 (dd, J = 
7.5, 3.2 Hz, 1H), 4.54 – 4.39 (m, 2H), 2.55 – 2.22 (m, 2H), 2.04 – 1.92 (m, 1H), 1.81 (s, 
3H), 1.77 – 1.61 (m, 1H). 13C NMR (75 MHz, CDCl3) δ: 185.6, 184.7, 167.0, 135.0, 133.1, 
132.8, 129.5, 129.1, 128.8, 127.9, 127.6, 63.1, 38.3, 29.5, 27.9, 15.3. UPLC-DAD-QTOF: 
C20H21N2O2S2 [M+H]
+ calcd.: 385.1044, found: 385.1046. 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-methyl-1H-imidazol-4(5H)-one (34A) 
The title compound was prepared from tert-butyl 5-methyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 690 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) 
to give the title compound as a white solid. Yield: 2.5 mmol, 806 mg, 84%. m. p. 145–
147 oC. 1H NMR (300 MHz, CDCl3) δ: 7.51 – 7.20 (m, 5H), 4.48 (d, J = 2.9 Hz, 2H), 4.29 
(q, J = 7.0 Hz, 2H), 1.60 (d, J = 7.1 Hz, 3H), 1.57 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 
186.0, 184.4, 148.5, 135.2, 129.5, 128.8, 127.9, 85.5, 59.6, 37.9, 28.1, 17.0. UPLC-DAD-
QTOF: C16H21N2O3S [M+H]
+ calcd.: 321.1273, found: 321.1273. 
2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-ethyl-1H-imidazol-4(5H)-one (34B) 
The title compound was prepared from tert-butyl 5-ethyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 732 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a white solid. Yield: 2.3 mmol, 762 mg, 76%. m. p. 125–
127 oC. 1H NMR (300 MHz, CDCl3) δ: 7.41 – 7.22 (m, 5H), 4.50 – 4.38 (m, 2H), 4.29 (dd, J 
= 5.7, 3.2 Hz, 1H), 2.22 – 1.98 (m, 2H), 1.53 (s, 2H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ: 185.4, 185.0, 148.6, 135.2, 129.5, 128.8, 127.9, 85.5, 64.3, 37.9, 28.1, 
23.6, 7.2. UPLC-DAD-QTOF: C17H23N2O3S [M+H]
+ calcd.: 335.1429, found: 335.1431. 
5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-4-oxo-1H-imidazol-4(5H)-one (34C) 
The title compound was prepared from tert-butyl 5-benzyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 918 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a white solid. Yield: 2.4 mmol, 950 mg, 80%. m. p. 132–
135 oC. 1H NMR (300 MHz, CDCl3) δ: 7.43 – 6.98 (m, 10H), 4.57 (dd, J = 5.8, 2.8 Hz, 2H), 
4.37 – 4.18 (m, 2H), 3.54 – 3.31 (m, 2H), 1.64 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 185.0, 
184.8, 148.4, 135.4, 133.8, 129.5, 129.4, 128.7, 128.7, 127.8, 127.5, 85.8, 64.5, 37.6, 
36.2, 28.2. UPLC-DAD-QTOF: C22H25N2O3S [M+H]
+ calcd.: 397.1586, found: 397.1588. 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-isobutyl-1H-imidazol-4(5H)-one (34D) 
The title compound was prepared from tert-butyl 5-isobutyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 816 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a yellow oil. Yield: 2.4 mmol, 869 mg, 80%. 1H NMR (300 
MHz, CDCl3) δ: 7.50 – 7.18 (m, 5H), 4.47 (d, J = 1.4 Hz, 2H), 4.37 – 4.16 (m, 1H), 2.07 – 
1.79 (m, 3H), 1.56 (s, 9H), 0.94 (dd, J = 6.2, 3.0 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ: 
185.7, 184.4, 148.5, 135.2, 129.5, 128.8, 127.9, 85.5, 62.3, 39.4, 37.9, 28.1, 23.8, 23.6, 
22.3. UPLC-DAD-QTOF: C19H27N2O3S [M+H]
+ calcd.: 363.1742, found: 363.1749 
2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-hexyl-1H-imidazol-4(5H)-one (34E) 
The title compound was prepared from tert-butyl 5-hexyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 900 mg) according to 
the general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 90:10 
to 70:30) to give the title compound as a yellow oil. Yield: 2.2 mmol, 842 mg, 72%. 1H 
NMR (300 MHz, CDCl3) δ: 7.43 – 7.24 (m, 4H), 4.51 – 4.41 (m, 2H), 4.34 – 4.28 (m, 1H), 
2.11 – 2.02 (m, 2H), 1.54 (s, 9H), 1.34 – 1.15 (m, 8H), 0.91 – 0.83 (m, 3H). UPLC-DAD-
QTOF: C21H31N2O3S [M+H]
+ calcd.: 391.2055, found: 391.2053. 
5-((Benzyloxy)methyl)-2-(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-
one (34G) 
The title compound was prepared from tert-butyl 5-
((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (3 
mmol, 1.08 g) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 90:10 to 70:30) to give the title compound as a white solid. 
Yield: 2.5 mmol, 1.05 g, 82%. m. p. 104-108 oC. 1H NMR (300 MHz, CDCl3) δ: 7.46 – 7.26 
(m, 10H), 4.64 – 4.44 (m, 4H), 4.32 – 4.30 (m, 1H), 4.11 – 3.96 (m, 2H), 1.48 (s, 9H). 13C 
NMR (75 MHz, CDCl3) δ: 185.7, 183.8, 148.4, 137.5, 135.3, 129.5, 128.8, 128.5, 127.9, 
127.9, 127.7, 85.5, 73.4, 67.0, 64.0, 38.0, 28.0. UPLC-DAD-QTOF: C23H27N2O4S [M+H]
+ 
calcd.: 427.1692, found: 427.1693. 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-4-oxo-5-phenyl-1H-imidazol-4(5H)-one 
(34H) 
 The title compound was prepared from tert-butyl 4-oxo-5-phenyl-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 876 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a white solid. Yield: 2.5 mmol, 940 mg, 82%. m. p. 153-
155 oC. 1H NMR (300 MHz, CDCl3) δ: 7.48 – 7.19 (m, 10H), 5.19 (s, 1H), 4.62 – 4.49 (m, 
2H), 1.25 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 185.4, 183.0, 148.3, 135.1, 134.4, 129.5, 
129.0, 128.9, 128.7, 128.0, 126.4, 85.4, 67.3, 38.0, 27.6. UPLC-DAD-QTOF: C21H23N2O3S 
[M+H]+ calcd.: 383.1429, found: 383.1433. 
1-(Benzyloxycarbonyl)-2-(benzylthio)-5-methyl-1H-imidazol-4(5H)-one (35A) 
The title compound was prepared from benzyl 5-methyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 792 mg) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a white solid. Yield: 2.3 mmol, 807 mg, 76%. m. p. 101-
103 oC. 1H NMR (300 MHz, CDCl3) δ: 7.50 – 7.22 (m, 10H), 5.28 (q, J = 12.0 Hz, 2H), 4.57 
– 4.40 (m, 2H), 4.32 (q, J = 7.0 Hz, 1H), 1.56 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ: 185.6, 184.3, 149.7, 135.0, 134.1, 129.4, 129.1, 128.8, 128.8, 128.7, 127.9, 69.4, 
59.4, 37.9, 17.0. UPLC-DAD-QTOF: C19H19N2O3S [M+H]
+ calcd.: 355.1116, found: 
355.1115. 
5-Benzyl-1-(Benzyloxycarbonyl)-2-(benzylthio)-1H-imidazol-4(5H)-one (35C) 
The title compound was prepared from benzyl 5-benzyl-4-oxo-2-
thioxoimidazolidine-1-carboxylate (3 mmol, 1,42 g) according to the 
general procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 70:30) 
to give the title compound as a yellow oil. Yield: 2.1 mmol, 903 mg, 70%.  m. p.: 111-
114 oC. 1H NMR (300 MHz, CDCl3) δ: 7.49 – 7.43 (m, 15H), 7.37 – 7.03 (m, 8H), 7.03 – 
6.57 (m, 2H), 5.61 – 5.22 (m, 1H), 4.59 (dd, J = 5.6, 2.8 Hz, 1H), 4.41 – 4.16 (m, 2H), 3.35 
(qd, J = 13.9, 4.3 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ: 185.0, 184.5, 149.6, 135.2, 134.1, 
133.4, 129.4, 129.3, 129.3, 129.0, 128.7, 128.6, 127.8, 127.4, 69.6, 64.2, 37.5, 36.1. 
UPLC-DAD-QTOF: C25H23N2O3S [M+H]
+ calcd.: 431.1429, found: 431.1425. 
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1-(Benzyloxycarbonyl)-5-((benzyloxy)methyl)-2-(benzylthio)-1H-imidazol-4(5H)-one 
(35G) 
The title compound was prepared from benzyl 5-
((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (3 
mmol, 1.11 g) according to the general procedure. The crude 
material was purified by flash column chromatography on silica gel 
(eluting with Hex/EtOAc 90:10 to 70:30) to give the title compound as a colourless oil. 
Yield: 2.3 mmol, 1.08 g, 78%. 1H NMR (300 MHz, CDCl3) δ: 7.52 – 7.10 (m, 15H), 5.27 – 
5.03 (m, 2H), 4.59 – 4.45 (m, 3H), 4.42 – 4.24 (m, 2H), 3.99 (qd, J = 10.0, 2.4 Hz, 2H). 13C 
NMR (75 MHz, CDCl3) δ: 185.2, 183.1, 149.2, 137.3, 135.0, 133.9, 129.2, 128.8, 128.5, 
128.5, 128.2, 127.6, 127.5, 127.3, 72.8, 69.0, 66.5, 63.5, 37.6. UPLC-DAD-QTOF: 
C26H25N2O4S [M+H]
+ calcd.: 461.1535, found: 461.1539.  
5.4.3. Preparation of N3-aryl templates 61-66 
5.4.3.1. Synthesis of N3-aryl thiohydantoins 55-6028 
 
The corresponding amino acid (50 mmol, 1.0 equiv) was added to a solution of 
phenyl isothiocyanate (5.92 mL, 50 mmol, 1.0 equiv) in 1,4-dioxane-H2O (120 mL, 1:1, 
v/v) and cooled to 0 oC. Then Et3N (14.0 mL, 100 mmol, 2.0 equiv) was slowly added 
and the solution was stirred for 1 h, followed by the addition of concentrated HCl 
(12.50 mL, 150 mmol, 3.0 equiv) at 0 oC until the pH was approximately 2. The reaction 
mixture was stirred for another 12 h at 50 oC, and the precipitate formed was filtered 
and dried to afford the desired compound. 
5-Methyl-3-phenyl-2-thioxoimidazolidin-4-one (55A) 
                                                 
28
 Zhu, L.; Lu, C.; Chen, Z.; Yang, G.; Li, Y.; Nie, J. Tetrahedron: Asymmetry 2015, 26, 6–15.  
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The title compound was prepared from alanine (4.45 g, 50 mmol) 
according to the general procedure. White solid. Yield: 6.99 g, 33.86 
mmol, 68% (two steps). 1H NMR (300 MHz, CDCl3) δ: 7.61 (s, 1H), 7.54 
– 7.31 (m, 5H), 4.35 (q, J = 7.0 Hz, 1H), 1.60 (d, J = 7.0 Hz, 4H). 
5-Benzyl-3-phenyl-2-thioxoimidazolidin-4-one (55C) 
The title compound was prepared from phenylalanine (8.25 g, 50 
mmol) according to the general procedure. White solid. Yield: 10.15 
g, 36 mmol, 72%. 1H NMR (300 MHz, CDCl3) δ: 7.49 – 7.25 (m, 8H), 
7.10 – 7.07 (m, 2H), 4.53 (dd, J = 7.9, 3.9 Hz, 1H), 3.39 – 3.33 (m, 1H), 
3.13 – 3.06 (m, 1H). 
5-Isobutyl-3-phenyl-2-thioxoimidazolidin-4-one (55D) 
The title compound was prepared from leucine (6.55 g, 50 mmol) 
according to the general procedure. White solid. Yield: 8.68 g, 35 
mmol, 70%. 1H NMR (300 MHz, CDCl3) δ: 8.57 (s, 1H), 7.55 – 7.45 
(m, 3H), 7.35 – 7.29 (m, 2H), 4.29 (dd, J = 9.2, 4.0 Hz, 1H), 1.97 – 
1.69 (m, 3H), 0.99 (t, J = 6.2 Hz, 6H). 
5-(2-(Methylthio)ethyl)-3-phenyl-2-thioxoimidazolidin-4-one (55F) 
The title compound was prepared from methionine (7.46 g, 50 
mmol) according to the general procedure. Orange solid. Yield: 
9.32 g, 35 mmol, 70%. 1H NMR (300 MHz, CDCl3) δ: 7.78 (s, 
1H), 7.54 – 7.43 (m, 3H), 7.34 – 7.31 (m, 2H), 2.77 – 2.72 (m, 
2H), 2.42-2.31 (m, 1H), 2.22 – 2.10 (m, 4H). 
Methyl 3-(5-oxo-1-phenyl-2-thioxoimidazolidin-4-yl)propanoate (55I) 
The title compound was prepared from glutamine (7.3 g, 50 
mmol) according to the general procedure. White solid Yield: 
9.03 g, 32.5 mmol, 65%. 1H NMR (300 MHz, CDCl3) δ: 7.82 (s, 
1H), 7.54 – 7.43 (m, 3H), 7.33 – 7.29 (m, 2H), 4.36 (dd, J = 6.6, 
5.0 Hz, 1H), 3.73 (s, 3H), 2.61 – 2.53 (m, 2H), 2.42 – 2.31 (m, 1H), 2.25– 2.13 (m, 1H). 
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5-Methyl-2-thioxo-3-(p-tolyl)imidazolidin-4-one (56A) 
The title compound was prepared from alanine (4.45 g, 50 
mmol) according to the general procedure. The resulting crude 
was purified by silica gel flash column chromatography 
(hexane/ethyl acetate, 90:10 to 70:30) to obtain the desired 
product as a yellow solid. Yield: 6.60 g, 30 mmol, 60%. m. p. 184–186 oC. 1H NMR (300 
MHz, CDCl3) δ: 8.07 (s, 1H), 7.65 – 6.94 (m, 4H), 4.31 (q, J = 7.0 Hz, 1H), 2.41 (s, 3H), 
1.56 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 183.9, 174.4, 139.6, 130.0, 130.0, 
128.1, 55.6, 21.4, 17.1. UPLC-DAD-QTOF: C11H13N2OS [M+H]
+ calcd.: 221.0749, found: 
221.0753. 
3-(4-Chlorophenyl)-5-methyl-2-thioxoimidazolidin-4-one (57A) 
The title compound was prepared from alanine (4.45 g, 50 
mmol) according to the general procedure. The resulting crude 
was purified by silica gel flash column chromatography 
(hexane/ethyl acetate, 90:10 to 70:30) to obtain the desired 
product as a white solid. Yield: 7.68 g, 32 mmol, 64%. m. p. 202–206 oC. 1H NMR (300 
MHz, CDCl3) δ: 10.58 (s, 1H), 7.59 – 7.53 (m, 2H), 7.38 – 7.32 (m, 2H), 4.45 (q, J = 7.0 
Hz, 1H), 1.39 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, DMSO) δ: 181.7, 174.8, 133.2, 132.4, 
130.8, 128.8, 55.2, 16.1. UPLC-DAD-QTOF: C10H10N2OSCl [M+H]
+ calcd.: 241.0202, 
found: 241.0196. 
3-(4-Bromophenyl)-5-methyl-2-thioxoimidazolidin-4-one (58A) 
The title compound was prepared from alanine (4.45 g, 50 
mmol) according to the general procedure. The resulting crude 
was purified by silica gel flash column chromatography 
(hexane/ethyl acetate, 90:10 to 70:30) to obtain the desired product as a white solid. 
Yield: 9.23 g, 32 mmol, 65%. m. p. 211–215 oC. 1H NMR (300 MHz, CDCl3) δ: 7.67 – 7.60 
(m, 2H), 7.53 (s, 1H), 7.33 – 7.14 (m, 2H), 4.35 (qd, J = 7.0, 1.3 Hz, 1H), 1.60 (d, J = 7.1 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 183.2, 173.7, 132.5, 131.7, 130.0, 123.5, 55.6, 
17.3. UPLC-DAD-QTOF: C10H10N2OSBr [M+H]
+ calcd.: 284.9697, found: 284.9702. 
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3-(4-Methoxyphenyl)-5-methyl-2-thioxoimidazolidin-4-one (59A) 
The title compound was prepared from alanine (4.45 g, 50 mmol) according to the 
general procedure. The resulting crude was purified by silica 
gel flash column chromatography (hexane/ethyl acetate, 
90:10 to 70:30) to obtain the desired product as a white solid. 
Yield: 7.79 g, 33 mmol, 66%. m. p. 182–185 oC. 1H NMR (300 
MHz, CDCl3) δ: 10.47 (s, 1H), 7.22 – 7.15 (m, 2H), 7.04 – 6.97 (m, 2H), 4.46 – 4.36 (m, 
1H), 3.78 (s, 3H), 1.38 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO) δ: 182.5, 175.2, 
159.1, 130.0, 126.0, 113.9, 55.4, 55.0, 16.3. UPLC-DAD-QTOF: C11H13N2O2S [M+H]
+ 
calcd.: 237.0698, found: 237.0700. 
3-(3-Chlorophenyl)-5-methyl-2-thioxoimidazolidin-4-one (60A) 
The title compound was prepared from alanine (4.45 g, 50 mmol) 
according to the general procedure. The resulting crude was purified 
by silica gel flash column chromatography (hexane/ethyl acetate, 
90:10 to 70:30) to obtain the desired product as a yellow solid. 
Yield: 7.44 g, 31 mmol, 62%. m. p. 169–171 oC. 1H NMR (300 MHz, 
CDCl3) δ: 8.00 (s, 1H), 7.56 – 7.22 (m, 4H), 4.37 (q, J = 7.1 Hz, 1H), 1.61 (d, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ: 183.1, 173.8, 134.8, 133.7, 130.2, 129.7, 128.8, 126.7, 
55.6, 17.1. UPLC-DAD-QTOF: C10H10N2OSCl [M+H]
+ calcd.: 241.0202, found: 241.0205. 
5.4.3.2. S-Benzylation of N3-aryl thiohydantoins 55-60. Products 61-66 
 
 
A solution of the corresponding thiohydantoin (5 mmol, 1 equiv.) in freshly distilled 
anhydrous CH3CN (2 mL/mmol) at 0 °C was treated with freshly distilled DIPEA (20 
mmol, 4 equiv.) and benzyl bromide (1.19 mL, 10 mmol, 2 equiv.), unless stated 
otherwise. The mixture was then warmed up to room temperature and monitored by 
Chapter 5 
292 
 
TLC (hexane/ethyl acetate, 50:50). After reaction completion (2–3 h), the reaction 
mixture was diluted with CH2Cl2 and washed with water. The clear yellow solution was 
dried over MgSO4, filtered and concentrated under reduced pressure. The resulting 
yellow oil was purified by silica gel flash column chromatography (hexane/ethyl 
acetate) to obtain the desired product.29 
2-(Benzylthio)-4-methyl-1-phenyl-1H-imidazol-5(4H)-one (61A) 
The title compound was prepared from 5-methyl-3-phenyl-2-
thioxoimidazolidin-4-one (5 mmol, 1.03 g) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with hexane/ethyl acetate, 80:20) 
to afford the title compound as a white solid. Yield: 4.1 mmol, 1.21 g, 82%. m. p. 113–
117 oC. 1H NMR (300 MHz, CDCl3) δ: 7.51-7.30 (m, 10H), 4.42 (s, 1H), 4.37 (q, 1.61 (d, J 
= 7.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 181.7, 161.2, 135.8, 132.3, 129.5, 129.3, 
129.1, 128.7, 127.8, 127.4, 64.9, 34.9, 17.2. UPLC-DAD-QTOF: C17H17N2OS [M+H]
+ 
calcd.: 297.1062, found: 297.1079. 
4-Benzyl-2-(benzylthio)-1-phenyl-1H-imidazol-5(4H)-one (61C) 
 The title compound was prepared from 5-benzyl-3-phenyl-2-
thioxoimidazolidin-4-one (5 mmol, 1.41 g) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with hexane/ethyl acetate, 
80:20) to afford the title compound as a colourless oil; yield: 3.9 mmol, 1.47 g, 79%. 1H 
NMR (300 MHz, CDCl3) δ: 7.59 – 7.18 (m, 13H), 7.09 – 6.75 (m, 2H), 4.74 – 4.57 (m, 1H), 
4.52 – 4.33 (m, 2H), 3.46 (dd, J = 13.5, 4.5 Hz, 1H), 3.30 (dd, J = 13.5, 5.5 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ: 180.2, 161.6, 136.1, 135.6, 132.0, 130.0, 129.3, 129.2, 129.1, 
128.6, 128.0, 127.7, 127.3, 126.9, 69.7, 37.5, 34.6. UPLC-DAD-QTOF: C23H20N2OS 
[M+H]+ calcd.: 373.1375, found: 373.1388. 
2-(Benzylthio)-4-isobutyl-1-phenyl-1H-imidazol-5(4H)-one (61D) 
The title compound was prepared from 5-isobutyl-3-phenyl-2-
thioxoimidazolidin-4-one (5 mmol, 1.24 g) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with hexane/ethyl 
                                                 
29
 Etxabe, J.; Izquierdo, J.; Landa, A.; Oiarbide, M.; Palomo, C. Angew. Chem. Int. Ed.  2015, 54, 6883–
6886.  
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acetate, 80:20) to afford the title compound as a white solid. Yield: 4.0 mmol, 1.35 g, 
80%. m. p. 90–93 oC. 1H NMR (300 MHz, CDCl3) δ: 7.55 – 7.29 (m, 10H), 4.47–4.33 (m, 
3H), 2.24 – 2.10 (m, 8H), 1.97 – 1.88 (m, 8H), 1.71 – 1.62 (m, 1H), 1.13 – 1.08 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ: 181.7, 160.7, 136.3, 132.4, 129.4, 129.3, 129.1, 128.6, 
127.7, 68.0, 41.0, 34.8, 25.5, 23.2, 22.3. UPLC-DAD-QTOF: C20H23N2OS [M+H]
+ calcd.: 
339.1531, found: 339.1548. 
2-(Benzylthio)-4-(2-(methylthio)ethyl)-1-phenyl-1H-imidazol-5(4H)-one (61F) 
The title compound was prepared from 5-(2-
(methylthio)ethyl)-3-phenyl-2-thioxoimidazolidin-4-one (5 
mmol, 1.33 g) utilizing 8 equiv. of freshly distilled DIPEA and 4 
equiv. of benzyl bromide. The reaction was carried out at –20 
oC for 6 h. The crude material was purified by flash column 
chromatography on silica gel (eluting with hexane/ethyl acetate, 80:20) to afford the 
title compound as a red oil; yield: 3.0 mmol, 1.07 g, 60%. 1H NMR (300 MHz, CDCl3) δ: 
7.48 – 7.26 (m, 10H), 4.45 – 4.31 (m, 3H), 2.71 (t, J = 7.2 Hz, 1H), 2.40 – 2.29 (m, 1H), 
2.14 (s, 3H). UPLC-DAD-QTOF: C19H21N2OS2 [M+H]
+ calcd.: 357.1095, found: 357.1110. 
Methyl 3-(2-(benzylthio)-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-yl)propanoate 
(61I) 
The title compound was prepared from methyl 3-(5-oxo-1-
phenyl-2-thioxoimidazolidin-4-yl)propanoate (5 mmol, 1.39 
g) according to the general procedure. The crude material 
was purified by flash column chromatography on silica gel 
(eluting with hexane/ethyl acetate, 80:20) to afford the title compound as a colourless 
oil; yield: 4.0 mmol, 1.47 g, 80%. 1H NMR (300 MHz, CDCl3) δ: 7.55 – 7.20 (m, 10H), 
4.60 – 4.36 (m, 2H), 3.74 (s, 3H), 2.63 – 2.58 (m, 2H), 2.49 – 2.37 (m, 1H), 2.26 – 2.05 
(m, 1H). 13C NMR (75 MHz, CDCl3) δ: 180.4, 173.2, 161.9, 136.0, 132.1, 129.5, 129.2, 
128.7, 127.7, 127.3, 67.9, 51.7, 34.7, 29.9, 26.9. UPLC-DAD-QTOF: C20H21N2O3S [M+H]
+ 
calcd.: 369.1273, found: 369.1286. 
2-(Benzylthio)-4-methyl-1-(p-tolyl)-1H-imidazol-5(4H)-one (62A) 
The title compound was prepared from 5-methyl-2-thioxo-3-(p-
tolyl)imidazolidin-4-one (5 mmol, 1.10 g) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with hexane/ethyl 
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acetate, 80:20) to afford the title compound as a yellow solid. Yield: 4.0 mmol, 1.25 g, 
81%. m. p. 78-81 oC.  1H NMR (300 MHz, CDCl3) δ: 7.45 – 7.05 (m, 9H), 4.40 (s, 2H), 4.34 
(q, J = 7.5 Hz, 1H), 2.41 (s, 3H), 1.59 (d, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 
181.9, 161.6, 139.4, 135.9, 130.2, 129.6, 129.3, 128.7, 127.8, 127.2, 65.0, 34.9, 21.3, 
17.2. UPLC-DAD-QTOF: C18H19N2OS [M+H]
+ calcd.: 311.1218, found: 311.1236. 
2-(Benzylthio)-1-(4-chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one (63A) 
 The title compound was prepared from 3-(4-chlorophenyl)-5-
methyl-2-thioxoimidazolidin-4-one (5 mmol, 1.20 g) according 
to the general procedure. The crude material was purified by 
flash column chromatography on silica gel (eluting with 
hexane/ethyl acetate, 80:20) to afford the title compound as a white solid. Yield: 4.1 
mmol, 1.37 g, 83%. m. p. 133-135 oC. 1H NMR (300 MHz, CDCl3) δ: 8.38 – 6.75 (m, 9H), 
4.40 (s, 2H), 4.34 (q, J = 7.5 Hz, 1H), 1.57 (d, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 
181.6, 160.7, 135.8, 135.2, 130.8, 129.8, 129.3, 128.8, 128.7, 128.0, 65.0, 35.0, 17.2. 
UPLC-DAD-QTOF: C17H16N2OSCl [M+H]
+ calcd.: 331.0672, found: 331.0675. 
2-(Benzylthio)-1-(4-bromophenyl)-4-methyl-1H-imidazol-5(4H)-one (64A) 
The title compound was prepared from 3-(4-bromophenyl)-5-
methyl-2-thioxoimidazolidin-4-one (5 mmol, 1.41 g) according 
to the general procedure. The crude material was purified by 
flash column chromatography on silica gel (eluting with 
hexane/ethyl acetate, 80:20) to afford the title compound as a white solid. m. p. 127-
131 oC. Yield: 4.0 mmol, 1.50 g, 80%. 1H NMR (300 MHz, CDCl3) δ: 7.63 – 7.56 (m, 2H), 
7.42 – 7.26 (m, 5H), 7.20 – 7.13 (m, 2H), 4.40 (s, 2H), 4.34 (q, J = 7.5 Hz, 1H), 1.57 (d, J = 
7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.5, 160.6, 135.8, 132.8, 131.3, 129.3, 128.9, 
128.8, 127.9, 123.2, 65.0, 35.0, 17.2. UPLC-DAD-QTOF: C17H16N2OSBr [M+H]
+ calcd.: 
375.0167, found: 375.0168. 
2-(Benzylthio)-1-(4-methoxyphenyl)-4-methyl-1H-imidazol-5(4H)-one (65A) 
 The title compound was prepared from 3-(4-
methoxyphenyl)-5-methyl-2-thioxoimidazolidin-4-one (5 
mmol, 1.18 g) according to the general procedure. The crude 
material was purified by flash column chromatography on 
silica gel (eluting with hexane/ethyl acetate, 80:20) to afford the title compound as a 
yellow solid. Yield: 3.9 mmol, 1.29 g, 79%. m. p. 94–98 oC. 1H NMR (300 MHz, CDCl3) δ: 
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7.50 – 7.15 (m, 2H), 7.06 – 6.81 (m, 2H), 4.40 (s, 2H), 4.34 (q, J = 7.5 Hz, 1H), 3.80 (s, 
3H), 1.59 (d, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.9, 161.7, 160.0, 135.8, 
129.2, 128.7, 128.6, 127.7, 124.6, 114.6, 114.5, 64.8, 55.4, 34.7, 17.1. UPLC-DAD-QTOF: 
C18H19N2O2S [M+H]
+ calcd.: 327.1167, found: 327.1178. 
2-(Benzylthio)-1-(3-chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one(66A) 
The title compound was prepared from 3-(3-chlorophenyl)-5-
methyl-2-thioxoimidazolidin-4-one (5 mmol, 1.20 g) according to 
the general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with hexane/ethyl 
acetate, 80:20) to afford the title compound as a yellow oil. Yield: 
4.0 mmol, 1.32 g, 80%. 1H NMR (300 MHz, CDCl3) δ: 7.59 – 7.03 (m, 9H), 4.41 (s, 2H), 
4.35 (q, J = 7.5 Hz, 1H), 1.58 (d, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.4, 
160.5, 135.7, 135.0, 133.4, 130.4, 129.4, 129.3, 128.8, 127.9, 127.6, 125.5, 64.9, 35.0, 
17.1. UPLC-DAD-QTOF: C17H16N2OSCl [M+H]
+ calcd.: 331.0672, found: 331.0676. 
5.4.3.3. Reaction scope. 
 
 
To a solution of the corresponding imidazolone 8-11 (1 equiv., 0.2 mmol) and 
nitroalkene (2.0 equiv., 0.4 mmol) in dichlorometane (0.6 mL) catalyst C3 (0.02 mmol, 
13.6 mg) was added at room temperature. The resulting mixture was stirred until 
consumption of the imidazolone (monitored by 1H-NMR). Afterwards, he reaction was 
purified by flash column chromatography on silica gel to afford the expected adducts. 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (37Ca) 
The title compound was prepared from 1-acetyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 32C (0.2 mmol, 68 mg) and 
(E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/DCM 
90:10 to 70:30) to give the title compound as a white foam. Yield: 0.16 mmol, 78 mg, 
80%. [α]D
25= –43.44 (c = 0.58, >98:2 dr, 99% ee, CH2Cl2).
 1H NMR (300 MHz, CD3Cl) δ: 
7.31 – 7.02 (m, 15H) 5.38 – 5.22 (m, 2H), 4.84 (dd, J = 10.4, 4.7 Hz, 1H), 4.17 (s, 2H), 
3.78 (d, J = 12.9 Hz, 1H), 3.49 (d, J = 12.8 Hz, 1H), 2.16 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ: 186.1, 167.8, 134.4, 133.5, 129.4, 129.3, 128.9, 128.8, 128.7, 128.3, 127.9, 127.8, 
48.1, 40.3, 39.0, 26.5. UPLC-DAD-QTOF: C27H26N3O4S [M+H]
+ calcd.: 488.1644, found: 
488.1644. 
(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (37Cb) 
The title compound was prepared from 1-acetyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 32C (0.2 mmol, 68 mg) and 
(E)-1-bromo-4-(2-nitrovinyl)benzene 36b (0.4 mmol, 91 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/DCM 90:10 to 70:30) to give the title compound as a 
white foam. [α]D
25= +2.64 (c = 1.30, >98:2 dr, 99% ee, CH2Cl2). Yield: 0.15 mmol, 82.5 
mg, 73%. 1H NMR (300 MHz, CD3Cl) δ: 7.37 – 6.92 (m, 14H), 5.35 – 5.10 (m, 2H), 4.81 
(dd, J = 10.8, 4.5 Hz, 1H), 4.26 – 4.07 (m, 2H), 3.72 (d, J = 12.9 Hz, 1H), 3.45 (d, J = 12.8 
Hz, 1H), 2.15 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 185.9, 167.9, 134.0, 133.5, 133.3, 
132.1, 129.6, 129.3, 129.0, 128.7, 128.4, 127.9, 123.0, 75.3, 47.6, 40.2, 39.1, 26.5. 
UPLC-DAD-QTOF: C27H25N3O4SBr [M+H]
+ calcd.: 566.0749, found: 566.0756.  
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-4(5H)-
one (37Cc) 
The title compound was prepared from 1-acetyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 32C (0.2 mmol, 68 mg) and 
(E)-1-methyl-4-(2-nitrovinyl)benzene 36c (0.4 mmol, 65 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/DCM 90:10 to 70:30) to give the title compound as a 
95:5 mixture of diastereomer (white foam). Yield: 0.15 mmol, 76.2 mg, 76%. 1H NMR 
(300 MHz, CD3Cl) δ: 7.34 – 6.95 (m, 14H), 5.37 – 5.19 (m, 2H), 4.79 (dd, J = 10.5, 4.6 Hz, 
1H), 4.27 – 4.09 (m, 2H), 3.77 (d, J = 12.9 Hz, 1H), 3.48 (d, J = 12.8 Hz, 1H), 2.28 (s, 3H), 
2.17 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 186.2, 167.8, 138.5, 134.3, 133.6, 131.2, 
129.6, 129.4, 129.3, 128.9, 128.6, 128.3, 127.7, 75.7, 47.8, 40.3, 38.9, 26.4, 21.2. UPLC-
DAD-QTOF: C28H28N3O4S [M+H]
+ calcd.: 502.1801, found: 502.1806.  
(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-methyl-1H-
imidazol-4(5H)-one (38Ad) 
The title compound was prepared from 1-benzoyl-2-
(benzylthio)-5-methyl-1H-imidazol-4(5H)-one 33A (0.2 mmol, 
67.6 mg) and (E)-1-chloro-2-(2-nitrovinyl)benzene 36d (0.4 
mmol, 73.2 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 97:3 
mixture of diastereomer (white foam). Yield: 0.14 mmol, 73.0 g, 72%.  1H NMR (300 
MHz, CD3Cl) δ: 7.52 – 6.88 (m, 14H), 5.35 – 5.18 (m, 3H), 4.25 – 4.13 (m, 1H), 2.07 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ: 187.3, 184.4, 166.9, 136.1, 134.4, 133.6, 133.4, 132.9, 
130.8, 129.9, 129.4, 129.2, 129.0, 128.9, 128.6, 128.2, 128.0, 127.6, 76.2, 72.5, 43.5, 
39.6, 24.5. UPLC-DAD-QTOF: C26H23N3O4SCl [M+H]
+ calcd.: 508.1098, found: 508.1104.  
(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-ethyl-1H-
imidazol-4(5H)-one (38Bd) 
The title compound was prepared from 1-benzoyl-2-(benzylthio)-
5-ethyl-1H-imidazol-4(5H)-one 33B (0.2 mmol, 67.6 mg) and (E)-
1-chloro-2-(2-nitrovinyl)benzene 36d (0.4 mmol, 73.2 mg) 
according to the general procedure. The crude material was 
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purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 
80:20) to give the title compound as a 97:3 mixture of diastereomer (white foam). 
Yield: 0.14 mmol, 104.2 mg, 70%. 1H NMR (300 MHz, CD3Cl) δ: 7.57 – 6.77 (m, 13H), 
5.32 – 5.11 (m, 2H), 4.25 (d, J = 13.4 Hz, 1H), 4.09 (d, J = 13.4 Hz, 1H), 2.95 – 2.83 (m, 
1H), 2.33 – 2.14 (m, 1H), 0.76 (t, J = 7.2 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 186.9, 
185.3, 166.9, 136.1, 134.6, 133.8, 133.5, 132.8, 130.8, 129.9, 129.3, 129.1, 128.8, 
128.5, 128.1, 128.0, 127.8, 76.2, 43.5, 39.5, 30.5, 8.0. UPLC-DAD-QTOF: C27H26N3O4SCl 
[M+H]+ calcd.: 522.1254, found: 522.1253. 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one (38Ca) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
(E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/DCM 
80:20 to 50:50) to give the title compound as a white foam. Yield: 0.15 mmol, 83.4 mg, 
76%. [α]D
25= –22.31 (c = 0.80, >98:2 dr, 98% ee, CH2Cl2).
  1H NMR (300 MHz, CD3Cl) δ: 
7.45 – 7.39 (m, 1H), 7.35 – 7.16 (m, 14H), 6.92 – 6.89 (m, 2H), 6.76 – 6.36 (m, 2H),  5.44 
– 5.30 (m, 2H), 4.96 (dd, J = 10.5, 4.5 Hz, 1H),  3.94 (d, J = 12.9 Hz, 1H), 3.84 (m, 2H), 
3.65 (d, J = 12.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 186.4, 185.6, 167.8, 134.8, 133.9, 
133.7, 133.0, 129.8, 129.3, 128.9, 128.9, 128.7, 128.6, 128.4, 128.1, 127.9, 76.1, 48.9, 
41.2, 39.9. UPLC-DAD-QTOF: C32H28N3O4S [M+H]
+ calcd.: 550.1801, found: 550.1806. 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cb) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
(E)-1-bromo-4-(2-nitrovinyl)benzene 36b (0.4 mmol, 91 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/DCM 90:10 to 50:50) to give the title compound as a 
yellow foam. Yield: 0.16 mmol, 97.8 mg, 78%. [α]D
25= –3.90 (c = 0.70, >98:2 dr, 98% ee, 
CH2Cl2). 
1H NMR (300 MHz, CD3Cl) δ: 7.80 – 7.04 (m, 15H), 7.03 – 6.92 (m, 2H), 6.59 – 
6.57 (m, 2H), 4.97 (dd, J = 10.9, 4.4 Hz, 1H), 3.95 – 3.78 (m, 3H), 3.68 – 3.63 (m, 1H). 13C 
NMR (75 MHz, CDCl3) δ: 186.1, 185.8, 167.9, 133.7, 133.6, 133.3, 132.5, 132.3, 129.8, 
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129.4, 129.0, 128.8, 128.7, 128.5, 128.2, 128.0, 123.2, 75.6, 48.5, 40.8, 40.1. UPLC-
DAD-QTOF: C32H27N3O4SBr [M+H]
+ calcd.: 628.0906, found: 628.0909. 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-
4(5H)-one (38Cc)  
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and  
(E)-1-methyl-4-(2-nitrovinyl)benzene 36c (0.4 mmol, 65.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 50:50) to give the title compound as a 
white foam. Yield: 0.15 mmol, 84.5 mg, 75%. [α]D
25= –31.73 (c = 0.9, >98:2 dr, 94% ee, 
CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.46 – 6.44 (m, 19H), 5.42 – 5.27 (m, 2H), 4.93 – 
4.88 (m, 1H), 3.95 – 3.79 (m, 3H), 3.66 – 3.61 (m, 1H), 2.33 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ: 186.5, 185.6, 167.8, 138.7, 134.0, 133.8, 133.0, 132.8, 131.7, 129.8, 129.3, 
128.8, 128.7, 128.3, 128.1, 127.8, 76.2, 48.6, 41.2, 40.0, 21.3. UPLC-DAD-QTOF: 
C33H30N3O4S [M+H]
+ calcd.: 564.1957, found: 564.1959. 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cd) 
The title compound 33C was prepared from 1-benzoyl-5-benzyl-
2-(benzylthio)-1H-imidazol-4(5H)-one 36d (0.2 mmol, 80 mg) 
and (E)-1-chloro-2-(2-nitrovinyl)benzene (0.4 mmol, 73.2 mmol) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 50:50) to give the title compound as a 94:6 mixture of 
diastereomers (orange foam). Yield: 0.18 mmol, 103.8 mg, 89%. 1H NMR (300 MHz, 
CD3Cl) δ: 7.47 – 6.54 (m, 19H), 5.63 – 5.58 (m, 1H), 5.46 – 5.30 (m, 2H), 4.11 (d, J = 12.7 
Hz, 1H), 3.87 (d, J = 13.4 Hz, 2H), 3.62 (d, J = 12.7 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 
186.7, 185.7, 167.1, 137.0, 134.0, 133.4, 133.3, 133.0, 132.9, 130.8, 130.0, 129.8, 
129.2, 128.7, 128.5, 128.0, 127.9, 127.8, 76.1, 43.6, 41.6, 39.7. UPLC-DAD-QTOF: 
C32H27N3O4SCl [M+H]
+ calcd.: 584.1411, found: 584.1422. 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(3-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Ce) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg)  and 
(E)-1-chloro-3-(2-nitrovinyl)benzene 36e (0.4 mmol, 73.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 50:50) to give the title compound as a 74:26 mixture of 
diastereomers (yellow oil). Yield: 0.16 mmol, 93.3 mg, 80%. 1H NMR (300 MHz, CD3Cl) 
δ: 7.53 – 6.88 (m, 17H), 6.62 (s, 2H), 5.38 – 5.29 (m, 2H), 4.98 (dd, J = 10.8, 4.3 Hz, 1H), 
3.91 – 3.77 (m, 3H), 3.64 (d, J = 12.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 186.0, 185.8, 
167.9, 136.7, 134.9, 133.6, 133.1, 130.4, 129.8, 129.2, 129.1, 129.0, 128.7, 128.5, 
128.1, 128.0, 75.3, 48.4, 40.7, 39.9. UPLC-DAD-QTOF: C32H27N3O4SCl [M+H]
+ calcd.: 
584.1411, found: 584.1418. 
 (S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(2-methoxyphenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cf) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg)  and 
(E)-1-methoxy-2-(2-nitrovinyl)benzene 36f (0.4 mmol, 71.6 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 50:50) to give the title compound as a 
colourless oil. Yield: 0.17 mmol, 100.7 mg, 87%. [α]D
25= –3.90 (c = 1.90, >98:2 dr, 98% 
ee, CH2Cl2). 
1H NMR (300 MHz, CD3Cl) δ: 7.56 – 6.71 (m, 19H), 5.49 – 5.33 (m, 2H), 4.78 
(t, J = 7.1 Hz, 1H), 4.10 (d, J = 12.6 Hz, 0H), 3.94 – 3.73 (m, 2H), 3.64 (s, 3H), 3.58 – 3.47 
(m, 1H). 13C NMR (75 MHz, CDCl3) δ: 185.2, 182.8, 167.7, 157.8, 134.2, 133.7, 132.6, 
130.2, 130.0, 129.1, 128.6, 128.5, 127.9, 127.7, 121.2, 110.6, 74.8, 54.0, 49.8, 42.9, 
39.4. UPLC-DAD-QTOF: C33H30N3O5S [M+H]
+ calcd.: 580.1906, found: 580.1915.  
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(furan-3-yl)-2-nitroethyl)-1H-imidazol-
4(5H)-one (38Cg) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
(E)-3-(2-nitrovinyl)furan 36g (0.4 mmol, 55.6 mg) according to 
the general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 50:50) to give the title compound as a 85:15 mixture of diastereomers 
(orange foam). Yield: 0.15 mmol, 79.8 mg, 74%. 1H NMR (300 MHz, CD3Cl) δ: 7.49 (tt, J 
= 7.5, 1.3 Hz, 1H), 7.39 – 7.13 (m, 11H), 7.04 – 6.93 (m, 2H), 6.75 (d, J = 7.8 Hz, 2H), 
6.34 – 6.24 (m, 1H), 5.21 (m, 2H), 4.98 (dd, J = 9.4, 5.6 Hz, 1H), 4.04 (d, J = 13.1 Hz, 1H), 
3.96 – 3.80 (m, 2H), 3.60 (d, J = 12.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 186.3, 185.7, 
167.8, 144.0, 142.0, 134.2, 133.8, 133.2, 132.8, 129.7, 129.3, 128.9, 128.7, 128.5, 
128.1, 127.9, 118.9, 108.8, 77.0, 75.8, 40.5, 40.3, 39.7. UPLC-DAD-QTOF: C30H26N3O5S 
[M+H]+ calcd.: 540.1593, found: 540.1594. 
(S)-1-Benzoyl-2-(benzylthio)-5-isobutyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one(38Da) 
The title compound was prepared from 1-benzoyl-2-
(benzylthio)-5-isobutyl-1H-imidazol-4(5H)-one 33D (0.2 mmol, 
73 mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 95:5 to 90:10) to give the title compound as a white foam. Yield: 0.18 
mmol, 90.6 mg, 88%. [α]D
25= –21.15 (c = 0.5, >98:2 dr, 92% ee, CH2Cl2).
 1H NMR (300 
MHz, CD3Cl) δ: 7.55 – 6.84 (m, 15H), 5.27 – 5.11 (m, 2H), 4.75 – 4.70 (m, 1H),  4.23 (d, J 
= 13.3 Hz, 1H),  4.00 (d, J = 13.3 Hz, 1H), 2.76 – 2.70 (m, 1H), 2.17 – 2.10 (m, 1H), 1.60 – 
1.47 (m, 1H), 0.96 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ: 186.8, 184.9, 167.4, 134.5, 134.5, 133.2, 132.9, 129.3, 129.1, 128.9, 128.7, 128.6, 
128.1, 76.2, 75.9, 49.8, 44.0, 39.7, 25.5, 24.2, 22.8. UPLC-DAD-QTOF: 
C29H30N3O4S[M+H]
+ calcd.: 516.1957, found: 516.1964. 
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(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (38Ea) 
The title compound was prepared from 1-benzoyl-2-
(benzylthio)-5-hexyl-1H-imidazol-4(5H)-one 33E (0.2 mmol, 78.8 
mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 50:50) to give the title compound as a yellow foam. Yield: 
0.15 mmol, 79.3 g, 73%. [α]D
25= –18.67 (c = 0.96, >98:2 dr, 97% ee, CH2Cl2).
 1H NMR 
(300 MHz, CD3Cl) δ: 7.50 – 7.45 (m, 1H), 7.34 – 7.07 (m, 12H), 6.91 – 6.71 (m, 2H), 5.25 
– 5.11 (m, 2H), 4.62 (dd, J = 10.6, 4.4 Hz, 1H), 4.26 (d, J = 13.4 Hz, 1H), 4.03 (d, J = 13.4 
Hz, 1H), 2.75 – 2.65 (m, 1H), 2.17 – 2.07 (m, 1H), 1.33 – 0.85 (m, 12H). 13C NMR (75 
MHz, CDCl3) δ 186.7, 185.0, 167.2, 135.1, 134.7, 133.2, 132.7, 129.3, 129.3, 129.0, 
128.9, 128.7, 128.5, 128.1, 76.5, 48.8, 39.5, 36.2, 31.6, 28.9, 23.8, 22.6, 14.2. UPLC-
DAD-QTOF: C31H34N3O4S [M+H]
+ calcd.: 544.2270, found: 544.2271. 
(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-(2-
(methylthio)ethyl)-1H-imidazol-4(5H)-one (38Fd) 
The title compound was prepared from 1-benzoyl-2-
(benzylthio)-5-(2-(methylthio)ethyl)-1H-imidazol-4(5H)-one 33F 
(0.2 mmol, 76.8 mg) and (E)-1-chloro-2-(2-nitrovinyl)benzene 
36d (0.4 mmol, 73.2 mg) according to the general procedure. 
The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as an orange foam. Yield: 0.15 mmol, 82.8 mg, 73%. [α]D
25= –9.42 (c = 0.85, 
99:1 dr, 98% ee, CH2Cl2). 
1H NMR (300 MHz, CD3Cl) δ: 7.57 – 6.91 (m, 14H), 5.35 – 5.16 
(m, 3H), 4.28 (d, J = 13.4 Hz, 1H), 4.11 (d, J = 13.4 Hz, 1H),  3.20 (ddd, J = 12.8, 10.7, 5.0 
Hz, 1H), 2.48 (ddd, J = 12.8, 10.0, 5.4 Hz, 1H), 2.30 (ddd, J = 13.0, 10.0, 5.0 Hz, 1H), 2.23 
– 1.96 (m, 4H). 13C NMR (75 MHz, CDCl3) δ: 186.2, 185.2, 167.0, 136.2, 134.5, 133.6, 
133.2, 132.5, 130.9, 130.0, 129.3, 129.1, 128.8, 128.6, 128.2, 127.9, 127.8, 76.1, 75.8, 
43.6, 39.6, 36.5, 28.1, 15.6.  UPLC-DAD-QTOF: C28H27N3O4S2Cl [M+H]
+ calcd.: 568.1132, 
found: 568.1144. 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-4-methyl-1-nitropentan-2-yl)-1H-
imidazol-4(5H)-one (38Ch) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
(E)-4-methyl-1-nitropent-1-ene 36h (51.6 mg, 0.4 mmol) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as an orange oil. Yield: 0.11 
mmol, 54.6 mg, 53%. [α]D
25= –29.24 (c = 0.75, >98:2 dr, 92% ee, CH2Cl2).
  1H NMR (300 
MHz, CD3Cl) δ: 7.56 – 7.49 (m, 2H), 7.37 – 7.20 (m, 8H), 7.15 – 7.06 (m, 3H), 7.02 – 6.85 
(m, 2H), 5.45 (dd, J = 14.4, 5.8 Hz, 1H), 4.42 (dd, J = 14.4, 4.8 Hz, 1H), 4.31 (d, J = 13.4 
Hz, 1H), 3.98 (d, J = 13.4 Hz, 1H), 3.68 – 3.49 (m, 2H), 1.63 – 1.52 (m, 1H), 1.22 – 1.12 
(m, 1H), 1.01 – 0.96 (m, 1H), 0.91 – 0.89 (m, 1H), 0.85 (t, J = 6.8 Hz, 6H). 13C NMR (75 
MHz, CDCl3) δ: 186.7, 185.4, 167.4, 134.7, 134.2, 133.2, 132.9, 129.7, 129.2, 129.0, 
128.9, 128.8, 128.5, 128.1, 127.8, 75.2, 40.7, 39.5, 39.3, 38.3, 29.8, 25.6, 23.9, 
21.7..UPLC-DAD-QTOF: C30H32N3O4S [M+H]
+ calcd.: 530.2114, found: 530.2122. 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-nitropentan-2-yl)-1H-imidazol-4(5H)-
one (38Ci) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
(E)-1-nitropent-1-ene 36i (0.4 mmol, 46.2 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a yellow oil. Yield: 0.08 mmol, 41.2 mg, 
40%. [α]D
25= –6.72 (c = 0.72, >98:2 dr, 90% ee, CH2Cl2).
 1H NMR (300 MHz, CD3Cl) δ: 
7.62 – 7.41 (m, 2H),  7.35 – 7.19 (m, 8H), 7.14 – 7.08 (m, 3H), 6.94 – 6.89 (m, 2H), 5.34 
(dd, J = 14.3, 5.1 Hz, 1H), 4.53 (dd, J = 14.3, 6.1 Hz, 1H),  4.29 (d, J = 13.4 Hz, 1H), 3.99 
(d, J = 13.4 Hz, 1H), 3.91 – 3.83 (m, 1H), 3.71 – 3.48 (m, 2H), 1.45 – 1.26 (m, 2H), 1.23 – 
1.12 (m, 2H), 0.83 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 186.7, 185.3, 167.5, 
134.7, 134.1, 133.3, 133.0, 130.1, 129.8, 129.4, 129.3, 129.0, 129.0, 128.8, 128.6, 
128.1, 128.0, 127.8, 75.1, 42.5, 39.7, 39.5, 31.1, 20.0, 14.2. UPLC-DAD-QTOF: 
C29H30N3O4S [M+H]
+ calcd.: 516.1957, found: 516.1968. 
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 (S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-
5-methyl-1H-imidazol-4(5H)-one (39Ad) 
The title compound was prepared from 2-(benzylthio)-1-(tert-
butyloxycarbonyl)-5-methyl-1H-imidazol-4(5H)-one 34A (0.2 
mmol, 64 mg) and (E)-1-chloro-2-(2-nitrovinyl)benzene 36d (0.4 
mmol, 73.4 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 91:9 
mixture of diastereomers (white foam). Yield: 0.17 mmol, 83.5 mg, 83%. 1H NMR (300 
MHz, CD3Cl) δ: 7.48 – 7.02 (m, 9H), 5.26 – 5.14 (m, 2H), 5.10 – 4.96 (m, 1H), 4.31 – 4.12 
(m, 2H), 1.85 (s, 3H), 1.65 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 186.9, 185.7, 135.1, 
132.3, 130.2, 129.8, 129.4, 128.8, 128.3, 127.9, 127.5, 87.1, 75.1, 70.7, 43.4, 38.5 
(minor. dr.), 37.9, 28.2, 25.5 (minor. dr.), 22.0, 20.7 (minor. dr.). UPLC-DAD-QTOF: 
C24H27N3O5SCl [M+H]
+ calcd.: 504.1360, found: 504.1364. 
(S)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-2-nitro-1-phenylethyl)-
1H-imidazol-4(5H)-one (39Ca) 
The title compound was prepared from 5-benzyl-1-(tert-
butyloxycarbonyl)-2-(benzylthio)-1H-imidazol-4(5H)-one 34C 
(0.2 mmol, 79.2 mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 
mmol, 60 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as a white foam. Yield: 0.14 mmol, 76.3 mg, 70%. [α]D
25= –38.53 (c = 1.00, 
>98:2 dr, 99% ee, CH2Cl2). 
1H NMR (300 MHz, CD3Cl) δ: 7.36 – 6.96 (m, 15H), 5.41 – 
5.22 (m, 2H), 4.82 – 4.63 (m, 1H), 4.01 (s, 2H), 3.71 – 3.56 (m, 1H), 3.48 (d, J = 12.8 Hz, 
1H), 1.81 – 1.50 (m, 9H).  13C NMR (75 MHz, CDCl3) δ: 186.16, 135.25, 134.36, 133.28, 
129.47, 129.19, 128.93, 128.88, 128.67, 128.02, 127.81, 127.72, 87.11, 75.67, 48.30, 
40.17, 37.67, 28.27. UPLC-DAD-QTOF: C30H32N3O5S [M+H]
+ calcd.: 546.2063, found: 
546.2074. 
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(R)-5-((Benzyloxy)methyl)-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)- 1H-imidazol-4(5H)-one (39Gd) 
The title compound was prepared from 5-((benzyloxy)methyl)-2-
(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-one 
34G (0.2 mmol, 85.2 mg) and (E)-1-chloro-2-(2-
nitrovinyl)benzene 36d (0.4 mmol, 73.4 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give 
the title compound as a 94:6 mixture of diastereomers (white foam). Yield: 0.17 mmol, 
102.3 mg, 84%.  1H NMR (300 MHz, CD3Cl) δ: 7.34 – 7.12 (m, 14H), 5.17 – 4.93 (m, 3H), 
4.58 – 4.47 (m, 2H), 4.36 – 4.14 (m, 3H), 3.96 (d, J = 8.3 Hz, 1H), 1.54 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ: 187.1, 185.9, 148.2, 136.9, 135.3, 135.1, 131.9, 130.2, 129.9, 129.6, 
129.3, 128.9, 128.7, 128.6, 128.5, 128.1, 127.8, 127.6, 86.8, 74.4, 73.8, 73.7, 70.2, 40.9, 
37.9, 28.1. UPLC-DAD-QTOF: C31H33N3O6SCl [M+H]
+ calcd.: 610.1779, found: 610.1798. 
(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-2-nitro-1-phenylethyl)-5-phenyl-
1H-imidazol-4(5H)-one (39Ha) 
The title compound was prepared from 2-(benzylthio)-1-(tert-
butyloxycarbonyl)-5-phenyl-1H-imidazol-4(5H)-one 34H (0.2 
mmol, 76.4 mg) and (E)-(2-nitrovinyl)benzene (0.4 mmol, 60 mg) 
36a according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 92:8 mixture of 
diastereomers (white foam). Yield: 0.14 mmol, 73.2 mg, 69%. 1H NMR (300 MHz, 
CD3Cl) δ: 7.53 – 7.21 (m, 15H), 5.28 – 5.17 (m, 2H), 4.39 (d, J = 13.4 Hz, 1H), 4.27 (d, J = 
13.4 Hz, 1H), 1.40 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 186.7, 186.2, 147.7, 135.1, 133.6, 
129.7, 129.5, 129.3, 129.2, 129.0, 128.8, 128.4, 128.0, 127.8, 86.8, 77.6, 77.2, 76.7, 
76.6, 74.9, 45.6, 38.1, 27.9. UPLC-DAD-QTOF: C29H30N3O5S [M+H]
+ calcd.: 531.1828, 
found: 531.1829.  
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(S)-5-Benzyl-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-4(5H)-one (40Ca) 
The title compound was prepared from 5-benzyl-1-
(benzyloxycarbonyl)-2-(benzylthio)-1H-imidazol-4(5H)-one 35C 
(0.2 mmol, 92.0 mg) and (E)-(2-nitrovinyl)benzene (0.4 mmol, 
60 mg) 36a according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound as a white 
foam. Yield: 0.18 mmol, 104.2 mg, 90%. [α]D
25= –31.04 (c = 0.23, >98:2 dr, 99% ee, 
CH2Cl2).
 1H NMR (300 MHz, CD3Cl) δ: 7.66 – 6.79 (m, 20H), 5.51 – 5.36 (m, 2H), 5.27 – 
5.24 (m, 2H), 4.03 – 3.93 (m, 2H), 3.45 – 3.41 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 
185.9, 135.0, 134.0, 132.9, 129.8, 129.5, 129.3, 129.2, 129.0, 128.8, 128.7, 127.8, 
127.2, 88.4, 75.5, 70.0, 48.3, 40.2, 37.6, 31.1, 29.8. UPLC-DAD-QTOF: C33H30N3O5S 
[M+H]+ calcd.: 580.1906, found: 580.1909. 
(R)-5-((Benzyloxy)methyl)-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)-1H-imidazol-4(5H)-one (40Gd) 
The title compound was prepared from 1-(benzyloxycarbonyl)-
5-((benzyloxy)methyl)-2-(benzylthio)-1H-imidazol-4(5H)-one 
35G (0.2 mmol, 92 mg) and (E)-1-chloro-2-(2-nitrovinyl)benzene 
36d (0.4 mmol, 73.4 mg) according to the general procedure. 
The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as a 95:5 mixture of diastereomers (white foam). Yield: 0.18 mmol, 117.1 
mg, 91%. 1H NMR (300 MHz, CD3Cl) δ: 7.48 – 6.97 (m, 19H), 5.34 (d, J = 11.8 Hz, 1H), 
5.19 (d, J = 11.8 Hz, 1H), 5.13 – 4.88 (m, 3H), 4.41 – 4.09 (m, 5H), 3.89 (d, J = 8.4 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ: 187.1, 185.4, 149.6, 137.0, 135.1, 135.0, 133.8, 131.5, 
130.4, 130.0, 129.6, 129.4, 129.3, 129.1, 129.0, 128.8, 128.6, 128.3, 128.1, 127.9, 
127.6, 127.5, 74.2, 73.8, 73.4, 70.0, 69.9, 40.8, 37.8. UPLC-DAD-QTOF: C34H31N3O6SCl 
[M+H]+ calcd.: 644.1622, found: 644.1617.  
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5.4.4.  Reaction of N1-acyl 2-benzylthioimidazolones 33-35 with vinyl ketones 41 and 
1a.  
 
To a solution of the corresponding imidazolone 33-35 (1 equiv., 0.2 mmol) in 
dichlorometane (0.6 mL) the corresponding vinyl ketone (2.0 equiv., 0.4 mmol) and the 
catalyst were added at room temperature. The resulting mixture was stirred until 
consumption of the nucleophile (monitored by 1H-NMR). Afterwards, the reaction was 
purified by flash column chromatography on silica gel to afford the expected adducts. 
(S)-1-Benzoyl-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Aa) 
The title compound was prepared from 1-benzoyl-2-(benzylthio)-
5-methyl-1H-imidazol-4(5H)-one 33A (0.2 mmol, 64.8 mg) and 
methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a colourless oil. Yield: 0.10 mmol, 37.8 
mg, 48%. [α]D
25= –13.9 (c = 0.51, 94% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.62 – 
7.24 (m, 10H), 4.53 – 4.27 (m, 2H), 2.52 – 2.40 (m, 1H), 2.31 – 2.13 (m, 3H), 2.08 (s, 
3H), 1.61 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 206.3, 187.9, 184.1, 168.0, 135.1, 133.6, 
133.1, 129.5, 128.9, 128.7, 128.1, 71.1, 39.1, 37.9, 31.1, 30.0, 23.1. UPLC-DAD-QTOF: 
C22H23N2O3S [M+H]
+ calcd.: 395.1429, found: 395.1429. 
(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ca) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and 
methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
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90:10 to 80:20) to give the title compound as a yellow oil. Yield: 0.13 mmol, 63.0 mg, 
67%. [α]D
25= –6.9 (c = 1.02, 96% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.55 – 6.97 
(m, 15H), 4.28 (d, J = 13.5 Hz, 1H), 4.02 (d, J = 13.4 Hz, 1H), 3.60 – 3.42 (m, 2H), 2.89 – 
2.75 (m, 1H), 2.49 – 2.37 (m, 1H), 2.32 – 2.21 (m, 2H), 2.08 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ: 206.2, 187.4, 184.5, 167.6, 135.0, 134.7, 133.1, 129.7, 129.3, 129.1, 128.8, 
128.7, 128.5, 128.0, 127.6, 76.6, 41.3, 39.2, 37.7, 31.1, 30.0. UPLC-DAD-QTOF: 
C28H27N2O3S [M+H]
+ calcd.: 471.1742, found: 471.1753. 
(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ea) 
The title compound was prepared from 1-benzoyl-2-(benzylthio)-
5-hexyl-1H-imidazol-4(5H)-one 33E (0.2 mmol, 78.8 mg) and 
methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a yellow oil. Yield: 0.10 mmol, 48.2 mg, 
52%. [α]D
25= –18.5 (c = 0.65, 96% ee, CH2Cl2).  
1H NMR (300 MHz, CDCl3) δ: 7.79 – 7.17 
(m, 10H), 4.60 – 4.22 (m, 1H), 2.52 – 2.43 (m, 1H), 2.34 – 2.12 (m, 3H), 2.09 (s, 3H), 
1.96 – 1.86 (m, 1H), 1.40 – 1.01 (m, 9H), 0.92 – 0.82 (m, 3H). 13C NMR (75 MHz, CDCl3) 
δ: 206.4, 187.6, 184.7, 167.8, 135.2, 133.5, 133.1, 129.4, 128.9, 128.8, 128.6, 128.1, 
75.4, 39.1, 37.6, 35.9, 31.6, 30.9, 30.0, 29.0, 23.8, 22.6, 14.1. UPLC-DAD-QTOF: 
C27H33N2O3S [M+H]
+ calcd.: 465.2212, found: 465.2220. 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ca) 
The title compound was prepared from 5-benzyl-2-(benzylthio)-1-
(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-one 34C (0.2 mmol, 
79.2 mg) and methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90: 10 to 80:20) to give the title compound as a white foam. Yield: 
0.12 mmol, 57.8 mg, 62%. [α]D
25= –20.76 (c = 1.145, 89% ee, CH2Cl2). 
1H NMR (300 
MHz, CDCl3) δ: 7.37 – 7.14 (m, 8H), 7.13 – 7.02 (m, 2H), 4.23 (q, J = 13.4 Hz, 2H), 3.40 
(d, J = 13.5 Hz, 1H), 3.21 (d, J = 13.4 Hz, 1H), 2.65 (ddd, J = 13.5, 9.7, 4.7 Hz, 1H), 2.50 – 
2.14 (m, 3H), 2.13 (s, 3H), 1.67 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 206.4, 187.1, 185.6, 
148.6, 135.3, 133.9, 129.3, 128.7, 128.6, 127.8, 127.6, 86.4, 74.4, 42.1, 37.7, 30.2, 29.6, 
28.3.  UPLC-DAD-QTOF: C26H31N2O4S [M+H]
+ calcd.: 467.2005, found: 467.2006. 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-isobutyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Da) 
The title compound x was prepared from 2-(benzylthio)-1-(tert-
butyloxycarbonyl)-5-isobutyl-1H-imidazol-4(5H)-one 34D (0.2 
mmol, 72.4 mg) and methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.16 mmol, 70.0 mg, 81%. [α]D
25= +4.3 (c = 0.465, 97% ee, CH2Cl2). 
1H NMR (300 MHz, 
CDCl3) δ: 7.51 – 7.21 (m, 5H), 4.50 (s, 2H), 2.56 – 2.22 (m, 2H), 2.20 – 1.97 (m, 6H), 1.87 
(dd, J = 14.1, 7.5 Hz, 1H), 1.59 (s, 9H), 1.51 – 1.35 (m, 1H), 0.85 (dd, J = 18.0, 6.6 Hz, 
6H). 13C NMR (75 MHz, CDCl3) δ: 206.5, 188.1, 185.3, 148.9, 135.4, 129.6, 128.9, 128.0, 
86.0, 72.5, 45.0, 38.0, 37.0, 31.1, 30.2, 28.1, 24.9, 24.00, 23.2. UPLC-DAD-QTOF: 
C23H33N2O4S [M+H]
+ calcd.: 433.2161, found: 433.2159. 
(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ea) 
The title compound was prepared from 2-(benzylthio)-1-(tert-
butyloxycarbonyl)-5-hexyl-1H-imidazol-4(5H)-one 34E (0.2 mmol, 
78.0 mg) and methyl vinyl ketone 1a (0.4 mmol, 28.0 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.12 mmol, 57.0 mg, 62%. [α]D
25= +1.4 (c = 0.25, 97% ee, CH2Cl2).  
1H NMR (300 MHz, 
CDCl3) δ: 7.43 – 7.25 (m, 4H), 4.46 (s, 2H), 2.47 – 2.21 (m, 2H), 2.19 – 2.07 (m, 3H), 2.06 
(d, J = 1.2 Hz, 3H), 1.87 (ddd, J = 13.5, 10.9, 5.5 Hz, 1H), 1.54 (s, 9H), 1.28 – 1.18 (m, 
6H), 0.98 (ddd, J = 16.5, 11.1, 6.8 Hz, 2H), 0.85 (td, J = 6.9, 6.0, 2.5 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ: 206.5, 187.9, 185.5, 148.9, 135.2, 129.59, 128.9, 128.0, 85.9, 73.3, 38.1, 
37.4, 36.36, 31.6, 30.2, 30.1, 29.0, 28.1, 23.3, 22.6, 14.1. UPLC-DAD-QTOF: C25H37N2O4S 
[M+H]+ calcd.: 461.2474, found: 461.2474. 
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(S)-1-(Benzyloxycarbonyl)-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-
one (44Aa) 
The title compound was prepared from 1-(benzyloxycarbonyl)-2-
(benzylthio)-5-methyl-1H-imidazol-4(5H)-one 35A (0.2 mmol, 
70.8 mg) and methyl vinyl ketone 41a (0.4 mmol, 28.0 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.12 mmol, 51.7 mg, 61%. [α]D
25= +18.9 (c = 1.2, 97% ee, CH2Cl2). 
1H NMR (300 MHz, 
CDCl3) δ: 7.44 – 7.28 (m, 10H), 5.31 (s, 2H), 4.48 (s, 2H), 2.54 – 2.38 (m, 1H), 2.30 – 2.05 
(m, 3H), 2.02 (s, 3H), 1.55 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 206.3, 187.7, 184.8, 
150.1, 135.0, 134.0, 129.6, 129.3, 129.1, 129.0, 129.0, 128.1, 69.8, 69.4, 38.2, 37.6, 
30.0, 23.0. UPLC-DAD-QTOF: C23H25N2O4S [M+H]
+ calcd.: 425.1535, found: 425.1537. 
(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxo-3-phenylpropyl)-1H-imidazol-4(5H)-
one (42Cb) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80 mg) and  
phenyl vinyl ketone 41b (0.4 mmol, 52.8 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a white foam. Yield: 0.16 mmol, 86.1 mg, 
81%. [α]D
25= –12.8 (c = 0.5, 94% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 8.27 – 6.32 
(m, 20H), 4.29 (d, J = 13.3 Hz, 1H), 4.03 (d, J = 13.4 Hz, 1H), 3.79 – 3.35 (m, 2H), 3.18 – 
2.50 (m, 4H). 13C NMR (75 MHz, CDCl3) δ: 197.8, 187.5, 184.6, 167.6, 136.5, 135.0, 
134.8, 133.3, 133.1, 129.7, 129.2, 129.1, 128.8, 128.7, 128.5, 128.2, 128.0, 127.5, 76.9, 
41.5, 39.2, 32.9, 31.7. UPLC-DAD-QTOF: C33H29N2O3S [M+H]
+ calcd.: 533.1899, found: 
533.1900. 
(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-ethyl-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Bb) 
The title compound was prepared from 2-(benzylthio)-1-
(tert-butyloxycarbonyl)-5-ethyl-1H-imidazol-4(5H)-one 
34B (0.2 mmol, 66.8 mg) and  phenyl vinyl ketone 41b (0.4 
mmol, 52.8 mg) according to the general procedure. The 
crude material was purified by flash column 
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chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as a colourless oil. Yield: 0.14 mmol, 65.2 mg, 70%. [α]D
25= –6.71 (c = 0.25, 
97% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.87 – 7.82 (m, 2H), 7.60 – 7.52 (m, 1H), 
7.47 – 7.25 (m, 7H), 4.42 (s, 2H), 2.90 – 2.79 (m, 1H), 2.68 – 2.58 (m, 2H), 2.29 – 2.11 
(m, 2H), 1.99 (dq, J = 14.4, 7.4 Hz, 1H), 1.55 (s, 9H), 0.73 (t, J = 7.4 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ: 198.2, 187.8, 185.8, 148.8, 136.5, 135.2, 133.4, 129.6, 128.9, 128.8, 
128.2, 128.0, 86.0, 74.2, 38.1, 32.4, 30.7, 29.6, 28.1, 7.8. UPLC-DAD-QTOF: C26H30N2O4S 
[M+H]+ calcd.: 467.2005, found: 467.2004. 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Cb) 
The title compound was prepared from 5-benzyl-2-
(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-
one 34C (0.2 mmol, 79.2 mg) and 1-phenylprop-2-en-1-one 
41b (0.4 mmol, 52.8 mg) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 
to 80:20) to give the title compound as a white foam. Yield: 0.17 mmol, 87.6 mg, 83%. 
[α]D
25= –8.3 (c = 0.99, 96% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.93 – 7.88 (m, 2H), 
7.64 – 7.56 (m, 1H), 7.50 – 7.44 (m, 2H), 7.31 – 7.20 (m, 5H), 7.20 – 7.14 (m, 2H), 7.13 – 
7.06 (m, 2H), 4.30 – 4.12 (m, 2H), 3.44 (d, J = 13.5 Hz, 1H), 3.26 (d, J = 13.4 Hz, 1H), 3.03 
– 2.79 (m, 2H), 2.70 – 2.56 (m, 1H), 2.51 – 2.42 (m, 1H), 1.67 (s, 9H). 13C NMR (75 MHz, 
CDCl3) δ: 198.1, 187.2, 185.7, 148.6, 136.4, 135.3, 133.9, 133.5, 129.4, 129.3, 128.8, 
128.7, 128.6, 128.3, 127.8, 127.6, 42.2, 37.7, 32.6, 30.4, 28.3. UPLC-DAD-QTOF: 
C31H33N2O4S [M+H]
+ calcd.: 529.2161, found: 529.2175. 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-1H-
imidazol-4(5H)-one (43Cc) 
The title compound was prepared from 5-benzyl-2-
(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-
4(5H)-one 34C (0.2 mmol, 79.2 mg) and 1-(p-tolyl)prop-
2-en-1-one 41c (0.4 mmol, 58.4 mg) according to the 
general procedure. The crude material was purified by 
flash column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to 
give the title compound as a yellow oil. Yield: 0.17 mmol, 91.1 mg, 84%. [α]D
25= –1.4 (c 
= 1.61, 96% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.82 (d, J = 8.2 Hz, 2H), 7.46 – 6.96 
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(m, 11H), 4.48 – 4.04 (m, 2H), 3.45 (d, J = 13.5 Hz, 1H), 3.27 (d, J = 13.4 Hz, 1H), 3.04 – 
2.78 (m, 2H), 2.70 – 2.49 (m, 2H), 2.44 (s, 3H), 1.68 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 
197.7, 187.2, 185.7, 148.6, 144.3, 135.3, 134.0, 129.4, 129.4, 129.3, 128.7, 128.6, 
128.4, 127.7, 127.5, 86.4, 74.7, 42.2, 37.7, 32.4, 30.5, 28.2, 21.8. UPLC-DAD-QTOF: 
C31H33N2O4S [M+H]
+ calcd.: 529.2161, found: 529.2168. 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-(4-chlorophenyl)-3-
oxopropyl)-1H-imidazol-4(5H)-one (43Cd) 
The title compound was prepared from 5-benzyl 2-
(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-
4(5H)-one 34C (0.2 mmol, 79.2 mg) and 1-(4-chloro-
phenyl)propenone 41d (0.4 mmol, 66.4 mg) according 
to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 
80:20) to give the title compound as a colourless oil. Yield: 0.17 mmol, 95.5 mg, 85%. 
[α]D
25= +5.7 (c = 1.9, 96% ee, CH2Cl2).  
1H NMR (300 MHz, CDCl3) δ: 7.85 (d, J = 8.6 Hz, 
2H), 7.45 (d, J = 8.6 Hz, 2H), 7.34 – 6.95 (m, 10H), 4.20 (q, J = 13.4 Hz, 2H), 3.45 (d, J = 
13.4 Hz, 1H), 3.26 (d, J = 13.4 Hz, 1H), 3.05 – 2.76 (m, 2H), 2.75 – 2.36 (m, 2H), 1.68 (s, 
9H). 13C NMR (75 MHz, CDCl3) δ: 196.9, 187.1, 185.7, 148.5, 140.0, 135.3, 134.7, 133.8, 
129.7, 129.4, 129.3, 129.1, 128.7, 128.6, 127.8, 127.6, 86.5, 74.6, 42.2, 37.7, 32.6, 30.3, 
28.3. UPLC-DAD-QTOF: C31H32N2O4SCl [M+H]
+ calcd.: 563.1771, found: 563.1763. 
(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-5-phenyl-1H-
imidazol-4(5H)-one (43Hc) 
The title compound was prepared from 2-(benzylthio)-1-
(tert-butyloxycarbonyl)-5-phenyl-1H-imidazol-4(5H)-one 
34H (0.2 mmol, 76.4 mg) and 1-(4-methylphenyl)prop-2-
en-1-one 41d (0.4 mmol, 58.4 mg) according to the 
general procedure. The crude material was purified by 
flash column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to 
give the title compound as a white foam. Yield: 0.17 mmol, 88.7 mg, 84%. [α]D
25= –32.5 
(c = 1.00, 99% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.84 – 7.78 (m, 2H), 7.48 – 7.24 
(m, 12H), 4.60 – 4.48 (m, 2H), 3.12 – 2.89 (m, 3H), 2.79 – 2.69 (m, 1H), 2.44 (s, 3H), 
1.24 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 197.6, 186.2, 185.9, 148.6, 144.4, 137.2, 
135.2, 134.0, 129.6, 129.5, 129.0, 128.9, 128.5, 128.4, 128.0, 127.7, 125.2, 85.8, 74.0, 
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38.2, 32.2, 29.0, 27.6, 21.8. UPLC-DAD-QTOF: C31H33N2O4S [M+H]
+ calcd.: 529.2161, 
found: 401.2156.  
(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(4-hydroxy-4-methyl-3-oxopentyl)-1H-
imidazol-4(5H)-one (45C) 
The title compound was prepared from 1-benzoyl-5-benzyl-2-
(benzylthio)-1H-imidazol-4(5H)-one 33C (0.2 mmol, 80.0 mg) 
and 4-hydroxy-4-methylpent-1-en-3-one 1a (0.4 mmol, 45.6 
mg) to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.16 mmol, 82.2 mg, 80%. [α]D
25= –1.9 (c = 1.33, 94% ee, CH2Cl2).
 1H NMR (300 MHz, 
CDCl3) δ: 7.59 – 6.71 (m, 15H), 4.25 (d, J = 13.4 Hz, 1H), 4.00 (d, J = 13.4 Hz, 1H), 3.58 
(d, J = 13.7 Hz, 1H), 3.44 (d, J = 13.0 Hz, 1H), 2.90 – 2.72 (m, 1H), 2.57 – 2.37 (m, 3H), 
1.29 (d, J = 6.4 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ: 212.6, 187.3, 184.6, 167.7, 134.9, 
134.6, 133.2, 133.0, 129.7, 129.3, 129.1, 128.9, 128.8, 128.6, 128.1, 127.6, 76.6, 76.5, 
41.5, 39.2, 31.0, 29.9, 26.8, 26.7. UPLC-DAD-QTOF: C30H31N2O4S [M+H]
+ calcd.: 
515.2005, found: 515.2013. 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-
oxopentyl)-1H-imidazol-4(5H)-one (46C) 
The title compound was prepared from 5-benzyl-2-
(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-one 
34C (0.2 mmol, 79.2 mg) and 4-hydroxy-4-methylpent-1-en-
3-one 1a (0.4 mmol, 45.6 mg) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 
to 80:20) to give the title compound as a colourless oil. Yield: 0.16 mmol, 82.6 mg, 
81%. [α]D
25= –12.5 (c = 0.25, 90% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.29 – 7.13 
(m, 8H), 7.08 – 7.03 (m, 2H), 4.27 – 4.12 (m, 2H), 3.51 (s, 1H), 3.39 (d, J = 13.4 Hz, 1H), 
3.20 (d, J = 13.4 Hz, 2H), 2.76 – 2.44 (m, 2H), 2.38 – 2.21 (m, 2H), 1.66 (s, 9H), 1.34 (s, 
3H), 1.30 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 212.7, 186.9, 185.7, 148.5, 135.2, 133.7, 
129.3, 129.3, 128.7, 128.6, 127.8, 127.6, 86.4, 76.5, 74.4, 42.2, 37.7, 29.97, 29.6, 28.2, 
26.6, 26.5. UPLC-DAD-QTOF: C28H35N2O5S [M+H]
+ calcd.: 511.2267, found: 511.2267. 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-oxopentyl)-5-
phenyl-1H-imidazol-4(5H)-one (46H) 
The title compound was prepared from 2-(benzylthio)-1-
(tert-butyloxycarbonyl)-5-phenyl-1H-imidazol-4(5H)-one 34H 
(0.2 mmol, 76.4 mg) and 4-hydroxy-4-methylpent-1-en-3-
one 1a (0.4 mmol, 45.6 mg) according to the general 
procedure. The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as a colourless oil. Yield: 0.16 mmol, 81.3 mg, 82%. [α]D
25= –44.7 (c = 4.2, 
91% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.65 – 7.00 (m, 10H), 4.90 – 4.33 (m, 2H), 
3.49 (s, 1H), 2.97 – 2.75 (m, 2H), 2.62 – 2.51 (m, 1H), 2.42 – 2.31 (m, 1H), 1.33 (d, J = 
9.3 Hz, 6H), 1.24 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 212.7, 186.2, 185.5, 148.5, 137.0, 
135.1, 129.5, 129.0, 128.9, 128.6, 128.1, 125.0, 85.8, 76.5, 73.7, 38.1, 29.7, 28.0, 27.6, 
26.6, 26.5. UPLC-DAD-QTOF: C27H33N2O5S [M+H]
+ calcd.: 497.2110, found: 497.2106. 
5.4.5. Reaction of N3-aryl 2-benzylthioimidazolones 61-66 and nitroolefins 36. 
 
To a solution of the corresponding imidazolone 61-66 (1 equiv., 0.2 mmol) and 
nitroalkene 36 (2.0 equiv., 0.4 mmol) in dichlorometane (0.6 mL) the catalyst was 
added at –20 oC. The resulting mixture was stirred until consumption of the 
imidazolone (monitored by 1H-NMR). Afterwards, the reaction was directly submitted 
to flash column chromatography on silica gel to afford the corresponding adducts 
67_72 essentially pure. 
(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-5(4H)-
one (67Aa) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60 mg) according to 
the general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a 97:3 mixture of diastereomers 
(colourless oil). Yield: 0.20 mmol, 88.1 mg, 99%. 1H NMR (300 MHz, CDCl3) δ: 7.48 – 
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7.02 (m, 15H), 4.89 (dd, J = 13.1, 10.1 Hz, 1H), 4.73 (dd, J = 13.1, 5.3 Hz, 1H), 4.43 – 
4.25 (m, 2H), 4.05 (dd, J = 10.1, 5.3 Hz, 1H), 1.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 
181.8, 161.0, 135.9, 135.2, 131.8, 129.6, 129.5, 129.2, 129.2, 128.8, 128.5, 128.4, 
127.9, 127.3, 75.6, 73.1, 50.1, 34.9, 22.7. UPLC-DAD-QTOF: C25H24N3O3S [M+H]
+ calcd.: 
446.1538, found: 446.1545. 
(S)-2-(Benzylthio)-4-((S)-1-(4-bromophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ab) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-bromo-4-(2-nitrovinyl)benzene 36b (0.4 mmol, 91.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 
yellow oil. Yield: 0.19 mmol, 99.4 mg, 95%. [α]D
25= –133.94 (c = 0.65, >98:2 dr, 99% ee, 
CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 7.49 – 7.03 (m, 14H), 4.78 – 4.56 (m, 2H), 4.32 (q, 
J = 13.5 Hz, 2H), 3.95 (dd, J = 10.3, 5.1 Hz, 1H), 1.38 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 
181.6, 161.3, 135.9, 134.3, 131.7, 131.0, 129.7, 129.6, 129.0, 128.8, 128.0, 127.2, 
122.5, 75.5, 72.9, 49.5, 34.8, 22.8. UPLC-DAD-QTOF: C25H23N3O3SBr [M+H]
+ calcd.: 
524.0644, found: 524.0640. 
(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-(p-tolyl)ethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Ac) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-methyl-4-(2-nitrovinyl)benzene 36c (0.4 mmol, 65.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 
colourless oil. Yield: 0.17 mmol, 79.9 mg, 87%. [α]D
25= –45.14 (c = 1.2, >98:2 dr, 97% 
ee, CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 7.47 – 7.02 (m, 14H), 4.80 (dd, J = 13.0, 10.1 
Hz, 1H), 4.65 (dd, J = 13.0, 5.2 Hz, 1H), 4.39 – 4.27 (m, 2H), 3.97 (dd, J = 10.1, 5.2 Hz, 
1H), 2.35 (s, 3H), 1.40 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.9, 160.9, 138.0, 136.0, 
132.1, 131.8, 129.6, 129.5, 129.2, 129.1, 129.1, 128.8, 127.9, 127.3, 75.8, 73.2, 49.8, 
34.9, 22.8, 21.3. UPLC-DAD-QTOF: C26H26N3O3S [M+H]
+ calcd.: 460.1695, found: 
460.1707. 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ad) 
The title compound was prepared from 2-(benzylthio)-4-
methyl-1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 
mg) and (E)-1-chloro-2-(2-nitrovinyl)benzene 36d (0.4 mmol, 
73.2 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound as a yellow oil. 
Yield: 0.18 mmol, 86.2 mg, 90%. [α]D
25= –32.86 (c = 1.00, >98:2 dr, 99% ee, CH2Cl2).
 1H 
NMR (300 MHz, CDCl3) δ: 7.76 – 6.90 (m, 14H), 4.97 – 4.63 (m, 3H), 4.37 (s, 2H), 1.45 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ: 181.5, 161.3, 136.3, 135.8, 133.6, 131.8, 130.1, 129.6, 
129.5, 129.4, 129.1, 128.8, 128.6, 127.9, 127.2, 127.0, 75.4, 73.3, 44.8, 34.9, 22.4. 
UPLC-DAD-QTOF: C25H23N3O3SCl [M+H]
+ calcd.: 480.1149, found: 480.1152. 
(S)-2-(Benzylthio)-4-((S)-1-(3-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ae) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-chloro-3-(2-nitrovinyl)benzene 36e (0.4 mmol, 73.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.17 mmol, 82.4 mg, 86%. [α]D
25= –25.74 (c = 0.90, >98:2 dr, 99% ee, CH2Cl2).
 1H NMR 
(300 MHz, CDCl3) δ: 7.48 – 7.17 (m, 12H), 7.10 – 7.05 (m, 2H), 4.72 (ddd, J = 13.4, 10.1, 
0.9 Hz, 1H), 4.60 (ddd, J = 13.3, 5.2, 1.0 Hz, 1H), 4.40 – 4.27 (m, 2H), 3.98 (dd, J = 10.1, 
5.1 Hz, 1H), 1.40 (d, J = 0.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.5, 161.4, 137.4, 
135.8, 134.4, 131.7, 129.8, 129.7, 129.6, 129.4, 129.1, 128.9, 128.6, 128.0, 127.5, 
127.2, 75.3, 72.8, 49.7, 35.0, 22.8. UPLC-DAD-QTOF: C25H23N3O3SCl [M+H]
+ calcd.: 
480.1149, found: 480.1154. 
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(S)-2-(Benzylthio)-4-((S)-1-(4-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Aj) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-chloro-4-(2-nitrovinyl)benzene 36j (0.4 mmol, 73.2 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 
yellow oil. Yield: 0.19 mmol, 90.1 mg, 94%. [α]D
25= –11.35 (c = 0.85, >98:2 dr, 99% ee, 
CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 7.62 – 7.23 (m, 12H), 7.14 – 7.02 (m, 2H), 4.88 – 
4.59 (m, 2H), 4.51 – 4.25 (m, 2H), 4.00 (dd, J = 10.3, 5.1 Hz, 1H), 1.41 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ: 181.6, 161.3, 135.9, 134.3, 133.8, 130.6, 129.7, 129.6, 129.0, 128.8, 
128.7, 128.0, 127.2, 75.6, 72.9, 49.4, 34.8, 22.8. UPLC-DAD-QTOF: C25H23N3O3SCl 
[M+H]+ calcd.: 480.1149, found: 480.1149. 
4-((S)-1-((S)-2-(Benzylthio)-4-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-yl)-2-
nitroethyl)benzonitrile (67Ak) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-4-(2-nitrovinyl)benzonitrile 36k (0.4 mmol, 69.6 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 
95:5 mixture of diastereomers (orange oil). Yield: 0.18 mmol, 82.7 mg, 88%. [α]D
25= –
27.32 (c = 0.3, 99:1 dr, 96% ee, CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 7.70 – 6.75 (m, 
14H), 4.87 – 4.56 (m, 2H), 4.48 – 4.20 (m, 2H), 4.03 (dd, J = 10.5, 4.9 Hz, 1H), 1.37 (s, 
1H). 13C NMR (75 MHz, CDCl3) δ: 181.2, 161.7, 140.8, 135.9, 132.2, 131.5, 130.2, 129.8, 
129.0, 128.9, 128.1, 127.1, 118.5, 112.4, 75.1, 72.7, 49.8, 34.8, 22.8. UPLC-DAD-QTOF: 
C26H23N4O3S [M+H]
+ calcd.: 471.1491, found: 471.1491. 
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 (S)-2-(Benzylthio)-4-((S)-1-(4-methoxyphenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Al) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-methoxy-4-(2-nitrovinyl)benzene 36l (0.4 mmol, 71.6 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 
95:5 mixture of diastereomers (colourless oil). Yield: 0.17 mmol, 80.8 mg, 85%. 1H NMR 
(300 MHz, CDCl3) δ: 7.48 – 7.25 (m, 10H), 7.09 – 7.07 (m, 2H), 6.87 – 6.84 (m, 2H), 4.81 
(dd, J = 12.9, 10.3 Hz, 0H), 4.66 (dd, J = 12.9, 5.3 Hz, 1H), 4.41 – 4.34 (m, 2H), 3.97 (dd, J 
= 10.3, 5.2 Hz, 1H), 3.83 (s, 3H), 1.42 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.9, 160.9, 
159.5, 136.0, 131.8, 131.0, 130.4, 130.0, 129.6, 129.5, 129.4, 129.2, 128.8, 128.1, 
127.9, 127.9, 127.6, 127.4, 127.3, 127.1, 75.9, 73.3, 55.4, 49.4, 34.9, 22.7. UPLC-DAD-
QTOF: C26H26N3O4S [M+H]
+ calcd.: 476.1644, found: 476.1645. 
(S)-2-(Benzylthio)-4-((S)-1-(3-methoxyphenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Am) 
The title compound was prepared from 2-(benzylthio)-4-methyl-
1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 mg) and 
(E)-1-methoxy-3-(2-nitrovinyl)benzene 36m (0.4 mmol, 71.6 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a orange oil. Yield: 0.19 
mmol, 89.3 mg, 94%. [α]D
25= –20.02 (c = 1.00, >98:2 dr, 98% ee, CH2Cl2).
 1H NMR (300 
MHz, CDCl3) δ: 7.52 – 6.84 (m, 14H), 4.84 (dd, J = 13.1, 9.9 Hz, 1H) 4.69 (dd, J = 13.1, 
5.3 Hz, 1H), 4.36 (s, 2H) 4.02 (dd, J = 9.9, 5.3 Hz, 1H), 3.81 (s, 3H), 1.44 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ: 181.8, 161.1, 159.6, 136.9, 135.8, 131.8, 129.6, 129.5, 129.2, 128.8, 
128.0, 127.3, 121.5, 115.3, 75.8, 73.1, 55.3, 50.1, 35.0, 22.8. UPLC-DAD-QTOF: 
C26H26N3O4S [M+H]
+ calcd.: 476.1644, found: 476.1649. 
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(S)-2-(Benzylthio)-4-((S)-1-(4-(dimethylamino)phenyl)-2-nitroethyl)-4-methyl-1-
phenyl-1H-imidazol-5(4H)-one (67An) 
The title compound was prepared from 2-(benzylthio)-4-
methyl-1-phenyl-1H-imidazol-5(4H)-one 61A (0.2 mmol, 59.2 
mg) and (E)-N,N-dimethyl-4-(2-nitrovinyl)aniline 36n (0.4 
mmol, 76.8 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on silica 
gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title 
compound as a colourless oil. Yield: 0.18 mmol, 89.8 mg, 92%. [α]D
25= –38.60 (c = 1.00, 
>98:2 dr, 99% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.64 – 6.87 (m, 14H), 4.87 (dd, J 
= 13.1, 10.3 Hz, 1H),  4.72 (dd, J = 13.2, 5.0 Hz, 1H), 4.41 (dd, J = 10.3, 5.0 Hz, 1H), 4.31 
(d, J = 3.0 Hz, 2H), 2.49 (s, 3H), 2.35 (s, 3H), 1.46 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 
160.7, 138.3, 137.5, 135.9, 131.9, 131.6, 131.2, 129.6, 129.4, 129.1, 128.8, 127.9, 
127.3, 126.9, 126.5, 76.1, 73.7, 44.4, 34.8, 22.8, 21.2, 20.3. UPLC-DAD-QTOF: 
C27H28N3O3S [M+H]
+ calcd.: 474.1854, found: 474.1849. 
(S)-4-Benzyl-2-(benzylthio)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-5(4H)-
one (67Ca) 
The title compound was prepared from 4-benzyl-2-(benzylthio)-
1-phenyl-1H-imidazol-5(4H)-one 61C (0.2 mmol, 74.4 mg) and 
(E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60.0 mg) according to 
the general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a 91:9 mixture of diastereomers 
(colourless oil). Yield: 0.18 mmol, 93.8 mg, 90%. 1H NMR (300 MHz, CDCl3) δ: 7.88 – 
7.07 (m, 16H), 7.10 – 6.91 (m, 2H), 6.61 – 6.35 (m, 2H), 4.90 – 4.52 (m, 2H), 4.36 (d, J = 
1.3 Hz, 2H), 4.19 (dd, J = 10.0, 5.2 Hz, 1H), 3.01 (d, J = 12.8 Hz, 1H), 2.83 (d, J = 12.7 Hz, 
1H). 13C NMR (75 MHz, CDCl3) δ: 180.5, 161.6, 136.3, 135.6, 134.2, 131.5, 130.6, 130.5, 
129.6, 129.5, 129.4, 129.2, 128.8, 128.7, 128.5, 128.0, 127.9, 127.3, 127.2, 76.5, 49.5, 
42.5, 34.8. UPLC-DAD-QTOF: C31H28N3O3S [M+H]
+ calcd.: 522.1851, found: 522.1848. 
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(S)-2-(Benzylthio)-4-isobutyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Da) 
The title compound was prepared from 2-(benzylthio)-4-
isobutyl-1-phenyl-1H-imidazol-5(4H)-one 61D (0.2 mmol, 67.2 
mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 60.0 mg) 
according to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting 
with Hex/EtOAc 90:10 to 80:20) to give the title compound as a colourless oil. Yield: 
0.18 mmol, 87.7 mg, 90%. [α]D
25= –16.85 (c = 0.25, >98:2 dr, 99% ee, CH2Cl2).
 1H NMR 
(300 MHz, CDCl3) δ: 7.57 – 7.21 (m, 14H), 6.98 – 6.86 (m, 1H), 5.06 (dd, J = 13.2, 10.9 
Hz, 1H), 4.83 (dd, J = 13.2, 4.6 Hz, 1H), 4.32 (s, 2H), 4.04 (dd, J = 10.9, 4.7 Hz, 1H), 1.98 
– 1.82 (m, 2H), 1.75 – 1.60 (m, 1H), 0.92 (dd, J = 12.2, 6.6 Hz, 6H). 13C NMR (75 MHz, 
CDCl3) δ: 181.6, 160.5, 136.0, 134.8, 131.8, 129.6, 129.4, 129.4, 129.3, 129.2, 128.8, 
128.7, 128.3, 127.9, 127.4, 127.1, 76.3, 75.0, 50.9, 44.6, 34.9, 24.9, 24.5, 23.4. UPLC-
DAD-QTOF: C28H30N3O3S [M+H]
+ calcd.: 488.2008, found: 488.2011. 
(S)-2-(Benzylthio)-4-(2-(methylthio)ethyl)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-
imidazol-5(4H)-one (67Fa) 
The title compound was prepared from 2-(benzylthio)-4-(2-
(methylthio)ethyl)-1-phenyl-1H-imidazol-5(4H)-one 61F (0.2 
mmol, 71.2 mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 
60.0 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on 
silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the 
title compound as colourless oil. Yield: 0.17 mmol, 85.9 mg, 85%. [α]D
25= –29.64 (c = 
0.40, >98:2 dr, 86% ee, CH2Cl2).
  1H NMR (300 MHz, CDCl3) δ: 7.49 – 7.28 (m, 13H), 7.07 
– 7.02 (m, 2H), 4.92 (dd, J = 13.1, 10.4 Hz, 1H), 4.76 (dd, J = 13.1, 5.0 Hz, 1H), 4.42 – 
4.29 (m, 2H), 4.06 (dd, J = 10.4, 5.0 Hz, 1H), 2.41 – 2.09 (m, 4H), 2.05 (s, 3H). UPLC-
DAD-QTOF: C27H28N3O3S2 [M+H]
+ calcd.: 506.1572, found: 506.1569. 
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Methyl 3-((S)-2-(Benzylthio)-4-((S)-2-nitro-1-phenylethyl)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-4-yl)propanoate (67Ia) 
 The title compound was prepared from methyl 3-
(2(benzylthio)-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-
yl)propanoate 61I (0.2 mmol, 73.6 mg) and (E)-(2-
nitrovinyl)benzene 36a (0.4 mmol, 60.0 mg) according to the 
general procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 
90:10 to 80:20) to give the title compound as a yellow foam. Yield: 0.18 mmol, 93.1 
mg, 90%. [α]D
25= –23.48 (c = 0.75, >98:2 dr, 99% ee, CH2Cl2).
 1H NMR (300 MHz, CDCl3) 
δ: 7.66 – 7.23 (m, 3H), 7.13 – 6.92 (m, 2H), 4.92 (dd, J = 13.1, 10.5 Hz, 1H), 4.46 – 4.25 
(m, 1H), 4.46 – 4.25 (m, 2H), 4.05 (dd, J = 10.5, 5.0 Hz, 1H), 3.68 (s, 3H), 2.30 – 2.08 (m, 
4H). 13C NMR (75 MHz, CDCl3) δ: 180.7, 172.7, 162.1, 135.9, 134.7, 131.6, 130.00, 
129.3, 129.2, 128.8, 128.5, 128.0, 127.3, 52.0, 49.7, 34.9, 30.8, 28.7. UPLC-DAD-QTOF: 
C28H28N3O5S [M+H]
+ calcd.: 518.1750, found: 518.1760. 
(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-3-(p-tolyl)-1H-imidazol-
5(4H)-one (68Aa) 
The title compound was prepared from 2-(benzylthio)-4-
methyl-1-(p-tolyl)-1H-imidazol-5(4H)-one 62A (0.2 mmol, 
62.0 mg) and (E)-(2-nitrovinyl)benzene 36a (0.4 mmol, 
60.0 mg) according to the general procedure. The crude 
material was purified by flash column chromatography on 
silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give the title compound as a 93:7 
mixture of diastereomers (yellow oil). Yield: 0.18 mmol, 81.7 mg, 89%. 1H NMR (300 
MHz, CDCl3) δ: 7.46 – 7.21 (m, 11H), 6.99 – 6.88 (m, 2H), 4.89 (dd, J = 13.1, 10.2 Hz, 
1H), 4.73 (dd, J = 13.1, 5.2 Hz, 1H), 4.45 – 4.27 (m, 2H), 4.04 (dd, J = 10.2, 5.2 Hz, 1H), 
2.39 (s, 3H), 1.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.9, 161.2, 139.7, 136.0, 135.2, 
130.2, 129.2, 129.1, 129.0, 128.7, 128.4, 128.3, 127.9, 127.1, 50.1, 34.8, 22.7, 21.3. 
UPLC-DAD-QTOF: C26H26N3O3S [M+H]
+ calcd.: 460.1695, found: 460.1700. 
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(S)-2-(Benzylthio)-1-(4-chlorophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (69Aa) 
The title compound was prepared from 2-(benzylthio)-
1-(4-chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one 
63A (0.2 mmol, 66.0 mg) and (E)-(2-nitrovinyl)benzene 
36a (0.4 mmol, 60.0 mg) according to the general 
procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give 
the title compound as a colourless oil. Yield: 0.18 mmol, 86.2 mg, 90%. [α]D
25= –12.73 
(c = 0.97, >98:2 dr, 94% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.51 – 7.22 (m, 12H), 
6.97 (d, J = 8.7 Hz, 2H), 4.94 – 4.68 (m, 2H), 4.35 (d, J = 2.5 Hz, 2H), 4.03 (dd, J = 9.8, 5.6 
Hz, 1H), 1.44 (s, 1H).  13C NMR (75 MHz, CDCl3) δ: 181.6, 160.4, 135.8, 135.5, 135.1, 
130.2, 129.8, 129.2, 128.8, 128.5, 128.5, 128.4, 128.0, 75.5, 73.1, 50.0, 34.9, 22.6. 
UPLC-DAD-QTOF: C25H23N3O3SCl [M+H]
+ calcd.: 480.1149, found: 480.1156. 
(S)-2-(Benzylthio)-1-(4-bromophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (70Aa) 
The title compound  was prepared from 2-(benzylthio)-
1-(4-bromophenyl)-4-methyl-1H-imidazol-5(4H)-one 
64A (0.2 mmol, 74.8 mg) and (E)-(2-nitrovinyl)benzene 
36a (0.4 mmol, 60.0 mg) according to the general 
procedure. The crude material was purified by flash 
column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 80:20) to give 
the title compound as a colourless oil. Yield: 0.17 mmol, 90.0 mg, 86%. [α]D
25= –15.32 
(c = 0.60, >98:2 dr, 99% ee, CH2Cl2).
  1H NMR (300 MHz, CDCl3) δ: 7.56 – 7.51 (m, 2H), 
7.40 – 7.22 (m, 10H), 6.91 – 6.85 (m, 2H), 4.85 (dd, J = 13.1, 9.8 Hz, 1H), 4.70 (dd, J = 
13.1, 5.5 Hz, 1H), 4.37 – 4.27 (m, 2H), 4.01 (dd, J = 9.8, 5.6 Hz, 1H), 1.41 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ: 181.5, 160.4, 135.8, 135.1, 132.8, 129.2, 128.8, 128.8, 128.5, 
128.4, 128.0, 123.6, 75.5, 73.2, 50.0, 35.0, 22.6. UPLC-DAD-QTOF: C25H23N3O3SBr 
[M+H]+ calcd.: 524.0644, found: 524.0653. 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1-(4-methoxyphenyl)-4-
methyl-1H-imidazol-5(4H)-one (71Ad) 
The title compound was prepared from 2-(benzylthio)-
1-(4-methoxyphenyl)-4-methyl-1H-imidazol-5(4H)-one 
65A (0.2 mmol, 65.2 mg) and (E)-1-chloro-2-(2-
nitrovinyl)benzene 36d (0.4 mmol, 73.2 mg) according 
to the general procedure. The crude material was 
purified by flash column chromatography on silica gel (eluting with Hex/EtOAc 90:10 to 
80:20) to give the title compound as a yellow oil. Yield: 0.18 mmol, 92.6 mg, 91%. 
[α]D
25= –32.62 (c = 0.82, >98:2 dr, 94% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.56 – 
7.23 (m, 8H), 7.07 (d, J = 8.9 Hz, 2H), 6.96 (d, J = 8.9 Hz, 2H), 4.90 – 4.62 (m, 1H), 4.36 
(s, 2H), 3.84 (s, 3H), 1.44 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.8, 161.9, 160.3, 136.3, 
135.9, 133.6, 130.1, 129.3, 129.0, 128.8, 128.6, 127.9, 126.0, 124.2, 114.9, 75.4, 73.2, 
55.6, 44.8, 34.8, 22.4. UPLC-DAD-QTOF: C26H25N3O4SCl [M+H]
+ calcd.: 510.1254, found: 
510.1254. 
(S)-2-(Benzylthio)-1-(3-chlorophenyl)-4-((S)-1-(4-methoxyphenyl)-2-nitroethyl)-4-
methyl-1H-imidazol-5(4H)-one (72Al) 
The title compound was prepared from 2-(benzylthio)-1-(3-
chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one 66A (0.2 
mmol, 66.0 mg) and (E)-1-methoxy-4-(2-nitrovinyl)benzene 
36l (0.4 mmol, 71.6 mg) according to the general procedure. 
The crude material was purified by flash column 
chromatography on silica gel (eluting with Hex/EtOAc 90:10 
to 80:20) to give the title compound as a yellow oil. Yield: 0.18 mmol, 91.6 mg, 90%. 
[α]D
25= –20.30 (c = 0.60, >98:2 dr, 87% ee, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ: 7.43 – 
6.82 (m, 13H), 4.89 – 4.65 (m, 2H), 4.36 (d, J = 2.3 Hz, 2H), 3.97 (dd, J = 10.1, 5.4 Hz, 
1H), 3.83 (s, 3H), 1.43 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 181.6, 160.2, 159.6, 135.8, 
135.1, 132.9, 130.5, 130.3, 129.7, 129.2, 128.8, 128.0, 127.6, 126.9, 125.5, 75.7, 73.4, 
55.4, 49.4, 35.0, 22.6. UPLC-DAD-QTOF: C26H25N3O4SCl [M+H]
+ calcd.: 510.1254, found: 
510.1264. 
Chapter 5 
324 
 
5.4.6. Reaction of 61A with vinylketone 1a/41a  
 
To a solution of imidazolone 61A (1 equiv., 0.2 mmol) in dichlorometane (0.6 mL) 
the corresponding vinyl ketone (2.0 equiv., 0.4 mmol) and the catalyst were added at 
room temperature. The resulting mixture was stirred until consumption of the 
nucleophile (monitored by 1H-NMR). Afterwards, the reaction was purified by flash 
column chromatography on silica gel to afford 76 and 76’ in (1:1) proportion. 
(S)-2-(Benzylthio)-4-(4-hydroxy-4-methyl-3-oxopentyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (76) 
White foam. 1H NMR (300 MHz, CDCl3) δ: 7.51 – 7.20 
(m, 10H), 4.40 – 4.26 (m, 2H), 3.72 (s, 1H), 2.69 – 2.46 
(m, 2H), 2.27 – 2.06 (m, 2H), 1.48 (s, 3H), 1.35 (d, J = 2.3 
Hz, 6H). 13C NMR (75 MHz, CDCl3) δ: 213.6, 182.9, 160.0, 
136.0, 132.2, 129.5, 129.3, 128.7, 127.8, 127.3, 76.4, 71.0, 34.8, 31.9, 30.1, 26.7, 26.7, 
23.3. UPLC-DAD-QTOF: C23H27N2O3S [M+H]
+ calcd.: 410.1664, found: 410.1666. 
2-(Benzylthio)-2-(4-hydroxy-4-methyl-3-oxopentyl)-4-methyl-1-phenyl-1H-imidazol-
5(2H)-one (76’) 
White foam. 1H NMR (300 MHz, CDCl3) δ: 7.45 – 7.11 (m, 10H), 
5.44 (d, J = 1.3 Hz, 1H), 4.53 (dd, J = 10.3, 8.9 Hz, 1H), 4.46 – 
4.21 (m, 2H), 3.41 – 3.29 (m, 1H), 2.74 (dd, J = 16.8, 8.9 Hz, 1H), 
1.50 (s, 3H), 1.27 (d, J = 1.4 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ: 
215.6, 174.9, 173.4, 137.0, 136.7, 129.1, 128.9, 128.7, 127.6, 
125.3, 120.6, 82.5, 78.0, 47.6, 43.5, 35.6, 27.5, 27.4, 23.2. UPLC-DAD-QTOF: 
C23H27N2O3S [M+H]
+ calcd.: 410.1664, found: 410.1667. 
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5.4.7. Reaction of thiohydantoins 29C, 55A, 78 and 80 with 36a  
 
To a solution of thiohidantoin 29C (1 equiv., 0.2 mmol) in dichlorometane (0.6 mL) 
nitroalkene 36a (2.0 equiv., 0.4 mmol) and the catalyst were added at 0 oC. The 
resulting mixture was stirred for 24h and no reation was observed (monitored by 1H-
NMR). 
 
To a solution of thiohidantoin 55A (1 equiv., 0.2 mmol) and nitroalkene 36a (2.0 equiv., 
0.4 mmol) in dichlorometane (0.6 mL) the catalyst was added at 0 oC. The resulting 
mixture was stirred until consumption of the thiohidantoin (monitored by 1H-NMR). 
Afterwards, the reaction was directly submitted to flash column chromatography on 
silica gel to afford the adduct 77 essentially pure. Yield: 56.8 mg, 0.16 mmol, 80%. Dr 
1.9:1, 94% ee. 
 
To a solution of thiohidantoin 78 (1 equiv., 0.2 mmol) and nitroalkene 36a (2.0 equiv., 
0.4 mmol) in dichlorometane (0.6 mL) the catalyst was added at 0 oC. The resulting 
mixture was stirred until consumption of the thiohidantoin (monitored by 1H-NMR). 
Afterwards, the reaction was directly submitted to flash column chromatography on 
silica gel to afford the adduct 79 essentially pure. Yield: 43.9 mg, 0.15 mmol, 76%. Dr 
1:1, 10% ee. 
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To a solution of thiohidantoin 80 (1 equiv., 0.2 mmol) in dichlorometane (0.6 mL) 
nitroalkene 36a (2.0 equiv., 0.4 mmol) and the catalyst were added at 0 oC. The 
resulting mixture was stirred for 24h and no reation was observed (monitored by 1H-
NMR).  
 
5.4.8. Elaboration of adducts  
5.4.8.1. Conversion of adduct 38Ca to 47 
 
Adduct 38Ca (549 mg, 1.0 mmol, 1 equiv.) was dissolved in 1,4-dioxane (2 mL/mmol). 
The solution was cooled to 0 °C and an aqueous solution of HCl 6M (1.9 mL, 11 mmol, 
11 equiv.) was added. The reaction mixture was stirred at 65 oC for 3 h. Afterwards 12 
equiv. more of HCl 6M were added and the reaction was stirred at 65 oC for an 
additional 3 h. Then, the reaction mixture was cooled to 0 °C, and a saturated solution 
of NaHCO3 was added until basic pH was obtained. The aqueous layer was extracted 
with CH2Cl2 (2x 5mL) and the combined organic phases were dried over MgSO4. The 
solvent was evaporated under reduced pressure and the resulting crude product was 
purified by silica gel flash column chromatography (hexane/ethyl acetate, 90:10 to 
70:30) to obtain the desired product as a white solid. m. p.: 239–243oC. Yield: 354 mg, 
0.80 mmol, 80%. [α]D
25= –25.30 (c = 1.00, >98:2 dr, 99% ee, CH2Cl2).
  1H NMR (300 MHz, 
CD3Cl) δ: 7.52 (s, 1H), 7.50 – 7.13 (m, 13H), 7.06 – 6.50 (m, 2H), 5.53 – 5.26 (m, 2H), 
5.08 (dd, J = 10.4, 4.8 Hz, 1H), 4.05 (d, J = 13.2 Hz, 1H), 3.59 (d, J = 13.2 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ: 172.4, 169.5, 150.9, 134.2, 133.1, 132.0, 129.8, 129.5, 129.4, 
129.1, 128.3, 127.8, 127.7, 75.9, 74.3, 47.6, 39.4. UPLC-DAD-QTOF: C25H22N3O5 [M+H]
+ 
calcd.: 444.1559, found: 444.1556. 
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5.4.8.2. Synthesis of 48 by saponification of 47 
 
N-Benzoylimide 47 (221.5 mg, 0.5 mmol, 1 equiv.) was dissolved in dioxane (2.5 mL). 
The solution was cooled to 0 °C and an aqueous solution of NaOH 6M (890 μL, 5.5 
mmol, 11 equiv.) was added. The reaction mixture was stirred at 100 oC for 2 h. After 
reaction completion, the reaction mixture was cooled to 0 °C, and a saturated solution 
of NH4Cl (sat.) was added until slightly acid pH. The aqueous layer was extracted with 
CH2Cl2 (2 x 5 mL) and the combined organic phases were dried over MgSO4. The 
solvent was evaporated under reduced pressure and the resulting crude product was 
purified by silica gel flash column chromatography (hexane/ethyl acetate, 80:20 to 
50:50) to obtain the desired product as a white solid. m. p.: 257–261 oC. Yield: 130.5 
mg, 0.39 mmol, 77%. [α]D
25= –30.40 (c = 0.85, >98:2 dr, 99% ee, CH2Cl2). 
1H NMR (300 
MHz, CD3Cl) δ: 7.40 (d, J = 4.1 Hz, 4H), 7.30 – 7.15 (m, 5H), 5.29 – 4.99 (m, 2H), 4.02 
(dd, J = 11.2, 4.4 Hz, 1H), 3.21 (d, J = 13.5 Hz, 1H), 2.67 (d, J = 13.4 Hz, 1H). 13C NMR (75 
MHz, MeOD) δ: 177.6, 158.5, 136.0, 135.1, 131.4, 130.2, 129.8, 129.5, 129.23, 128.3, 
76.8, 70.5, 51.2, 42.5. UPLC-DAD-QTOF: C18H18N3O4 [M+H]
+ calcd.: 340.1297, found: 
340.1290. 
5.4.8.3. Synthesis of adduct 48 by acid hydrolysis of 39Ca 
 
The reaction adduct 39Ca (545 mg, 1.0 mmol, 1 equiv.) was dissolved in dioxane (5 
mL). The solution was cooled to 0 °C and an aqueous solution of HCl 6M (1.9 mL, 11 
mmol, 11 equiv.) was added. The reaction mixture was stirred at 65 oC for 3 h. 
Afterwards 12 equiv. more of HCl 6M were added and the reaction stirred at 65 oC for 
additional 3 h. Then, the reaction mixture was cooled to 0 °C, and a saturated solution 
of NaHCO3 was added until basic pH was obtained. The aqueous layer was extracted 
with CH2Cl2 (2 x 5 mL) and the combined organic phases were dried over MgSO4. The 
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solvent was evaporated under reduced pressure and the resulting crude product was 
purified by silica gel flash column chromatography (hexane/ethyl acetate, 80:20 to 
20:80) to obtain the desired product as a white solid. Yield: 247 mg, 0.73 mmol, 73%.  
5.4.8.4. Synthesis of adduct 49 by N-alkylation of hydantoin 4730  
 
To a mixture of 47 (1 equiv., 0.5 mmol, 222 mg) and 18-crown-6 (1% w/w) in 5 mL of 
dry toluene were added K2CO3 (0.1 equiv., 0.05 mmol, 7 mg) and KI (0.1 equiv., 0.05 
mmol, 8.3 mg). After stirring for 20 min, BnBr (1.1 equiv., 0.55 mmol, 65.4 μL) in 10 mL 
of dry toluene was added dropwise. The mixture was then refluxed for 36 h and 
cooled. After filtration over a short column of celite, the organic phase was 
concentrated under reduced pressure and the crude was purified by silica gel flash 
column chromatography (hexane/ethyl acetate, 90:10 to 70:30) ) to obtain the desired 
product as a white foam. Yield: 173 mg, 0.325 mmol, 65%. [α]D
25= –34.76 (c = 0.50, 
>98:2 dr, 99% ee, CH2Cl2). 
1H NMR (300 MHz, CD3Cl) δ: 7.48 – 6.97 (m, 20H), 6.80 – 
6.76 (m, 2H), 5.36 – 5.28 (m, 2H), 5.04 (dd, J = 9.8, 5.4 Hz, 1H), 4.32 (s, 2H), 4.00 (d, J = 
13.1 Hz, 1H), 3.57 (d, J = 13.1 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ: 172.7, 169.9, 152.5, 
135.2, 134.7, 134.6, 133.6, 132.2, 130.5, 130.1, 129.9, 129.8, 129.6, 129.5, 129.4, 
129.0, 128.8, 128.6, 128.2, 128.1, 76.6, 72.8, 48.2, 43.4, 39.9. UPLC-DAD-QTOF: 
C32H28N3O5 [M+H]
+ calcd.: 534.2029, found: 534.2036.  
5.4.9. Synthesis of ADAMTS inhibitors 53 and 54  
Synthesis of (R)-5-(4-Hydroxy-4-methyl-3-oxopentyl)-5-phenylimidazolidine-2,4-
dione (50) 
 
                                                 
30
 Pesquet, A.; Van Hijfte, L.; Daïch A. ARKIVOC 2010, 27. 
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Adduct 46H (496 mg, 1.0 mmol, 1 equiv.) was dissolved in dioxane (5 mL). The solution 
was cooled to 0 °C and an aqueous solution of HCl 6M (1.9 mL, 11 mmol, 11 equiv.) 
was added. The reaction mixture was stirred at 65 oC (bath temperature) for 3 h. 
Afterwards 12 equiv. more of HCl 6M were added and the reaction was stirred at 65 oC 
for additional 3 h. Then, the reaction mixture was cooled to 0 °C, and a saturated 
solution of NaHCO3 was added until basic pH was obtained. The aqueous layer was 
extracted with CH2Cl2 (2 x 5 mL) and the combined organic phases were dried over 
MgSO4. The solvent was evaporated under reduced pressure and the resulting crude 
product was purified by silica gel flash column chromatography (hexane/ethyl acetate, 
80:20 to 0:100) to obtain the desired product as a white solid. m. p.: 205–209 oC. Yield: 
212 mg, 0.73 mmol, 73%. [α]D
25= –17.54 (c = 0.40, 99% ee, CH2Cl2). 
1H NMR (300 MHz, 
MeOD) δ: 7.63 – 7.53 (m, 2H), 7.51 – 7.30 (m, 3H), 2.80 – 2.66 (m, 2H), 2.45 – 2.29 (m, 
2H), 1.27 (d, J = 1.6 Hz, 6H). 13C NMR (75 MHz, MeOD) δ: 215.7, 178.1, 159.0, 139.7, 
129.8, 129.4, 126.5, 77.9, 69.1, 33.3, 31.8, 26.7. UPLC-DAD-QTOF: C15H19N2O4 [M+H]
+ 
calcd.: 291.1345, found: 291.1353. 
Synthesis of (R)-3-(2,5-dioxo-4-phenylimidazolidin-4-yl)propanoic acid (51) 
 
Hydantoin 50 (290 mg, 1 mmol, 1 equiv.) was dissolved in dioxane (10 mL) and HIO4 
(1.36 g, 6 mmol, 6 equiv.) was added. The solution was stirred at room temperature for 
1 h. The reaction mixture was then diluted with brine (15 mL) and extracted with 
EtOAc (3 x 20 mL). The organic phase was dried over MgSO4, filtered and concentrated 
under reduced pressure obtaining a white solid. m. p.: 198–200 oC. Yield: 223 mg, 0.9 
mmol, 90%. [α]D
25= –22.94 (c = 0.5, 99% ee, CH2Cl2). 
1H NMR (300 MHz, MeOD) δ: 7.59 
– 7.54 (m, 2H), 7.47 – 7.33 (m, 3H), 2.60 – 2.24 (m, 4H). 13C NMR (75 MHz, MeOD) δ: 
177.8, 175.9, 158.9, 139.4, 129.8, 129.4, 126.5, 69.0, 34.6, 29.7. UPLC-DAD-QTOF: 
C12H13N2O4 [M+H]
+ calcd.: 249.0875, found: 249.0884. 
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Synthesis of (R)-5-(3-oxo-3-(piperidin-1-yl)propyl)-5-phenylimidazolidine-2,4-dione 
(52) 
 
To a solution of acid 51 (1 equiv., 0.5 mmol, 157 mg) in CH2Cl2 (5 mL) were successively 
added piperidine (1 equiv., 0.5 mmol, 49.4 µL), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) (1.4 equiv, 0.7 mmol, 134 mg) and 
hydroxybenzotriazole (HOBt) (1 equiv., 0.5 mmol, 77 mg) at 0 oC and the reaction 
mixture was stirred for 1 h and then 16 h at room temperature. Afterwards, the 
reaction was quenched with H2O (10 mL), extracted with CH2Cl2 (3 x 10 mL), dried over 
MgSO4, filtered and the solvent evaporated. The crude material was purified by flash 
column chromatography on silica gel (eluting wit Hex/EtOAc 80:20 to 0:100) to give 
product 52 as a white solid. m. p.: 201–204 oC. Yield: 102.4 mg, 0.33 mmol, 65%. 
[α]D
25= –34.17 (c = 0.5, 99% ee, CH2Cl2). 
1H NMR (300 MHz, MeOD) δ: 7.62 – 7.55 (m, 
2H), 7.47 – 7.33 (m, 3H), 3.56 – 3.49 (m, 2H), 3.43 – 3.36 (m, 2H), 2.49 – 2.31 (m, 4H), 
1.73 – 1.48 (m, 6H). 13C NMR (75 MHz, MeOD) δ: 177.9, 171.9, 158.9, 139.5, 129.8, 
129.4, 126.5, 69.1, 44.1, 35.1, 28.8, 27.5, 26.6, 25.4. UPLC-DAD-QTOF: C17H22N3O3 
[M+H]+ calcd.: 316.1661, found: 316.1662. 
Synthesis of (R)-5-(3-oxo-3-(4-phenylpiperazin-1-yl)propyl)-5-phenylimidazolidine-
2,4-dione (53): 
 
The above procedure was followed using 1-phenylpiperazine (1 equiv., 0.5 mmol, 75.7 
µL) as the coupling amine partner. White solid. m. p.: 203-207 oC. Yield: 137.2 mg, 0.35 
mmol, 70%.  [α]D
25= –40.36 (c = 1.0, 99% ee, CH2Cl2). 
1H NMR (300 MHz, DMSO-d6) δ: 
10.83 (s, 1H), 8.71 (s, 1H), 7.59 – 7.14 (m, 7H), 6.98 – 6.73 (m, 3H), 3.61 – 3.43 (m, 4H), 
3.12 – 3.05 (m, 4H), 2.47 – 2.10 (m, 4H). 13C NMR (75 MHz, DMSO) δ: 176.0, 169.3, 
156.4, 150.7, 138.5, 129.0, 128.6, 128.0, 125.4, 119.3, 115.8, 66.9, 48.5, 48.2, 44.6, 
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41.0, 33.6, 27.2. UPLC-DAD-QTOF: C22H25N4O3 [M+H]
+ calcd.: 393.1927, found: 
393.1929. 
5.4.9.1. Synthesis of adduct 73 
 
Adduct 67Aa (445 mg, 1.0 mmol, 1 equiv.) was dissolved in 1,4-dioxane (5 mL). The 
solution was cooled to 0 °C and an aqueous solution of HCl 6M (1.9 mL, 11 mmol, 11 
equiv.) was added. The reaction mixture was stirred at room temperature for 3 days. 
Then, the reaction mixture was cooled to 0 °C, and a saturated solution of NaHCO3 was 
added until basic pH was obtained. The aqueous layer was extracted with CH2Cl2 (2 x 
5mL) and the combined organic phases were dried over MgSO4. The solvent was 
evaporated under reduced pressure and the resulting crude product was purified by 
silica gel flash column chromatography (hexane/ethyl acetate, 80:20 to 0:100) to 
obtain the desired product as a white solid. Yield: 271 mg, 0.80 mmol, 80%. m. p. 169–
172 oC. [α]D
25= –23.55 (c = 0.60, >98:2 dr, 99% ee, CH2Cl2).
 1H NMR (300 MHz, CDCl3) δ: 
7.70 – 7.03 (m, 10H), 6.74 (s, 1H), 5.31 – 4.63 (m, 2H), 3.98 (dd, J = 10.4, 5.0 Hz, 1H), 
1.52 (s, 3H). 13C NMR (75 MHz, Acetone) δ: 182.9, 175.9, 135.3, 134.3, 129.9, 129.7, 
129.6, 129.6, 129.5, 75.6, 66.8, 51.1, 22.2. UPLC-DAD-QTOF: C18H18N3O4 [M+H]
+ calcd.: 
340.1297, found: 340.1304. 
5.4.9.2. Conversion of 73 to thiohydantoin 74 from adduct 67Aa 
 
A suspension of hydantoin 73 (0.5 mmol) and Lawesson’s reagent (202.2 mg, 0.5 
mmol) in 2.3 mL of dry dioxane was refluxed for 24 h. The mixture was then 
concentrated, and the residue was submitted to flash chromatography on silica gel, 
eluent hexane/ethyl acetate (80:20 to 50:50) to afford 74 as a white solid. Yield: 149 
mg, 0.42 mmol, 84%. m. p. 235–237 oC. [α]D
25= –29.01 (c = 1.00, >98:2 dr, 99% ee, 
CH2Cl2). 
1H NMR (300 MHz, Acetone) δ: 9.51 (s, 1H), 7.46 – 7.36 (m, 8H), 7.07 – 7.00 
(m, 2H), 5.38 – 5.24 (m, 2H), 4.12 (dd, J = 9.8, 6.2 Hz, 1H), 1.74 (s, 4H). 13C NMR (75 
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MHz, Acetone) δ: 182.80, 175.81, 135.25, 134.20, 129.76, 129.62, 129.57, 129.48, 
129.45, 129.41, 75.47, 66.76, 50.98, 22.15. UPLC-DAD-QTOF: C18H18N3O3S [M+H]
+ 
calcd.: 356.1069, found: 356.1069. 
5.4.9.3. Conversion of 73 to acid 75 
 
A solution of 73 (0.19 mmol, 64 mg), sodium nitrite (3 equiv., 0.55 mmol, 34 mg) and 
acetic acid (10 equiv., 1.9 mmol, 120 µL) in DMSO (0.5 mL) was stirred at 35 oC for 6 h. 
After this period, the reaction mixture was quenched with HCl 1N (5 mL) and the 
product was extracted with Et2O (4 x 5 mL). The combined organic phases were dried 
with anhyd. MgSO4 and filtered. Evaporation of the solvent under reduced pressure 
and ulterior washing of the solid with Et2O gave essentially pure 75 as orange foam. 
Yield: 48.6 mg, 0.15 mmol, 79%. [α]D
25= –32.99 (c = 1.00, >98:2  dr, 99% ee, CH2Cl2). 
1H 
NMR (300 MHz, Acetone) δ: 7.51 – 7.33 (m, 10H), 7.24 (s, 1H), 4.23 (s, 1H), 2.57 (s, 3H), 
1.36 (s, 3H). 13C NMR (75 MHz, Acetone) δ: 206.3, 176.7, 172.5, 156.6, 135.2, 134.0, 
131.1, 129.4, 129.4, 128.8, 128.4, 127.6, 62.6, 56.9, 24.0. UPLC-DAD-QTOF: 
C18H18N3O3S [M+H]
+ calcd.: 325.1183, found: 325.1190.
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5.4.10.  X-Ray analysis: ORTEP diagram of compounds 47 and 74 
CCDC 1581118 contains the supplementary crystallographic data for the structural 
analysis of 47. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/deposit/. 
 
CCDC 1581122 contains the supplementary crystallographic data for the structural 
analysis of 74 derivate. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/deposit/. 
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5.4.11.  1H and 13C NMR Spectra 
1-Acetyl-5-benzyl-2-thioxoimidazolidin-4-one (28) 
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1-Benzoyl-5-methyl-2-thioxoimidazolidin-4-one (29A) 
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1-Benzoyl-5-ethyl-2-thioxoimidazolidin-4-one (29B) 
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1-Benzoyl-5-benzyl-2-thioxoimidazolidin-4-one (29C) 
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1-Benzoyl-5-isobutyl-2-thioxoimidazolidin-4-one (29D) 
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1-Benzoyl-5-hexyl-2-thioxoimidazolidin-4-one (29E) 
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tert-Butyl 5-methyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30A) 
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tert-Butyl 5-ethyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30B) 
 
 
 
Chapter 5 
342 
 
tert-Butyl 5-benzyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30C) 
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tert-Butyl 5-isobutyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30D) 
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tert-Butyl 5-hexyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (30E) 
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tert-Butyl 5-((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (30G) 
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tert-Butyl 4-oxo-5-phenyl-2-thioxoimidazolidine-1-carboxylate (30H) 
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Benzyl 5-benzyl-4-oxo-2-thioxoimidazolidine-1-carboxylate (31C) 
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Benzyl 5-((benzyloxy)methyl)-4-oxo-2-thioxoimidazolidine-1-carboxylate (31G) 
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1-Acetyl-5-benzyl-2-(benzylthio)-1H-imidazol-4(5H)-one (32C) 
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1-Benzoyl-2-(benzylthio)-5-methyl-1H-imidazol-4(5H)-one (33A) 
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1-Benzoyl-2-(benzylthio)-5-ethyl-1H-imidazol-4(5H)-one (33B) 
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1-Benzoyl-5-benzyl-2-(benzylthio)-1H-imidazol-4(5H)-one (33C) 
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1-Benzoyl-2-(benzylthio)-5-isobutyl-1H-imidazol-4(5H)-one (33D) 
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1-Benzoyl-2-(benzylthio)-5-hexyl-1H-imidazol-4(5H)-one (33E)  
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1-Benzoyl-5-benzyl-2-(benzylthio)-1H-imidazol-4(5H)-one (33F) 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-methyl-1H-imidazol-4(5H)-one (34A) 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-ethyl-1H-imidazol-4(5H)-one (34B) 
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5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-one (34C) 
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2-(Benzylthio)- 1-(tert-butyloxycarbonyl)-5-isobutyl-1H-imidazol-4(5H)-one (34D) 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-hexyl-1H-imidazol-4(5H)-one (34E) 
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5-((Benzyloxy)methyl)-2-(benzylthio)-1-(tert-butyloxycarbonyl)-1H-imidazol-4(5H)-
one (34G) 
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2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-phenyl-1H-imidazol-4(5H)-one (34H) 
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1-(Benzyloxycarbonyl)-2-(benzylthio)-5-methyl-1H-imidazol-4(5H)-one (35A) 
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5-Benzyl-1-(benzyloxycarbonyl)-2-(benzylthio)-1H-imidazol-4(5H)-one (35C) 
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1-(Benzyloxycarbonyl)-5-((benzyloxy)methyl)-2-(benzylthio)-1H-imidazol-4(5H)-one 
(35G) 
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5-Methyl-3-phenyl-2-thioxoimidazolidin-4-one (55A) 
 
5-Benzyl-3-phenyl-2-thioxoimidazolidin-4-one (55C) 
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5-Isobutyl-3-phenyl-2-thioxoimidazolidin-4-one (55D) 
 
5-(2-(Methylthio)ethyl)-3-phenyl-2-thioxoimidazolidin-4-one (55F) 
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Methyl 3-(5-oxo-1-phenyl-2-thioxoimidazolidin-4-yl)propanoate (55I) 
 
  
Experimental section 
369 
 
5-Methyl-2-thioxo-3-(p-tolyl)imidazolidin-4-one (56A) 
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3-(4-Chlorophenyl)-5-methyl-2-thioxoimidazolidin-4-one (57A) 
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3-(4-Bromophenyl)-5-methyl-2-thioxoimidazolidin-4-one (58A) 
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3-(4-Methoxyphenyl)-5-methyl-2-thioxoimidazolidin-4-one (59A) 
 
 
 
Experimental section 
373 
 
3-(3-Chlorophenyl)-5-methyl-2-thioxoimidazolidin-4-one (60A) 
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2-(Benzylthio)-4-methyl-1-phenyl-1H-imidazol-5(4H)-one (61A) 
 
 
 
Experimental section 
375 
 
4-Benzyl-2-(benzylthio)-1-phenyl-1H-imidazol-5(4H)-one (61C) 
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2-(Benzylthio)-4-isobutyl-1-phenyl-1H-imidazol-4(5H)-one (61D) 
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2-(Benzylthio)-4-(2-(methylthio)ethyl)-1-phenyl-1H-imidazol-5(4H)-one (61F) 
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Methyl 3-(2-(benzylthio)-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-yl)propanoate 
(61I) 
 
 
 
Experimental section 
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2-(Benzylthio)-4-methyl-1-(p-tolyl)-1H-imidazol-5(4H)-one (62A) 
 
 
 
Chapter 5 
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2-(Benzylthio)-1-(4-chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one (63A) 
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2-(Benzylthio)-1-(4-bromophenyl)-4-methyl-1H-imidazol-5(4H)-one (64A) 
 
 
 
 
Chapter 5 
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2-(Benzylthio)-1-(4-methoxyphenyl)-4-methyl-1H-imidazol-5(4H)-one (65A) 
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2-(Benzylthio)-1-(3-chlorophenyl)-4-methyl-1H-imidazol-5(4H)-one (66A) 
 
 
 
Chapter 5 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (37Ca) 
 
 
Experimental section 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (37Cb) 
 
 
Chapter 5 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-4(5H)-
one (37Cc) 
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(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-methyl-1H-
imidazol-4(5H)-one (38Ad) 
 
 
 
Chapter 5 
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(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-ethyl-1H-
imidazol-4(5H)-one (38Bd) 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one (38Ca) 
 
 
 
Chapter 5 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cb) 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-
4(5H)-one (38Cc)  
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cd) 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(3-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Ce) 
 
 
Chapter 5 
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 (S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(furan-3-yl)-2-nitroethyl)-1H-imidazol-
4(5H)-one (38Cg) 
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(S)-1-Benzoyl-2-(benzylthio)-5-isobutyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one(38Da) 
 
 
Chapter 5 
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(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (38Ea) 
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397 
 
(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-(2-
(methylthio)ethyl)-1H-imidazol-4(5H)-one (38Fd) 
 
 
Chapter 5 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-4-methyl-1-nitropentan-2-yl)-1H-
imidazol-4(5H)-one (38Ch) 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-nitropentan-2-yl)-1H-imidazol-4(5H)-
one (38Ci) 
 
 
 
Chapter 5 
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 (S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-
5-methyl-1H-imidazol-4(5H)-one (39Ad) 
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(S)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-2-nitro-1-phenylethyl)-
1H-imidazol-4(5H)-one (39Ca) 
 
 
Chapter 5 
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(R)-5-((Benzyloxy)methyl)-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)- 1H-imidazol-4(5H)-one (39Gd) 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-2-nitro-1-phenylethyl)-5-phenyl-
1H-imidazol-4(5H)-one (39Ha) 
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(S)-5-Benzyl-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-4(5H)-one (40Ca) 
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(R)-5-((Benzyloxy)methyl)-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)-1H-imidazol-4(5H)-one (49Gd) 
 
 
 
Chapter 5 
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(S)-1-Benzoyl-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Aa) 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ca) 
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(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ea) 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ca) 
 
 
 
Chapter 5 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-isobutyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Da) 
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(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ea) 
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(S)-1-(Benzyloxycarbonyl)-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-
one (44Aa) 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxo-3-phenylpropyl)-1H-imidazol-4(5H)-
one (42Cb) 
 
 
 
Chapter 5 
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(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-ethyl-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Bb) 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Cb) 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-1H-
imidazol-4(5H)-one (43Cc) 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-(4-chlorophenyl)-3-
oxopropyl)-1H-imidazol-4(5H)-one (43Cd) 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-5-phenyl-1H-
imidazol-4(5H)-one (43Hc) 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(4-hydroxy-4-methyl-3-oxopentyl)-1H-
imidazol-4(5H)-one (45C) 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-
oxopentyl)-1H-imidazol-4(5H)-one (46C) 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-oxopentyl)-5-
phenyl-1H-imidazol-4(5H)-one (46H) 
 
 
 
Chapter 5 
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(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-5(4H)-
one (67Aa) 
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(S)-2-(Benzylthio)-4-((S)-1-(4-bromophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ab) 
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(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-(p-tolyl)ethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Ac) 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ad) 
 
 
 
Chapter 5 
426 
 
 
(S)-2-(Benzylthio)-4-((S)-1-(3-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ae) 
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(S)-2-(Benzylthio)-4-((S)-1-(4-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Aj) 
 
 
 
Chapter 5 
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4-((S)-1-((S)-2-(Benzylthio)-4-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-yl)-2-
nitroethyl)benzonitrile (67Ak) 
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(S)-2-(Benzylthio)-4-((S)-1-(3-methoxyphenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Am) 
 
 
 
Chapter 5 
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(S)-2-(Benzylthio)-5-((S)-1-(4-(dimethylamino)phenyl)-2-nitroethyl)-5-methyl-3-
phenyl-1H-imidazol-5(4H)-one (67An) 
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(S)-4-Benzyl-2-(benzylthio)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-5(4H)-
one (67Ca) 
 
 
 
Chapter 5 
432 
 
(S)-2-(Benzylthio)-4-isobutyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Da) 
 
 
 
Experimental section 
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(S)-2-(Benzylthio)-4-(2-(methylthio)ethyl)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-
imidazol-5(4H)-one (67Fa) 
 
  
Chapter 5 
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Methyl 3-((S)-2-(Benzylthio)-4-((S)-2-nitro-1-phenylethyl)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-4-yl)propanoate (67Ia) 
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(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-3-(p-tolyl)-1H-imidazol-
5(4H)-one (68Aa) 
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(S)-2-(Benzylthio)-1-(4-chlorophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (69Aa) 
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(S)-2-(Benzylthio)-1-(4-bromophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (70Aa) 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1-(4-methoxyphenyl)-4-
methyl-1H-imidazol-5(4H)-one (71Ad) 
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(S)-2-(Benzylthio)-1-(3-chlorophenyl)-4-((S)-1-(4-methoxyphenyl)-2-nitroethyl)-4-
methyl-1H-imidazol-5(4H)-one (72Al) 
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(S)-2-(Benzylthio)-4-(4-hydroxy-4-methyl-3-oxopentyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (76) 
 
 
 
Experimental section 
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2-(Benzylthio)-2-(4-hydroxy-4-methyl-3-oxopentyl)-4-methyl-1-phenyl-1H-imidazol-
5(2H)-one (76’) 
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(S)-1-Benzoyl-5-benzyl-5-((S)-2-nitro-1-phenylethyl)imidazolidine-2,4-dione (47) 
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(S)-5-Benzyl-5-((S)-2-nitro-1-phenylethyl)imidazolidine-2,4-dione (48)
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(S)-1-Benzoyl-3,5-dibenzyl-5-((S)-2-nitro-1-phenylethyl)imidazolidine-2,4-dione (49) 
 
 
 
Experimental section 
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(R)-5-(4-Hydroxy-4-methyl-3-oxopentyl)-5-phenylimidazolidine-2,4-dione (50) 
 
 
 
Chapter 5 
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(R)-3-(2,5-Dioxo-4-phenylimidazolidin-4-yl)propanoic acid (51) 
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(R)-5-(3-Oxo-3-(piperidin-1-yl)propyl)-5-phenylimidazolidine-2,4-dione (52) 
 
 
 
Chapter 5 
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(R)-5-(3-Oxo-3-(4-phenylpiperazin-1-yl)propyl)-5-phenylimidazolidine-2,4-dione (53) 
 
 
 
 
Experimental section 
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(S)-5-Methyl-5-((S)-2-nitro-1-phenylethyl)-3-phenylimidazolidine-2,4-dione (73) 
 
 
 
Chapter 5 
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(S)-5-Methyl-5-((S)-2-nitro-1-phenylethyl)-3-phenyl-2-thioxoimidazolidin-4-one (74)
 
 
Experimental section 
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(R)-2-((S)-4-Methyl-2,5-dioxo-1-phenylimidazolidin-4-yl)-2-phenylacetic acid (75)
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5.4.12.  HPLC chromatograms of representative compounds 
(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (37Ca) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/ethanol 80/20, flow rate = 0.5 mL/min, 
retention times: 32.0 min (major.) and 23.7 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 23.714 44.23 
2 32.600 44.20 
3 36.196 5.74 
4 37.261 5.82 
 
 
 Retention Time % Area 
1 23.670 0.95 
2 32.045 97.33 
3 36.090 1.72 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (37Cb) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IC, hexane/isopropanol 75/25, flow rate = 0.5 mL/min, 
retention times: 29.0 min (major.). Processed Channel Descr.: 
PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 26.391 47.16 
2 28.497 46.36 
3 34.026 3.33 
4 38.426 3.15 
 
 
 Retention Time % Area 
1 29.020 98.86 
2 34.626 1.14 
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(S)-1-Acetyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-4(5H)-
one (37Cc) 
 The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 40/60, flow rate = 
0.5 mL/min, retention times: 21.4 min (major.) and 14.1 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 14.083 42.10 
2 21.846 42.89 
3 22.902 8.00 
4 34.193 7.01 
 
 
 Retention Time % Area 
1 14.065 1.14 
2 21.383 93.63 
3 22.738 2.65 
4 33.736 2.57 
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(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-methyl-1H-
imidazol-4(5H)-one (38Ad) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 22.3 min (major.) and 20.9 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 20.828 45.15 
2 22.282 40.90 
3 23.233 7.00 
4 31.403 6.95 
 
 
 Retention Time % Area 
1 20.917 1.47 
2 22.276 94.71 
3 31.480 3.82 
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(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-ethyl-1H-
imidazol-4(5H)-one (38Bd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 36.5 min (major.) and 20.8 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 19.746 38.13 
2 26.992 24.64 
3 35.179 37.23 
 
 
 Retention Time % Area 
1 20.767 1.16 
2 28.319 3.31 
3 36.528 95.52 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one (38Ca) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times for major diastereoisomer: 53.2 min 
(major.) and 33.9 min (min.), minor diastereoisomer: 36.2 min 
and 38.0 min. Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 34.064 43.69 
2 36.357 7.22 
3 38.124 7.39 
4 53.919 41.70 
 
 
  
 Retention Time % Area 
1 33.864 1.36 
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3 37.940 0.27 
4 53.190 98.27 
 
 
 
 
A
U
0,00
0,02
0,04
0,06
0,08
Minutes
30,00 32,00 34,00 36,00 38,00 40,00 42,00 44,00 46,00 48,00 50,00 52,00 54,00 56,00 58,00 60,00
3
4
,0
6
4
3
6
,3
5
7
3
8
,1
2
4 5
3
,9
1
9
A
U
0,00
0,20
0,40
0,60
0,80
Minutes
30,00 32,00 34,00 36,00 38,00 40,00 42,00 44,00 46,00 48,00 50,00 52,00 54,00 56,00 58,00 60,00
3
3
,8
6
4
3
6
,1
6
3
3
7
,9
4
0
5
3
,1
9
0
Chapter 5 
458 
 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(4-bromophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cb) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/isopropanol 50/50, flow rate = 0.5 mL/min, 
retention times for major diastereoisomer: 28.4 min (major.) and 
19.2 min (min.), minor diastereoisomer: 20.5 min and 22.4 min. 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 
 Retention Time % Area 
1 19.357 47.43 
2 20.666 1.19 
3 22.506 1.07 
4 29.473 50.31 
 
 
   
 
A
U
0,00
0,02
0,04
0,06
0,08
0,10
0,12
Minutes
10,00 12,00 14,00 16,00 18,00 20,00 22,00 24,00 26,00 28,00 30,00 32,00 34,00 36,00 38,00 40,00
1
9
,3
5
7
2
0
,6
6
6
2
2
,5
0
6
2
9
,4
7
3
A
U
0,00
0,50
1,00
1,50
2,00
Minutes
10,00 12,00 14,00 16,00 18,00 20,00 22,00 24,00 26,00 28,00 30,00 32,00 34,00 36,00 38,00 40,00
1
9
,2
4
4
2
0
,5
1
0
2
2
,3
7
6
2
8
,4
0
8
 Retention Time % Area 
1 19.244 1.08 
2 20.510 0.08 
3 22.376 1.33 
4 28.408 97.51 
Experimental section 
459 
 
(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-2-nitro-1-(p-tolyl)ethyl)-1H-imidazol-
4(5H)-one (38Cc)  
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 48.5 min (major.) and 28.3 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 28.959 46.21 
2 35.209 6.84 
3 49.554 46.94 
 
 
 Retention Time % Area 
1 28.316 3.20 
2 35.925 0.13 
3 48.523 96.67 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 36.3 min (major.) and 57.7 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 36.531 49.43 
2 46.336 2.28 
3 57.719 48.29 
 
 
 Retention Time % Area 
1 28.959 94.80 
2 35.209 4.16 
3 49.554 1.05 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(3-chlorophenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Ce) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 33.3 min (major.) and 19.5 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 19.302 49.01 
2 26.841 2.71 
3 33.103 48.28 
 
 
 Retention Time % Area 
1 19.467 0.61 
2 27.038 28.29 
3 33.297 71.11 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(2-methoxyphenyl)-2-nitroethyl)-1H-
imidazol-4(5H)-one (38Cf) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 38.5 min (major.) and 27.5 min 
(min.).Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 27.852 44.89 
2 30.538 10.28 
3 38.982 44.83 
 
 
 Retention Time % Area 
1 27.495 0.96 
2 30.199 1.03 
3 38.536 98.02 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-(furan-3-yl)-2-nitroethyl)-1H-imidazol-
4(5H)-one (38Cg) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 70/30, flow rate = 
0.5 mL/min, retention times: 19.3 min (major.) and 15.6 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 27.284 48.15 
2 40.244 49.02 
3 47.498 2.83 
 
 
 Retention Time % Area 
1 27.506 1.08 
2 41.354 85.01 
3 47.788 13.92 
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(S)-1-Benzoyl-2-(benzylthio)-5-isobutyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-
4(5H)-one(38Da) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 30.9 min (major.) and 18.8 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 18.792 46.97 
2 23.562 2.53 
3 25.589 3.05 
4 31.036 47.45 
 
 
 Retention Time % Area 
1 18.772 3.87 
2 23.475 1.12 
3 25.562 0.66 
4 30.902 94.35 
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(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-((S)-2-nitro-1-phenylethyl)-1H-imidazol-4(5H)-
one (38Ea) 
 The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 24.8 min (major.) and 16.2 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 16.316 50.40 
2 19.689 0.08 
3 20.773 0.11 
4 24.903 49.41 
 
 
 Retention Time % Area 
1 16.281 1.48 
2 19.592 0.13 
3 24.775 98.39 
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(S)-1-Benzoyl-2-(benzylthio)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-(2-
(methylthio)ethyl)-1H-imidazol-4(5H)-one (38Fd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times for major diastereoisomer: 62.8 min 
(major.) and 28.5 min (min.). Processed Channel Descr.: PDA 
210.0 nm). 
 
 Retention Time % Area 
1 29.527 48.93 
2 37.963 3.25 
3 64.339 47.83 
 
 
 Retention Time % Area 
1 28.520 1.14 
2 36.048 1.33 
3 62.846 97.52 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-4-methyl-1-nitropentan-2-yl)-1H-
imidazol-4(5H)-one (38Ch) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 19.3 min (major.) and 15.6 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 15.793 49.86 
2 19.574 50.14 
 
 
 Retention Time % Area 
1 15.629 3.86 
2 19.337 96.14 
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(S)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-((S)-1-nitropentan-2-yl)-1H-imidazol-4(5H)-
one (38Ci) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 70/30, flow rate = 
0.5 mL/min, retention times: 26.9 min (major.) and 23.4 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 23.301 49.21 
2 26.722 50.79 
 
 
 Retention Time % Area 
1 23.372 4.53 
2 26.932 95.47 
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(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-chlorophenyl)-2-nitroethyl)-5-
methyl-1H-imidazol-4(5H)-one (39Ad) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 75/25, flow rate = 0.5 
mL/min, retention times: 31.3 min (major.) and 46.8 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 32.308 45.29 
2 35.323 4.64 
3 47.915 45.38 
4 65.944 4.68 
 
 
 Retention Time % Area 
1 31.327 90.83 
2 34.369 8.85 
3 46.807 0.32 
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(S)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-2-nitro-1-phenylethyl)-
1H-imidazol-4(5H)-one (39Ca) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC-IB, hexane/isopropanol 60/40, flow rate = 
0.5 mL/min, retention times: 35.4 min (major.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 29.981 2.29 
2 33.739 49.60 
3 35.444 45.83 
4 38.551 2.27 
 
 
 Retention Time % Area 
1 30.029 0.91 
2 35.410 90.09 
 
 
A
U
0,00
0,02
0,04
0,06
0,08
0,10
Minutes
28,00 30,00 32,00 34,00 36,00 38,00 40,00 42,00 44,00
2
9
,9
8
1
3
3
,7
3
9
3
5
,4
4
4
3
8
,5
5
1
A
U
0,00
0,20
0,40
0,60
Minutes
28,00 30,00 32,00 34,00 36,00 38,00 40,00 42,00 44,00
3
0
,0
2
9
3
5
,4
1
0
Experimental section 
471 
 
(R)-5-((Benzyloxy)methyl)-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)- 1H-imidazol-4(5H)-one (39Gd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 34.6 min (major.) Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 21.703 8.47 
2 26.673 40.80 
3 35.706 41.82 
4 45.146 8.91 
 
 
 Retention Time % Area 
1 34.646 93.98 
2 44.084 6.02 
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(S)-5-Benzyl-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-4(5H)-one (40Ca) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 65/35, flow rate = 0.5 
mL/min, retention times: 22.5 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 20.353 46.49 
2 22.698 48.33 
3 33.472 2.50 
4 36.076 2.68 
 
 
 Retention Time % Area 
1 22.461 91.16 
2 35.648 8.84 
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(R)-5-((Benzyloxy)methyl)-1-(benzyloxycarbonyl)-2-(benzylthio)-5-((S)-1-(2-
chlorophenyl)-2-nitroethyl)-1H-imidazol-4(5H)-one (40Gd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 50/50, flow rate= 
0.5 mL/min, retention times: 49.8 min (major.) and 32.8 min 
(min.) Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 23.393 5.71 
2 33.432 44.24 
3 48.505 5.60 
4 52.826 44.44 
 
 
 Retention Time % Area 
1 23.244 0.13 
2 32.844 0.71 
3 46.532 4.92 
4 49.854 94.25 
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(S)-1-Benzoyl-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Aa) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 mL/min, 
retention times: 24.6 min (major.) and 28.2 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 25.216 46.57 
2 28.641 53.43 
 
 
 Retention Time % Area 
1 24.668 97.70 
2 28.238 2.30 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ca) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IB, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 19.9 min (major.) and 22.4 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 22.812 50.68 
2 25.561 49.32 
 
 
 Retention Time % Area 
1 19.966 97.71 
2 22.368 2.29 
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(S)-1-Benzoyl-2-(benzylthio)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-one (42Ea) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 mL/min, 
retention times: 17.5 min (major.) and 20.1 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 17.386 49.96 
2 19.812 50.04 
 
 
 Retention Time % Area 
1 17.520 98.02 
2 20.100 1.98 
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 (R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ca) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IB, hexane/isopropanol 80/20, flow rate = 0.5 mL/min, 
retention times: 15.7 min (major.) and 14.3 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 13.845 49.29 
2 15.341 50.71 
 
 
 Retention Time % Area 
1 14.290 5.85 
2 15.739 94.15 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-isobutyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Da) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IC, hexane/isopropanol 60/40, flow rate = 0.5 mL/min, 
retention times: 26.9 min (major.) and 19.0 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 19.020 49.37 
2 27.214 50.63 
 
 
 Retention Time % Area 
1 18.996 1.28 
2 26.904 98.72 
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(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-hexyl-5-(3-oxobutyl)-1H-imidazol-
4(5H)-one (43Ea) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak AD-H, hexane/isopropanol 90/10, flow rate = 0.5 
mL/min, retention times: 12.7 min (major.) and 14.8 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 12.791 49.09 
2 14.801 50.91 
 
 
 Retention Time % Area 
1 12.752 98.43 
2 14.803 1.57 
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(S)-1-(Benzyloxycarbonyl)-2-(benzylthio)-5-methyl-5-(3-oxobutyl)-1H-imidazol-4(5H)-
one (44Aa) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IB, hexane/isopropanol 80/20, flow rate = 0.5 mL/min, 
retention times: 37.2 min (major.) and 28.0 min (min.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 27.982 50.19 
2 37.472 49.81 
 
 
 Retention Time % Area 
1 28.734 1.55 
2 37.167 98.45 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(3-oxo-3-phenylpropyl)-1H-imidazol-4(5H)-
one (42Cb) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 80/20, flow rate = 
0.5 mL/min, retention times: 55.4 min (major.) and 45.8 min 
(min.).Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 44.230 49.95 
2 53.496 50.05 
 
 
 Retention Time % Area 
1 45.798 3.15 
2 55.431 96.85 
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(S)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-ethyl-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Bb) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 90/10, flow rate 
= 0.5 mL/min, retention times: 18.9 min (major.) and 16.9 
min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 16.514 50.09 
2 18.617 49.91 
 
 
 Retention Time % Area 
1 16.862 1.40 
2 18.916 98.60 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-phenylpropyl)-1H-
imidazol-4(5H)-one (43Cb) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IB, hexane/isopropanol 80/20, flow rate = 
0.5 mL/min, retention times: 16.0 min (major.) and 14.5 
min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 14.600 50.47 
2 16.333 49.53 
 
 
 Retention Time % Area 
1 14.518 2.08 
2 16.038 97.92 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-1H-
imidazol-4(5H)-one (43Cc) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 50/50, flow rate = 
0.5 mL/min, retention times: 29.4 min (major.) and 22.2 
min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 22.937 48.97 
2 30.911 51.03 
 
 
 Retention Time % Area 
1 22.227 1.73 
2 29.391 98.27 
 
 
A
U
0,00
0,50
1,00
1,50
2,00
Minutes
20,00 22,00 24,00 26,00 28,00 30,00 32,00 34,00 36,00
2
2
,9
3
7
3
0
,9
1
1
A
U
0,00
0,50
1,00
Minutes
20,00 22,00 24,00 26,00 28,00 30,00 32,00 34,00
2
2
,2
2
7
2
9
,3
9
1
Experimental section 
485 
 
(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-(4-chlorophenyl)-3-
oxopropyl)-1H-imidazol-4(5H)-one (43Cd) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 70/30, flow rate 
= 0.5 mL/min, retention times: 33.0 min (major.) and 23.3 
min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 23.277 49.81 
2 33.226 50.19 
 
 
 Retention Time % Area 
1 23.328 1.95 
2 32.990 98.05 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(3-oxo-3-(p-tolyl)propyl)-5-phenyl-1H-
imidazol-4(5H)-one (43Hc) 
The enantiomeric purity was determined by HPLC 
analysis (Daicel Chiralpak IA, hexane/isopropanol 80/20, 
flow rate = 0.5 mL/min, retention times: 12.4 min 
(major.) and 14.2 min (min.). Processed Channel Descr.: 
PDA 210.0 nm). 
 
 Retention Time % Area 
1 12.848 50.38 
2 14.694 49.62 
 
 
 Retention Time % Area 
1 12.460 99.83 
2 14.242 0.17 
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(R)-1-Benzoyl-5-benzyl-2-(benzylthio)-5-(4-hydroxy-4-methyl-3-oxopentyl)-1H-
imidazol-4(5H)-one (45C) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 60/40, flow rate = 
0.5 mL/min, retention times: 21.3 min (major.) and 19.4 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 19.661 49.46 
2 21.588 50.54 
 
 
 Retention Time % Area 
1 19.459 6.18 
2 21.311 93.82 
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(R)-5-Benzyl-2-(benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-
oxopentyl)-1H-imidazol-4(5H)-one (46C) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 60/40, flow rate = 
0.5 mL/min, retention times: 22.2 min (major.) and 20.2 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 19.661 49.47 
2 21.588 50.53 
 
 
 Retention Time % Area 
1 20.258 3.39 
2 22.170 96.61 
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(R)-2-(Benzylthio)-1-(tert-butyloxycarbonyl)-5-(4-hydroxy-4-methyl-3-oxopentyl)-5-
phenyl-1H-imidazol-4(5H)-one (46H) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 70/30, flow rate 
= 0.5 mL/min, retention times: 12.0 min (major.) and 15.2 
min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 11.678 50.12 
2 14.601 49.88 
 
 
 Retention Time % Area 
1 12.002 95.67 
2 15.164 4.33 
 
 
 
A
U
0,00
0,20
0,40
0,60
0,80
Minutes
8,00 10,00 12,00 14,00 16,00 18,00 20,00
1
1
,6
7
8
1
4
,6
0
1
A
U
0,00
0,20
0,40
0,60
Minutes
8,00 10,00 12,00 14,00 16,00 18,00 20,00
1
2
,0
0
2
1
5
,1
6
4
Chapter 5 
490 
 
 (S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Aa) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 0.5 
mL/min, retention times: 37.3 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 24.037 22.62 
2 28.220 27.42 
3 32.677 27.77 
4 53.838 20.14 
 
 
 Retention Time % Area 
1 29.841 0.52 
2 37.702 99.48 
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(S)-2-(Benzylthio)-4-((S)-1-(4-bromophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ab) 
The enantiomeric purity was determined by HPLC analysis (Daicel 
Chiralpak IA, hexane/isopropanol 95/5, flow rate = 0.5 mL/min, 
retention times: 33.3 min (major.). Processed Channel Descr.: 
PDA 210.0 nm). 
 
 
 
 Retention Time % Area 
1 34.436 29.02 
2 38.098 21.61 
3 45.282 29.22 
4 13.978 20.14 
 
 
 Retention Time % Area 
1 33.321 100.00 
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(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-(p-tolyl)ethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Ac) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 0.5 
mL/min, retention times: 27.1 min (major.) and 60.5 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 27.155 22.63 
2 30.184 27.11 
3 40.806 27.40 
4 61.748 22.86 
 
 
 
 Retention Time % Area 
1 27.055 98.52 
2 60.512 1.48 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ad) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 90/10, flow rate = 1.0 
mL/min, retention times: 22.6 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 11.634 31.60 
2 16.389 27.14 
3 21.570 20.39 
4 62.206 20.87 
 
 
 Retention Time % Area 
1 22.562 100.00 
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 (S)-2-(Benzylthio)-4-((S)-1-(3-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Ae) 
 The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 1.0 
mL/min, retention times: 22.9 min (major.) and 21.5 min 
(min.).Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 16.470 21.57 
2 20.460 27.23 
3 21.921 29.64 
4 29.261 21.56 
 
 
 Retention Time % Area 
1 17.450 0.20 
2 21.452 0.33 
3 22.860 99.47 
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(S)-2-(Benzylthio)-4-((S)-1-(4-chlorophenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Aj) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 1.0 
mL/min, retention times: 40.5 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 
 Retention Time % Area 
1 29.854 24.57 
2 30.060 24.10 
3 41.052 25.55 
4 126.524 25.78 
 
 
 Retention Time % Area 
1 29.771 0.91 
2 40.479 99.09 
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4-((S)-1-((S)-2-(Benzylthio)-4-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-4-yl)-2-
nitroethyl)benzonitrile (67Ak) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 23.8 min (major.) and 21.3 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 19.083 18.03 
2 21.317 31.43 
3 23.847 32.53 
4 43.764 18.01 
 
 
 Retention Time % Area 
1 18.814 0.99 
2 21.259 1.80 
3 23.782 97.21 
 
A
U
0,00
0,05
0,10
0,15
0,20
0,25
0,30
Minutes
15,00 20,00 25,00 30,00 35,00 40,00 45,00 50,00
19
,0
83
21
,3
17
23
,8
47
43
,7
64
A
U
0,00
0,05
0,10
0,15
Minutes
15,00 20,00 25,00 30,00 35,00 40,00 45,00 50,00
1
8
,8
1
4
2
1
,2
5
9
2
3
,7
8
2
Experimental section 
497 
 
(S)-2-(Benzylthio)-4-((S)-1-(4-methoxyphenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Al) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 0.5 
mL/min, retention times: 48.9 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 38.360 29.71 
2 41.744 20.44 
3 49.347 30.47 
4 82.188 19.37 
 
 
 Retention Time % Area 
1 48.839 95.55 
2 80.117 4.45 
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(S)-2-(Benzylthio)-4-((S)-1-(3-methoxyphenyl)-2-nitroethyl)-4-methyl-1-phenyl-1H-
imidazol-5(4H)-one (67Am) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IB, hexane/isopropanol 95/5, flow rate = 1.0 
mL/min, retention times: 19.5 min (major.) and 17.5 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 16.555 28.58 
2 18.978 29.16 
3 24.139 21.24 
4 42.287 21.01 
 
 
 Retention Time % Area 
1 17.481 0.79 
2 19.541 99.21 
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(S)-2-(Benzylthio)-4-((S)-1-(4-(dimethylamino)phenyl)-2-nitroethyl)-4-methyl-1-
phenyl-1H-imidazol-5(4H)-one (67An) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 95/5, flow rate = 0.5 
mL/min, retention times for major diastereoisomer: 21.3 min 
(major.) and 19.9 min (min.). Processed Channel Descr.: PDA 
210.0 nm). 
 
 
 Retention Time % Area 
1 14.413 33.30 
2 16.384 32.78 
3 20.479 16.42 
4 22.027 17.51 
 
 
 Retention Time % Area 
1 19.913 0.13 
2 21.339 99.87 
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(S)-4-Benzyl-2-(benzylthio)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-5(4H)-
one (67Ca) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 70/30, flow rate = 0.5 
mL/min, retention times: 42.6 min (major.) and 24.2 min (min.). 
Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 18.520 25.93 
2 25.031 24.03 
3 36.361 25.77 
4 43.837 24.26 
 
 
 Retention Time % Area 
1 17.782 6.98 
2 24.174 0.68 
3 35.465 0.01 
4 42.648 92.32 
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(S)-2-(Benzylthio)-4-isobutyl-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-imidazol-
5(4H)-one (67Da) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IB, hexane/isopropanol 95/5, flow rate = 0.5 
mL/min, retention times: 19.1 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 20.013 23.85 
2 23.337 26.36 
3 26.109 26.50 
4 51.946 23.28 
 
 
 Retention Time % Area 
1 19.153 100.00 
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(S)-2-(Benzylthio)-4-(2-(methylthio)ethyl)-4-((S)-2-nitro-1-phenylethyl)-1-phenyl-1H-
imidazol-5(4H)-one (67Fa) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IB, hexane/ethanol 90/10, flow rate = 0.5 
mL/min, retention times: 30.2 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 24.231 29.67 
2 26.052 31.37 
3 28.949 20.62 
4 80.322 18.33 
 
 
 Retention Time % Area 
1 30.205 92.74 
2 78.112 7.26 
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Methyl 3-((S)-2-(Benzylthio)-4-((S)-2-nitro-1-phenylethyl)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-4-yl)propanoate (67Ia) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/ethanol 95/5, flow rate = 1.0 
mL/min, retention times: 29.0 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 23.498 18.17 
2 27.640 17.28 
3 29.847 33.18 
4 82.964 31.38 
 
 
 Retention Time % Area 
1 28.964 100.00 
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(S)-2-(Benzylthio)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-3-(p-tolyl)-1H-imidazol-
5(4H)-one (68Aa) 
The enantiomeric purity was determined by HPLC 
analysis (Daicel Chiralpak IA, hexane/isopropanol 90/10, 
flow rate = 0.5 mL/min, retention times: 35.3 min 
(major.) and 29.5 min (min.). Processed Channel Descr.: 
PDA 210.0 nm). 
 
 Retention Time % Area 
1 23.240 4.26 
2 29.326 47.03 
3 35.089 48.71 
 
 
 Retention Time % Area 
1 29.475 1.18 
2 35.329 98.82 
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(S)-2-(Benzylthio)-1-(4-chlorophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (69Aa) 
The enantiomeric purity was determined by HPLC 
analysis (Daicel Chiralpak AD-H, hexane/isopropanol 
80/20, flow rate = 0.5 mL/min, retention times: 24.9 
min (major.) and 19.5 min (min.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 16.649 41.22 
2 21.350 7.48 
3 25.189 8.35 
4 68.705 42.96 
 
 
 Retention Time % Area 
1 16.519 0.16 
2 19.532 3.14 
3 24.876 96.70 
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(S)-2-(Benzylthio)-1-(4-bromophenyl)-4-methyl-4-((S)-2-nitro-1-phenylethyl)-1H-
imidazol-5(4H)-one (70Aa) 
The enantiomeric purity was determined by HPLC 
analysis (Daicel Chiralpak IC, hexane/isopropanol 80/20, 
flow rate = 0.5 mL/min, retention times: 34.8 min 
(major.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 32.916 36.79 
2 34.867 13.84 
3 37.211 36.30 
4 40.938 13.06 
 
 
 Retention Time % Area 
1 32.935 1.98 
2 34.847 98.02 
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(S)-2-(Benzylthio)-4-((S)-1-(2-chlorophenyl)-2-nitroethyl)-1-(4-methoxyphenyl)-4-
methyl-1H-imidazol-5(4H)-one (71Ad) 
The enantiomeric purity was determined by HPLC 
analysis (Daicel Chiralpak AD-H, hexane/isopropanol 
80/20, flow rate = 0.5 mL/min, retention times: 73.9 
min (major.) and 32.3 min (min.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 17.962 35.53 
2 22.718 36.56 
3 31.955 14.16 
4 70.470 13.76 
 
 
 Retention Time % Area 
1 17.438 0.13 
2 22.871 0.24 
3 32.319 3.35 
4 73.880 96.28 
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(S)-2-(Benzylthio)-1-(3-chlorophenyl)-4-((S)-1-(4-methoxyphenyl)-2-nitroethyl)-4-
methyl-1H-imidazol-5(4H)-one (72Al) 
 The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 80/20, flow 
rate = 0.5 mL/min, retention times: 21.9 min (major.) and 
48.5 min (min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 
 Retention Time % Area 
1 20.280 46.58 
2 21.559 3.57 
3 22.151 3.62 
4 48.894 46.23 
 
 
 Retention Time % Area 
1 19.946 0.41 
2 21.936 93.06 
3 48.454 6.53 
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(S)-5-Benzyl-5-((S)-2-nitro-1-phenylethyl)imidazolidine-2,4-dione (48) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 70/30, flow rate = 
0.5 mL/min, retention times: 17.9 min (major.) and 20.4 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 17.792 49.88 
2 20.247 50.12 
 
 
 Retention Time % Area 
1 17.875 99.43 
2 20.434 0.57 
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(S)-1-Benzoyl-3,5-dibenzyl-5-((S)-2-nitro-1-phenylethyl)imidazolidine-2,4-dione (49) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 
0.5 mL/min, retention times: 29.5 min (major.) and 26.1 min 
(min.). Processed Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 18.145 5.54 
2 20.208 5.21 
3 25.704 44.55 
4 29.127 44.69 
 
 
 Retention Time % Area 
1 18.498 2.31 
2 20.603 0.73 
3 26.074 0.52 
4 29.523 96.44 
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(R)-5-(4-Hydroxy-4-methyl-3-oxopentyl)-5-phenylimidazolidine-2,4-dione (50) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IC, hexane/isopropanol 90/10, flow rate = 0.5 
mL/min, retention times: 44.4 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 44.397 48.61 
2 52.296 51.39 
 
 
 Retention Time % Area 
1 43.812 100,00 
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(R)-5-(3-Oxo-3-(piperidin-1-yl)propyl)-5-phenylimidazolidine-2,4-dione (52) 
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak AD-H, hexane/isopropanol 50/50, flow rate 
= 0.5 mL/min, retention times: 15.0 min (major.). Processed 
Channel Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 14.990 49.26 
2 17.861 50.74 
 
 
 Retention Time % Area 
1 15.021 100.00 
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(S)-5-Methyl-5-((S)-2-nitro-1-phenylethyl)-3-phenylimidazolidine-2,4-dione (73)  
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 20.8 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 12.345 23.67 
2 14.271 25.54 
3 20.831 25.40 
4 23.587 25.38 
 
 
 Retention Time % Area 
1 20.032 100.00 
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(S)-5-Methyl-5-((S)-2-nitro-1-phenylethyl)-3-phenyl-2-thioxoimidazolidin-4-one (74)  
The enantiomeric purity was determined by HPLC analysis 
(Daicel Chiralpak IA, hexane/isopropanol 80/20, flow rate = 0.5 
mL/min, retention times: 15.1 min (major.). Processed Channel 
Descr.: PDA 210.0 nm). 
 
 Retention Time % Area 
1 13.556 16.06 
2 15.263 32.65 
3 16.772 34.18 
4 23.755 17.11 
 
 
 Retention Time % Area 
1 15.093 100.00 
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5.4.13.  Kinetic studies 
 
 
The reaction was performed in the NMR tube using 20 mg (1. eq., 0.05 mmol) of 
33C, 15 mg (2 eq, 0.1 mmol) of nitrostyrene 36a and 10 mol % of catalyst C12 (0.005 
mmol, 3.46 mg) in 0.5 mL CD2Cl2. The reaction mixture was partially soluble and the 
measurements were made every 15 minutes. 
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Catalytic Enantioselective Synthesis of N,Ca,Ca-Trisubstituted
a-Amino Acid Derivatives Using 1H-Imidazol-4(5H)-ones as Key
Templates**
Julen Etxabe, Joseba Izquierdo, Aitor Landa, Mikel Oiarbide, and Claudio Palomo*
Abstract: 1H-Imidazol-4(5H)-ones are introduced as novel
nucleophilic a-amino acid equivalents in asymmetric synthesis.
These compounds not only allow highly efficient construction
of tetrasubstituted stereogenic centers, but unlike hitherto
known templates, provide direct access to N-substituted
(alkyl, allyl, aryl) a-amino acid derivatives.
Because of the continuous interest in a,a-disubstituted
(quaternary) a-amino acids,[1] many methods for their ste-
reoselective preparation have been reported,[1, 2] but catalytic
approaches still remain underdeveloped.[2d–f, 3] A major cata-
lytic, enantioselective entry to quaternary NH a-amino acids
consists of the a-functionalization of a nucleophilic template,
for example, either an a-iminoester or azlactone, and
subsequent hydrolysis (Figure 1a).[4] However, the majority
of these methods are unable to afford the N-substituted
analogues directly,[5] and an additional N-alkylation process is
required.[6] This limitation is unfortunate since N-methyl (or
superior N-alkyl) a-amino-acid-derived compounds are
potential therapeutic candidates owing to their comparatively
higher lipophilicity and membrane permeability.[7] We
hypothesized that 1H-imidazol-4(5H)-ones might serve as
appropriate templates for addressing this deficiency (Fig-
ure 1b): 1) the NR2 group would be easily pre-installed,
2) base-catalyzed enolization appears suitable (aromatic
enolate formation), and 3) unlike azlactones and related
heterocycles, the new template would not present the Ca/Cg
selectivity complication.[8] However, this realization would
require effective control of the stereochemistry of the C¢C
bond-forming step and, to the best of our knowledge,
asymmetric reactions of 1H-imidazol-4(5H)-ones are unpre-
cedented.
For validation of the idea we selected the readily available
2-thio-1H-imidazol-4(5H)-ones 2–15 (Scheme 1)[9] whose
base-catalyzed conjugate addition reaction[10] to nitroole-
fins[11] was evaluated first (Table 1). After examining several
chiral Brønsted bases,[9] it was gratifying to find that by using
the Rawal catalyst C1[12] the reactions of the N-methyl
imidazolones 2A–6A with nitroolefins (16) proceeded effec-
tively in terms of yield and stereocontrol, regardless of the
electron-neutral, electron-rich, and electron-poor character
of either the b-aryl or heteroaryl substituent in 16 (entries 1–3
and 7–10). The reactions with b-alkyl-substituted nitroolefins
(16h–j) using C1 proceeded with poorer diastereocontrol, but
it was improved by changing to the catalyst C2[13] (compare
entries 4 and 6, 12 and 13, and 18 and 19), and the
enantioselectivity for the major diastereomer was excellent
in all the cases. The imidazolones 7A–12A, bearing N-
substituents other than methyl, for example, benzyl, allyl,
isobutyl, phenyl, p-chlorophenyl, and m-methoxyphenyl,
Figure 1. Enantioselective approaches to N,Ca,Ca-trisubstituted a-
amino acid units. BB=Brønsted base.
Scheme 1. 1H-Imidazol-4(5H)-ones employed in this study.
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were all tolerated (entries 11–17, 20, and 21). Also bicyclic
imidazolones, such as 13A and 14A, provided the corre-
sponding adducts (28a, 28e, 29a) with equal effectiveness.
These latter products represent quaternary proline and
related derivatives which cannot be accessed directly through
established catalytic methodologies.[14] Of practical interest,
the catalyst loading may be reduced from 10 to 5 mol%
without affecting the results (entry 15 versus 16). In contrast,
the nature of the S-substituent group appears to have limited
impact on stereoselectivity as results obtained from the
imidazolones 2B and 2C, to produce 30a and 31a, respec-
tively, are comparable to those obtained with 2A.
In addition to these observa-
tions, it was also found that Michael
acceptors, which are less reactive
than nitroolefins, may participate in
these reactions with equal effective-
ness (Table 2). For example, the
reaction of 2A with the acrylate
surrogate 32,[15] promoted by cata-
lyst C1, provided, after desilylation
of the intermediate adduct, the
product 33 in good yield (74%),
albeit with moderate enantioselec-
tivity (84% ee).[16] Improved selec-
tivity (91% ee) was observed using
C2, and even better selectivity was
obtained with C3[17] (94% ee) and
the new catalyst C4 (96% ee,
Table 2, entry 1). Under these
latter conditions, the enone 32 also
reacted efficiently with other imid-
azolones (entries 2–7).[18]
The chemical manipulation of
adducts was briefly investigated to
illustrate the synthetic potential of
this approach (Scheme 2). Thus,
nucleophilic displacement of the
thioether group served to establish
concise routes to various classes of
heterocycles of interest in medicinal
chemistry,[19] that is, imidazolidi-
nones (40, 41), 2-aryl imidazolones
(43), 2-amino imidazolones (44),
and hydantoins (45–47). Eventually,
acid hydrolysis of 41 afforded the
amino amide 42 with all the above
reactions proceeding in good yields.
Similarly, the hydantoins 48–50
could be obtained upon smooth
hydrolysis of the corresponding
adducts 33–35. Further oxidative
elaboration of the ketol moiety in
these products[9, 15] led to the corre-
sponding carboxylic acids 51/52, the
aldehyde 53, and ketone 54. The
present catalytic approach thus
facilitates a novel entry for the
rapid construction of functionalized
5,5-disubstituted hydantoins, a well-recognized scaffold for
drug discovery.[20] Finally, the X-ray structure analyses of
hydantoins 46 and 51 served to establish the configuration of
the adducts.[21]
On the other hand, given that the new template allows
direct access to N-substituted quaternary a-amino acid
derivatives, additional ways for the elaboration of adducts
can be envisaged in which the NR2 moiety plays a strategic
role. For instance (Scheme 3), from the common adduct 47,
the densely functionalized bi- (55) and tricyclic (56)
compounds were prepared in two and four steps, respec-
tively.[9]
Table 1: Catalytic reaction between imidazolones 2–14 and nitroolefins 16.[a]
Entry Prod. R1 R2 R3 Yield [%][b] d.r. [%][c] ee [%][d]
1 17a Me Me Ph 97 93:7 99
2 17b Me Me 4-MeC6H4 91 90:10 96
3 17c Me Me 4-BrC6H4 82 94:6 98
4 17h Me Me iPr 66[e] 60:40 96
5 77[e,f ] 50:50 ¢90
6 58[e,g] 80:20 ¢90
7 18d Bn Me 3-MeC6H4 82 92:8 95
8 19a nHex Me Ph 81 98:2 98
9 20 f iBu Me 2-thienyl 84 92:8 86
10 21g iPr Me 2-furyl 75 93:7 92
11 22a Me Bn Ph 85 98:2 98
12 22 i Me Bn c-C6H11 40
[e] 75:25 94
13 40[e,f ] 80:20 ¢90
14 23a Me iBu Ph 78 98:2 93
15 24a Me CH2CH=CH2 Ph 77 92:8 94
16 65[h] 90:10 95
17 25a Me Ph Ph 65 93:7 92
18 25 j Me Ph nPr 51[e] 50:50 94
19 51[e,g] 80:20 ¢90
20 26b Me 4-ClC6H4 4-MeC6H4 83 98:2 98
21 27a Me 3-MeOC6H4 Ph 85 88:12 95
[a] Reactions conducted on a 0.3 mmol scale in 0.5 mL CH2Cl2 (mol ratio of imidazolone/nitroolefin/C1
catalyst 1:2:0.1) unless otherwise stated. [b] Yield of the isolated major diastereomer. [c] Determined by
1H NMR (300 MHz) analysis of the crude reaction mixture. [d] Determined by HPLC analysis using
a chiral stationary phase. [e] Reaction run at 50 8C in 1,2-dichloroethane. [f ] Using ent-C1. [g] Using C2.
[h] Reaction run at 4 mmol scale using 5 mol% catalyst (reaction time 30 h).
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The fidelity with which chirality is transferred in the above
conjugate addition reactions may be explained by assuming
the catalyst tightly bound to both the reactants in the TS, as
shown in models A and B (Figure 2). It should be noted that
models similar to A and B, which define two major patterns
for catalyst–substrate hydrogen bonding, have been previ-
ously proposed as heuristic or calculation-driven TS for
related reactions involving bifunctional squaramide tertiary
amine catalysis, and the prevalence of one over the other
seems to be highly substrate-dependent.[15, 22] As strong
evidence in favor of model A, we found that the chemical
shift of the ortho-ArH in C1 is considerably affected (Dd=
+ 0.11 ppm) by addition of 1 equivalent of 2A, whereas it
remains unaffected by addition of nitrostyrene (Figure 2 and
see the Supporting Information). This observation also
suggests that the polarized aromatic ortho protons in this
type of catalysts contribute to TS stabilization.[23]
In summary, we have demonstrated for the first time that
2-thio-1H-imidazol-4(5H)-ones may serve as effective equiv-
alents of N-substituted (alkyl, aryl, allyl) a-amino acids.
Specifically, their base-catalyzed addition reaction to nitro-
olefins and enones to afford the corresponding quaternary a-
amino acid derivatives can be carried out with very high
diastereo- and enantiocontrol. Further elaboration of the thus
obtained adducts opens straightforward access to an array of
different N-substituted quaternary a-amino acid derivatives,
including 5,5-disubstituted hydantoins and other complex N-
heterocycles, in enantiomerically pure form. The scope of
these imidazolones as new pronucleophiles against other
acceptors, including C=X systems (1,2-addition), may be
easily anticipated.
Keywords: amino acids · asymmetric catalysis ·
Michael additions · organocatalysis · synthetic methods
How to cite: Angew. Chem. Int. Ed. 2015, 54, 6883–6886
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Table 2: 1,4-Addition of 1H-imidazolo-4(5H)ones to the a’-silyloxy
enone 32.[a]
Entry Imidazo-
lone
R1 R2 Prod. Yield [%][b] ee [%][c]
1 2A Me Me 33 82 96[d]
2 3A Bn Me 34 75 96
3 4A nHex Me 35 81 94
4 5A iBu Me 36 71 96
5 7A Me Bn 37 78 96
6 9A Me CH2=CHCH2 38 77 94
7 15A Bn Bn 39 83 92
[a] Reactions conducted on a 0.3 mmol scale (mol ratio of imidazolone/
enone/catalyst 1:2:0.1) using C4 unless otherwise stated. Desilylation
conducted in CH3CN (1 mL), H2O (0.5 mL), AcOH (0.3 mL). [b] Yield of
isolated product after chromatography. [c] Determined by HPLC analysis
using a chiral stationary phase. [d] Using catalyst C1, ¢84% ee ; using
catalyst C2, 91% ee; using catalyst C3, 94% ee.
Scheme 2. Elaboration of the 2-thio-1H-imidazol-4(5H)-one moiety.
CAN=ceric ammonium nitrate.
Figure 2. Plausible TS models and selected 1H NMR data.
Scheme 3. New entries to functionalized polycyclic hydantoins.
NMO=N-methyl-morpholine N-oxide.
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ABSTRACT: A simple, new strategy for the direct
asymmetric α-functionalization of 2-alkyl azaarenes is
described. Speciﬁcally, a Brønsted base catalyzed conjugate
addition of substituted 2-cyanomethylpyridine (and
pyrazine) N-oxides to acrylate equivalents to aﬀord
hitherto elusive 2-tert-alkyl azaaryl adducts with high
enantioselectivity (up to 94% ee) is realized. Extension of
the method to the α-amination reaction by using
azodicarboxylate esters as electrophiles is also demon-
strated. Key for success is the N-oxide functionality of
substrates that acts as a removable activating and
stereodirecting group. A bifunctional Brønsted base
catalyst bearing a squaramide with an attached bulky silyl
group is also disclosed.
Ortho-substituted pyridines, and more generally azaarenes, are
widespread structural motifs,1 with the congeners that are chiral
by virtue of an α-stereogenic o-substituent constituting a relevant
subset. Several catalytic approaches have recently been reported
for the enantioselective synthesis of such chiral units via α-
deprotonation of the corresponding 2-alkylazaarene (Figure
1a).2 With simple 2-alkylazaarenes (R: H, alkyl, etc.), substrate
activation requires a (super)stoichiometric strong base
(LiHMDS),3 thus compromising practicality. Milder conditions
have been developed for the α-functionalization of preactivated
substrates, i.e. those with electron-withdrawing substituents
(EWG) in either the azaarene ring (p-nitroazaarenes, poly-
heteroarenes) or the Cα (α-ester, amide, electron-deﬁcient aryl)
or both (strategy 2).4,5 In these cases, α-stereogenic 2-substituted
azaarenes can be produced with high enantioselectivities by
means of a chiral Pd(II),4a Ni(II),4b or amine5 catalyst and no
base, or only a catalytic weak base, being added. However, none
of these methods address the generation of a quaternary α-
stereocenter,6 an issue of general importance in organic
synthesis,7 and of particular signiﬁcance to the present context
given the interest in 1,1-diaryl quaternary compounds as
potential pharmacophores.8 Here we describe an enantioselec-
tive α-functionalization of o-substituted azaarenes that is
complementary to the known procedures in several aspects: (i)
successfully aﬀords hitherto elusive all-carbon quaternary
stereocenters, (ii) relies on a Brønsted base activation strategy
using newly designed chiral bifunctional organocatalysts, and
(iii) uses azaarene N-oxides, more speciﬁcally substituted 2-
cyanomethyl azaarene N-oxides,9 as enabling substrates (Figure
1b).
Two key elements that make 2-cyanomethyl azaarene N-
oxides perfect substrate candidates a priori are their relatively
high CH Brønsted acidity as compared to most alkylazaarenes10
and the presence of the N → O group as a potentially
coordinating site for catalyst binding.11 Considering this, one
might expect that bifunctional chiral Brønsted bases12 would
suﬃce for an eﬀective α-deprotonation and subsequent stereo-
selective bond formation. As far as we know azaarene N-oxides
have not been investigated within the context of asymmetric
C(sp3)−H functionalizations.13,14
At the outset, we studied the behavior of 2-cyanoalkylpyridine
1 under Brønsted base catalysis conditions and selected as a
reaction partner enone 2, an acrylate surrogate well suited for
organocatalytic conjugate additions.15 As data in Scheme 1 show,
the reactions in the presence of typical cinchona-based
bifunctional Brønsted base catalysts C1−C316 were sluggish,
with low conversion after an extended reaction time (96 h) at
room temperature and poor enantioselectivity. The reactivity
increased substantially when the correspondingN-oxide17 4awas
employed instead (Scheme 2). Thus, conversions of ∼70% were
reached after 2 days at ambient temperature, almost complete at
40 °C, but with yet suboptimal enantioselectivity (75% ee with
C3). After some additional screening,18 we tested the new
Received: December 22, 2015
Published: March 3, 2016
Figure 1. Enantioselective routes to o-substituted azaarenes.
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squaramide catalysts19 C4−C9, which show as a novel feature a
R4Si site that might play a steric function or even participate in
some speciﬁcN−O→ Si interaction.20 Gratifyingly, we observed
that while catalystC4 performed poorly, the reaction between 4a
and 2 catalyzed by C5 and C6 led to the highest selectivity (90%
and 92% ee, respectively) in dichloromethane at temperatures in
the range 20−40 °C.
Catalyst C6 was thus selected to explore the scope of the
reaction with a range of 2-cyanomethyl azaareneN-oxides (Table
1). It was found that under these conditions the reaction
tolerated well pyridine N-oxides 4 with both electron-releasing
and -withdrawing groups attached at diﬀerent positions of the
pyridine ring. Similarly, substrates bearing both electron-rich and
-poor aryl substituents at Cα were equally eﬀective in providing
the corresponding addition adducts 5 in generally very good yield
and high enantioselectivity. Nonetheless, the method was less
tolerant with the corresponding α-alkyl substituted 2-(cyano-
methyl)azaareneN-oxides 4 (R = alkyl, products 5m−o). Then it
was proven that variation of the azaarene system did not
apparently aﬀect the reaction course, as the corresponding 2-
cyanomethylpyrazines 6 added eﬃciently to 2 to aﬀord the
quaternary 1,1′-diaryls 7a−c in good yields. In these latter cases
somewhat lower enantioselectivity was obtained, although they
were still acceptable considering the challenge posed by these
types of targets.9
It was subsequently proven that these 2-cyanomethylpyridine
N-oxides may also work as enabling substrates for stereoselective
α-heterofunctionalization reactions under conditions similar to
those mentioned above. For example, the pyridine N-oxide 4a
reacted with di(tert-butyl) azodicarboxylate 8 in the presence of
10 mol % C8 to aﬀord α-aminated adduct 10a in 90% isolated
yield and 81% ee. The same reaction using catalyst C9 led to
product with 90% ee. The scope of this α-amination process using
either di(tert-butyl) or dibenzyl azodicarboxylate 8 or 9 as the
amination reagent was brieﬂy investigated for a range of 2-
cyanoalkylpyridine N-oxides. As data collected in Table 2 show,
reactions proceeded successfully to give products 10 and 11 in
good yields and ee’s, with catalyst C9 providing the best results
for most of the entries. Once again, the parent pyridine 1 proved
to be less eﬃcient for these transformations. For instance, the
reaction of 1 and di(tert-butyl) azodicarboxylate 8 in the
presence of 10 mol % catalystC8 proceeded to a limited extent of
30% conversion after 15 h at 0 °C.
The detailed mechanism of these catalytic transformations as
well as the precise role played by each element involved remains
unclear. However, data in Figure 2 indicate that the N-oxide
group and its ortho-relationship to the cyanoalkyl substituent are
key for optimal reaction outcome.21 As a general trend, for the
three positional isomers ortho,meta, and para, the corresponding
pyridine N-oxide was more reactive than the parent pyridine in
Scheme 1. Diﬃculties in the Brønsted Base Catalyzed
Reaction of 2-Cyanomethylpyridine 1
Scheme 2. Catalyst Screening for the Reaction of 2-
Cyanomethylpyridine N-Oxide 4a and Enone 2
Table 1. Scope of the Reaction of α-Substituted 2-
(Cyanomethyl)azaarene N-Oxides with 2 Catalyzed by C6a
aReactions conducted on a 0.2 mmol scale in 1 mL of CH2Cl2 (molar
ratio of 4 or 6/2/catalyst 1:3:0.1). Yields of isolated product.
Enantioselectivity determined by HPLC analysis using a chiral
stationary phase. b20 mol % C6 was used.
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both the catalyzed and uncatalyzed reactions. In fact, among the
six experiments involving cyanoalkylpyridines, only that using p-
cyanoalkylpyridine in the presence of C6 provided practical
conversion after 24 h, leading to a racemic product. Equally
important is the position of the N-oxide group relative to the
cyanoalkyl substituent on the ring. Among the three cyanoalkyl-
pyridine N-oxides, the meta and para isomers proved to be
inherently more reactive than the ortho isomer, also in the
presence of catalystC6, although both led to essentially a racemic
product. In contrast, the ortho isomer led to 92% ee.
Adducts obtained from these catalytic transformations can be
modiﬁed in several ways. For instance, reduction of the N-oxide
group on adduct 5a by treatment with (Bpin)2
22 aﬀorded
pyridine 12 in 74% isolated yield and unaltered enantioselectivity
(92% ee, Scheme 3). Furthermore, elaboration of the ketol
moiety in adducts by applying well established protocols allows
the corresponding ketone (13), aldehyde (14), or carboxylic acid
(15) product to be furnished from a common single intermediate
and with formation of acetone as the only organic waste. These
results are of particular interest in that the direct conjugate
addition of azaareneN-oxide 4 to simple enones, i.e. methyl vinyl
ketone, or unsaturated esters, i.e. methyl acrylate, did not work
under the present catalytic conditions. In addition, the reaction
of 4 with acrolein aﬀorded the corresponding 1,4-addition
adduct, but with a poor 15% ee. Another illustration of the
synthetic versatility of adducts is shown by transformation of the
nitrile carboxylic acid 15 into the protected amine 16 and amide
17, respectively. On the other hand, the conﬁguration of adducts
5a and 10a was established by single crystal X-ray analysis,23 and
for the remaining adducts it was assigned by assuming a uniform
reaction mechanism.
In summary, a mild and highly enantioselective carbo- and
hetero-α-functionalization of 2-cyanomethylazaareneN-oxides is
developed as the ﬁrst direct and asymmetric entry to α-
quaternary alkylazaarenes. The N-oxide group plays a strategic
role as a removable activating and stereodirecting element in
conjunction with newly designed bifunctional squaramide-
Brønsted base catalysts bearing a bulky silyl group. While the
speciﬁc role played by the silyl group during catalysis is not clear
yet,24 its easy variation makes this new subclass of squaramides
very attractive for further asymmetric transformations under
proton transfer conditions. Work to address these issues is
currently underway in our laboratory.
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Braüer, T. M.; Jørgensen, K. A. Eur. J. Org. Chem. 2013, 2013, 5262−
5265.
(6) Recent catalytic approaches to nonracemic chiral azaarenes that,
however, do not address the synthesis of the α-quaternary congeners:
(Reductive coupling of 2-alkenyl azaarenes with ketones) (a) Saxena, A.;
Choi, B.; Lam, H. W. J. Am. Chem. Soc. 2012, 134, 8428−8431.
(Stereospecific coupling of sec-organoboronic esters with azaaryl-
lithium) (b) Llaveria, J.; Leonori, D.; Aggarwal, V. K. J. Am. Chem.
Soc. 2015, 137, 10958−10961. (Reductive cross-coupling between
heteroaryl iodides and α-chloronitriles) (c) Kadunce, N. T.; Reisman, S.
E. J. Am. Chem. Soc. 2015, 137, 10480−10483.
(7) (a) Liu, Y.; Han, S.-J.; Liu, W.-B.; Stoltz, B. M.Acc. Chem. Res. 2015,
48, 740−751. (b) Hong, A. Y.; Stoltz, B. M. Eur. J. Org. Chem. 2013,
2013, 2745−2759. (c) Hawner, C.; Alexakis, A. Chem. Commun. 2010,
46, 7295−7306. (d) Das, J. P.; Marek, I. Chem. Commun. 2011, 47,
4593−4623. (e) Bella, M.; Gasperi, T. Synthesis 2009, 2009, 1583−1614.
(f) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. Eur. J. Org. Chem. 2007,
2007, 5969−5994. (g) Trost, B. M.; Jiang, C. Synthesis 2006, 369−396.
(h) Quaternary Stereocenters; Christoffers, J., Baro, A., Eds.; Wiley-VCH:
Weinheim, 2005. (i) Douglas, C. J.; Overman, L. E. Proc. Natl. Acad. Sci.
U. S. A. 2004, 101, 5363−5367.
(8) Ameen, D.; Snape, T. J. MedChemComm 2013, 4, 893−907.
(9) For challenges associated with α-cyanoalkylations, see: Loṕez, R.;
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Enantioselective Synthesis of 5,5-Disubstituted Hydantoins by
Brønsted Base/H-Bond Catalyst Assisted Michael Reactions of a
Design Template
Joseba Izquierdo, Julen Etxabe, Eider DuÇabeitia, Aitor Landa, Mikel Oiarbide,* and
Claudio Palomo*[a]
Abstract: A new method for the enantioselective synthesis
of 5,5-disubstituted (quaternary) hydantoins was developed
on the basis of an organocatalytic Michael reaction approach
involving the use of 2-benzylthio-3,5-dihydroimidazol-4-ones
as key hydantoin surrogates. The method is general with re-
spect to the substitution pattern at the hydantoin N1 (alkyl,
aryl, acyl), N3 (aryl), and C5 (linear/branched alkyl, aryl) posi-
tions and affords essentially single diastereomeric products
with enantioselectivities higher than 95%ee in most cases.
Among the bifunctional Brønsted base/H-bond catalysts ex-
amined, a known squaramide–tertiary amine catalyst and a
newly prepared squaramide–tertiary amine catalyst provide
the highest selectivity so far with either nitroolefins or vinyl
ketones as the acceptor components. Kinetic measurements
support a first-order rate dependence on both reaction part-
ners, the donor template and the Michael acceptor, whereas
competitive 1H NMR spectroscopy experiments reveal the
high ability of the template for catalyst binding.
Introduction
Hydantoins (2,4-imidazolidinediones) constitute a family of ni-
trogen heterocycles that are present in natural products[1] and
comprise a variety of pharmaceutical uses.[2] In particular, 5-
substituted and 5,5-disubstituted hydantoins are important
medicinal compounds.[3] Examples include the anticonvulsant
phenytoin, used for the treatment of epilepsy and cardiac ar-
rhythmia;[4] compounds with antidepressant[5] and antiviral[6]
activity ; inhibitors of platelet aggregation,[7] human aldose re-
ductase,[8] and human leukocyte elastase;[9] and antagonists for
use in Hedgehog pathway-dependent malignancies.[10] On the
other hand, hydantoins are also interesting from a purely
chemical point of view.[11] 5-Substituted hydantoins have been
employed in the context of molecular recognition,[12] as chiral
auxiliaries in organic synthesis,[13] and as constituents of opti-
cally active polymers[14] and metal complexes.[15] Structurally,
they can be viewed as masked a-amino acids, and as such, 5-
substituted hydantoins also serve as precursors to unnatural a-
amino acid derivatives.[16]
Although alternative routes from ketones or a-dicarbonyl
compounds exist,[11] the main synthetic route to 5-substituted
hydantoins starts from the corresponding a-amino acid deriva-
tives,[17] which are condensed with an isocyanate or equivalent
with the assistance of some highly reactive coupling reagent
(Figure 1).[18] Whereas this route is, in principle, simple and
straightforward, its realization depends on the availability of
the corresponding a-amino acid precursors in enantiomerically
pure form. This is a serious problem, especially if 5,5-disubsti-
tuted (quaternary) hydantoins are targeted.[19]
Only very recently have practical syntheses of enantiomeri-
cally enriched quaternary hydantoins involving new carbon–
carbon bond-forming reactions been reported. Clayden devel-
oped an elegant protocol to access quaternary hydantoins and
compounds derived thereof with good diastereoselectivity on
the basis of a substrate-controlled anionic aryl group N!C re-
arrangement on lithiated ureas[20] (Figure 2a). On the other
hand, Terada recently reported a chiral phosphoric acid cata-
lyzed Friedel–Crafts-type addition of 2-methoxyfuran to in situ
generated ketimines (Figure 2b).[21] Despite these significant
advances, the scope of available optically active quaternary hy-
dantoins continues to be rather narrow and is essentially re-
stricted to some particular 5-aryl-substituted subfamilies.
Figure 1. Conventional synthesis of optically active 5,5-disubstituted hydan-
toins from the chiral pool.
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Recently, we found[22a] that heterocycles I could react
smoothly with some Michael acceptors (i.e. , nitroolefins and an
acrylate equivalent) triggered by bifunctional Brønsted base/H-
bond catalysts, thus serving, via the intermediate hydantoin, as
N-substituted a-amino acids surrogates. Herein, we present a
full study on the ability not only of I but also of related hetero-
cycles II and III to engage in bifunctional Brønsted base/H-
bond catalyzed highly enantioselective Michael reactions with
some selected acceptors, including simple vinyl ketones. This
work, which discloses newly prepared and active squaramide–
tertiary amine catalyst C3, represents the first catalyst-con-
trolled, enantioselective, and broad-scope method for the syn-
thesis of 5,5-disubstituted (quaternary) hydantoins with a varie-
ty of substitution patterns at N1, N3, and C5 (Figure 3).
Results and Discussion
Background and working plan
We recently communicated a novel, highly enantioselective ap-
proach for the synthesis of N-substituted a-amino acid deriva-
tives via corresponding enantioenriched 1,5,5-trisubstituted hy-
dantoins 3 (Scheme 1).[22] A distinguishing feature of this se-
quence is that the synthesis of hydantoins 3 no longer relies
on the availability of the precursor a-amino acid in enantio-
pure form; instead, 3 is prepared through a Brønsted base cat-
alyzed conjugate addition[23,24] of racemic dihydroimidazolones
1, followed by basic hydrolysis of resulting Michael adduct 2.
The 1!2 transformation serves to install a second substituent
at C5 of the heterocycle and creates a new tetrasubstituted
carbon stereocenter adjacent to a tertiary one with high dia-
stereo- and enantioselectivity. To the best of our knowledge,
methods for that goal have not yet been described.[11] During
these preliminary studies, we found that the squaramide–terti-
ary amine catalysts pioneered by Rawal,[25] such as C1, efficient-
ly promoted the addition reaction of 1 to aromatic nitroolefins
under very smooth conditions (CH2Cl2 at 20 8C) to afford cor-
responding adducts 3 (EWG=NO2) in diastereomeric ratios
typically higher than 9:1 with excellent enantioselectivity. In
some instances, particularly with aliphatic nitroolefins (R=
alkyl), catalyst C1 led to modest diastereoselectivities, but
using C2[26] instead, both the diastereo- and the enantioselec-
tivity were high. Importantly, this system tolerated a range of
dihydroimidazolones 1 with varying substituents at N1 (R2=
alkyl, allyl, aryl) and C5 (R1= linear and branched alkyl groups),
including bicyclic dihydroimidazoles [R1,R2= (CH2)3] . One of the
problems of using template 1, or in general structures I (R2=
alkyl or aryl), is their limited thermal stability, as they partially
decompose upon storage at room temperature for several
hours or during standard silica gel chromatographic purifica-
tion, making storage in the freezer at 40 8C necessary.
Given the simplicity and the high selectivity of the method
and the mild reaction conditions involved, we sought to inves-
tigate the behavior of related heterocyclic systems II and III. If
successful, a broad-scope approach for the enantioselective
synthesis of diversely 1,3,5-substituted hydantoins would be at
hand. The effectiveness of template I to react under the above
soft enolization conditions may be ascribed to the aromatic
character of transiently formed enolate I’ (Figure 4). By similar
reasoning, it was envisaged that, in the presence of a base pro-
moter, related heterocyclic systems II (N1-acyl) and III would
lead to corresponding aromatic enolates II’ and III’. Moreover,
in view of the structural similarities of the three enolates, their
interaction with the protonated amine–squaramide catalyst
might be equally productive in affording the Michael-addition
adducts.
Figure 2. Advances in the asymmetric synthesis of 5,5-disubstituted hydan-
toins involving CC bond construction.
Figure 3. Template-based catalytic enantioselective synthesis of diversely
substituted quaternary hydantoins.
Scheme 1. Our preliminary finding.[22a]
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Preparation of substrates
The preparation of N-acyl templates 8–11 was performed by
the sequence described in Scheme 2a. Racemic hydantoins 4–
7, prepared in bulk quantities through classic condensation re-
actions of the corresponding free or N-acyl amino acids and
suitable reagents,[27–29] were first silylated with trimethylchloro-
silane and triethylamine and were then treated with benzyl
bromide to afford, after aqueous workup, desired N1-acyl 2-
benzylthioimidazolones 8–11. Notably, at this point, these
compounds turned out to be solids and were comparatively
more stable than corresponding N-alkyl and N-aryl compounds
I. For instance, compounds 8–11 were perfectly stable at room
temperature for several days. On the other hand, the prepara-
tion of N3-aryl templates 19–24 (Scheme 2b) started with the
condensation of the respective amino acid with phenyl(aryl)
isothiocyanate 12 and triethylamine to yield thiohydantoins
13–18. Each one was S-benzylated by treatment with benzyl
bromide and N,N-diisopropylethylamine (DIPEA) to yield 19–
24, which were also found to be bench-stable compounds.
Reactions of N1-acyl-2-thiobenzyl-3,5-dihydroimidazol-5-
ones
To assess the viability of these substrates, their behavior to-
wards nitroolefins under the same conditions as those previ-
ously reported for N-alkyl/aryl congeners 1 was evaluated.
Gratifyingly, as the brief screening in Table 1 shows, the reac-
tion of N-acetyl 8C with nitrostyrene 25a to afford adduct
26Ca proceeded at room temperature in the presence of vari-
ous bifunctional Brønsted base catalysts with remarkable selec-
tivity, whereas reactivity was more catalyst dependent. For in-
stance, both catalysts C1 and C2 were able to afford adduct
26Ca as a 97:3 mixture of diastereomers in very high (but op-
posite) enantioselectivity, although no full conversion could be
reached in either case after 24 h (Table 1, entries 1 and 5). As
Figure 4. Enolization of templates leading to enolates with aromatic charac-
ter.
Scheme 2. Preparation of N1-acyl- and N3-aryl-2-benzylthio-3,5-dihydroimida-
zol-4-ones. DMAP=4-(dimethylamino)pyridine, Py=pyridine, n-Hex=n-
hexyl.
Table 1. Catalyst screening for the reaction of 8C/9C with nitrostyrene
25a (R=Ph).[a]
Entry Catalyst R2 T
[8C]
t
[h]
Conversion
[%]
d.r. ee
[%]
1 C1 COMe RT 24 80 97:3 98
2 ent-C1 COMe RT 24 80 97:3 98
3 ent-C1 COPh RT 16 >98 >98:2 98
4 ent-C1 COPh 20 96 NR – –
5 C2 COMe RT 24 50 97:3 98
6 C2 COPh RT 16 >98 >98:2 97
7 C2 COPh 20 96 65 >98:2 98
8 C3 COMe RT 16 90 98:2 99
9 C3 COPh RT 4 >98 98:2 99
10 C3 COPh 20 48 >98 >98:2 98
11 C4 COMe RT 16 95 90:10 99
12 C5 COMe RT 16 60 80:20 90
[a] The reactions were performed by using 8C/9C (0.3 mmol), nitrostyr-
ene (0.6 mmol), and catalyst (10 mol%) in CH2Cl2 (0.6 mL). The ee values
of the major diastereomers were determined by HPLC. NR=no reaction.
Chem. Eur. J. 2018, 24, 1 – 12 www.chemeurj.org  2018 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim3 &&
These are not the final page numbers! 
Full Paper
expected, catalyst ent-C1 (Table 1, entry 2) afforded the same
enantiomer as C2 with reproducible reactivity and selectivity
compared to C1 and was employed from this point on.
Newly developed catalyst C3[30] was more active and essen-
tially led to full conversion after 24 h (90% conversion after
16 h) with nearly the same degree of diastereo- and enantio-
control (Table 1, entry 8). Regardless of the catalyst employed,
N-benzoyl analogue 9C proved to be more reactive than N-
acetyl derivative 8C and upon reaction with nitrostyrene af-
forded corresponding adduct 27Ca, again, with essentially per-
fect diastereo- and enantioselectivity (Table 1, entries 3, 6, and
9). This same order of catalyst activity, namely, ent-C1<C2<
C3, was observed at subzero temperatures, despite the fact
that ent-C1 was perfectly soluble, whereas both C2 and C3
were only partially soluble. Thus, whereas ent-C1 was com-
pletely inactive at 20 8C, C2 (Table 1, entry 7) and especially
catalyst C3 (Table 1, entry 10), promoted the reaction between
9C and nitrostyrene at that temperature to afford compound
27Ca with very high stereoselectivity. It was also observed that
cinchona-based squaramide catalyst C4[31] was equally active,
Table 2. Scope of the reaction of N1-acyl-2-benzylthio-3,5-dihydroimidazol-4-ones 8–11 with nitroalkenes 25.[a]
[a] Reaction conditions: a mixture of dihydroimidazolone 8–11 (0.2 mmol, 1 equiv), nitroolefin 25 (0.4 mmol, 2 equiv), and C3 (10 mol%) in CH2Cl2 (1.0 mL)
was stirred at 20 8C for 16 h unless otherwise stated. Diastereomeric ratios and ee values were determined by HPLC. [b] Reaction was run for 48 h. [c] Reac-
tion was performed in deoxygenated DME at 50 8C by using nitroalkene (5 equiv) and catalyst (20 mol%). [d] Reaction was run for 72 h.
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albeit less selective (d.r. 90:10; Table 1, entry 11), whereas cor-
responding thiourea analogue C5[32] was both less active and
less selective (Table 1, entry 12). In turn, quinine and hydroqui-
nidine-2,5-diphenyl-4,6-pyrimidinediyl diether [(DHQD)2PYR]
were completely ineffective catalysts for this reaction. With
these initial results in hand, the scope of the reaction was ex-
plored by using catalyst C3, although ent-C1 and C2 could be
employed with almost equal effectiveness. As the data in
Table 2 show, the reactions were performed at room tempera-
ture and worked uniformly well for N-acyl heterocycles 8/9
bearing a variety of substituents at the C5 position of the het-
erocycle (benzyl, short and long linear alkyl, branched alkyl,
heteroalkyl). A range of 5,5-disubstituted cycloadducts 26/27
were isolated in very high yields and enantioselectivities, and
with dr values generally 94:6; adduct 27Cd (d.r. 74:26) was
an exception. The reactions involving more problematic ali-
phatic nitroolefins also proceeded with very good diastereo-
and enantioselectivity (adducts 27Cm and 27Cn). However,
these latter substrates were comparatively less reactive than
their aromatic congeners and required 5 equivalents of the ni-
troalkene and 20 mol% catalyst in 1,2-dimethoxyethane (DME)
at 50 8C for practical reaction conversions. Under these condi-
tions, deoxygenated solvent was optimal to prevent the a-hy-
droxylation reaction. Dihydroimidazolone templates with N-
tert-butoxycarbonyl (N-Boc) and N-benzyloxycarbonyl (N-Cbz)
groups (i.e. , compounds 10 and 11) were also competent sub-
strates for this reaction and afforded adducts 28 and 29 with
essentially perfect stereoselectivity in good yields. As formation
of product 28 Ia in 69% yield and high selectivity proves, the
method is also suitable for templates with an aryl group at the
C5 position. Notably, in some instances and with extended re-
action times the formation of small amounts (5%) of overad-
dition of the initially formed adduct to a second molecule of
nitroolefin was observed. Adjusting the reaction time was gen-
erally enough to minimize or even cancel this undesired side
reaction.
At this stage, the efficacy of this catalytic system against
simple vinyl ketones, a less active but yet relevant Michael ac-
ceptor category, was explored. Initial screening of catalysts for
the reaction of 9C with methyl vinyl ketone (30a) as a repre-
sentative reaction model (Scheme 3) showed a trend in catalyst
activity and selectivity similar to that observed with nitroal-
kenes. Thus, ent-C1 promoted the addition of 9C to 30a, al-
though the reaction progressed slowly and with suboptimal
enantioselectivity. In contrast, catalyst C3 and, especially, cata-
lyst C2 were comparatively more active (reaction conversions
after 48 h at room temperature: 70 and 85%, respectively) and
led to ee values of 95 and 96%, respectively.
Then, the reactions of 9, 10, and 11 with vinyl ketones 30
were explored by using C2 as the catalyst. As the data in
Table 3 show, independent of the substitution pattern, vinyl ke-
tones 30a–d were all equally competent reaction partners and
gave rise to respective Michael adducts 31–33 in generally
good yields and selectivities. However, intrinsically less-reactive
Michael acceptors, such as a,b-unsaturated esters and, in par-
ticular, acrylates, were not competent reaction partners. None-
theless, this deficiency may be surmounted in part by using a-
hydroxy enone 30e, an acrylate equivalent (see below) that is
very easy to prepare from acetone or commercially available 3-
hydroxy-3-methyl-2-butanone in two steps.[33] Thus, adducts
such as 31Ce, 32Ce, and 32 Ie were obtained in good yields
and selectivities and, as will be shown later, could be convert-
ed into the corresponding carboxylic acid products through
conventional ketol cleavage.
Scheme 3. Catalyst screening for the reaction of 9C with methyl vinyl
ketone (30a).
Table 3. Reaction of N-acyl-2-benzylthioimidazolones 9–11 with vinyl ke-
tones 30.[a]
[a] The reactions were performed by using 9–11 (0.3 mmol), vinyl ketone
30 (0.6 mmol), and catalyst C2 (10 mol%) in CH2Cl2 (0.6 mL). The ee
values were determined by HPLC.
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Reactions of N3-aryl-2-thiobenzyl-3,5-dihydroimidazol-4-
ones 19–24 with nitroolefins
In all of the examples shown, masked hydantoins of type I/II
were used exclusively. Accordingly, the hydrolysis of the iso-
thiourea moiety of the resulting adducts would deliver a route
to N3-unsubstituted hydantoins (see below). To develop a simi-
lar catalytic approach useful for the synthesis of the comple-
mentary N3-protected N1-unsubstituted hydantoins, we next
studied the behavior of 2-benzylthiodihydroimidazolones 19–
24. Although it was expected that these compounds would
also provide extended pseudoaromatic enolate species III’
upon enolization in the presence of a bifunctional Brønsted
base catalyst (Figure 4), whether or not these latter would
react as efficiently as I’/II’ remained unanswered. To begin the
study, the reaction of 19A with b-nitrostyrene 25a was per-
formed in the presence of a base catalyst. As the results in
Scheme 4 show for the title reaction, catalyst ent-C1 was able
to promote the formation of the contiguous quaternary and
tertiary carbon stereocenters of 34Aa in good yield with mod-
erate diastereoselectivity (62:38) and very high enantioselectiv-
ity for the major isomer. Under such smooth reaction condi-
tions, among the catalyst examined, catalysts C2 and C3 were
both, once again, the best in affording product 34Aa in nearly
quantitative yield with diastereoselectivities higher than 95:5
and excellent enantioselectivities (96 and 95%ee, respectively,
for the almost-exclusive diastereomer).
With catalyst C2 selected for further reaction development,
the robustness of the method with respect to structural varia-
tion of both reactants was explored (Table 4). As the data illus-
trate (Table 4, entries 1–11), aryl-substituted nitroolefins 25a–k
with either electron-rich, electron-neutral, or electron-poor
character were equally competent reaction partners and upon
reaction with 19A afforded corresponding adducts 34A in
very good yields with nearly perfect diastereo- and enantiose-
lectivity in most cases. During this substrate screening, catalyst
C3 was found to be less efficient than C2, as the inferior dia-
stereoselectivity attained for products 34Ag and 34Ah indicat-
ed (Table 4, entries 7/6 vs. 9/8). Variation of the R1 substituent
of the imidazolidinone substrate did not have any appreciable
impact on the reaction outcome. Thus, not only methyl but
also benzyl (Table 4, entries 12 and 13) and other alkyl (Table 4,
entry 14) and functionalized chains (Table 4, entries 15 and 16)
were tolerated at the substrate C5 position without affecting
the reaction efficiency or selectivity. On the other hand, N3-aryl
substrates 20–24 bearing aryl groups other than phenyl also
Scheme 4. Catalyst screening for the reaction of 19A with nitrostyrene.
Table 4. Scope of the catalytic reaction of N3-substituted 2-benzylthio-3,5-dihydroimidazol-4-ones with nitroolefins.[a]
Entry Ar R1 R Product Catalyst Yield [%] d.r. ee [%]
1 Ph Me 4-BrC6H4 34Ab C2 95 >98:2 99
2 Ph Me 4-ClC6H4 34Ac C2 94 >98:2 99
3 Ph Me 3-ClC6H4 34Ad C2 86 >98:2 99
4 Ph Me 2-ClC6H4 34Ae C2 90 >98:2 99
5 Ph Me 4-NCC6H4 34Af C2 88 >98:2 96
6 Ph Me 4-MeC6H4 34Ag C2 87 >98:2 97
7 Ph Me 4-MeC6H4 34Ag C3 83 84:16 96
8 Ph Me 4-MeOC6H4 34Ah C2 85 95:5 90
9 Ph Me 4-MeOC6H4 34Ah C3 86 70:30 90
10 Ph Me 3-MeOC6H4 34Ai C2 94 >98:2 98
11 Ph Me 4-Me2NC6H4 34Ak C2 92 >98:2 99
12 Ph Bn Ph 34Ca C2 90 93:7 98
13 Ph Bn Ph 34Ca C3 92 91:9 99
14 Ph (CH3)2CHCH2 Ph 34Da C2 90 >98:2 99
15 Ph MeSCH2CH2 Ph 34Ga C2 85 >98:2 86
16 Ph MeO2CCH2CH2 Ph 34Ha C2 90 >98:2 99
17 4-MeC6H4 Me Ph 35Aa C2 89 93:7 97
18 4-ClC6H4 Me Ph 36Aa C2 90 >98:2 94
19 4-BrC6H4 Me Ph 37Aa C2 86 >98:2 99
20 4-MeOC6H4 Me 2-ClC6H4 38Ae C2 91 >98:2 94
21 3-ClC6H4 Me 4-MeOC6H4 39Ah C2 90 >98:2 87
[a] Reaction conditions: a mixture of 19–24 (0.3 mmol, 1 equiv), 25 (0.6 mmol, 2 equiv), and catalyst (10 mol%) in CH2Cl2 (0.6 mL) was stirred at 20 8C for
15–20 h. Diastereomeric ratios and ee values of the major diastereomers were determined by HPLC.
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participated in this reaction satisfactorily (Table 4, entries 17–
21).
Vinyl ketones were also competent electrophilic partners in
the reactions of N3-substituted 2-benzylthioimidazolones 19–
24. However, in contrast to that observed with nitroalkenes,
the reactions involving vinyl ketones followed two divergent
pathways: one producing 5-addition products 40 and one pro-
ducing 3-addition products 40’ (Scheme 5). The configuration
of products 40’ was not determined and that of products 40
was assigned by assuming a uniform reaction mechanism.
Attempts to favor either reaction pathway were unsuccessful,
and regardless of the catalyst and reaction temperature, an es-
sentially equimolar ratio of either product was formed for the
studied cases (Scheme 5). Similar observations were previously
reported in Brønsted base catalyzed addition reactions involv-
ing azlactones as the nucleophiles.[34]
Control experiments using the related thiohydantoins
To put the reactivity and, particularly, the selectivity profiles of
templates I–III into context under the present soft enolization
conditions, the behavior of 5C, 13A, 42, and 44, four parent
thiohydantoins with comparable substitution patterns at N1
and N3, was explored (Scheme 6). Initial control experiments
showed that, in contrast to templates I–III (see above), none of
these four thiohydantoins reacted at all with nitrostyrene 25a
in the presence of catalyst C3 at low temperature (experiments
performed at 20 8C). This lack of reactivity was most evident
in the case of thiohydantoin 5C, which remained unchanged
even after stirring the mixture for 24 h at 0 8C. We ascribe the
comparatively higher reactivity of templates I–III to their ten-
dency to undergo enolization owing to the aromatic character
of the resulting enol/enolate intermediate species. At higher
temperatures (0 8C), N3-phenylthiohydantoin 13A reacted with
nitrostyrene 25a in the presence of catalyst C3, but product
41 was obtained as a 1.9:1 mixture of diastereomers. Similarly,
N1-methylthiohydantoin 42 also reacted with nitrostyrene 25a
at 0 8C but, again, led to a roughly equimolecular mixture of
diastereomers with marginal enantioselection. In turn, Rios[35]
reported that upon treatment with nitrostyrene at room tem-
perature 13 l gave a complex mixture. Finally, N,N-dibenzoyl
derivative 44 was completely unreactive under these condi-
tions.
Hydrolysis of adducts into 5,5-disubstituted hydantoins
Removal of the benzylthio adjuvant from adducts obtained
through these series of catalytic conjugate addition reactions
could be performed by hydrolysis under various convenient
conditions. As shown in Scheme 7, treatment of N1-benzoyl
adduct 27Ca with 6m HCl in dioxane at 65 8C for 6 h gave rise
to corresponding N-acylhydantoin 45 in 80% yield. Subse-
quent treatment of 45 with 6m NaOH at 100 8C produced free
hydantoin 47 in 77% yield. On the other hand, the same acid
hydrolytic conditions applied to N-Boc adduct 28Ca induced
concomitant deprotection of the Boc group to afford hydan-
toin 47. Interestingly, alkylation of the imide nitrogen atom in
product 45 under standard Williamson conditions allowed
access to corresponding N-benzyl adduct 46 in good yield. In
turn, hydrolysis of 2-phenylthio-4,5-dihydroimidazol-4-one
34Aa to respective hydantoin 48 could be performed by treat-
ment with 1m HCl at room temperature. Temperature control
of this reaction was important for clean hydrolysis. The same
reaction performed under more forcing conditions (65 8C) led
to a 1:1 mixture of compound 48 and thio analogue 49. In any
event, resulting adduct 48 could be fully converted into thio-
hydantoin analogue 49 by applying Lawesson’s reagent, which
served to establish the compound identity and configuration
by X-ray analysis. On the other hand, Nef-type oxidation of the
nitro group in 48 under Mioskowski conditions[36] proceeded
smoothly to furnish carboxylic acid 50 in 79% yield. The con-
figurational integrity of the adducts was not affected during all
Scheme 5. Reaction of 2-benzylthiodihydroimidazolones 19A with vinyl ke-
tones 30a and 30e.
Scheme 6. Reactivity profile of the related thiohydantoins 5C, 13A, 13 l, 42,
and 44. SM= starting material.
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of these transformations, and the final products were obtained
as essentially single enantiomers (99%ee).
Scheme 8 shows a specific application to the synthesis of
pharmacologically active constituents based on a three-step
sequence. Both amides 53 and 54 have been reported to pres-
ent significant inhibitory activity as ADAMTS (A disintegrin and
metalloproteinase) inhibitors.[37] Starting from adduct 32 le
(Table 2, 82%, 91%ee), acid hydrolysis of the S-benzylisothiour-
ea moiety in dioxane at 65 8C, followed by ketol oxidative scis-
sion with HIO4, provided carboxylic acid 52 in 74% yield over
two steps. Final coupling of acid 52 with piperidine and N-phe-
nylpiperazine by using N’-(3-dimethylaminopropyl)-N-ethylcar-
bodiimide/1-hydroxybenzotriazole (EDC/HOBt) coupling re-
agent led to amides 53 and 54 in 65 and 70% yield, respec-
tively. These examples show that the adducts can be
manipulated easily, with minimum production of
waste organic materials (e.g. , acetone is obtained as
a byproduct in the 51!52 transformation) and,
most important, with preserved configurational in-
tegrity.
Mechanistic insight
Several experiments were performed to obtain in-
sight into the reaction mechanism. In a first set of
experiments (Figure 5), the conversion for the reac-
tion between 10C and 25a was measured as a func-
tion of time, maintaining the concentration of 25a
pseudoconstant (15 equiv) in the presence of
10 mol% catalyst C3. A plot of ln([10C]/[10C]0)
versus time gave a straight line (R2=0.996), which
indicated first-order dependence in the nucleophile.
The reaction order in the electrophilic component
was determined similarly by measuring the reaction
conversion as a function of time at a pseudoconst-
ant concentration of nucleophile 10C (15 mol equiv)
in the presence of 10 mol% catalyst C3. In this in-
stance, a plot of ln([25a]/[25a]0) versus time again
afforded a straight line (R2=0.9815), indicating first-
order reaction with respect to the acceptor compo-
nent. Unfortunately, the reaction order in the cata-
lyst could not be determined by this means owing
to the limited solubility of the catalyst.
On the other hand, the collective experimental data shown
in Tables 1–4 reveal the unique reactivity profile of templates
I–III, in contrast to the variable results attained with the parent
thiohydantoins (see Scheme 6). An interesting aspect of this
high reactivity is that it appears quite general regardless of the
catalyst employed, and therefore, it should be ascribed to an
inherent feature of the template design. As shown in the Intro-
ductory section (Figure 4), the pseudoaromatic character of
enol forms I’–III’ would facilitate the enolization process, but
this effect alone would not necessarily justify the subsequent
reactivity against the electrophilic acceptor. To obtain addition-
al insight into this aspect, and more specifically with regard to
Scheme 7. Hydrolysis of cycloadducts to 5,5-disubstituted hydantoins and further elabo-
ration. 18-C-6=18-crown-6.
Scheme 8. Synthesis of ADAMTS (A disintegrin and metalloproteinase) inhib-
itors 53 and 54.
Figure 5. Plot of reaction conversion versus time for the C3-catalyzed reac-
tion between 10C and 25a with pseudoconstant concentrations of 25a (^)
and 10C (&).
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the affinity of the templates for these type of bifunctional cata-
lysts, we performed competitive 1H NMR spectroscopy experi-
ments involving template 9C, nitroolefin 25a, and catalyst ent-
C1 (Figure 6). Catalyst ent-C1 was chosen because of its com-
plete solubility in halogenated solvents, as noted above. As a
comparison of spectra 1, 2, and 4 shows (Figure 6), admixing
25a and ent-C1 caused a slight downfield shift in the olefinic
Hc/Hd protons of 25a along with an upfield shift in Ha and Hb
of ent-C1, quite significant (Dd0.1 ppm) in the former case,
clearly indicating some degree of molecular recognition be-
tween nitrostyrene 25a and the catalyst. In turn, variation of
the chemical shifts upon admixing template 9C and the cata-
lyst (compare spectra 2, 3, and 5 in Figure 6) seemed to be less
pronounced, with only a slight downfield shift in Hb. However,
spectrum 6, in which both substrates 25a and 9C must com-
pete for best catalyst binding, reveals that the molecular affini-
ty between 9C and ent-C1 is relatively high. Indeed, the chemi-
cal shift pattern of ent-C1 in spectrum 6, in particular the
chemical shifts of both Ha and Hb, remained essentially the
same as that in spectrum 5 and distinct from that in spec-
trum 4. These observations reinforce the idea that the new hy-
dantoin template upon enolization would remain tightly
bound to the catalyst during the key CC bond-forming event,
allowing efficient transfer of chiral information.
To obtain more insight into the structural/functional require-
ments of these catalysts for optimal activity and selectivity, the
performances of catalyst C3, featuring a free NH amide, and its
N-Me derivative were compared. As the conversion profiles in
Figure 7 show for the reaction between 9C and 25a, catalyst
C3 was significantly more active than its N-methylated form.
For instance, with C3 the reaction conversion was over 70%
after 30 min at room temperature (over 90% after 1 h), where-
as with C3-NMe the conversion barely reached 27% after
30 min (45% after 1 h). Although erosion of the stereoselectiv-
ity was less important (C3, d.r. 98:2, 99%ee, Table 1, entry 9;
C3-NMe, dr>98:2, 90%ee), the difference in catalyst activities
is significant, especially considering that, unlike C3, C3-NMe is
completely soluble, and this may be attributable to the ability
of the free amide in C3 to form additional H-bonds. Although
the number of individual H-bonding interactions within the
substrate–catalyst complex in the transition state and their
precise orientation remain unknown, on the basis of previous
studies on related catalytic systems,[38] simultaneous activation
of both reactants as in stereomodels A/A’ (Figure 8) may be
proposed tentatively for reactions catalyzed by C3. The free
amide NH group would be H-bonded internally, as in A, to
assist catalyst preorganization or intermolecularly, as in A’, to
fix better one of the approaching reactants. Similar models are
conceivable for the remaining templates and catalysts in which
the approaching trajectory of both reactants correctly explains
the observed configuration, both relative and absolute, of the
adducts.
Conclusions
A new, quick entry to the enantioselective synthesis of 5,5-di-
substituted hydantoins was developed on the basis of an orga-
nocatalytic Michael reaction approach by using easy-to-prepare
and easy-to-handle 2-benzylthiodihydroimidazol-4-ones as key
hydantoin surrogates. The method was found to be general
with respect to the substitution pattern at the N1 (alkyl, aryl,
acyl), N3 (aryl), and C5 (linear/branched alkyl, aryl) positions of
the resulting hydantoins and afforded essentially single diaste-
reomeric products with enantioselectivities higher than 95%ee
in most cases. These hydantoin surrogates were demonstrated
to be clearly superior to the parent thiohydantoins, which
were inefficient in terms of reactivity and/or selectivity under
similar catalytic conditions. Among the catalysts examined, C2
Figure 6. Insets of the 1H NMR spectra corresponding to individual samples
of 9C, 25a, and ent-C1 and three 1:1 combinations of them taken in CDCl3
at room temperature (concentration0.1m).
Figure 7. Conversions for the reaction between 9C and 25a catalyzed by C3
(~) and its N-Me derivative (^) under standard conditions.
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and newly prepared squaramide–tertiary amine catalyst C3
provided the highest selectivity in the reactions with either ni-
troolefins or vinyl ketones as the acceptor components. One
designing advantage of C3 is its adaptability to particular reac-
tion needs owing to easy modification of the carboxamide
unit. Kinetic studies of these catalytic Michael reactions sup-
port a first-order rate dependence on both the donor and ac-
ceptor reactants. On the other hand, 1H NMR spectroscopy
monitoring of mixtures of donor template, acceptor, and cata-
lyst suggested that the good reactivity and high fidelity of chir-
ality transfer with these templates was bound to the unique
capacity of the benzylthiodihydroimidazolone system to bind
the catalyst. As the adducts obtained through the present
method may display a tetrasubstituted stereogenic center ad-
jacent to a tertiary one and can be chemically manipulated in
many ways, new perspectives are opened in the field of hydan-
toin chemistry. The potential of this method was illustrated
with an expeditious synthesis of ADAMTS (A disintegrin and
metalloproteinase) inhibitors 53 and 54. Further applications
of templates I–III as pronucleophiles in related catalytic set-
tings can be foreseen.
Experimental Section
For a detailed description of the experimental procedures (prepara-
tion of templates, catalytic enantioselective reactions, transforma-
tions of adducts, kinetic measurements), characterization of the
compounds, and spectroscopic/chromatographic information, see
the Supporting Information.
CCDC 1581118 (45) and 1581122 (49) contain the supplementary
crystallographic data for this paper. These data can be obtained
free of charge from The Cambridge Crystallographic Data Centre.
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